[
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is breast cancer. The corresponding ICD-10 codes for the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being tested in the trial is a combination of trastuzumab, docetaxel, and carboplatin, administered in a dose-dense regimen. The eligibility criteria for participants in this trial include having HER-2 overexpressing breast cancer, being in clinical stage 2-3B, and having a normal ejection fraction. Participants with metastatic disease or low ejection fraction are excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 2. The disease mentioned is gastroesophageal reflux disease. The ICDCodes associated with this disease are K21.9, K21.00, and K21.01. The drugs being tested in this trial are 10 mg ilaprazole, 15 mg ilaprazole, and 40 mg esomeprazole. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria state that patients must be 18-70 years old, have at least one of the symptoms (heartburn and reflux), and have documented erosive esophagitis confirmed by esophagogastroduodenoscopy (EGD) within 5 days before randomization. Female patients must also meet certain requirements regarding pregnancy and contraception.\n\nExclusion criteria state that patients with certain conditions such as cancerous or peptic ulcers, Zollinger-Ellison syndrome, varices of esophagus or fundus of stomach, and other severe complications or diseases are ineligible. Patients who have recently taken proton pump inhibitors, participated in another clinical trial, have hypersensitivity to certain drugs, or have improper habits are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"carcinoma of the appendix\" and \"colorectal cancer.\" The corresponding ICDCodes for these diseases are \"C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31\" for carcinoma of the appendix and \"C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2\" for colorectal cancer. The drug being investigated in this trial is \"thalidomide.\" \n\nThe eligibility criteria for this trial include specific disease characteristics such as confirmed peritoneal carcinomatosis or adenomucinosis secondary to colorectal or appendiceal cancer, and having undergone cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IPHC) within the past 12 weeks. Patients with residual disease or no evidence of disease after IPHC are eligible. Other patient characteristics include ECOG performance status 0-3, being free of infection or postoperative complications, and meeting certain blood count and liver function criteria. There are also criteria related to pregnancy, contraception, medical history, and prior concurrent therapy.\n\nOverall, this sample provides a snapshot of a Phase 2 clinical trial focusing on carcinoma of the appendix and colorectal cancer, with thalidomide as the investigational drug, and specific eligibility criteria for potential participants.",
    "The sample is a phase 2 clinical trial for the treatment of peripheral arterial disease. The trial focuses on the use of sodium nitrite as a potential drug. The eligibility criteria for participants include being between the ages of 35 and 85, having a confirmed history of peripheral arterial disease, and having stable lower extremity symptoms for at least 1 month prior to screening. Participants must also provide written informed consent.\n\nThere are several exclusion criteria, such as having non-atherosclerotic peripheral arterial disease, recent lower extremity revascularization, or a history of myocardial infraction or unstable angina within the past 3 months. Other exclusion criteria include poorly controlled diabetes or hypertension, hypersensitivity to sodium nitrite, renal insufficiency, pregnancy or nursing, and a life expectancy of less than 6 months.\n\nThe sample also includes a list of diseases and their corresponding ICD-10 codes, which in this case is \"peripheral arterial disease\" with the codes ['A18.2', 'H11.043', 'H11.053', 'H18.463', 'H35.40', 'H81.393', 'I73.9'].\n\nOverall, the sample provides detailed information about the phase 2 clinical trial, including the eligibility and exclusion criteria, the specific disease being studied, and the potential drug being tested.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied include \"adenocarcinoma, scirrhous\", \"linitis plastica\", \"stomach neoplasms\", \"stomach diseases\", \"neoplasms by site\", and \"neoplasms\". The corresponding ICDCodes for these diseases are provided as well. The drug being tested in this trial is \"tki258\". The eligibility criteria for this trial include various inclusion and exclusion criteria, such as a diagnosis of advanced/metastatic scirrhous gastric carcinoma, evidence of diffusely infiltrating gastric lesions, previous treatment with one or two systemic lines, documented radiological confirmation of disease progression, ECOG performance status of 0 to 2, and adequate liver, renal, and hematologic function. Exclusion criteria include prior treatment with an FGFR inhibitor, known brain metastases or symptoms attributable to brain metastases, and another primary malignancy within 3 years prior to starting study treatment. Additional protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on two specific diseases: female sexual arousal disorder and hypoactive sexual desire disorder. The corresponding ICD-10 codes for these diseases are \"F52.22\" and \"F52.0\" respectively. The trial involves the use of a drug called bremelanotide.\n\nThe eligibility criteria for participants in this trial include being a female who is at least 21 years old and premenopausal. They should have previously experienced sexual arousal during sexual activity and/or had a normal level of desire for at least 2 years. Participants should also be willing to engage in sexual activities and be in a stable relationship with a partner (male or female) for at least 6 months. If the participant has a male sexual partner, they should have recorded a score of \"not impotent\" or \"minimally impotent\" on a Single-question Assessment of ED.\n\nAdditionally, participants should have met the diagnostic criteria for either FSAD (Female Sexual Arousal Disorder), HSDD (Hypoactive Sexual Desire Disorder), or mixed FSAD/HSDD for at least 6 months before screening. They should have a negative serum pregnancy test and, if their partner is male, have used a medically acceptable form of contraception for the 3 months before screening and be willing to continue its use throughout the trial and for 1 month after the last dose of the trial drug.\n\nOther criteria include having a normal pelvic examination, normal Pap test results, and meeting necessary questionnaire scores at screening and visit 2.\n\nThere are also exclusion criteria, such as having unstable or uncontrolled medical conditions, a history of unresolved sexual trauma or abuse, being pregnant or nursing, and having certain sexual disorders or diseases. Participants should not have certain medical conditions or have had specific events within a certain timeframe before screening. They should not have used prohibited medications within the 3 months before screening and should not have currently active vaginitis or significant vaginal infection. Other exclusion criteria include having significant gynecologic conditions, receiving treatment for certain mental health disorders or substance abuse, currently receiving psychotherapy for FSAD and/or HSDD, and having uncontrolled hypertension or recent changes in hypertension treatment. Participants who have had a hysterectomy with or without bilateral oophorectomy or are taking contraceptives that have affected the menstrual cycle or caused amenorrhea are also excluded.\n\nOverall, this sample provides detailed information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for participants in a clinical trial.",
    "The sample is a phase 2 trial for the treatment of opioid-induced constipation. The trial is focused on participants who have undergone orthopedic procedures and are currently receiving opioid analgesics. The inclusion criteria specify that participants must be experiencing acute constipation following the procedure and be expected to require daily opioid analgesics for at least 7 days. Participants must also have a body weight within the range of 40 kilograms to 150 kilograms. \n\nThe exclusion criteria state that participants with known hypersensitivity to certain drugs, those who have received any investigational new drug in the previous 30 days, and those who have taken laxatives or enemas within 48 hours prior to the first dose are not eligible. Participants with constipation not attributed to post-procedure opioids, a history of substance abuse, or chronic active hepatitis B, hepatitis C, or HIV infection are also excluded. \n\nFemale participants of childbearing potential must have a negative pregnancy test and use appropriate birth control throughout the study. Participants are required to sign an informed consent form. The study drugs being tested are methylnaltrexone bromide and placebo. Participants must receive all doses of the study drug in hospitals or rehabilitation facilities.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is asthma. The corresponding ICD-10 codes for asthma are ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The drugs being used in the trial are tiotropium bromide, placebo, and salmeterol xinafoate. \n\nThe eligibility criteria for the trial are as follows:\n- Patients must be homozygous for arginine at the 16th amino acid position of the beta2 adrenergic receptor (B16 Arg/Arg).\n- All patients must sign an Informed Consent Form before participating in the trial.\n- Patients must be outpatients, either male or female, between 18 and 65 years old.\n- Patients must have a documented history of asthma.\n- Patients must be non-smokers or ex-smokers with a cigarette smoking history of less than 10 pack-years.\n- Patients must be on a maintenance treatment with inhaled corticosteroids, with a daily dose of 400 - 1000 mcg budesonide or equivalent.\n\nThe exclusion criteria for the trial are as follows:\n- Patients with any significant disease other than asthma.\n- Patients with a recent history (within the past six months) of myocardial infraction.\n- Patients who have been hospitalized for heart failure (New York Heart Association class III or IV) within the past year.\n- Patients with any unstable or life-threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year.\n- Patients with malignancy that has been treated with resection, radiation therapy, or chemotherapy within the last five years. Patients with treated basal cell carcinoma are allowed.\n- Patients with a diagnosis of chronic obstructive pulmonary disease (COPD).\n- Patients with a history of life-threatening pulmonary obstruction, cystic fibrosis, or clinically evident bronchiectasis.\n- Patients with known active tuberculosis.\n- Patients who have undergone thoracotomy with pulmonary resection.\n- Patients who have completed a pulmonary rehabilitation program in the six weeks prior to visit 1 or patients who are currently in a pulmonary rehabilitation program that will not be maintained throughout the duration of the study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on studying the effectiveness of a drug called saracatinib in treating hormone-resistant prostate cancer, recurrent prostate cancer, and stage IV prostate cancer. The diseases are also associated with specific ICD-10 codes. \n\nThe eligibility criteria for participants in this trial include having histologically or cytologically confirmed prostate cancer with progressive disease, which can be defined as either new clinical or radiographic metastases or rising PSA levels. Previous treatment with docetaxel for disease progression following hormonal therapy is required. Other criteria include having an ECOG performance status of 0-1, specific blood counts and levels within normal ranges, and no history of certain medical conditions or allergies. \n\nParticipants must also meet certain time requirements, such as being at least 2 weeks away from previous chemotherapy, surgery, or radiotherapy, and having been on zoledronic acid or other bisphosphonate therapy for at least 6 weeks prior to participation. The use of certain prohibited medications is not allowed during the trial. Concurrent use of non-FDA approved medications is also not permitted.",
    "The sample from the table represents a phase 2 clinical trial. The trial focuses on patients with cancer and pain. The diseases are specified using ICD-10 codes. The drug being studied is sublingual methadone. The eligibility criteria for inclusion in the trial include having controlled baseline pain, experiencing episodes of breakthrough pain every day with a severity of \"4/10\" or greater, lasting at least 10 minutes, and being responsive to short-acting oral opioids. Additionally, participants must be able to hold a volume of 1.0cc of water under their tongue for 5 minutes, provide written informed consent, and fill out study forms. The exclusion criteria include having severe underlying respiratory disease, prior sensitivity to methadone, currently being administered methadone, having breakthrough pain that is likely to change within the next seven days due to radiation therapy, chemotherapy, or other interventions, and being clinically unstable or having a life expectancy of less than one month.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on non-small cell lung cancer. The trial includes a list of diseases, which in this case is only non-small cell lung cancer. The icd-10 codes associated with the disease are also provided. The trial involves the use of two different interventions, each consisting of a combination of drugs. The eligibility criteria for participants are listed, including requirements such as having a histologic or cytologic diagnosis of SCLC, specific age range, and adequate bone marrow, liver, and renal function. The criteria also include recovery from previous surgeries and radiation therapy, agreement to practice approved methods of birth control, and providing written informed consent. The inclusion and exclusion criteria are detailed, specifying conditions that would make a participant eligible or ineligible for the trial.",
    "The sample is a phase 2 trial for non-small cell lung cancer (NSCLC) patients. The trial includes patients with recurrent NSCLC, stage IIIB NSCLC with pleural effusion, and stage IV NSCLC. The trial is testing the drug sorafenib tosylate. The eligibility criteria for the trial include having histologically or cytologically confirmed NSCLC, measurable disease, no known brain metastases, a performance status of ECOG 0-2, and meeting certain blood count and organ function requirements. Patients must also not have any other severe underlying diseases, not be pregnant or nursing, and not have any other malignancy within the past 5 years except for certain types of skin cancer. Prior immunotherapy, biologic therapy, gene therapy, and chemotherapy for NSCLC are not allowed. The sample also includes additional criteria related to radiotherapy, adjuvant therapy, and concurrent medications.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on non-small cell lung cancer (NSCLC). The trial involves the drug cetuximab. The eligibility criteria for the trial are listed, including the requirement of a confirmed diagnosis of NSCLC, specific disease stage, measurable disease, age over 18, and certain organ and marrow function levels. The sample also includes exclusion criteria, such as a history of pulmonary fibrosis, prior therapy with specific inhibitors, and uncontrolled illnesses. It also mentions that pregnant women and those with immune deficiency are excluded from the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is kidney cancer. The ICDCodes associated with this disease are D17.71, D30.00, D30.01, D30.02, D41.00, D41.01, and D41.02. The drug being tested in this trial is gefitinib. \n\nThe eligibility criteria for this trial include the following disease characteristics: the patient must have histologically or cytologically confirmed renal cell carcinoma, either metastatic or advanced/unresectable. The patient must also have measurable or nonmeasurable disease as defined by RECIST criteria, and should not have uncontrolled brain metastases, although patients with adequately treated brain metastases who are not taking anticonvulsants and corticosteroids may still be eligible.\n\nThe patient characteristics required for participation in this trial include a Karnofsky performance status of 60-100%, a life expectancy of at least 12 weeks, a white blood cell count (WBC) of at least 3,500/mm\u00b3, a platelet count of at least 100,000/mm\u00b3, an absolute granulocyte count of at least 1,500/mm\u00b3, a creatinine level of \u2264 2.0 mg/dL or a creatinine clearance of \u2265 50 mL/min, a bilirubin level of \u2264 1.5 mg/dL, and an aspartate aminotransferase (AST) level of \u2264 2 times the upper limit of normal (ULN). \n\nOther patient characteristics include not being pregnant or nursing, having a negative pregnancy test, using effective contraception if fertile, not having any other malignancy within the past 5 years except for adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or adequately treated stage I or II cancer from which the patient is currently in complete remission. The patient should also not have any known severe hypersensitivity to gefitinib or its excipients, no incomplete healing from previous oncologic or major surgery, and no unresolved chronic toxicity > grade 2 from previous anticancer therapy (except for alopecia and anemia). \n\nAdditionally, the patient should not have evidence of clinically active interstitial lung disease, no evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease), and no other significant clinical disorder or laboratory finding that would prevent study participation.\n\nRegarding prior concurrent therapy, the patient should not have taken nonapproved or investigational drugs within the past 30 days, aldesleukin or interferon within the past 6 weeks (unless recovered), or received radiotherapy within the past 3 weeks. The patient should not have received prior gefitinib, but prior chemotherapy or biological therapy is allowed. Concurrent bisphosphonate therapy for bone metastases is also allowed, but concurrent use of phenytoin, carbamazepine, rifampin, barbiturates, phenobarbital, or Hypericum perforatum (St. John's wort) is not allowed. Additionally, no other concurrent agents specifically designed to inhibit the epidermal growth factor receptor (EGFR) are allowed, and concurrent radiotherapy to measurable lesions is not permitted.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is esophageal cancer. The ICDCodes associated with this disease are \"K22.2\", \"K22.81\", \"Q39.4\", \"P78.83\", \"I85.00\", \"I85.01\", and \"I85.10\". The drugs being used in the trial are cisplatin and fluorouracil. \n\nThe eligibility criteria for this trial are divided into three categories: disease characteristics, patient characteristics, and prior concurrent therapy. \n\nUnder disease characteristics, the inclusion criteria state that the patient must have histologically confirmed epidermoid or glandular carcinoma of the thoracic esophagus, invasive disease, and only Siewert type I gastroesophageal carcinoma is allowed. The disease must also be resectable, with specific staging criteria and no metastases or extensions compromising resectability. \n\nThe exclusion criteria for disease characteristics include inoperable disease, invasion of the tracheo-bronchial tree, recurring esophageal paralysis, esopho-tracheal fistula, cervical esophageal carcinoma, multifocal esophageal carcinoma, superficial esophageal carcinoma, esophageal carcinoma in lymph nodes that cannot be included in radiotherapy field or completely surgically resected, and proven metastatic disease. \n\nUnder patient characteristics, the inclusion criteria include specific performance status, weight loss, blood counts, creatinine levels, PTT, albumin levels, FEV1, and pregnancy/nursing status. Fertile patients must use effective contraception. \n\nThe exclusion criteria for patient characteristics include known liver cirrhosis, renal insufficiency, respiratory insufficiency, progressive coronary insufficiency, recent myocardial infraction, legal incapacitation, inability to receive study therapy due to geographical/social/psychological reasons, noncompliance with study constraints, and presence of hematologic malignancy or other cancers (with exceptions). \n\nUnder prior concurrent therapy, the exclusion criteria include prior anticancer chemotherapy or radiotherapy, treatment with endoprosthesis, and planned surgery (esophagectomy) without thoracotomy.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is smoking. The corresponding ICD-10 codes for the disease are 'O99.334', 'O99.335', 'Y93.G2', 'O99.330', 'O99.331', 'O99.332', and 'O99.333'. The drug being tested is taranabant. The eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The participant must be a smoker, consuming at least 10 cigarettes per day for at least 1 year.\n- The participant must have laboratory test results that meet the study's criteria.\n- The participant must be in overall good health, as determined by the investigator.\n\nExclusion Criteria:\n- Participants with psychiatric diagnoses are not eligible.\n- Participants with certain cancers are not eligible.\n- Participants who use nicotine replacement therapy are not eligible.\n- Participants on a diet regimen are not eligible.",
    "The sample provided is for a phase 2 trial. The disease being studied is chronic obstructive pulmonary disease (COPD). The ICD-10 codes associated with this disease are J44.9, J44.1, and J44.0. The drugs being tested in this trial include a single dose of 5 mcg, placebo, 40 mcg, 20 mcg, 2 mcg, and 10 mcg. The eligibility criteria for this trial include a diagnosis of COPD and a smoking history of more than 10-pack years. The exclusion criteria include a history of asthma, allergic rhinitis, myocardial infraction, or unstable or life-threatening cardiac arrhythmias, as well as marked baseline prolongation of the QT/QTc interval.",
    "The sample is a record from a table that contains information about clinical trials. It is specifically for a phase 2 trial. The disease being studied is non-Hodgkin's lymphoma. The ICD-10 codes associated with this disease are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drug being used in the trial is a combination of cyclophosphamide, epirubicin, etoposide, and prednisolone. The eligibility criteria for participants in the trial are listed, including requirements such as histologically proven NHL, HBsAg-positive status, no previous chemotherapy or radiotherapy, and specific blood test results. There are also exclusion criteria, such as age restrictions, pregnancy or breastfeeding, history of brain metastasis or CNS involvement, and impaired cardiac function. The use of glucocorticoids for other reasons is also not allowed.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is breast cancer. The ICDCodes associated with this disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are pd 0332991 and letrozole. The eligibility criteria for this sample include having inoperable estrogen receptor positive and HER2 negative breast cancer, being in a postmenopausal state, having available tumor tissue for biomarker studies, and meeting acceptable bone marrow, liver, and kidney function. The exclusion criteria include having prior or concomitant treatment for advanced breast cancer, having had another major cancer in the past 3 years, and experiencing important cardiovascular events in the past 6 months.",
    "The sample is a phase 2 trial for breast cancer. The trial includes patients who have a performance status of 0 to 2 on the ECOG performance status schedule. Patients may have had up to one prior systemic chemotherapy for metastatic disease, and prior adjuvant therapy is allowed if it has been more than one year since the end of therapy. Patients must have measurable disease as defined by RECIST criteria. Adequate organ function is also required. Patients with serious concomitant systemic disorders that would compromise their safety or ability to complete the study are excluded. The drugs being tested in this trial are pemetrexed and gemcitabine. The icd-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60.",
    "The sample provided is for a phase 2 clinical trial. The trial is focused on treating various types of cancers, including ovarian, breast, prostate, pancreatic, and advanced tumors. The diseases are identified using their respective ICD-10 codes. The drug being tested in this trial is olaparib. \n\nThe eligibility criteria for this trial include having a confirmed deleterious or suspected deleterious BRCA mutation, having malignant solid tumors with no standard treatment available, and having at least one measurable or non-measurable lesion that can be assessed using CT/MRI scans. \n\nThe exclusion criteria for this trial include previous treatment with a PARP inhibitor (including olaparib), inability to swallow orally administered medication, gastrointestinal disorders that may interfere with medication absorption, and recent systemic chemotherapy or radiotherapy (except for palliative reasons).",
    "The sample provided is a record from a table that contains information about a clinical trial. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for participants in the trial.\n\nIn this specific sample, the phase of the trial is phase 2. The disease being studied is \"psoriasis vulgaris\" and its corresponding ICD-10 code is \"L40.0\". The drugs being tested are \"daivobet\u00ae gel applied then removed after 10 minutes (+/- 2 minutes)\", \"daivobet\u00ae gel applied then removed after 20 minutes (+/- 2 minutes)\", \"daivobet\u00ae gel applied for 24 hours (+/- 2 hours)\", and \"daivobet\u00ae gel vehicle applied for 24 hours (+/- 2 hours)\". \n\nThe eligibility criteria for participants in this trial include providing signed and dated informed consent, being 18 years of age or older, having a diagnosis of psoriasis vulgaris with lesions located on the arms, legs, and/or trunk, having stable psoriasis based on Total Plaque Score evaluation, having psoriasis lesions with a Total Clinical Score of 4 to 9, being willing and able to follow all study procedures, being affiliated to a social security system, and using a reliable method of contraception for female subjects of childbearing potential.\n\nThere are also exclusion criteria listed, which include being pregnant or breastfeeding, having received systemic treatment with certain biological therapies within a specific time period, having used certain topical drugs within a specific time period, having certain skin conditions or disorders, having a history of severe diseases or serious current conditions, having received treatment with non-marketed drugs within a specific time period, currently participating in another clinical trial, having known or suspected hypersensitivity to the investigational products, having concomitant medical or dermatological disorders that may affect the evaluation of psoriasis, and various other criteria.\n\nOverall, this sample provides information about the phase, diseases, icd codes, drugs, and eligibility criteria for participants in a specific clinical trial focused on psoriasis vulgaris.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on Alzheimer's disease. The ICD-10 codes associated with the disease are G30.8, G30.9, G30.0, and G30.1. The drugs being tested in the trial are octohydroaminoacridine succinate tablets and a placebo. \n\nThe eligibility criteria for participants in the trial are as follows:\n1. The patient must have a clinical diagnosis of probable Alzheimer's disease based on DSM-IV and NINCDS-ADRDA criteria.\n2. The patient must be between the ages of 50 and 85.\n3. For patients with a middle school education or above, the MMSE score must be between 11 and 25. For patients with an elementary school education, the MMSE score must be between 8 and 20. For illiterate patients, the MMSE score must be between 5 and 16.\n4. A CT or MRI scan must have been done within the past year to exclude any other structural brain disease.\n5. The patient must have no significant abnormalities in their neurological examination.\n6. The Hachinski Ischemic Score must be less than 4 and the Hamilton Depression Scale must be less than or equal to 10. The patient must be able to complete the test procedure and have the audio-visual and physical ability to complete the neuropsychological measure.\n7. The patient must have a stable chaperone who spends more than 2 hours a day with them or accumulates fewer than 14 hours per week.\n8. The patient (or their legal representative) and the caregiver must provide informed consent to participate in the study.\n\nThe exclusion criteria for participants in the trial are as follows:\n1. The patient must not have any other type of dementia such as vascular dementia, Lewy body dementia, Parkinson's disease, frontotemporal dementia, g - Jakob disease, or normal pressure hydrocephalus.\n2. The patient must not have had a sudden onset of early dementia or have gait disorders, seizures, or behavioral changes.\n3. The patient must not have clinical manifestations of focal neurological signs or early extrapyramidal tract signs.\n4. The patient must not have a history of cerebrovascular disease or stroke.\n5. The patient must not have a serious lack of folic acid and VitB12, be syphilis antibody positive, or have thyroid dysfunction.\n6. The patient must not have mechanical intestinal obstruction, a resting pulse less than 60, or severe liver or renal disease.\n7. The patient must not have a history of bone marrow transplantation or mental illness such as severe depression.\n8. The patient must not have cognitive damage caused by alcohol or drug abuse that would prevent the correct evaluation of cognitive function.\n9. The patient must not be in a critical condition that would prevent the accurate evaluation of the efficacy and safety of the new drug.\n10. The patient must not have used any agent for the treatment of dementia within 4 weeks of randomization.\n11. The patient must be sensitive to ACHEI.\n12. The patient must be sensitive to two or more foods/drugs.\n13. The patient must not have used another investigational agent within one month of screening.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on diabetes, specifically type 1 diabetes mellitus. The trial includes patients with specific ICD-10 codes related to diabetes. The drugs being tested in the trial are liraglutide and a placebo. The eligibility criteria for inclusion in the trial include having type 1 diabetes for at least 5 years, being a candidate for islet cell transplantation, and having reduced awareness of hypoglycemia. The exclusion criteria include recent use of any anti-diabetic medication other than insulin, previous organ transplantation, a history of pancreatitis, and a family or personal history of certain endocrine neoplasia conditions.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of nausea, vomiting, and chemotherapy-related symptoms. The diseases being studied are listed as \"nausea,\" \"vomiting,\" and \"chemotherapy.\" The corresponding ICD-10 codes for these diseases are provided as well.\n\nThe drugs being investigated in this trial are \"palonosetron\" and \"granisetron.\" The eligibility criteria for participants in the trial are also listed. Inclusion criteria include being male or female aged 18 to 70 with a confirmed malignant disease, being either chemotherapy-naive or nonnaive with a Karnofsky score of at least 60, and scheduled to receive two courses of moderately emetogenic chemotherapy or cisplatin 60-80 mg/m2 on study Day 1. Other criteria include the use of reliable contraceptive measures for females of childbearing potential, negative pregnancy test at baseline visit, and a predicted life expectancy of at least 3 months.\n\nExclusion criteria include the inability to understand or cooperate with study procedures, recent receipt of investigational drugs, seizure disorder or conditions requiring anticonvulsants or sedatives, CNS malignancy or metastasis, ongoing emesis due to digestive tract obstruction, moderate or severe nausea and vomiting after previous chemotherapy, scheduled receipt of highly emetogenic chemotherapeutic agents or radiotherapy during the study period, scheduled receipt of other drugs with potential antiemetic efficacy within 24 hours of study initiation and throughout day 5, contraindications to 5-HT3 receptor antagonists, and contraindications to chemotherapy.\n\nOverall, this sample provides a snapshot of the phase 2 clinical trial, including the diseases being studied, the drugs being investigated, and the eligibility criteria for participants.",
    "The sample from the table is for a phase 2 clinical trial for colorectal cancer. The eligibility criteria for this trial include having histologically confirmed colon cancer that is metastatic or unresectable, having progressed on cetuximab plus irinotecan based combination prior to enrolling in the study, and having a tumor tissue tested for KRAS mutation and confirmed to carry a wild type. Other criteria include having an ECOG score of less than or equal to 1, adequate organ and marrow function, and the ability to understand and sign a written informed consent document. Presence of measurable disease is also required, defined as a lesion of at least 2 cm by CT (or 1 cm by spiral CT). Patients should have failed or been deemed intolerant to other standard chemotherapy treatments such as oxaliplatin and fluoropyrimidines.\n\nExclusion criteria for this trial include not receiving any other investigational agents that are not included in the study, not having significant symptomatology from brain metastases (if present), not having current evidence of other invasive cancers, being off chemotherapy or other targeted therapies for at least 3 weeks before study treatment, not having a history of allergic reactions to irinotecan or severe infusion reaction to cetuximab, not having a history of allergic reaction to tetracycline or doxycycline, not needing prior dose reduction on cetuximab due to grade 3 skin toxicity, not having active skin toxicity of grade 2 or higher at the time of study enrollment, not having uncontrolled intercurrent illness, not being pregnant or breastfeeding, and not having grade 2 or higher hypomagnesemia at baseline evaluation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is hepatocellular carcinoma. The ICDCodes associated with this disease are ['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']. The drugs being used in the trial are etoposide, oxaliplatin, and capecitabine. \n\nThe eligibility criteria for this trial include:\n- Histologically verified intra- or extrahepatic inoperable hepatocellular carcinoma or hyperdense liver lesion at computed tomography and concurrent elevated alpha-feto-protein > 400 ng/ml\n- PS 0-2 (performance status)\n- Age 18-75\n- Life expectancy > 12 weeks\n- Normal bone marrow function (neutrophiles > 1,5 x 109/l and platelets > 100 x 109/l)\n- Bilirubin < 2 x UNL (upper normal limit)\n- Transaminases < 3 x UNL\n- Normal renal function, Cr-EDTA clearance > 50 ml/min\n- No chemotherapy, radiotherapy, or immunotherapy 4 weeks prior to inclusion\n- No uncontrolled, severe concurrent medical disease\n- Fertile women must have a negative pregnancy test\n- Fertile women must use adequate contraceptives during and 3 months after trial exposure\n- Signed informed consent\n\nThe exclusion criteria for this trial include:\n- Chemotherapy, radiotherapy, or immunotherapy 4 weeks prior to inclusion\n- Experimental therapy < 8 weeks prior to inclusion\n- Known DPD-deficiency\n- Known neuropathy\n- Uncontrolled, severe concurrent medical disease\n- Prior malignancy during the last 5 years, except for non-melanoma skin cancer and carcinoma in situ cervix uteri.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of mild persistent asthma. The ICD-10 codes associated with this disease are 'J45.30', 'J45.31', and 'J45.32'. The drugs being tested in this trial are 'bdp/formoterol', 'bdp/formoterol', and 'placebo'. \n\nThe eligibility criteria for this trial are as follows:\n- Patients must be between 18 and 50 years old and have signed an informed consent form.\n- They must have clinical evidence of asthma and be steroid-na\u00efve.\n- The FEV1 (forced expiratory volume in 1 second) at the screening visit must be greater than 70% of the predicted value and at least 2.0 L.\n- The patients' body mass index (BMI) should be between 18 and 35.\n- They should be sensitive to AMP (adenosine monophosphate) at the screening visit.\n- FENO (fractional exhaled nitric oxide) levels should be greater than 25 ppb at the screening visit.\n\nThe exclusion criteria for this trial are as follows:\n- Patients who have received an investigational product within 2 months of the screening visit.\n- Patients who are unable to comply with study procedures or treatment intake.\n- Patients with any significant lung disease considered clinically significant by the investigator.\n- Patients who suffer from Chronic Obstructive Pulmonary Disease (COPD).\n- Previous or current smokers with a smoking history greater than 5 pack years.\n- Patients with any uncontrolled disease that may place them at undue risk or compromise the study results.\n- Patients with a QTc (corrected QT interval) greater than 450 msec at the screening visit.\n- Patients with serum potassium levels below 3.5 mEq/L or above 6 mEq/L.\n- Patients with intolerance/hypersensitivity or contraindication to treatment with beta2-agonists and/or inhaled corticosteroids.\n- Patients with a history of alcohol or substance abuse that may be clinically significant.\n- Patients who have undergone major surgery in the previous 3 months.\n- Patients who have had an asthma exacerbation requiring oral steroid treatment in the last month prior to the screening visit.\n- Patients treated with slow-release corticosteroids within 2 months prior to the screening visit.\n- Patients currently treated with anti-IgE antibodies.\n- Patients who have had a respiratory tract infection within 4 weeks prior to the screening visit.\n- Females who are not willing to use effective contraceptive measures such as oral contraceptives or intra-uterine devices (IUD).\n- Females who are pregnant, lactating, or planning to become pregnant.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of soft tissue sarcoma. The trial includes patients who are 18 years or older and have histologically proven advanced metastatic or unresectable soft tissue sarcoma. Patients must have previously received treatment with a doxorubicin-containing regimen, either in the adjuvant setting or for metastatic/advanced disease. Patients with sex cord tumors may be included after prior treatment with a platinum-containing regimen. \n\nThe eligibility criteria also state that patients must have at least one site of measurable nodal disease at baseline, with specific size requirements. The trial requires patients to have an ECOG performance status of 2 or lower and adequate hematological, liver, and renal function. Other criteria include clinical euthyroidy, the ability to swallow capsules or tablets, a life expectancy of at least 12 weeks, mandatory affiliation with health security insurance, and signed written informed consent.\n\nExclusion criteria for the trial include prior treatment with any HDAC or HSP90 inhibitor drug, unresolved toxicities from prior therapy that could compromise patient safety, and the presence of severe and/or uncontrolled medical conditions that could affect participation in the study. Other exclusion criteria include current treatment with specific medications, major surgery within the past two weeks, a history of brain metastases, absence of a certain size metastatic lesion, recent systemic treatment with anti-cancer drugs, pregnancy or breastfeeding for women, current immunosuppressive syndrome, history of another clinically significant malignancy, and refusal or inability to comply with the protocol.\n\nOverall, this sample provides detailed information about the phase 2 clinical trial, including the diseases being targeted, the drugs being used, and the eligibility and exclusion criteria for potential participants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on two diseases: cognitive dysfunction and schizophrenia. The diseases are identified by their corresponding ICD-10 codes. The trial involves the use of two drugs: tc-5619 and placebo. The eligibility criteria for participants are listed, including requirements such as a diagnosis of schizophrenia, stable symptoms, specific age range, and absence of certain medical conditions. There are also exclusion criteria, which specify conditions or circumstances that would disqualify individuals from participating in the trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 2, and the disease being studied is psoriasis. The icd-10 codes associated with psoriasis are 'L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', and 'L40.50'. The drugs being tested in this trial are placebo, rg3421 120mg, and rg3421 20mg. The eligibility criteria for participants include being an adult between 18-70 years old and having medically stable moderate to severe chronic plaque psoriasis. Exclusion criteria include having any skin condition that may interfere with the evaluation of the study medication on plaque lesions, as well as any confounding or concomitant condition or treatment.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is neuropathic pain. The ICDCodes associated with this disease are E85.1, E85.0, N31.0, N31.1, N31.2, E10.610, and E11.610. The drugs mentioned are krn5500 and placebo. The eligibility criteria for this trial include being 18 years or older, having a diagnosis of advanced or recurrent cancer, having no options for curative chemotherapy (palliative chemotherapy is allowed under certain conditions), having refractory neuropathic pain rated 4 or greater on a 0-10 scale, and failure to respond to two commonly used treatments. Other criteria include having a stable opioid regimen if taking opioids for pain, having a Karnofsky performance status of 40 or more, and females must be sterile or post-menopausal. The exclusion criteria include having received radiation to the site of neuropathic pain in the past 4 weeks, having undergone major surgery within the past 2 weeks, having liver function and other key labs outside normal parameters, having an ECG showing significant abnormality, having had a myocardial infraction (heart attack) within the past 6 months, having a history of interstitial lung disease, having a history of severe allergic reaction to drugs containing polysorbate 80, and having taken another investigational drug within 2 weeks or 5 half-lives (whichever is longer).",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease being studied is schizophrenia. The ICDCodes associated with schizophrenia are ['F20.0', 'F20.1', 'F20.2', 'F20.3', 'F20.5', 'F20.89', 'F20.9']. The drugs being tested are vabicaserin and risperidone. The sample also includes the inclusion and exclusion criteria for the trial. Inclusion criteria include being generally healthy, aged 18 to 65, and having a diagnosis of schizophrenia established for more than 1 year. Exclusion criteria include having a primary psychiatric diagnosis other than schizophrenia, a history of substance abuse or dependence within the past 3 months, and taking high or chronic doses of benzodiazepine at the screening evaluation.",
    "The sample from the table represents a phase 2 clinical trial for non-small cell lung cancer. The trial is focused on patients who have undergone complete surgical resection for stage IB, II, and select III NSCLC. The eligibility criteria include having histologically-confirmed non-small cell lung cancer, no evidence of metastatic disease, and meeting certain blood count and organ function requirements. Patients must not have received previous chemotherapy, radiation therapy, angiogenesis inhibitor, or tyrosine kinase inhibitor for non-small cell lung cancer. They must also be able to understand the study and provide written informed consent. The age requirement is 18 years or older, and patients must be able to start treatment between 8 and 12 weeks following surgery. The exclusion criteria include preoperative radiologic evidence of N2 disease, mixed small cell and non-small cell histologies, positive bronchial margins, and history of certain prior malignancies. Other exclusion criteria include pregnancy or breastfeeding, recent treatment with non-approved or investigational drugs, uncontrolled seizures or active infection, recent major surgical procedures or traumatic injuries, and certain medical conditions such as serious nonhealing wounds, bleeding diathesis, and inadequately controlled hypertension. The sample also lists additional exclusion criteria related to cardiac conditions, peripheral neuropathy, hypersensitivity to study drugs, impaired oral absorption, and inability to comply with study procedures.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is ovarian neoplasms. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being used in the trial is sagopilone (zk 219477) in combination with carboplatin. The eligibility criteria for participants include having evidence of ovarian cancer measurable by CT scan or CA125 blood levels, no recent radiation therapy or chemotherapy, good response to previous treatment with carboplatin or cisplatin followed by worsening of the ovarian cancer after at least 6 months, and additional criteria to be determined during the screening visit. Exclusion criteria include having had more than one treatment regimen with carboplatin or cisplatin, prior treatment with other epothilones, use of any investigational drug in the last 4 weeks, previous radiation to the whole pelvis, symptomatic brain tumors requiring radiation to the brain, active infection, and being pregnant or breastfeeding. Additional criteria will also be determined during the screening visit.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease mentioned is \"Primary Central Nervous System Lymphoma.\" The corresponding ICDCodes for this disease are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drug mentioned is \"pemetrexed.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include histological confirmation of Primary Central Nervous System Lymphoma, being 18 years of age or older, negative pregnancy test (if of childbearing potential), any number of previous recurrences allowed, Karnofsky Performance Status > 60, hematocrit > 30,000, platelet count > 100,000, absolute neutrophil count > 1,500, bilirubin < 1.5 x upper limits of normal, transaminases (ALT and AST) < 1.5 x upper limits of normal, creatinine < 1.5 x upper limits of normal, creatinine clearance > 45 mL/min, adequate medical health to participate, adequate documentation of menopause or commitment to reliable birth control, ability to read and understand the patient informed consent form, and willingness to follow all study requirements.\n\nExclusion criteria include Karnofsky Performance Status < 60, hematocrit < 30,000, platelet count < 100,000, absolute neutrophil count < 1,500, bilirubin > 1.5 x upper limits of normal, transaminases (ALT and AST) > 1.5 x upper limits of normal, creatinine > 1.5 x upper limits of normal, creatinine clearance < 45 mL/min, and inability to undergo gadolinium-contrasted MRIs, including severe claustrophobia or insufficient allergy prophylaxis.",
    "The sample is a phase 2 clinical trial for the treatment of psoriasis vulgaris. The trial is evaluating the effectiveness of two drugs, leo 22811 and placebo. The eligibility criteria for participants include having a clinical diagnosis of psoriasis vulgaris for at least 6 months, with the condition currently covering at least 10% of the body surface area. Candidates for systemic anti-psoriatic treatment are eligible, with a Psoriasis Area and Severity Index (PASI) score of 10 or higher and a disease severity of moderate, severe, or very severe according to the Investigators' Global Assessment. Participants must be 18 years or older, of any race or ethnicity, and attending a hospital outpatient clinic or the private practice of a dermatologist.\n\nExclusion criteria include recent systemic treatment with biological therapies or other therapies that may affect psoriasis vulgaris. PUVA therapy and UVB therapy within specific time periods prior to randomization are also exclusion criteria. Any topical treatment, except for emollients/medicated shampoo, within 2 weeks prior to randomization is not allowed. Participants should not have current diagnoses of erythrodermic, exfoliative, or pustular psoriasis, or any other skin conditions that may confound the evaluation of psoriasis vulgaris. They should also be generally in good health without any major diseases or conditions that would put them at risk during the study.\n\nOther exclusion criteria include current active tuberculosis or latent tuberculosis, planned sun exposure during the study that may affect psoriasis vulgaris, known or suspected hypersensitivity to the investigational product, current participation in any other interventional trial, and treatment with any non-marketed drug substance within a specific time period prior to randomization. Participants who have previously been randomized in this study or are unlikely to comply with the Clinical Study Protocol are also excluded.\n\nMale participants must agree to use adequate contraception during the study to prevent their partner from becoming pregnant. Participants with known or history of malignancy, live vaccination within a specific time period prior to randomization, or known or suspected hypersensitivity to the investigational product are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and the disease being studied is pancreatic cancer. The ICD-10 code for pancreatic cancer is C25.3. The drugs being used in the trial are docetaxel, liposomal doxorubicin, and enoxaparin. The record also includes the eligibility criteria for participants in the trial, which includes requirements such as having histologically-confirmed pancreatic carcinoma, being at least 18 years old, and having certain blood test results within normal ranges. The record also lists exclusion criteria, which are conditions or factors that would disqualify someone from participating in the trial, such as recent chemotherapy or radiation therapy, certain medical conditions, and pregnancy or breastfeeding.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is functional dyspepsia. The corresponding ICD-10 code for functional dyspepsia is K30. The drug being tested is called z-338. The eligibility criteria for this trial include subjects who have been diagnosed with functional dyspepsia according to the Rome II criteria, and those who experience postprandial fullness and/or early satiety as their most bothersome symptom. There are no specific exclusion criteria mentioned in this sample.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is diabetes. The ICD-10 codes associated with the disease are E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, and E10.65. The drugs being tested are phentermine/topiramate and placebo. The eligibility criteria for this trial include having completed a previous trial called OB-202, using adequate contraception for females of child-bearing potential, providing written informed consent, and being willing and able to comply with scheduled study visits, treatment plan, lab tests, and other study procedures. The exclusion criteria state that subjects who have developed one or more morbidities during the OB-202 trial that would pose a safety concern are not eligible for this trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is epithelial ovarian cancer. The ICDCodes associated with this disease are H18.523, H18.521, H18.522, and H18.529. The drugs being used in the trial are gemcitabine, carboplatin, and paclitaxel. The eligibility criteria for this trial include histologically verified epithelial ovarian cancer, FIGO stage III-IV, presence of measurable disease, and specific size requirements for lesions. There are also exclusion criteria, such as excluding ovarian tumors with low malignant potential, non-epithelial ovarian or mixed epithelial non-epithelial tumors, and patients who have received previous chemotherapy or radiotherapy.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease being studied is \"diabetic neuropathies.\" The corresponding ICDCodes for this disease are \"G60.8.\" The drugs being tested are \"placebo\" and \"[s,s]-reboxetine.\" The eligibility criteria for this trial include being at least 18 years old, having a diagnosis of painful, distal, symmetrical, sensory-motor polyneuropathy due to diabetes for at least 1 year, and having a Pain Visual Analogue Scale score of at least 40 mm. The exclusion criteria include having significant hepatic impairment, having neurological disorders unrelated to diabetic neuropathy, having any other pain or condition that may confound the assessment of neuropathic pain, having amputations other than toes, having a current or recent diagnosis of major depressive disorder or uncontrolled depression, having a history of transient ischemic attack or stroke, and having had a myocardial infraction or unstable angina within the past three months.",
    "The sample from the table represents a phase 2 clinical trial. The trial focuses on patients with cancer, pain, and constipation. The diseases are identified by their corresponding ICD-10 codes. The trial involves the use of two drugs, oxycodone and oxycodone/naloxone. The eligibility criteria for participants include being at least 18 years old, having a diagnosis of cancer, experiencing constipation induced or worsened by opioid medication, and having moderate to severe chronic cancer pain. Participants must also be willing to discontinue their current opioid analgesic routine and take study-specific laxative medication. Other criteria include being willing and able to participate in all aspects of the study, having no contraindications to opioids, and not having certain medical conditions or taking specific medications. The exclusion criteria include a history of hypersensitivity to the study drugs, severe respiratory or pulmonary diseases, significant cardiovascular, renal, hepatic, or psychiatric diseases, abnormal liver or kidney function, brain metastases or spinal cord compression, uncontrolled seizures, increased intracranial pressure, and other factors that may confound the study results. The sample also excludes subjects with ongoing irritable bowel syndrome, diarrhea or opioid withdrawal, recent or planned surgery or radiotherapy that may affect pain or bowel function, recent use of naloxone, and participation in other clinical research studies involving new drugs within 30 days prior to the study entry.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is \"diabetes mellitus, type 2\". The ICDCodes associated with this disease are \"E11.65\", \"E11.9\", \"E11.21\", \"E11.36\", \"E11.41\", \"E11.42\", and \"E11.44\". The drugs mentioned in this sample are \"mk-0893\", \"sitagliptin\", \"metformin\", \"placebo for mk-0893\", \"placebo for sitagliptin\", and \"placebo for metformin\". The eligibility criteria for this sample include specific inclusion and exclusion criteria related to participants with type 2 diabetes mellitus.",
    "The sample from the table represents a clinical trial for the treatment of metastatic breast cancer. The trial is in phase 2/phase 3, indicating that it is in an advanced stage of testing. The disease being studied is metastatic breast cancer, and the corresponding ICD-10 codes for this disease are provided. The drug being investigated in the trial is capecitabine.\n\nThe eligibility criteria for the trial are listed, including the following:\n\n1. Patients must be diagnosed with metastatic breast cancer.\n2. Patients may or may not have received previous treatment with anthracyclines and/or taxanes.\n3. Patients must have a functional ECOG status of less than 2.\n4. Patients must have at least one measurable lesion according to RECIST criteria.\n5. Patients must have a life expectancy of at least 3 months.\n6. Patients must agree to and be able to fulfill the requirements of the entire study.\n\nThere are also exclusion criteria listed, which include:\n\n1. Patients who have previously had severe reactions to therapy with fluoropyrimidines or have a known sensitivity to 5-fluorouracil.\n2. Patients who have previously been treated with capecitabine.\n3. Patients who have had organ transplants.\n4. Patients with other diseases or severe conditions, such as convulsions, central nervous system diseases, psychiatric diseases, severe intellectual impairment, established depression, clinical significant cardiac disease, severe renal impairment, signs of metastasis in the CNS, active infection, history of other neoplasias, and abnormal laboratory values.\n5. Patients who have undergone recent radiotherapy or major surgery.\n6. Patients who lack upper gastrointestinal tract physical integrity or have malabsorption syndrome.\n7. Patients who have received more than two cycles of chemotherapy for the metastatic disease.\n8. Patients who are Her2+ per FISH or +++ Immunohistochemistry.\n\nOverall, the sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial focused on treating metastatic breast cancer with capecitabine.",
    "The sample is a phase 2 trial for the treatment of multiple sclerosis. The trial is specifically targeting patients with relapsing-remitting multiple sclerosis (RRMS) who have a confirmed diagnosis according to the McDonald criteria. The patients must also have prior brain MRI showing lesions consistent with multiple sclerosis. Their Expanded Disability Status Scale (EDSS) score should be between 0.0 and 5.0. \n\nIn terms of medication, the patients must be taking the same dose of a prescribed IFN\u03b2 (Avonex, Betaseron, Rebif) or GA for at least 12 months consecutively at the time of enrollment and continue this treatment throughout the study. If the patients are on Rebif, they must be prescribed 44 \u03bcg by subcutaneous injection three times per week.\n\nThere are also exclusion criteria, such as not having primary progressive, secondary progressive, or progressive relapsing MS. Patients with other chronic diseases of the immune system, malignancies, acute urologic or pulmonary disease, and pregnant or nursing women are also excluded. Additionally, patients who have participated in any other drug, biologic, or device study within 6 months prior to enrollment are not eligible.\n\nIt is important to note that there may be other inclusion/exclusion criteria defined by the protocol.",
    "The sample is a record from a table that contains information about clinical trials. In this particular record, the phase of the trial is Phase 2. The disease being studied is multiple myeloma. The ICD-10 codes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are dexamethasone and bortezomib. \n\nThe record also includes the eligibility criteria for participants in the trial. Inclusion criteria include being diagnosed with symptomatic multiple myeloma based on specific criteria, having measurable disease, having received at least one prior line of chemotherapy for multiple myeloma, and having a certain performance status and creatinine clearance level. Exclusion criteria include previous use of bortezomib with progressive disease, recent use of certain medications or therapies, history of allergic reaction to certain compounds, having peripheral neuropathy of a certain intensity, and being pregnant or breastfeeding.\n\nOverall, this record provides information about the phase, disease, ICD-10 codes, drugs, and eligibility criteria for a clinical trial focused on multiple myeloma.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is gastric cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested in this trial is trastuzumab. The eligibility criteria for this trial include being an adult between 18-75 years old, having metastatic or advanced gastric cancer, experiencing disease progression after prior chemotherapy, having at least 4 weeks since the last chemotherapy treatment, having at least one measurable lesion, and having HER2 overexpression (IHC [2+] or [3+]). The exclusion criteria include not receiving concurrent chemotherapy or immunotherapy, not having brain or meningeal metastases, not having clinically significant cardiac disease, advanced pulmonary disease, or severe dyspnea, not having any other malignancies diagnosed within the last 5 years (except basal cell cancer or cervical cancer in situ), and not being pregnant or breastfeeding for women.",
    "The sample from the table represents a clinical trial with a combination of phase 1 and phase 2. The trial focuses on patients with high-risk hematologic malignancies, including acute leukemia, myelodysplastic syndromes (MDS), Hodgkin's lymphoma, non-Hodgkin's lymphoma, myeloma, and chronic myelogenous leukemia (CML) resistant to STI therapy. The trial aims to evaluate the effectiveness of allogeneic hematopoietic stem cell transplantation (HSCT) as a treatment option for these patients.\n\nThe eligibility criteria for the trial include patients who have already undergone front-line therapy and have a high-risk diagnosis. Patients must also have a related donor who is a 4 antigen match at the HLA-A, B, C, and DR loci. Adequate organ function, including heart, lung, liver, and kidney function, is required for participation. Patients must also have a performance status above a certain threshold and a HCT-CI score within a specific range. Patients must be willing to use contraception if they have childbearing potential and must be able to provide informed consent.\n\nExclusion criteria for the trial include patients with a lower performance status or a higher HCT-CI score. Patients who are HIV positive, have active central nervous system involvement with malignancy, are unable to provide informed consent, or are pregnant are also excluded. Patients with a life expectancy of less than 6 months for reasons other than their hematologic/oncologic disorder are not eligible. Patients who have received certain medications within a specific timeframe or have evidence of another malignancy, excluding skin cancer that only requires local treatment, are also excluded.\n\nThe donor selection process ensures that donors are able to provide infection-free apheresis products for the patient without putting the donor at risk. Donor selection follows regulatory guidelines and program standard operating procedures.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is allergic rhinitis. The ICD-10 codes associated with this disease are 'J30.89', 'J30.9', 'J30.2', 'J30.1', 'J30.5', and 'J30.81'. The drugs being tested in this trial are placebo, allegra, allegra-d, and pf-03654746. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- Male or female subjects aged 19-55 years with allergic rhinitis requiring treatment within the previous 2 years.\n- Subjects that respond to a ragweed nasal allergen challenge at screening.\n\nExclusion Criteria:\n- History of asthma or FEV1 (forced expiratory volume in 1 second) less than 80% predicted.\n- Significant concomitant disease or medications.\n- Symptoms of allergic rhinitis within 2 weeks prior to screening.",
    "The sample is from a table that contains information about clinical trials. In this specific sample, the trial is in phase 2 and is focused on the disease called polycythemia vera. The disease is identified by the ICD-10 code \"D45\". The drug being tested in this trial is erlotinib. The sample also includes the eligibility criteria for the trial, which includes specific requirements for the diagnosis of polycythemia vera, hemoglobin levels, presence of a specific mutation, and other factors. There are also exclusion criteria listed, such as having an active malignancy or significant cardiac disease.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The diseases being studied are nausea and vomiting. The ICDCodes associated with these diseases are \"R11.0\", \"R11.11\", \"R11.2\" for nausea and \"R11.10\", \"R11.12\", \"R11.14\", \"R11.11\", \"K91.0\", \"O21.2\", \"O21.8\" for vomiting. The drugs being used in the trial are fosaprepitant dimeglumine, 5-ht3 ra, dexamethasone, and rescue medication. The eligibility criteria for participants include being diagnosed with breast or gynecological cancer, receiving specific types of chemotherapy, experiencing vomiting or retching after the first cycle of chemotherapy, and meeting certain medical status requirements. There are also exclusion criteria listed, such as the use of certain medications, recent radiation therapy, pregnancy or breastfeeding, and other medical conditions.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating melanoma, specifically recurrent or unresectable stage III disease, stage IV disease, or non-choroidal origin melanoma. The trial involves the use of two drugs, sorafenib tosylate and temsirolimus. The eligibility criteria for participants include having histologically or cytologically confirmed melanoma, accessible tumor for biopsy, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, normal bilirubin and creatinine levels, not being pregnant or nursing, and using effective contraception during and after the study. Other criteria include not having a history of allergic reactions to similar compounds, not having uncontrolled hypertension or bleeding diathesis, and not having conditions that impair the ability to swallow pills. The sample also includes information about prior treatments, concurrent medications, and various health parameters that need to be met for participation in the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on various diseases related to autism spectrum disorders. The diseases listed include autistic disorder, autism, Asperger's disorder, Asperger syndrome, and pervasive developmental disorder - not otherwise specified (PDD-NOS). The corresponding ICD-10 codes for these diseases are also provided.\n\nThe trial involves the use of drugs, specifically memantine hydrochloride (HCl) and placebo capsules. The eligibility criteria for participants in the trial are outlined, including requirements such as completing a lead-in study, having a knowledgeable caregiver, having normal physical examination results, and being able to speak and understand English (or their native language if accommodated by the site).\n\nThere are also exclusion criteria, which include having concurrent medical conditions that may interfere with the study, having a significant risk of suicidality, having a history of malignancy or other significant diseases, and not using or willing to use contraception for female patients of child-bearing potential.\n\nAdditionally, the sample mentions prohibited concomitant medications, the need for suitability for the study as determined by the investigator, and the exclusion of employees or immediate relatives of Forest Laboratories, Inc., its affiliates or partners, or the study center.\n\nOverall, the sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for participants in a clinical trial focused on autism spectrum disorders.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is non-small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are carboplatin, vinorelbine, and panitumumab. \n\nThe eligibility criteria for this trial include the following inclusion criteria:\n- The patient must have histologically confirmed metastatic (stage IV) NSCLC.\n- The disease must be measurable according to RECIST v.1.0 2009.\n- The primary tumor or metastatic tissue must be KRAS, BRAF, and PI3K wild type.\n- The patient must be at least 18 years old.\n- The patient's performance status (PS) must be less than 2.\n- The patient must have adequate organ function, including specific requirements for hematology, hepatic function, renal function, and metabolic function.\n- The patient must consent to translational research studies and provide written informed consent.\n\nThe exclusion criteria for this trial include:\n- The patient must not have clinically significant cardiovascular disease, active severe infections, or other concurrent diseases.\n- The patient must not have known CNS metastasis.\n- The patient must not have received prior chemotherapy for metastatic disease.\n- The patient must not have an indication for radiation therapy or have received prior radiotherapy within 30 days before treatment start.\n- The patient must not have had other malignant diseases within 5 years prior to inclusion, except for basal cell squamous carcinoma of the skin and cervical carcinoma-in-situ.\n- The patient must not have received other experimental therapy within 30 days prior to treatment initiation.\n- The patient must not have a history of interstitial lung disease or evidence of it on baseline chest CT scan.\n- The patient must not be pregnant or breastfeeding, or planning to become pregnant within 6 months after the end of treatment.\n- The patient must be willing to use highly effective methods of contraception during treatment and for 6 months after the end of treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease mentioned is \"stable coronary artery disease,\" and its corresponding ICDCodes are ['I25.84', 'I25.41', 'I25.42', 'Z98.61', 'Q24.5', 'T46.3X6S', 'I25.82']. The drugs involved in this trial are ticagrelor, clopidogrel, and aspirin. The eligibility criteria for this trial include specific inclusion and exclusion criteria. Inclusion criteria involve patients with documented stable Coronary Artery Disease, while exclusion criteria include a history of Acute Coronary Syndromes within 12 months, any acute or chronic unstable condition in the past 30 days, increased bleeding risk, and a history of intolerance or allergy to aspirin or clopidogrel.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of bacterial infections. The diseases being studied are listed as \"infections, bacterial\" and are associated with specific ICD-10 codes. The drugs being used in the trial are \"retapamulin\" and \"placebo\". \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being between the ages of 18 and 65, having a specific body weight and body mass index range, being able to understand and comply with the requirements of the study, and providing written informed consent. Exclusion criteria include having a negative nasal culture for S. aureus, concurrent treatment with antimicrobials, recent nasal surgery, and evidence of certain medical conditions or abnormalities.\n\nOverall, the sample provides information about the phase, diseases, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on chronic lymphocytic leukemia. The trial involves the drugs bendamustine and rituximab. The eligibility criteria for participants include having confirmed chronic lymphocytic leukemia, experiencing certain disease-related symptoms, not having received prior therapy for CLL, being over 65 years old, having a life expectancy of more than 1 year, and having a performance status better than or equal to 2 according to the ECOG scale. Participants must also have normal organ and marrow function. The record also includes exclusion criteria, such as previous chemotherapy or radiotherapy for CLL, not receiving any other investigational agents, and having certain medical conditions or illnesses.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and the disease being studied is non-Hodgkin's lymphoma. The ICD-10 codes associated with this disease are listed as well. The drugs being used in the trial include rituximab, etoposide, methylprednisolone, cytarabine, and cisplatin. The eligibility criteria for this trial are also provided, including inclusion and exclusion criteria. Inclusion criteria include a clinical diagnosis of aggressive non-Hodgkin's lymphoma, being refractory to first-line chemotherapy or having relapsed, expression of CD20 on lymphoma cells, and having measurable lesions on imaging studies. Exclusion criteria include not meeting certain blood cell count requirements, having circulating lymphoma cells above a certain threshold, having hepatic dysfunction, renal insufficiency, cardiac dysfunction or arrhythmia, severe infection, CNS involvement, other malignancies, or being pregnant or breastfeeding.",
    "The sample from the table represents a phase 2 clinical trial for lung cancer. The trial is focused on patients who have a history of completely resected non-small cell lung cancer (NSCLC) and have undergone adjuvant/neoadjuvant chemotherapy with a platinum-based regimen. The patients must have confirmed recurrence of NSCLC after curative therapy with surgery and adjuvant/neoadjuvant chemotherapy. They should also have measurable disease according to RECIST criteria and an ECOG Performance Score of 0-2.\n\nOther inclusion criteria include expected survival of more than 12 weeks, adequate bone marrow function, adequate renal function, and adequate hepatic function. The patients must have recovered from any prior surgery, radiotherapy, or other antineoplastic therapy. They must also provide signed informed written consent and agree to use effective contraception during the study.\n\nExclusion criteria for the trial include patients who are amenable to a \"curative intent\" therapeutic approach, those with an active infection or fever, and those with active CNS metastases. Patients with a prior malignancy within the past 5 years, except for specific cases, are also excluded. Other exclusion criteria include hypersensitivity to the study drugs, concurrent or recent investigational therapy, significant peripheral neuropathy, pregnancy or lactation, and any other medical condition that may interfere with the patient's ability to participate in the study or interpret the results.\n\nIt is important to note that this is just a sample from the table, and there may be additional information and criteria present in the complete dataset.",
    "The sample from the table is for a phase 2 trial for rheumatoid arthritis. The sample includes information about the diseases, icd-10 codes, drugs, and eligibility criteria. The disease mentioned is rheumatoid arthritis, and the icd-10 codes associated with it are M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, and M06.019. The drugs mentioned in the sample are azd5672, etanercept, and placebo. The eligibility criteria for inclusion include a diagnosis of rheumatoid arthritis with active disease, a certain number of swollen and tender/painful joints, and elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) levels. Additional criteria include a positive rheumatoid factor, radiographic erosion, or presence of serum anti-cyclic citrullinated peptide antibodies. The exclusion criteria include the presence of other inflammatory diseases or chronic pain disorders such as fibromyalgia and chronic fatigue syndromes.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 2 and focuses on two diseases, atrial fibrillation and thromboembolism. The corresponding ICD-10 codes for these diseases are provided as well. The trial involves the use of two drugs, edoxaban (du-176b) and warfarin. The eligibility criteria for participants are also listed, including age requirements, the need for written consent, and specific medical conditions. The exclusion criteria mention certain medical conditions and contraindications that would disqualify potential participants from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include chronic myeloproliferative disorders, graft versus host disease, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases. The corresponding ICDCodes for these diseases are also provided.\n\nThe drugs being used in the trial are methotrexate, sirolimus, and tacrolimus. The eligibility criteria for the trial are listed in a structured format, including disease characteristics, patient characteristics, prior concurrent therapy, and other factors.\n\nThe disease characteristics include specific requirements for the diagnosis of hematological malignancy and restrictions on certain types of leukemia and myelodysplastic syndromes. The patient characteristics include age, performance status, life expectancy, and various health parameters such as hematopoietic, hepatic, renal, cardiovascular, and pulmonary conditions.\n\nThe prior concurrent therapy section outlines restrictions on biologic therapy, chemotherapy, radiotherapy, and other treatments. Finally, there are additional criteria related to pregnancy, HIV status, systemic infection, hypersensitivity to certain antibiotics, and prior intolerance or unresponsiveness to sirolimus.\n\nOverall, this sample provides a snapshot of the information stored in the table, including the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 2. The disease being studied is hypertension. The ICD-10 codes associated with the disease are I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, and I10. The drugs being tested are pl3994 and placebo. The sample also includes the eligibility criteria for the trial. The inclusion criteria state that subjects must have had a diagnosis of essential hypertension for at least 1 year, be on a stable dose of 1-3 antihypertensive medications for at least 3 months, and have a systolic blood pressure between 100 and 150 mmHg and a diastolic blood pressure not exceeding 105 mmHg. The exclusion criteria state that subjects must not weigh more than 100 kg or less than 50 kg, and should not have any significant medical conditions or abnormal safety laboratory results that would place them at significant risk, as determined by the investigator.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 2 and phase 3. The disease mentioned is \"gastroesophageal reflux disease\". The ICDCodes associated with this disease are \"K21.9\", \"K21.00\", and \"K21.01\". The drugs being used in the trial are \"rabeprazole 20mg, placebo dinner and bedtime\", \"rabeprazole 20 mg two times, placebo at bedtime\", and \"rabeprazole 20mg, placebo dinner, low dose tricyclic antidepressant\". \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The participant must currently be treated with a PPI (Proton Pump Inhibitor) but still experience GERD (gastroesophageal reflux disease) symptoms, such as heartburn, at least 2 times per week.\n\nExclusion Criteria:\n- The participant must not have a known allergy or intolerance to TCA (Tricyclic Antidepressant).\n- The participant must not have a history of serious arrhythmia or use of anti-arrhythmics.\n- The participant must not have a history of seizures.\n- The participant must not have significant co-morbidities in various body systems.\n- The participant must not have evidence or history of drug abuse within the past 6 months.\n- The participant must not have certain conditions like erosive esophagitis, esophageal ulceration, peptic stricture, Barrett's esophagus, adenocarcinoma of the esophagus, or a history of esophagogastric surgery.\n- The participant must not have gastric or duodenal lesions (ulcer, tumor, etc.).\n- Women who are pregnant or of childbearing age and not on contraception are excluded.\n- Patients who are unwilling or unable to provide informed consent are excluded.\n- Patients with insulin-dependent diabetes are excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is esophageal cancer. The ICDCodes associated with this disease are \"K22.2\", \"K22.81\", \"Q39.4\", \"P78.83\", \"I85.00\", \"I85.01\", and \"I85.10\". The drugs being used in the trial are carboplatin and pemetrexed. The eligibility criteria for this trial include specific disease characteristics, such as the type and stage of esophageal cancer, as well as patient characteristics, such as performance status, blood counts, organ function, and previous medical history. Prior concurrent therapies, including chemotherapy and radiotherapy, are also mentioned in the criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are fallopian tube cancer, primary peritoneal cavity cancer, recurrent ovarian epithelial cancer, and stage IV ovarian epithelial cancer. The ICDCodes associated with these diseases are provided as well. The drug being used in the trial is erlotinib hydrochloride. The eligibility criteria for participants in this trial include having a confirmed diagnosis of ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer, having measurable disease, having received a platinum-containing chemotherapy regimen for primary disease, and meeting various health and medical requirements. There are also exclusions and other criteria listed.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the disease \"amyotrophic lateral sclerosis\" (ALSO). The corresponding ICD-10 code for ALSO is \"G12.21\". The drug being studied is \"zinc and copper\". \n\nThe sample also includes the eligibility criteria for participants in the trial. The inclusion criteria state that participants must be between the ages of 18 and 85, clinically diagnosed with ALSO according to the El Escorial criteria, have an ALSO-FRS score greater than 25, and be capable of providing informed consent and complying with trial procedures. \n\nThe exclusion criteria list conditions that would disqualify a participant from the trial, such as having a forced vital capacity (FVC) below 50%, a history of liver disease or severe renal failure, elevated creatinine levels, intolerance to zinc or copper, evidence of motor neuron disease for more than 5 years, or any other co-morbid condition that would make completing the trial unlikely. Other exclusion criteria include being pregnant or breastfeeding (for females), unwillingness to use birth control (for females of childbearing age), taking other trial medications, having a history of significant anemia, elevated levels of zinc at baseline, or copper levels below normal at baseline.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied include male breast cancer, stage II breast cancer, stage IIIA breast cancer, and stage IIIB breast cancer. The corresponding ICDCodes for these diseases are also listed. The drugs being used in the trial include doxorubicin hydrochloride, cyclophosphamide, paclitaxel, tamoxifen citrate, and aromatase inhibition therapy. The eligibility criteria for participants in this trial are listed in detail, including requirements related to the type and stage of breast cancer, previous surgeries, laboratory values, cardiac health, medication use, and pregnancy status.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is phase 2. The diseases being studied are asthma and GERD (gastroesophageal reflux disease). The corresponding ICD-10 codes for these diseases are provided. The drugs being tested in this trial are esomeprazole and a placebo. The sample also includes the eligibility criteria for participants in the trial. The inclusion criteria state that adults with a diagnosis of asthma for at least 6 months, experiencing symptoms of asthma during the run-in period, and having symptoms related to GERD are eligible to participate. The exclusion criteria specify that patients with clinically relevant abnormalities, a smoking history of at least 10 pack-years, or previous surgery on the esophagus or stomach are not eligible to participate.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease of hypertension. The ICD-10 codes associated with this disease are ['I15.0', 'I97.3', 'K76.6', 'P29.2', 'G93.2', 'H40.053', 'I10']. The drugs being studied in this trial are fimasartan, amlodipine, and a placebo. The eligibility criteria for participants are listed under inclusion and exclusion criteria. Inclusion criteria include subjects who have agreed to participate, are aged 20 to 75 years, have essential hypertension with specific blood pressure measurements, and are able to understand and cooperate throughout the study. Exclusion criteria include severe hypertension, secondary hypertension, abnormal renal or liver function, hypokalemia or hyperkalemia, certain surgical or medical conditions, severe diabetes or heart disease, significant arrhythmias, certain cardiac or cerebrovascular conditions, wasting or autoimmune diseases, severe or malignancy retinopathy, hepatitis B or C or HIV positive, history of alcohol or drug abuse, significant blood pressure differences between arms, allergic reaction to angiotensin II antagonist, chronic inflammation disease, recent history of malignant tumor, childbearing or breastfeeding women, women planning to become pregnant, recent medication use or participation in another clinical trial, and subjects deemed unsuitable by the investigator.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"type 2 diabetes\". The corresponding ICD-10 codes for this disease are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']. The trial involves two drugs, namely \"mci-196\" and a placebo of the \"mci-196\" tablet. The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include patients with fasting blood glucose levels between 130mg/dL and 200mg/dL and HbA1c levels of 7.0% or above. Exclusion criteria include patients with serious cardiac, hepatic, or renal complications, serious diabetic complications, complete biliary obstruction or ileus, and pregnant, lactating, or potentially pregnant patients who cannot agree to contraception.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of proliferative diabetic retinopathy and macular edema. The diseases are described using their names and corresponding ICD-10 codes. The drug being tested in this trial is ranibizumab. The eligibility criteria for participants include having specific pre-PRP protocol tests and being able to provide written informed consent. The age requirement is 21 years or older. The inclusion criteria also specify that the patients must be previously untreated PDR patients with high-risk characteristics who develop edema within 7-14 days after PRP therapy. The exclusion criteria include pregnancy, any condition that may pose a significant hazard to the subject, participation in another simultaneous medical investigation or trial, pre-PRP clinically significant diabetic macular edema, neovascularization of the iris or neovascular glaucoma, increased central foveal thickness for any other reason, concurrent macular diseases that could confound the results, prior vitrectomy in the study eye, and prior treatment with specific intravitreal injections.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of cancer. The specific type of cancer is not mentioned. The trial uses a combination of drugs including \"gsk1120212\", \"gemcitabine\", and a placebo. The eligibility criteria for participants are listed, including age requirement, confirmed diagnosis of metastatic adenocarcinoma of the pancreas, performance status score, prior treatment toxicities, organ function, ability to swallow medication, and absence of certain medical conditions. The exclusion criteria include prior systemic therapy for metastatic pancreatic adenocarcinoma, history of other malignancies (with exceptions), pre-existing medical or psychiatric disorders that could interfere with the study, history of lung disease or retinal issues, presence of certain metastases or spinal cord compression, and history of recent coronary syndromes or procedures.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"adenocarcinoma of the prostate,\" \"hormone-refractory prostate cancer,\" \"recurrent prostate cancer,\" and \"stage IV prostate cancer.\" The corresponding ICDCodes for these diseases are provided as well.\n\nThe drug being used in the trial is \"eribulin mesylate.\" The eligibility criteria for participants in this trial include having a confirmed diagnosis of adenocarcinoma of the prostate, progressive metastatic disease or stable metastatic disease with rising PSA, previous treatment with bilateral orchiectomy or other primary hormonal therapy, and evidence of treatment failure.\n\nOther criteria include specific requirements for hormone levels, performance status, bone marrow function, liver function, kidney function, and the use of effective contraception for fertile patients. The criteria also mention the allowed use of certain chemotherapy regimens, the time since prior chemotherapy or radiotherapy, and the confirmation of disease progression.\n\nExclusion criteria are also listed, which include various medical conditions, prior malignancies, concurrent medical illnesses or infections, concurrent use of certain medications, prior use of specific radioisotopes, and concurrent use of certain therapies.\n\nOverall, this sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"prostatic neoplasms\" and its corresponding ICDCodes are ['B38.81', 'N42.31', 'Z87.430', 'N40.0', 'N40.1']. The drug mentioned is \"tak-700\". The eligibility criteria for this trial include various conditions such as being male and at least 18 years old, having confirmed prostate adenocarcinoma with metastatic, progressive disease, having undergone orchiectomy or receiving luteinizing hormone-releasing hormone analogue therapy, and meeting specific laboratory values and physical examination results. There are also exclusion criteria listed, such as known hypersensitivity to TAK-700 or related compounds, prior therapy with aminoglutethimide or ketoconazole, prior chemotherapy for prostate cancer, and various other medical conditions or psychiatric illnesses that may affect life expectancy or make it difficult to follow the protocol.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on various diseases, including hematologic diseases, acute-graft-versus-host disease, leukemia, non-hodgkin lymphoma (nhl), and hodgkin lymphoma. The diseases are associated with specific ICD-10 codes. The trial involves the use of drugs such as sirolimus, mycophenolate mofetil (mmf), carmustine, etoposide, cyclophosphamide (cyclo, cy), and ftbi. The eligibility criteria for participants are listed, including age ranges, specific types and stages of leukemia, myelodysplastic syndrome, myeloproliferative disorders, and lymphomas. Other criteria include performance status, donor compatibility, willingness to take oral medications, and signing an informed consent document. The exclusion criteria include prior stem cell transplants, HIV infection, pregnancy or lactation, uncontrolled active infection, certain abnormal laboratory values, and other medical conditions.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of rectal adenocarcinoma and stage II/III rectal cancer. The trial involves the use of drugs such as capecitabine, fluorouracil, leucovorin calcium, and oxaliplatin. The eligibility criteria for the trial include having locally advanced, non-metastatic primary T3 or T4 adenocarcinoma of the rectum, absence of tumor outside of the pelvis, and not having undergone intra-operative radiotherapy or brachytherapy treatment to the pelvis. Other criteria include specific tumor characteristics, Eastern Cooperative Oncology Group (ECOG) performance status, certain blood test results, and absence of certain medical conditions. Patients must also agree to use contraception during the study and not be pregnant or breastfeeding.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"lupus nephritis.\" The ICD-10 codes associated with this disease are \"B26.83,\" \"A51.44,\" \"N11.8,\" \"N11.9,\" and \"N12.\" The drugs being studied in this trial are \"mycophenolate sodium,\" \"prednisone,\" and \"methylprednisolone.\" \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion criteria:\n- Male or female patients with systemic lupus erythematosus (SLE) who meet at least 4 classification criteria.\n- Patients must be aged 18 years or older.\n- Patients must have proliferative lupus nephritis classified as ISN/RPS class III or IV.\n- Patients must have had a renal biopsy within the last 24 months prior to study entry.\n- Proteinuria must be present, defined as >0.5 gram urine protein per gram urine creatinine at screening and baseline.\n- Clinical activity must be present, defined by one or more of the following changes in renal function: serum creatinine >1.0 mg/dl (88.4 \u03bcmol/l), microscopic hematuria defined as >5 red cells per high power field, and presence of cellular casts.\n\nExclusion criteria:\n- Patients with calculated creatinine clearance <30 ml/min (using the Cockcroft-Gault formula).\n- Patients who have received an intravenous corticosteroid bolus during the last 3 months.\n- Patients who have received oral or intravenous cyclophosphamide during the last 3 months.\n- Patients who have received mycophenolate mofetil (MMF) within the preceding 3 months.\n- Use of any antibody therapy within the past 6 months.\n- Pregnant or nursing women, or women of child-bearing potential who are planning to become pregnant or are not willing to use effective contraception throughout the study and for one month after the end of the study.\n- Use of other investigational drugs within 1 month of enrollment (except for antibodies, which is within 6 months of enrollment).\n- History of hypersensitivity to any of the study drugs or drugs with similar chemical structures.\n- History of malignancy of any organ system, treated or untreated, within the past 5 years, except for localized basal cell carcinoma of the skin.\n\nIt is important to note that there may be additional inclusion/exclusion criteria defined by the protocol of the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are gastroesophageal reflux disease, heartburn, and regurgitation. The corresponding ICDCodes for these diseases are K21.9, K21.00, K21.01, and R12. The drugs being tested in this trial are lesogaberan (azd3355) and placebo. The eligibility criteria for this trial include providing informed consent, having at least 6 months history of GERD, and being continuously treated with daily optimized unchanged PPI therapy for the last 4 weeks. The exclusion criteria include patients who have not experienced any improvement in GERD symptoms during PPI treatment, those who have undergone upper gastrointestinal tract surgery, and individuals with certain conditions or diseases such as heart disease, angina, seizure disorders, congestive heart failure, liver disease, kidney disease, lung disease, or cancer.",
    "The sample from the table is for a clinical trial that is in phase 2/phase 3. The trial is focused on studying the effectiveness of a drug called sodium valproate in treating neuralgia and neuropathic peripheral pain. The diseases included in the trial are neuralgia and neuropathic peripheral pain, which are identified by the ICD-10 codes G50.0, M54.81, B02.22, and M79.2. The eligibility criteria for participants include having peripheral neuropathic pain and providing signed written informed consent. However, individuals with central neuropathic pain or current or past hepatic disease are excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 2, and the disease being studied is thyroid cancer. The icd-10 codes associated with this disease are 'C73', 'D34', 'D44.0', and 'Z85.850'. The drug being investigated is imatinib. \n\nThe eligibility criteria for this trial include:\n- Patients must have histologically confirmed anaplastic thyroid carcinoma with measurable disease.\n- Patients with brain metastases are eligible if they have been stable for at least six weeks post-radiation therapy.\n- Patients must be at least 18 years old and have a Karnofsky performance status (KPS) of > 70%.\n- Patients must have a life expectancy of at least 12 weeks.\n- Hematologic requirements include ANC (absolute neutrophil count) of 1,500 mm3, hemoglobin level of 8.0 g/dl, and platelet count of 100,000/mm3.\n- Patients must have a normal serum calcium level within normal limits documented within 14 days prior to registration.\n- Hepatic function must be adequate, with a serum bilirubin level not exceeding 1.5 times the institutional upper limit of normal (ULN), and ALT and AST levels less than 2.5 times ULN.\n- Patients must have a serum creatinine level less than 1.5 times the institutional upper limits of normal (adjusted for age) within 14 days of registration.\n- Women of childbearing potential must have a negative pregnancy test before receiving any study drug, and effective contraception must be practiced during the study and for at least six months after the last dose of study drug.\n- All patients must sign an informed consent prior to enrollment.\n- Patients must not have a prior history of non-thyroid malignancy, except for adequately treated skin cancer or in situ cervical carcinoma, or any other cancer in complete remission for at least two years.\n- Prior chemotherapy, chemoradiation, radiation therapy, or surgery must have been completed at least 28 days prior to registration, and all toxicities must have resolved. Patients who have been treated with nitrosourea or mitomycin C must be off these drugs for at least 6 weeks prior to registration.\n- Patients must be able to take oral medications.\n\nThe exclusion criteria for this trial include:\n- Anaplastic thyroid cancer that does not overexpress PDGF receptors or c-Abl by immunohistochemistry.\n- Any medical or psychiatric illness that would compromise the patient's ability to tolerate the treatment regimen.\n- No concurrent radiotherapy or chemotherapy may be given to the patient during the administration of the study drug.\n- Pregnant or lactating women, women of childbearing potential with a positive pregnancy test at baseline, or sexually active females not using reliable contraceptive methods while on the study and for at least six months after chemotherapy.\n- Sexually active males not using reliable contraceptive methods while on the study and for at least six months after chemotherapy.\n- Patients with malabsorption syndromes.\n- Serious concurrent infections.\n- Patients who have had previous organ allografts.\n- Prisoners.\n- Patients with chronic liver disease (i.e., chronic active hepatitis and cirrhosis).\n- Patients with a known diagnosis of human immunodeficiency virus (HIV) infection.\n- Patients who have had major surgery within 2 weeks of study entry.\n- Patients with grade III/IV cardiac problems as defined by the New York Heart Association Criteria (i.e., congestive heart failure, myocardial infraction within 6 months of study entry).",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of chronic hepatitis C. The trial includes patients who are at least 18 years old and have had hepatitis C for at least 6 months. The patients must have genotype 1 of the hepatitis C virus and quantifiable levels of HCV RNA. They should not have received any previous treatment with interferon. The trial also has specific requirements for the patients' body mass index (BMI) and weight. Female patients of child-bearing potential and male patients with female partners of child-bearing potential must use two forms of effective non-hormonal contraception. \n\nThere are also exclusion criteria, which include pregnant or lactating women, patients with decompensated liver disease or impaired liver function, patients with cirrhosis or incomplete/transition to cirrhosis, patients with non-hepatitis C chronic liver disease, patients with hepatitis B or HIV infection, patients with a history of neoplastic disease within the last 5 years (except for localized or in situ carcinoma of the skin), patients with pre-existing renal disease (except for nephrolithiasis) or severe cardiac disease, and patients with a history of drug or alcohol abuse within the last year (except for cannabinoid use).",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on pancreatic cancer. The ICD-10 code for pancreatic cancer is C25.3. The drug being studied is vorinostat. The sample also includes the eligibility criteria for the trial, which include factors such as the patient's age, performance status, proof of adenocarcinoma of the pancreas, and staging with physical exams and imaging tests. The sample also lists exclusion criteria, such as prior abdominal radiotherapy, participation in other experimental drug studies, and certain medical conditions or infections.",
    "The sample is a phase 2 trial for the treatment of xerostomia and Sj\u00f6gren's syndrome. The trial is focused on the drug rebamipide. The eligibility criteria for inclusion in the trial include being diagnosed with Sj\u00f6gren's syndrome, being 20 years or older, experiencing dry mouth and decreased salivation. Exclusion criteria include having dry mouth due to a cause other than Sj\u00f6gren's syndrome, inability to perform the Saxon test, recent use of rebamipide, pregnancy or lactation, hypersensitivity to rebamipide, recent use of any other investigational drug, and being deemed inappropriate for inclusion by the investigator.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is prostate cancer. The ICDCodes associated with this disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drugs being used in the trial are docetaxel and zd1839. The eligibility criteria for inclusion in the trial include having clinical stage T2b-3 or serum PSA>20 ng/ml or Gleason sum score 8-10 for prostate carcinoma, having specific conditions for clinical T2 patients, having an ECOG performance status of 0, 1, or 2, having adequate hematological, liver, and renal function, having peripheral neuropathy below grade 1, and being able to tolerate oral medications. The exclusion criteria include concurrent or prior treatment with radiation, cytotoxic, or biologic therapy for prostate cancer, major surgery within four weeks, and prior hormonal therapy except for finasteride for obstructive voiding symptoms. Additionally, evidence of metastatic disease must be confirmed by physical examination, computed tomography of the abdomen and pelvis within 45 days, and a bone scan within 60 days of signing informed consent.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is ovarian cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are genexol\u00ae-pm 260mg/m2 plus carboplatin 5 auc and genexol\u00ae 175mg/m2 plus carboplatin 5 auc. \n\nThe eligibility criteria for this trial include:\n- Subjects must be 18 years or older.\n- Subjects must provide written informed consent.\n- Subjects must have histologically or cytologically confirmed unresectable or metastatic epithelial cancer of the exocrine pancreas. High-quality contrast-enhanced CT scanning is required to evaluate resectability. Measurable disease is not required.\n\nThe exclusion criteria for this trial include:\n- Subjects who have received prior radiation therapy (XRT) for pancreatic cancer, unless progression was documented after XRT and 6 weeks have elapsed between completion of XRT and start of trial medication.\n- Subjects who have had systemic treatment such as chemotherapy or immunotherapy for pancreatic cancer, except for prior use of chemotherapy for radiation sensitization or gemcitabine given in the adjuvant setting.\n- Subjects who have had a major surgery within 2 weeks prior to the screening/baseline visit.",
    "The sample provided is for a phase 2 clinical trial focusing on postherpetic neuralgia (PHN), a condition characterized by persistent pain following the healing of a herpes zoster skin rash. The trial aims to evaluate the effectiveness of the drugs retigabine and placebo in managing PHN pain. \n\nThe inclusion criteria for participants in this sample include being able to provide informed consent, being male or female between the ages of 18 and 85, having PHN for more than 6 months after the healing of the rash, and having a pain score that qualifies at both the screening and randomization stages.\n\nOn the other hand, the exclusion criteria state that individuals with other significant pain that may interfere with the assessment of PHN pain, those who have undergone previous neurolytic or neurosurgical therapy for PHN, and those with evidence of progressive central nervous system diseases or significant psychiatric or neuropsychiatric disorders are not eligible to participate. Additionally, individuals with clinically significant abnormalities in physical examination, vital signs, electrocardiogram (ECG), or laboratory tests at the screening visit are also excluded.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on prostate cancer. The ICD-10 codes associated with the disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drugs being studied in the trial are pi-88, docetaxel, and prednisone. The sample also includes the eligibility criteria for the trial, which include specific requirements for patients to be included or excluded from the study. These criteria cover factors such as the type and stage of the disease, previous treatments, medical history, and laboratory values.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on Alzheimer's disease. The ICD-10 codes associated with the disease are G30.8, G30.9, G30.0, and G30.1. The drugs being tested in the trial are pf-04494700 and placebo. The eligibility criteria for participants include having a Mini Mental State Exam (MMSE) score between 14-26, being on a stable dose of acetylcholinesterase inhibitors for at least 4 months prior to randomization. The exclusion criteria include having any neurological, psychiatric, or other illness that could contribute to non-Alzheimer's dementia, a history of familial AD or early onset AD associated with genetic mutations, diabetes mellitus Type 1 or Type 2, and a history or symptoms of autoimmune disorders.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 2. The disease being studied is lung cancer. The ICD-10 codes associated with the disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are erlotinib hydrochloride, pemetrexed disodium, and docetaxel. The eligibility criteria for the trial are listed, including requirements such as a pathologic diagnosis of stage IIIB or IV non-small cell lung cancer, progression following previous treatment with erlotinib, measurable lesions, specific performance status, and various laboratory values within certain ranges. The sample also includes exclusion criteria, such as active central nervous system disease, prior treatment with certain chemotherapy regimens, and pregnancy or breastfeeding.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on diseases such as gout, hyperuricemia, arthritis, joint disease, and renal insufficiency. The corresponding ICD-10 codes for these diseases are also listed. The drugs being studied in the trial include a placebo and two doses of ulodesine (bcx4208). \n\nThe eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being between the ages of 18 and 70, having a documented diagnosis of gout, moderate renal insufficiency, and being willing to take allopurinol 200 mg every day. There are also specific criteria for female and male participants regarding sexual abstinence and contraception.\n\nExclusion criteria include being unable to tolerate allopurinol, having prior participation in a clinical study with BCX4208, having unstable cardiac disease or poorly controlled hypertension, and having certain abnormal laboratory values or medical conditions. The list also includes restrictions on the use of certain medications, vaccines, and substances, as well as a history of allergies, infections, cancer, and substance abuse.\n\nOverall, this sample provides a snapshot of the phase 2 trial, including the diseases being studied, the drugs being tested, and the criteria for participant eligibility.",
    "The sample from the table represents a phase 2 clinical trial for lung cancer. The disease being studied is extensive stage small cell lung cancer, which has been confirmed through histological or cytological examination. The trial allows patients with measurable or evaluable disease, including those with pleural effusions. Patients with stable brain metastases are also eligible for the study.\n\nThe trial is open to patients who are 18 years or older and have an ECOG performance status of 0-2. The expected life expectancy of participants should be more than 2 months. Certain hematopoietic, hepatic, and renal criteria must be met, such as having a minimum absolute neutrophil count and platelet count, as well as specific levels of bilirubin and creatinine.\n\nOther eligibility criteria include not being pregnant or nursing, having a negative pregnancy test, and using effective contraception for fertile patients. Participants should be able to swallow capsules and should not have had any other concurrent or prior malignancy within the past 5 years, except for inactive nonmelanomatous skin cancer or carcinoma in situ of the cervix. Additionally, participants should not have any other serious medical or psychiatric illness that would hinder their ability to comply with the study requirements.\n\nRegarding prior concurrent therapy, the use of biologic therapy and endocrine therapy is not specified. However, participants should not have received any prior chemotherapy. Prior radiotherapy for brain metastasis is allowed, but no other prior or concurrent radiotherapy is permitted. The use of surgery is not specified in this trial.\n\nOverall, this sample represents the eligibility criteria and characteristics of patients who can participate in a phase 2 clinical trial for lung cancer, specifically extensive stage small cell lung cancer.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"severe sepsis\". The ICD-10 codes associated with this disease are \"R65.20\" and \"R65.21\". The drugs being studied in this trial are \"talactoferrin alfa\" and \"placebo\". The eligibility criteria for participants are listed, including age, onset of severe sepsis within the previous 24 hours, receiving antibiotic therapy, signed informed consent, and ability to take medication orally or through a feeding tube. The exclusion criteria are also provided, which include factors such as recent use of investigational medication, pregnancy or breastfeeding, severe congestive heart failure, severe HIV infection, severe burns, high dose immunosuppressants, imminent death, life expectancy less than 6 months due to concurrent illness, severe hypoxic encephalopathy or persistent vegetative state, severe liver disease, and lack of commitment to providing full, aggressive life support by the patient, legal representative, or primary physician.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease being studied is Attention Deficit Hyperactivity Disorder (ADHD), and the corresponding ICDCodes for this disease are F90.2, F90.8, F90.9, F90.0, and F90.1. The drug being used in the trial is extended-release methylphenidate (Ritalin LA) in combination with behavior therapy. \n\nThe eligibility criteria for this trial are as follows:\n- Children of both genders, aged 6-12 years old\n- Written informed consent from the parent and the patient (if over 7 years old)\n- Diagnosis of ADHD\n- Age-appropriate cognitive functioning\n- All patients who had at least one post-baseline cytogenetic assessment in the core study can enter the observation phase.\n\nThere are also exclusion criteria, which include:\n- History of malignant neoplasm (cancer)\n- History of seizures, except for childhood febrile seizures\n- Hyperthyroidism\n- Concurrent medical condition that may interfere with the study\n\nIt is important to note that there may be additional inclusion/exclusion criteria defined by the protocol of the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of acute, uncomplicated human influenza. The trial involves the use of the drugs peramivir and placebo. The eligibility criteria for participants are listed, including age, positive influenza test results, presence of fever and respiratory symptoms, and onset of symptoms within a specific time frame. The sample also includes exclusion criteria, such as pregnancy, respiratory distress, and certain medical conditions or treatments. The record provides detailed information about the inclusion and exclusion criteria for potential participants in the trial.",
    "The sample is a phase 2 trial for nicotine dependence. The trial is focused on women aged 18-65 years who smoke 10 or more cigarettes per day and have a confirmed nicotine dependence. The participants must be willing to take the study medication and be motivated to quit smoking. Women of childbearing potential must have a negative pregnancy test and agree to use contraception during the study. The trial has inclusion and exclusion criteria to ensure the participants meet the necessary requirements. The sample also lists various exclusion criteria, such as severe medical illnesses, recent cardiovascular events, abnormal laboratory results, use of tobacco-containing products other than cigarettes, substance abuse or dependence, and certain mental health disorders. Additionally, previous non-response to nicotine replacement therapy, history of adverse drug reactions, and recent use of investigational drugs or devices are also exclusion criteria. The sample specifies that participants should not be concurrently enrolled in another study involving drug or device exposure and should not have a positive urine test for drugs of abuse. The use of statins during the investigation period is also not allowed.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 2 and phase 3. The disease being studied is schizophrenia, and the corresponding ICDCodes for schizophrenia are listed as ['F20.0', 'F20.1', 'F20.2', 'F20.3', 'F20.5', 'F20.89', 'F20.9']. The drugs being tested in this trial are 'mp-214 low dose', 'mp-214 middle dose', and 'mp-214 high dose'. The eligibility criteria for inclusion in the trial include obtaining written informed consent from the patient, a diagnosis of schizophrenia according to the DSM-IV-TR criteria, and normal physical examination, laboratory, vital signs, and/or electrocardiogram results. The exclusion criteria state that patients with schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder are not eligible for the trial.",
    "The sample from the table represents a clinical trial for the treatment of unipolar depression. The trial is in phase 2/phase 3, indicating that it is in an advanced stage of testing. The disease being studied is unipolar depression, and the corresponding ICD-10 codes associated with this disease are \"F32.A\", \"F53.0\", \"P91.4\", \"Z13.31\", and \"Z13.32\".\n\nThe drugs being tested in this trial are escitalopram and pindolol. The eligibility criteria for participants include being between the ages of 18 and 65, suffering from major depression according to DSM-IV criteria with a MADRS score of at least 25, and not currently being treated with an antidepressant (except for non-responders or those experiencing intolerable side effects). Informed consent is also required.\n\nExclusion criteria for participants include having any other Axis I disorder (excluding anxiety disorders that do not dominate the clinical picture) or nicotine abuse, being a non-responder to escitalopram in the past, currently taking pindolol, being pregnant or breastfeeding, having contraindications to either of the two treatments (due to medical conditions or other drug treatments), having significant somatic comorbidity that may interfere with the study procedures, being at high risk of suicidality, or being a woman of childbearing age without a safe means of contraception.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is anal cancer. The ICDCodes associated with this disease are C21.1, C44.500, C44.590, D12.9, and C21.8. The drugs being used in the trial are fluorouracil and mitomycin c. \n\nThe eligibility criteria for this trial include the following disease characteristics: histologically confirmed carcinoma of the anal canal, including subtypes such as squamous cell, basaloid, and cloacogenic; primary invasive disease; and T2-4, N0-3 disease. Clinically positive small inguinal nodes must be confirmed by biopsy, while enlarged inguinal, perirectal, or pelvic nodes that are \u2265 1.0 cm and clinically positive do not require biopsy.\n\nThe patient characteristics required for eligibility include Zubrod performance status of 0-1, hemoglobin \u2265 8.0 g/dL, ALT and AST < 3 times the upper limit of normal, absolute neutrophil count \u2265 1,800/mm\u00b3, serum creatinine \u2264 1.5 mg/dL, platelet count \u2265 100,000/mm\u00b3, bilirubin < 1.4 mg/dL, WBC \u2265 3,000/mm\u00b3, INR \u2264 1.5, no known AIDS (HIV-positive patients without AIDS are eligible), no other invasive malignancy within the past 3 years except for nonmelanomatous skin cancer, and no severe, active comorbidity.\n\nPrior concurrent therapy includes no prior radiation therapy to the pelvis that would result in overlap of radiation therapy fields, no prior systemic chemotherapy for cancer of the anus, no prior surgery for cancer of the anus that removed all macroscopic anal cancer, no concurrent use of sargramostim (GM-CSF), and no concurrent use of amifostine.\n\nIt is also mentioned that pregnant or nursing individuals are not eligible, and a negative pregnancy test is required. Fertile patients must use effective contraception.",
    "The sample from the table is for a phase 2 clinical trial for Parkinson's disease. The trial is testing the effectiveness of a drug called azd3241 at two different doses (300 mg bid and 600 mg bid) compared to a placebo. The eligibility criteria for the trial include patients who are able and willing to provide informed consent, aged between 30 and 80 years, diagnosed with idiopathic Parkinson's disease according to the UKPDS Brain Bank criteria, and have a modified Hoehn and Yahr stage between 1 and 2.5. Patients must not be currently receiving treatment for Parkinson's disease or have the need to add anti-Parkinson's disease treatment during the 14 weeks of the study, unless they are on stable anti-Parkinson's disease medication. The exclusion criteria include patients with unclear diagnosis or suspicion of other Parkinsonian syndromes, those who have undergone surgery for Parkinson's disease or any other brain surgery, presence of dyskinesias, motor fluctuations, swallowing difficulties, or loss of postural reflexes, current or history of psychiatric disorders, and current significant major or unstable respiratory, heart, cerebrovascular, hematological, hepatic, renal, gastrointestinal, or other major diseases as judged by the investigator.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is non-small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being used in the trial is a combination of pemetrexed and gemcitabine plus bevacizumab. \n\nThe eligibility criteria for this trial include the patient providing voluntary written informed consent, being 65 years of age or older with an ECOG score of 0 to 1, having histologically/cytologically confirmed Stage IIIB/IV NSCLC, and having measurable disease. Other criteria include not having received radiotherapy within a certain timeframe, having a negative pregnancy test or undergoing hysterectomy, having a life expectancy of greater than 12 weeks, and being free of active infection. \n\nThere are also exclusion criteria, such as prior systemic or concurrent chemo for metastatic NSCLC, certain types of lung carcinoma, ongoing treatment with full-dose warfarin, hypersensitivity to certain components of the drugs, and recent use of certain medications. Other exclusion criteria include the presence of certain medical conditions, such as serious heart failure, uncontrolled hypertension, and significant vascular disease. Additionally, patients with certain medical history, such as prior malignancy within the past 5 years or allogeneic transplant, are also excluded. Patients who are pregnant, lactating, or have known HIV infection or Hepatitis B or C are also excluded.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is colorectal cancer. The ICD-10 codes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being tested in this trial are bevacizumab (brand name Avastin), capecitabine (brand name Xeloda), and oxaliplatin. The eligibility criteria for inclusion in the trial are as follows: the patient must be an adult aged 75 or younger, must be chemotherapy-naive for stage IV colorectal cancer with unresectable liver metastasis, must have at least one measurable lesion, and must have an ECOG status of 0-2. The exclusion criteria include prior exposure to Avastin, clinical or radiological evidence of CNS metastases, uncontrolled hypertension or clinically significant cardiovascular disease, and ongoing treatment with high-dose aspirin or other medications that can cause gastrointestinal ulceration.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on gastric cancer. The ICD-10 codes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being studied in the trial are olaparib, paclitaxel, and a placebo. The sample also includes the eligibility criteria for the trial, including inclusion criteria such as having recurrent or metastatic gastric cancer that has progressed after first-line therapy, confirmed ATM protein status, and at least one assessable lesion. The exclusion criteria include having received more than one prior chemotherapy regimen for gastric cancer, previous treatment with a PARP inhibitor, and having a second primary cancer, except for certain exceptions.",
    "The sample is a record from a table that contains information about clinical trials. In this particular record, the trial is in phase 2 and is focused on colorectal cancer. The ICD-10 codes associated with the disease are provided. The drugs being studied in the trial include capecitabine, fluorouracil, irinotecan hydrochloride, and leucovorin calcium. The eligibility criteria for patients participating in the trial are also listed, including requirements related to the disease characteristics, patient characteristics, and prior concurrent therapy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied include \"pulmonary disease, chronic obstructive,\" \"lung diseases,\" \"respiratory tract diseases,\" \"chronic obstructive airway disease,\" and \"COPD.\" The corresponding ICDCodes for these diseases are \"J44.9,\" \"J44.1,\" \"J44.0,\" \"J84.115,\" \"M05.10,\" \"M05.111,\" \"M05.112,\" \"M05.119,\" \"M05.121,\" \"M05.122,\" \"G91.1,\" \"I42.1,\" \"N11.1,\" \"J05.0,\" \"G47.33,\" \"J44.9,\" and \"N13.8.\" The drugs being tested in this trial are \"placebo,\" \"active comparator,\" \"low dose pf-03635659,\" \"mid dose pf-03635659,\" and \"high dose pf-03635659.\" The eligibility criteria for this sample include specific inclusion and exclusion criteria related to age, diagnosis, body mass index, weight, smoking status, exacerbations, and respiratory tract infections.",
    "The sample provided is for a phase 2 clinical trial. The diseases being studied are colorectal neoplasm, head and neck neoplasm, carcinoma non-small-cell lung, and esophageal neoplasm. The corresponding ICD-10 codes for these diseases are also listed. The drug being tested in this trial is temozolomide. The eligibility criteria for participants include being at least 18 years old, having metastatic colorectal cancer, recurrent or metastatic head and neck or esophageal cancer, or locally advanced, inoperable, or metastatic non-small cell lung cancer. Participants must also have a positive biomarker test result, up to a certain number of prior regimens for each disease, at least one measurable lesion, and a specific performance status. Adequate hematologic, renal, and liver functions are required, and participants must be able to take the study medication orally or through a feeding tube. Participants of childbearing potential must agree to use contraception. Exclusion criteria include recent treatment for another malignancy, unstable or progressing central nervous system metastasis, and prior treatment with temozolomide or dacarbazine.",
    "The sample from the table is for a phase 2 clinical trial for esophageal cancer. The eligibility criteria for patients to participate in the trial are listed. The criteria include having metastatic squamous cell carcinoma or adenocarcinoma of the esophagus or gastroesophageal junction, with supporting evidence from histologic, cytologic, or radiologic documentation. Different types of tumors and their classifications are also specified. Patients must have at least one paraffin block or 15 unstained slides available for analysis of tumor EGFR status. Measurable disease is required for inclusion, with specific size criteria. Prior treatment restrictions include no prior chemotherapy or radiotherapy, no prior therapy targeting the EGF(R) pathway, and no concurrent use of investigational agents. Patient characteristics such as ECOG Performance Status, age, weight stability, and pregnancy/breastfeeding status are also considered. Exclusion criteria include recent myocardial infraction, severe diarrhea, central nervous system metastases, interstitial pneumonia, seizure disorder, peripheral neuropathy, and evidence of Gilbert's Syndrome. Initial laboratory data requirements include specific values for granulocytes, platelet count, creatinine, AST (SGOT), total bilirubin, and albumin.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is knee osteoarthritis. The ICDCodes associated with this disease are M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, and M17.30. The drugs being tested in this trial are crx-102 (2.7/90), prednisolone, placebo, crx-102 (2.7/180), and crx-102 (2.7/360). The eligibility criteria for participants include age, knee pain duration, WOMAC pain score, radiographic evidence of knee OA, functional class, willingness to take specific vitamins, and various exclusion criteria related to medical history, surgeries, infections, allergies, medications, and other factors.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"systemic sclerosis\". The ICD-10 codes associated with this disease are \"M34.0\", \"M34.89\", \"M34.9\", \"M34.82\", \"M34.83\", \"M34.81\", and \"M34.2\". The drug being tested in this trial is \"imatinib mesylate\". \n\nThe sample also includes the eligibility criteria for participants in the trial. The inclusion criteria are:\n1. Age greater than or equal to eighteen years.\n2. Clinical diagnosis of diffuse systemic sclerosis by ACR criteria, with a stable modified Rodnan skin score in the one month preceding introduction of oral Gleevec therapy. The modified Rodnan skin score must be greater than or equal to sixteen at screening and initiation of therapy.\n3. Disease duration of less than or equal to 10 years.\n4. Estimated ejection fraction of greater than 50% by echocardiography.\n\nThe exclusion criteria are:\n1. Inability to render informed consent in accordance with institutional guidelines.\n2. Disease duration of greater than 10 years.\n3. Patients with mixed connective tissue disease or \"overlap\" (i.e. those who satisfy more than one set of ACR criteria for a rheumatic disease.)\n4. Ongoing treatment with other immunosuppressive therapies including cyclophosphamide, azathioprine, mycophenolic acid, methotrexate, or cyclosporine, or use of those medications within 3 months of trial entry.\n5. Concurrent serious medical condition which in the opinion of the investigator makes the patient inappropriate for this study such as uncontrollable CHF, arrhythmia, severe pulmonary or systemic hypertension, severe GI involvement, serum creatinine of greater than 2.0, active infection, severe diabetes, unstable atherosclerotic cardiovascular disease, malignancy, HIV, or severe peripheral vascular disease.\n6. The use of other anti-fibrotic agents including colchicine, D-penicillamine, minocycline, or Type 1 oral Collagen in the three months prior to enrollment.\n7. Limited scleroderma.\n8. Systemic sclerosis-like illness associated with environmental or ingested agents such as toxic rapeseed oil, vinyl chloride, or bleomycin.\n9. A positive pregnancy at entry into this study. Men and women with reproductive potential will be required to use effective means of contraception through the course of the study.\n10. Use in the prior month of corticosteroids at doses exceeding the equivalent of prednisone 10 mg daily. Use of corticosteroid at < 10 mg of prednisone can continue but not be increased during the course of the study.\n11. Participation in another clinical research study involving the evaluation of another investigational drug within ninety days of entry into this study.\n12. The presence of severe lung disease as defined by a diffusion capacity of less than 30% of predicted.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are kidney transplantation, kidney disease, and kidney failure. The corresponding ICDCodes for these diseases are provided as well. The drugs being used in the trial are alemtuzumab, mycophenolate mofetil, sirolimus, and tacrolimus. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include requirements such as a minimum weight of 40 kg, receiving a living-related primary kidney allograft, negative B-cell and T-cell cytotoxic and flow cytometry crossmatch, normal echocardiogram, completed vaccination for hepatitis B virus, willingness to comply with study visits, and willingness to use acceptable forms of contraception. \n\nExclusion criteria include factors such as previous or current organ transplant other than a kidney, ABO incompatible donor kidney, HIV infection, hepatitis C or B virus positivity, tuberculosis, current or recent history of cancer, significant liver disease, uncontrolled infections or unstable medical conditions, current or recent use of investigational drugs or immunosuppressive agents, contraindications to taking medications orally or via nasogastric tube, certain medication requirements, known hypersensitivity to study medications, certain screening laboratory values, substance abuse or psychiatric disorders, contraindication to tacrolimus administration, undergoing peritoneal dialysis, PRA value less than 10%, Graves disease (unless adequately treated), and CMV or EBV negative recipient receiving a kidney from a CMV or EBV positive donor. Pregnancy or breastfeeding is also listed as an exclusion criterion.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is phase 2, the disease is HIV infections, the icd-10 code is Z21, and the drugs are matching placebo and bevirimat. The eligibility criteria include requirements such as having a negative pregnancy test for females of child-bearing potential, having HIV-1 infection, having a specific range of plasma HIV-1 RNA value, having documented evidence of genotypic resistance, being on a specific antiretroviral therapy regimen, being free from acute infection or serious medical illness, providing informed consent, and being willing to comply with the study's meal requirements. The exclusion criteria include having a current opportunistic infection characteristic of AIDS, being unable or unwilling to comply with the dosing schedule and protocol evaluations, having malabsorption syndromes affecting drug absorption, having abnormal blood pressure, having a history of seizures, migraines, headaches, CVA or TIA, having abnormal hemoglobin, neutrophil count, platelet count, AST or ALT levels, having received certain treatments or participated in other drug studies within a specific timeframe, having a history of alcoholism or drug addiction, having difficulty donating blood or inadequate venous access, and having donated blood or plasma within a certain timeframe. It is also noted that patients with a CD4 count less than 100 cells/mm3 may be considered for enrollment after discussion and agreement between the Investigator and the Sponsor.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease of atherosclerosis. The ICD-10 codes associated with this disease are 'I67.2', 'I70.90', 'I70.91', 'I70.0', 'I70.1', 'I70.8', and 'I25.83'. The drugs being studied in this trial are 'mldl1278a', 'mldl1278a', 'placebo', and 'statin, stable dose'. \n\nThe eligibility criteria for this trial are as follows:\n- The patient must have evidence of qualifying vessel (carotid or aortic) plaque inflammation.\n- The patient must have documented atherosclerotic vascular disease that is clinically stable for at least 3 months prior to screening, or they must have type 2 diabetes mellitus with elevated cardiovascular risk.\n- The patient must be using a stable dose of statin therapy for at least 6 weeks prior to screening and be capable of maintaining that dose until the last follow-up visit.\n- If the patient is taking angiotensin-converting enzyme (ACE) inhibitors (ACE-I) or angiotensin-receptor blockers (ARBs), non-statin lipid-modifying therapy, thiazolidinediones, inhaled steroids, or leukotriene modifying agents, they must have been using a stable dose for at least 6 weeks prior to screening and be capable of continuing with that dose for the duration of the study.\n\nThe exclusion criteria for this trial are as follows:\n- The patient must not have had a cardiovascular event within 6 months prior to screening.\n- The patient must not be pregnant, planning to become pregnant during the study, or breastfeeding.\n- The patient must not have clinically significant abnormal laboratory values or abnormal ECG or vital signs.\n- The patient must not have a history of anaphylactic reactions.\n- The patient must not have newly discovered Type 2 diabetes mellitus (T2DM) prior to study entry or have started medical treatment for T2DM less than 3 months prior to study entry.\n- The patient must not be using insulin, corticosteroids (oral, rectal, or injectable), or other immunosuppressive medications.\n- The patient must not have a current or recent infection, including signs, symptoms, or serology of any infection, including HIV, hepatitis B or C, within 4 weeks prior to screening.\n- The patient must not have impaired renal function.\n- The patient must not have a history of malignancy within 2 years prior to screening.\n- The patient must not have a current life-threatening condition other than vascular disease that may prevent them from completing the study.\n- The patient must not have used an investigational drug or biologic within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study medication.\n- The patient must not have been exposed to substantial radiation within 12 months prior to screening.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease of multiple sclerosis. The ICD-10 codes associated with this disease are 'G35' and 'C81.18'. The drugs being studied in this trial are teriflunomide and a placebo specifically designed for teriflunomide. The eligibility criteria for participants in this trial include having clinically confirmed multiple sclerosis, an Expanded Disability Status Scale (EDSS) score of 6 or less, two documented relapses in the past 3 years with one relapse in the previous year, and a screening MRI scan that confirms the diagnosis of MS. There are also exclusion criteria, such as having certain cardiovascular, hepatic, hematologic, neurological, endocrine, or other major systemic diseases, being pregnant or nursing, and having prior treatment with specific immunomodulatory therapies. The sample concludes by stating that the information provided is not exhaustive and there may be additional considerations for potential participants in the trial.",
    "The sample is a phase 2 trial for the treatment of hypertension. The trial is testing a drug called mk8141, as well as a comparator drug called placebo (unspecified) and enalapril. The eligibility criteria for participants include being between the ages of 35 and 65, not having been treated for hypertension in the past 14 days, and not having taken more than 2 medications for high blood pressure in the past 14 days. Women who are unable to have children or do not use birth control are also eligible. Exclusion criteria include taking more than 2 medications for high blood pressure, having a history of stroke, heart attack, or other heart conditions, having diabetes, liver disease, gallbladder disease, bowel disease, HIV positive status, certain types of cancer, drug or alcohol abuse, and having participated in another clinical study in the last 4 weeks.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"rhinitis, allergic, perennial\" and \"rhinitis, allergic, nonseasonal\". The corresponding ICDCodes for these diseases are \"J30.0\", \"J31.0\", \"J30.89\", \"J30.9\", \"A50.05\", \"J30.2\", and \"J30.1\". The drugs being tested in this trial are \"placebo\", \"mk-8237 6 du\", and \"mk-8237 12 du\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having a history of allergic rhinitis/rhinoconjunctivitis to house dust for at least 1 year, and if female and of childbearing potential, having a negative urine pregnancy test and agreeing to use birth control methods during the study. Exclusion criteria include being sensitized and regularly exposed to animal dander and molds, being sensitized and regularly exposed to seasonal allergens, recent immunosuppressive treatment, history of chronic urticaria and/or angioedema, previous immunotherapy treatment with any HDM allergen, ongoing treatment with any specific immunotherapy, history of anaphylaxis with prior immunotherapy, unstable or severe asthma, chronic sinusitis, certain nasal conditions, pregnancy or breastfeeding, participation in another investigational study during the same time frame, and having a direct association with the administration of the study or being a family member of the study staff.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is phase 2.\n- Diseases: A list of diseases related to the trial, including fallopian tube cancer, primary peritoneal serous adenocarcinoma, recurrent ovarian epithelial cancer, stage I ovarian epithelial cancer, and stage II ovarian epithelial cancer.\n- ICD Codes: The ICD-10 codes associated with the diseases mentioned.\n- Drugs: The drug being used in the trial, which is cediranib maleate.\n- Criteria: The eligibility criteria for participants in the trial, including requirements such as confirmed diagnosis of ovarian, peritoneal, or fallopian tube cancer, specific prior treatments, normal lab values, and other factors.\n\nThe record also includes both inclusion and exclusion criteria, which outline the requirements and restrictions for potential participants in the trial. These criteria cover aspects such as previous treatments, medical conditions, pregnancy status, and other factors that may affect eligibility.\n\nOverall, this sample provides a snapshot of a specific clinical trial, including the phase, diseases being studied, the drug being tested, and the criteria for participant eligibility.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating metastatic colorectal cancer. The trial includes patients who have confirmed locally advanced or metastatic colorectal cancer and meet certain criteria. These criteria include having measurable or evaluable disease, a performance status of 2 or lower, being between the ages of 18 and 72, and having progressed after 1st line therapy with FOLFOX/AVASTIN. Patients must also have adequate liver, renal, and bone marrow function. They must be able to understand the nature of the study and provide written informed consent.\n\nThere are also exclusion criteria, which include a history of serious cardiac disease, recent myocardial infraction or stroke, peripheral vascular disease, abdominal fistula or abscess, recent major surgical procedure or traumatic injury, central nervous system or brain metastasis, bleeding diathesis or coagulopathy, high blood pressure, pregnancy or lactation, a life expectancy of less than 3 months, recent radiotherapy, significant liver metastasis, chronic diarrhea or bowel obstruction, active infection requiring antibiotics, a second primary malignancy (except for non-melanoma skin cancer and in situ cervical cancer), and psychiatric illness or social situation that would prevent study compliance.\n\nThis sample provides a detailed description of the eligibility criteria for patients participating in the clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease called myelofibrosis. The associated ICD-10 codes for this disease are 'D75.81', 'C94.41', 'C94.42', and 'C94.40'. The drug being studied in this trial is aplidin (plitidepsin). \n\nThe eligibility criteria for participants in this trial include being diagnosed with Primary Myelofibrosis (PMF) or Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (post-ET/PV MF) according to the revised World Health Organization (WHO) criteria. Participants must also have high-risk or intermediate-2 risk Myelofibrosis (MF) as defined by the International Prognostic Scoring System (IPSS), or intermediate-I risk MF associated with symptomatic splenomegaly/hepatomegaly and/or unresponsiveness to available therapy. \n\nOther criteria include being at least 18 years old with a life expectancy of at least 12 weeks, being able to provide informed consent, having an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower, and having acceptable organ function. \n\nThere are also exclusion criteria, such as previous treatment with plitidepsin, recent chemotherapy or immunomodulatory drug therapy, incomplete recovery from major surgery or recent radiation therapy, pregnancy or breastfeeding, and various other conditions or infections. \n\nOverall, this sample provides specific details about the phase, disease, associated codes, drug, and eligibility criteria for participants in a clinical trial focused on myelofibrosis.",
    "The sample from the table is for a phase 2 clinical trial for colorectal cancer. The disease characteristics include having histologically or cytologically confirmed adenocarcinoma of the colon or rectum that is incurable with conventional therapy, metastatic or recurrent disease, and at least one measurable lesion. The disease must also be accessible to biopsy and there should be no known brain metastases.\n\nThe patient characteristics include being 18 years or older, having an ECOG performance status of 0-1 or Karnofsky performance status of 70-100%, and a life expectancy of more than 3 months. Hematopoietic requirements include an absolute granulocyte count of at least 1,500/mm^3, a white blood cell count of at least 3,000/mm^3, and a platelet count of at least 100,000/mm^3.\n\nHepatic requirements include a bilirubin level no greater than 1.25 times the upper limit of normal (ULN) and AST or ALT levels no greater than 3 times ULN (less than 5 times ULN if liver metastases are present). Renal requirements include a creatinine level no greater than 1.25 times the ULN or a creatinine clearance of at least 50 mL/min.\n\nCardiovascular criteria include no symptomatic congestive heart failure, no unstable angina pectoris, and no cardiac arrhythmia. Other requirements include not being pregnant or nursing, having a negative pregnancy test, using effective contraception if fertile, having no psychiatric illness or social situation that would hinder study compliance, having no other uncontrolled concurrent illness or ongoing active infection, and having no other active malignancy within the past 3 years except for curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix.\n\nPrior concurrent therapy includes no specified biologic therapy, no more than 1 line of prior chemotherapy for metastatic disease (including fluorouracil, irinotecan, and/or oxaliplatin), at least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered, prior adjuvant chemotherapy is allowed, and no concurrent cytotoxic chemotherapy.\n\nRadiotherapy requirements include more than 4 weeks since prior radiotherapy and recovered, no prior radiotherapy to measurable target lesion unless disease progression has occurred after radiotherapy, and no concurrent radiotherapy to the sole site of measurable disease. Surgery should have been performed more than 21 days prior to the trial. Other requirements include no other concurrent investigational agents and no concurrent combination antiretroviral therapy for HIV-positive patients.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and includes information about the diseases being studied, the corresponding ICD-10 codes, the drugs being tested, and the eligibility criteria for participants.\n\nIn this particular trial, the diseases being studied are glaucoma, ocular hypertension, and eye disease. The ICD-10 codes associated with these diseases are provided as well. The drugs being tested are called ama0076 and placebo.\n\nThe eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being an adult between 30-85 years old, having a diagnosis of ocular hypertension or primary open-angle glaucoma in both eyes, not currently receiving medication for intraocular pressure (IOP), and having elevated IOP levels within a specific range. Exclusion criteria include having uncontrolled intraocular hypertension, receiving more than one medication for IOP, having certain measurements outside of specified ranges (such as central corneal thickness and best-corrected visual acuity), having significant visual field loss, or having certain types of glaucoma or narrow anterior chamber angles.\n\nOverall, this sample provides a snapshot of a phase 2 clinical trial focusing on glaucoma and ocular hypertension, with specific eligibility criteria for potential participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is acute myeloid leukemia. The ICDCodes associated with this disease are C92.A1, C92.A2, C92.61, C92.62, C92.A0, and C92.60. The drugs being used in the trial are azacitidine and lenalidomide. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being at least 60 years old and fit for intensive chemotherapy, having no significant co-morbidities, being less than 75 years old, having acute myeloid leukemia with high-risk features, poor risk cytogenetics, a life expectancy of more than 1 month, being affiliated to social security regimen, not having granulocytic sarcoma as the sole site of disease, and being able and willing to provide written and signed informed consent.\n\nExclusion criteria include having total bilirubin levels higher than 2 times the upper limit of normal, having elevated levels of AST, ALT, and/or alkaline phosphatase, having Factor V levels below 50% without DIC, having NYHA class III or IV congestive heart failure, unstable angina pectoris, or serious cardiac arrhythmia, having renal failure not related to AML, being HIV positive, having prior therapy with azacitidine or lenalidomide, having psychiatric illness or social situations that would preclude compliance with study requirements, having uncontrolled infection, requiring urgent chemotherapy for certain conditions, being pregnant or breastfeeding (for women), and being unwilling or unable to use an acceptable contraceptive method (for women) or birth control method (for men).\n\nOverall, this sample provides specific details about the phase, disease, ICDCodes, drugs, and eligibility criteria for a clinical trial focused on acute myeloid leukemia.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on breast neoplasms. The ICD-10 codes associated with the diseases are ['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']. The drugs being studied are 'endotag-1 + paclitaxel', 'endotag-1', and 'paclitaxel'. The eligibility criteria for this trial include having histologically proven triple-receptor-negative metastatic or relapsed breast cancer, a minimum interval of 6 months after the end of any previous taxane-containing chemotherapy regimen, at least one measurable tumor lesion according to RECIST criteria, being female, being at least 18 years old, having a negative pregnancy test (for females of childbearing potential), willingness to use double-barrier contraception during the study and for 6 months after chemotherapy treatment, having an ECOG performance status of 0, 1, or 2, and signing informed consent. The exclusion criteria include having more than 1 previous chemotherapeutic treatment for metastatic or relapsed disease, major surgery within 4 weeks prior to enrollment, immunotherapy within 2 weeks prior to enrollment, severe pulmonary obstructive or restrictive disease, uncontrolled inflammatory disease (autoimmune or infectious), clinically significant cardiac disease (NYHA stadium > 2), laboratory tests (hematology, chemistry) outside specified limits, pregnancy or nursing status, known positive HIV testing, known hypersensitivity to any component of the EndoTAG-1 or taxane formulations, history of malignancy other than breast cancer within 5 years prior to enrollment (except for skin cancer treated locally), known progressive cerebral metastasis (patients with stable cerebral metastases or after successful surgical or radiological treatment are allowed to participate), history of active or significant neurological or psychiatric disorder that would prohibit understanding and giving informed consent or interfere with the evaluation of the central nervous system during the trial, and concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease mentioned is \"neoplasms, gastrointestinal tract.\" The corresponding ICDCodes for this disease are ['A21.3', 'A22.2', 'B46.2', 'K92.2', 'K92.81', 'K91.0', 'P54.3']. The drug being tested is 'gsk1363089 (formerly xl880)'. The eligibility criteria for this trial include various conditions such as a confirmed diagnosis of advanced or metastatic gastric carcinoma, measurable disease, consent to provide tumor biopsies, specific performance status, ability to ingest the drug capsules, certain hormone levels, liver/kidney/marrow function, understanding and compliance with the protocol, contraception use, negative pregnancy test, no other recent malignancy diagnosis, and specific QTc interval. The exclusion criteria include prior cytotoxic chemotherapy, recent investigational drug use, recent chemotherapy/immunotherapy/radiation therapy, adverse events from previous medications, brain metastases, uncontrolled illnesses, pregnancy/breastfeeding, HIV positive status, allergy to the drug formulation, and unwillingness to abide by the study protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied include childhood high-grade cerebellar astrocytoma, childhood high-grade cerebral astrocytoma, recurrent childhood anaplastic astrocytoma, recurrent childhood anaplastic oligoastrocytoma, recurrent childhood anaplastic oligodendroglioma, recurrent childhood brain tumor, recurrent childhood cerebellar astrocytoma, recurrent childhood cerebral astrocytoma, recurrent childhood glioblastoma, and recurrent childhood visual pathway and hypothalamic glioma. The ICDCodes associated with these diseases are also provided. The drug being tested in this trial is cilengitide. The eligibility criteria for participants in this trial are listed, including requirements such as confirmed primary central nervous system high-grade glioma, recurrent or progressive disease, radiographically documented measurable disease, and various medical parameters such as blood counts, kidney function, and liver function.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating non-small-cell lung carcinoma. The trial is specifically targeting patients with unresectable Stage IIIB or Stage IV relapsed or recurrent NSCLC. The sample includes the ICD-10 codes for the disease, which are ['D02.20', 'D02.21', 'D02.22']. The drug being tested in the trial is called xl647. The sample also includes the eligibility criteria for the trial, including requirements for documented progressive disease, measurable disease, ECOG performance status, contraception use, and negative pregnancy test for female subjects. The sample also lists exclusion criteria, such as recent radiation or other anticancer therapy, use of investigational drugs, certain medical conditions, and brain metastases.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is hypercholesterolemia. The ICDCodes associated with this disease are E78.01, E78.00, and Z83.42. The drugs being used in the trial are atorvastatin and aegr-733. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- Participants must be male or female between the ages of 18 and 70.\n- Participants with 0-1 risk factor must have a mean LDL-C level greater than 160 mg/dL and less than 250 mg/dL (Visit 2 & 3).\n- Participants with 2+ risk factors must have a mean LDL-C level greater than 130 mg/dL and less than 250 mg/dL (Visit 2 & 3).\n- Fasting mean TGs (triglycerides) must be less than 400 mg/dL.\n- Participants must have an understanding of and be compliant with the protocol.\n- Participants must sign consent.\n\nExclusion Criteria:\n- Females who are pregnant, lactating, or of childbearing potential and have not been using acceptable contraceptive methods for the previous 3 months.\n- Participants with uncontrolled hypertension, with blood pressure greater than 180/95 at screening.\n- Participants with a history of chronic renal insufficiency, with serum creatinine levels greater than 2.5 mg/dL.\n- Participants with a history of liver disease or transaminases (liver enzymes) greater than 1.5 times the upper limit of normal (ULN).\n- Participants who test positive for Hepatitis B or C.\n- Participants who have undergone major surgery within the past 3 months.\n- Participants with cardiac insufficiency defined as functional Class II-Class IV.\n- Participants with a history of malignancy within the previous 5 years.\n- Participants who have participated in another investigational drug study within the past 6 weeks.\n- Participants with serious or unstable medical or psychological conditions.\n- Participants who regularly consume more than 1 drink of alcohol per day.\n- Participants who regularly consume grapefruit juice or medications known to be metabolized by CYP 3A4.\n- Participants who use other lipid-lowering medications (washout permitted).\n- Participants with acute cardiovascular disease (CVD).\n- Participants with diabetes mellitus.\n- Participants with fasting glucose levels greater than 110 mg/dL.\n- Participants with a BMI (Body Mass Index) greater than 40 kg/m2.\n- Participants with significant gastrointestinal symptoms such as irritable bowel syndrome (IBS).\n- Participants who use fish oils, niacin, or herbal weight loss products (washout permitted).",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of psoriasis. The ICD-10 codes associated with psoriasis are provided. The trial involves several drugs, including cnto 1959 at different dosages, adalimumab, and a placebo. The eligibility criteria for participants are listed, including the requirement of a diagnosis of plaque-type psoriasis, being a candidate for phototherapy or systemic treatment, and being considered suitable for adalimumab therapy. There are also specific criteria for women regarding their reproductive status. The exclusion criteria include having severe or uncontrolled diseases, contraindications to anti-TNF therapy, history of chronic or recurrent infectious disease, nonplaque form of psoriasis, previous treatment with adalimumab, and recent use of certain therapeutic agents.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is non-small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being tested is abi-007. The eligibility criteria for patients participating in this trial include being histologically or cytologically confirmed with advanced stage IV NSCLC, having no other active malignancy, having measurable disease, not having received prior chemotherapies for metastatic disease, and meeting certain baseline laboratory values. Additionally, patients must have an expected survival of greater than 12 weeks and an ECOG performance status of 0-1. Finally, the patient or their legally authorized representative must have been informed about the study and have agreed to participate by signing the Informed Consent form.",
    "The sample provided is a record from a table that contains information about clinical trials for different phases of a trial (phase I, phase II, phase III). The sample specifically pertains to a trial for the treatment of ischemic stroke. \n\nThe phase of the trial is described as \"phase 1/phase 2\". The disease being studied is \"ischemic stroke\". The corresponding ICD-10 codes for the disease are listed as \"['I25.5', 'H47.013', 'H93.013', 'G45.9', 'H47.011', 'H47.012', 'H47.019']\". The drug being tested is \"rp-1127 (glyburide for injection)\". \n\nThe sample also includes the eligibility criteria for the trial. The inclusion criteria are as follows:\n- The patient must have a clinical diagnosis of acute ischemic stroke in the MCA or MCA/ACA territory.\n- The patient's pre-morbid mRS (modified Rankin Scale) score should be between 0 and 1.\n- The patient's baseline DWI (Diffusion-Weighted Imaging) lesion on MRI should be between 82 cm3 and 210 cm3.\n- Patients treated with IV rtPA (intravenous recombinant tissue plasminogen activator) should meet the established criteria for IV rtPA administration within specific time periods.\n- The start of infusion of the study compound must be within 10 hours after the time of symptom onset.\n- The patient's age should be between 18 and 70 years.\n- The patient or their legally authorized representative must provide written informed consent according to institutional guidelines and national regulations.\n\nThe exclusion criteria for the trial are also listed:\n- Evidence from imaging or pre-enrollment investigation of any diagnosis other than acute ischemic stroke that could cause the presenting symptoms and signs.\n- Commitment to decompressive craniectomy (DC) prior to enrollment or after enrollment but before the start of the study compound.\n- Treatment with IA rtPA (intra-arterial recombinant tissue plasminogen activator) or mechanical means for clot disruption or with hypothermia.\n- Inability to tolerate MRI scanning, such as having pacemakers or automatic defibrillators.\n- Pre-morbid mRS score of 2 or higher.\n- Clinical signs of herniation, such as dilated, fixed pupils or unconsciousness.\n- CT or MRI evidence of hemorrhage or anteroseptal/pineal shift greater than or equal to 2 mm prior to enrollment.\n- Rapidly improving symptoms.\n- Severe renal disorder or severe liver disease.\n- Blood glucose levels below 55 mg/dL or a history of hypoglycemia.\n- Diagnosis of decompensated heart failure or sulfonylurea treatment within 30 days.\n- Known allergy to sulfa or specific allergy to sulfonylurea drugs.\n- Known G6PD enzyme deficiency.\n- Pregnancy or breastfeeding.\n- Patients already enrolled in another non-observation-only stroke study, or with a life expectancy of less than 3 months not related to the current stroke, or those unlikely to be compliant with follow-up.\n- Patients deemed unsuitable for the study according to the investigator's judgment.\n\nOverall, this sample provides information about the phase, disease, ICD-10 codes, drug, and eligibility criteria for a clinical trial focused on the treatment of ischemic stroke.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is pancreatic cancer. The ICDCodes associated with this disease are C25.3. The drugs being used in the trial are erlotinib and gemcitabine. The eligibility criteria for this trial include being an adult patient aged 18 or older, having locally advanced and/or metastatic pancreatic cancer (stage III or IV), and having a Karnofsky performance status of 60% or higher. The exclusion criteria include having local pancreatic cancer in stages IA to IIB, having received adjuvant chemotherapy within the last 6 months, having received previous systemic therapy for metastatic pancreatic cancer, having had another primary tumor within the last 5 years (except for adequately treated cancer in situ of the cervix or basal cell skin cancer), and having clinically significant cardiovascular disease.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is metastatic colorectal cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug mentioned for this trial is chemotherapy, specifically capecitabine, oxaliplatin, 5-fu, and leucovorin. The eligibility criteria for this trial include no prior treatment for metastatic disease, PS (performance status) of 0-2, and measurable disease. The exclusion criteria include neuropathy grade 2 or higher, concomitant radiation therapy or other systemic cancer therapies, and brain metastases.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is rheumatoid arthritis. The ICDCodes associated with this disease are ['M06.9', 'M05.9', 'M06.08', 'M06.00', 'M06.011', 'M06.012', 'M06.019']. The drugs being used in the trial include 'bms-945429 placebo', 'methotrexate', and 'adalimumab placebo'. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- Inadequate response to Methotrexate\n- Must have been taking Methotrexate for at least 3 months at a minimal weekly dose of at least 15 mg and stable dose for 4 weeks prior to randomization\n- American College of Rheumatology (ACR) global function status class 1-3\n- Minimum of 6 swollen and 6 tender joints with evidence of synovitis in at least 1 hand or wrist\n- High sensitivity C-reactive protein (hsCRP) \u2265 0.8 mg/dL\n\nExclusion Criteria:\n- Previously received or currently receiving concomitant biologic therapy",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and includes information about the diseases being studied, the associated ICD-10 codes, the drug being tested, and the eligibility criteria for participants.\n\nIn this particular trial, the diseases being studied are \"carcinoma, non-small-cell lung\" and \"adenocarcinoma, bronchiolo-alveolar\". The corresponding ICD-10 codes for these diseases are \"D02.20\", \"D02.21\", and \"D02.22\". The drug being tested in the trial is \"velcade\".\n\nThe eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having confirmed BAC or adenocarcinoma with BAC features, being at stage IIIB or IV of the disease, having progressed on or after prior chemotherapy, having radiographic documentation of progressive disease, having measurable disease by RECIST, being 18 years or older, having a life expectancy greater than 3 months, having an ECOG performance status of 0, 1, or 2, being able to provide written informed consent, and having the ability to understand the risks and benefits of the trial.\n\nExclusion criteria include having received chemotherapy or an EGFR TKI within 4 weeks prior to enrollment, having peripheral neuropathy of Grade 2 or greater intensity, having been previously treated with VELCADE, having certain heart conditions, having received radiation therapy or monoclonal antibody therapy within 4 weeks prior to enrollment, having had major surgery within 4 weeks prior to enrollment, having inadequate organ function, having symptomatic brain metastases, having uncontrolled active systemic infection, having had treatment for a cancer other than BAC within 5 years prior to enrollment (with exceptions), having a history of allergic reactions to certain compounds, having HIV or hepatitis B/C infection, having poorly controlled hypertension, diabetes, or other serious medical or psychiatric illness, being pregnant or breastfeeding, and not employing adequate means of contraception.\n\nOverall, this sample provides a snapshot of the phase 2 trial, the diseases being studied, the drug being tested, and the criteria that potential participants must meet or exclude in order to participate in the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and the disease being studied is \"multiple myeloma and plasma cell neoplasm\". The corresponding ICD-10 codes for the disease are \"C96.20\", \"C96.29\", and \"D47.09\". The drugs being used in the trial are \"dexamethasone\", \"lenalidomide\", and \"melphalan\". \n\nThe eligibility criteria for the trial are listed, including requirements for the disease characteristics of the patients, such as confirmation of multiple myeloma through biopsy or bone marrow analysis, and being ineligible for stem cell transplantation. The patients must also have previously untreated disease and measurable levels of certain proteins in their blood or urine.\n\nThe patient characteristics include criteria such as performance status, life expectancy, blood counts, kidney and liver function, and pregnancy status. The patients must not have any other malignancies within the past 5 years, and should not have any hypersensitivity or serious medical conditions that would prevent their participation in the study.\n\nThe prior concurrent therapy section specifies that patients should not have received prior chemotherapy or corticosteroids for the treatment of multiple myeloma, except for specific cases. Prior radiotherapy and bisphosphonates are allowed, but other concurrent anticancer therapy or investigational therapy is not permitted.\n\nOverall, this sample provides detailed information about the phase 2 clinical trial, the disease being studied, the drugs being used, and the eligibility criteria for the patients.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease being studied is \"infection, human immunodeficiency virus.\" The corresponding ICDCodes for this disease are \"Z21.\" The drugs being tested in this trial include \"bms-663068 400 mg,\" \"bms-663068 800 mg,\" \"bms-663068 600 mg,\" \"bms-663068 1200 mg,\" \"raltegravir 400 mg,\" \"tenofovir 300 mg,\" \"ritonavir 100 mg,\" and \"atazanavir 300 mg.\" The eligibility criteria for this trial include specific requirements for plasma HIV-1 RNA levels, previous treatment experience, PHENOSENSE Entry results, and CD4+ T-cell count. There are also exclusion criteria related to genotypic resistance to certain study regimen components and specific laboratory and electrocardiogram values.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of soft tissue sarcoma. The trial includes patients with advanced and/or metastatic malignant soft tissue sarcoma of high or intermediate grade, with specific histologies such as leiomyosarcoma, adipocytic, synovial sarcoma, and various other types of sarcoma. The trial excludes certain tumor types like embryonal rhabdomyosarcoma, chondrosarcoma, osteosarcoma, and others.\n\nTo be eligible for the trial, patients must have formalin-fixed paraffin-embedded tumor blocks and representative H/E slides available for histological central review. They should have relapsed, refractory, and/or metastatic disease that is incurable by surgery or radiotherapy. Objective progression within the last 6 months must be documented, and the presence of measurable disease is required. Patients should have received no more than one combination or two single-agent chemotherapy regimens for advanced disease.\n\nOther eligibility criteria include no major surgery, hormonal therapy, chemotherapy, radiotherapy, immunotherapy, or other investigational agent within the last 28 days. Patients should not have brain or subdural metastases, pre-existing neuropathy greater than Grade 2, and should be at least 18 years old with a WHO performance status of 0 or 1. Adequate bone marrow, hepatic, and renal function is also required.\n\nFor female participants, they should either not be of childbearing potential or not be pregnant, and they should agree to use contraceptive methods during treatment and for 3 months after the end of treatment. Male participants must use barrier methods of contraception. Written informed consent is necessary before registration.\n\nExclusion criteria include a prior history of malignancies other than sarcoma, significant cardiovascular impairment, anti-coagulant therapy with warfarin, severe/uncontrolled intercurrent illness/infection, known hypersensitivity to halichondrin B and/or its chemical derivative, prior participation in a prior E7389 clinical trial, and certain conditions that may hamper compliance with the study protocol and follow-up schedule.\n\nThis sample provides detailed information about the eligibility criteria for the clinical trial, including the specific disease, histological requirements, treatment history, and various medical conditions that may affect participation.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 design. The trial is focused on hematologic malignancies, specifically acute myeloid leukemia (AML). The trial is investigating the use of a drug called CP-4055, both as a single agent and in combination with idarubicin. \n\nThe eligibility criteria for the trial include patients who have relapsed or refractory leukemias for which standard therapies are not expected to result in a durable response, or patients who have failed potentially curative therapy, or patients who refuse or are considered unsuitable for standard therapy. Patients must be 18 years of age or older and have an ECOG performance status of 0-2. Women of child-bearing potential must have a negative pregnancy test and both male and female patients must use acceptable contraceptive methods during the study. \n\nThe interval from prior treatment to the administration of the study drug should be at least 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents. Patients must also meet certain clinical laboratory values, including serum creatinine, total bilirubin, and liver enzyme levels. \n\nFor phase 2 of the trial, patients must have a confirmed diagnosis of AML and have received cytotoxic chemotherapy. \n\nThere are also exclusion criteria for both phase 1 and phase 2, including a history of allergic reactions to similar compounds, positive status for HIV or hepatitis B or C, pregnancy or nursing, uncontrolled intercurrent illness, active heart disease, receiving other cytotoxic treatments, and any medical condition that places the patient at high risk for toxicities. In arm C of the trial, there is an additional exclusion criterion for patients with hypersensitivity to idarubicin or other anthracyclines or anthracenediones.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease is prostate cancer. The ICDCodes associated with the disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drugs being used in the trial are docetaxel, ly2181308 sodium, and prednisone. The eligibility criteria for inclusion in the trial include having histologically or cytologically confirmed adenocarcinoma of the prostate that is metastatic and/or unresectable, hormone refractory prostate cancer, Eastern Cooperative Oncology Group (ECOG) status of 0-2, and adequate hematological, liver, and renal functions. The exclusion criteria include known hypersensitivity to docetaxel or taxane therapy, central nervous system or leptomeningeal metastasis, recent treatment with chemotherapy or bone-seeking radionuclides, evidence of painful and/or destructive bone metastases, and recent treatment with a drug that has not received regulatory approval.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is metastatic breast cancer. The ICDCodes associated with this disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs mentioned in this sample are bevacizumab and paclitaxel. The eligibility criteria for this trial include being at least 20 years old and having obtained written informed consent. Additionally, the criteria specify that the participant must have advanced breast cancer (Stage IV) or inoperable metastatic breast cancer, be HER2 negative, have at least one measurable lesion based on RECIST criteria, and have not received previous chemotherapy for metastatic breast cancer.",
    "The sample is a phase 2 clinical trial for patients with head and neck cancer. The trial is specifically for patients with newly diagnosed stage III-IV HNSCC, with no evidence of distant metastasis. The trial aims to evaluate the effectiveness of the drug lapatinib in treating this type of cancer. \n\nThe inclusion criteria for the trial include being 18 years or older, having a confirmed diagnosis of HNSCC, not having received prior radiation therapy to the head and neck sites, and having a left ventricular ejection fraction within the normal range. Additionally, patients must meet certain parameters that would preclude the use of concurrent CRT (chemoradiotherapy), such as having an ECOG PS (Eastern Cooperative Oncology Group Performance Status) score greater than 2, certain levels of creatinine, AST or ALT, total bilirubin, history of hearing loss, pre-existing peripheral neuropathy, or refusal or intolerance to chemotherapy. \n\nThe exclusion criteria for the trial include known hypersensitivity to lapatinib, uncontrolled angina, arrhythmia or congestive heart failure, history of myocardial infraction within the past 6 months, recent treatment with non-approved or investigational drugs, prior treatment with EGFR or Her2/Neu directed therapies, and being HIV-positive and receiving combination anti-retroviral therapy. Patients with an absolute neutrophil count below 1500/uL are also excluded from the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on patients with chronic obstructive pulmonary disease (COPD). The trial aims to evaluate the effectiveness of different drugs, including indacaterol/glycopyrrolate, indacaterol, and a placebo. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n1. Patients must be male or female adults aged 40 years or older and have signed an informed consent form.\n2. Patients must have moderate to severe stable COPD according to the Global Initiative for Obstructive Lung Disease (GOLD) Guidelines 2006.\n3. Patients must have a smoking history of at least 10 pack years.\n4. Patients must have a post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) between 30% and 80% of the predicted normal and a post-bronchodilator FEV1/Forced Vital Capacity (FVC) ratio less than 0.70.\n\nThe exclusion criteria for the trial are as follows:\n1. Pregnant or nursing women, or women of child-bearing potential who are not using acceptable methods of contraception.\n2. Patients requiring long-term oxygen therapy (>15 hours a day) or who have been hospitalized or visited an emergency department for a COPD exacerbation in the 6 weeks prior to screening.\n3. Patients who have had a respiratory tract infection within 6 weeks prior to screening.\n4. Patients with concomitant pulmonary disease, pulmonary tuberculosis (unless confirmed to be no longer active), or clinically significant bronchiectasis.\n5. Patients with a history of asthma indicated by a blood eosinophil count >400/mm3.\n6. Patients with clinically relevant laboratory abnormalities or clinically significant conditions.\n7. Patients with uncontrolled Type I and Type II diabetes.\n8. Patients with a history of malignancy of any organ system within the past 5 years.\n9. Patients who are contraindicated for or have shown an untoward reaction to inhaled anticholinergic agents.\n10. Patients with a history of long QT syndrome or a prolonged QTc interval measured at screening.\n11. Patients with a history of untoward reactions to sympathomimetic amines, inhaled medication, or any of the study drugs or drugs with similar chemical structures.\n\nIt is important to note that there may be additional inclusion/exclusion criteria defined by the protocol of the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease of insomnia. The ICD-10 codes associated with insomnia are ['F51.01', 'F51.02', 'F51.03', 'F51.04', 'G47.00', 'G47.09', 'A81.83']. The drugs being tested in the trial are 'pd 0200390' and 'placebo'. The eligibility criteria for participants include having a 3-month history of primary insomnia, being between 18 and 64 years old, experiencing regular sleep disturbances, and having difficulty falling asleep or staying asleep at least 3 nights a week for the past month. Exclusion criteria include having a history of psychiatric diagnoses, breathing-related sleep disorders, medical or neurological conditions that could affect sleep, and excessive alcohol consumption.",
    "The sample is a phase 2 trial for major depressive disorder. The trial is testing the effectiveness of quetiapine extended release (xr) compared to a placebo. The eligibility criteria for participants include a diagnosis of major depressive disorder, a lack of response to previous antidepressant treatment, and specific scores on the Hamilton Depression Rating Scale. Exclusion criteria include recent or concurrent mental disorders, history of substance abuse or dependence, and certain medical conditions. Participants must also not have a history of hypersensitivity to quetiapine or any component of the study drug.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is Type 2 Diabetes Mellitus. The corresponding ICD-10 codes for the disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being used in the trial are p2202 and placebo. The eligibility criteria for participants include being willing to give informed consent, being between 18 and 65 years old with a BMI between 27 kg/m2 and 40 kg/m2, having established Type 2 Diabetes Mellitus for at least 3 months, having inadequate glycemic control with an HbA1c level of 7.5% to 10%, being on a stable dose of Metformin and/or Sulfonylurea for up to 2 months prior to screening, and having specific fasting plasma glucose levels. The exclusion criteria include having Type 1 Diabetes Mellitus or other rare forms of diabetes, experiencing severe hypoglycemia episodes, having a history of acute diabetic complications, being treated with certain medications in the 3 months prior to screening, and receiving systemic glucocorticoids for 14 days or more.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease called eosinophilic esophagitis. The ICD-10 code for this disease is K20.0. The trial involves the use of two drugs, namely \"qax576 placebo\" and \"qax576\". The eligibility criteria for participants in this trial are listed under both inclusion and exclusion criteria. Inclusion criteria include being between the ages of 18-50, having symptomatic eosinophilic esophagitis, having tried an elimination diet, and being on a protocol pump inhibitor for at least two months prior to enrollment. Female participants must be women of non-childbearing potential and appropriate contraception must be used by males. Participants must also be able to communicate well with the investigator, understand and comply with the study requirements, and sign the informed consent. Exclusion criteria include having received corticosteroids within 3 months prior to the study, having any other eosinophilic disorders, having a history of clinical schistosomiasis or recent travel to areas with endemic schistosomiasis, having donated or lost a significant amount of blood within the past 8 weeks, having a history of immunodeficiency diseases or a positive HIV test result, and having a history of drug or alcohol abuse within the past 12 months. The sample concludes by mentioning that there may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is breast cancer. The ICDCodes associated with this disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being tested is called mkc-1. \n\nThe eligibility criteria for this trial include the following inclusion criteria:\n- The patient must have histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the breast.\n- The patient must be 18 years or older.\n- The Karnofsky performance status must be greater than or equal to 70%.\n- There must be radiographic or physical examination evidence of at least one site of unidimensionally-measurable disease, using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.\n- The patient must have failed both a taxane and an anthracycline, given sequentially or in combination, either in an adjuvant or metastatic setting.\n- All acute toxicity of any prior chemotherapy, surgery, or radiotherapy must have resolved to National Cancer Institute Common Toxicity Criteria (NCI CTC) Grade less than or equal to 1.\n- Lab results, within 10 days of MKC-1 administration, must meet certain criteria for hemoglobin, absolute neutrophil count, platelet count, serum creatinine, AST, serum albumin, total bilirubin, and alkaline phosphatase.\n- The patient must have signed informed consent.\n\nThe exclusion criteria for this trial include:\n- Pre-existing hepatomegaly with disease measures greater than or equal to 2 cm below the costal margin, secondary to malignancy.\n- Administration of cancer-specific therapy within specific periods prior to study drug initiation (chemotherapy less than 3 weeks prior, hormonal therapy less than one week prior, radiation therapy less than 2 weeks prior).\n- Being pregnant or lactating without employing effective birth control.\n- Having known central nervous system (CNS) metastases unless treated, clinically stable, and not requiring steroids.\n- Having clinical evidence of bowel obstruction, active uncontrolled malabsorption syndromes, or a history of total gastrectomy.\n- Administration of any investigational agent (therapeutic or diagnostic) within 4 weeks prior to receipt of study medication.\n- Uncontrolled hypercalcemia (serum calcium-corrected greater than 12 mg/dL).\n- Having a serious cardiac condition.\n- Having any medical conditions that, in the investigator's opinion, would impose excessive risk to the patient.\n- Having previous malignancies unless free of recurrence for at least 5 years, except basal cell carcinoma of the skin or carcinoma-in-situ of the uterine cervix.\n- Treatment with antiretroviral therapy metabolized through CYP3A4.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include brain and central nervous system tumors, extragonadal germ cell tumor, ovarian cancer, teratoma, and testicular germ cell tumor. The corresponding ICDCodes for these diseases are also provided.\n\nThe drugs being used in the trial are carboplatin, ifosfamide, and paclitaxel. The eligibility criteria for the trial are listed under \"criteria\" and include specific disease characteristics, patient characteristics, and prior concurrent therapy requirements.\n\nThe disease characteristics include histologically confirmed germ cell tumor, primary CNS GCT allowed, unidimensionally measurable disease or elevated serum tumor markers, and advanced disease resistant to cisplatin-based chemotherapy. Known residual disease after post-chemotherapy surgery is also allowed.\n\nThe patient characteristics include specific blood count requirements, creatinine clearance, liver function, pregnancy status, fertility and contraception, absence of active infection, and negative serology for various viruses.\n\nThe prior concurrent therapy requirements include recovery from recent surgery, a minimum time since prior chemotherapy, no prior high-dose therapy with autologous bone marrow transplantation, and no other concurrent chemotherapy or treatment.\n\nOverall, this sample provides a snapshot of the trial phase, diseases being studied, drugs used, and the eligibility criteria for potential participants.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on colorectal carcinoma.\n- ICD Codes: The ICD-10 codes associated with the disease are ['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31'].\n- Drugs: The drugs being tested in the trial are su011248, irinotecan, and cetuximab.\n- Criteria: The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". These criteria include factors such as histologic proof of adenocarcinoma, previous chemotherapy treatment, time elapsed since surgery or radiotherapy, organ and marrow function, measurable disease, age, performance status, life expectancy, and various exclusion factors such as previous treatment with specific drugs, medical conditions, and concurrent participation in other clinical trials.\n\nOverall, this sample record provides information about a clinical trial focused on colorectal carcinoma, its phase, the drugs being tested, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"minimal residual disease,\" \"leukemia, lymphoblastic, acute,\" and \"leukemia, myelogenous, acute.\" The corresponding ICDCodes for these diseases are \"K13.22,\" \"C91.01,\" \"C91.02,\" \"C91.00,\" \"C95.91,\" \"C95.92,\" \"Z80.6,\" \"Z85.6,\" \"C90.11,\" \"C90.12,\" and \"C91.01.\" The drugs being used in the trial are \"clofarabine,\" \"cytarabine intravenous,\" \"methotrexate,\" and \"intrathecal (it) cytarabine.\" The eligibility criteria for this sample include age restrictions, specific diagnosis requirements, minimal residual disease detection, blood counts, performance level, prior therapy recovery, renal and hepatic function, cardiac function, reproductive function, and exclusion criteria such as previous HSCT, previous treatment with clofarabine, specific disease conditions, infections, use of investigational agents, concomitant therapies, pregnancy or lactation, concurrent diseases or psychiatric disorders, previous malignancies, and active acute or chronic extensive GVHD.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is adult attention deficit hyperactivity disorder (ADHD). The ICD-10 codes associated with this disease are F90.2, F90.8, F90.9, F90.0, and F90.1. The drugs being tested in the trial are sep-225289 and placebo. \n\nThe eligibility criteria for the trial include meeting the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition; Text Revision (DSM-IV-TR) criteria for a primary diagnosis of ADHD, having a certain score on the ADHD Rating Scale-IV (ADHD RS-IV), having a certain score on the Clinical Global Impressions-Severity (CGI-S) scale, having a lifetime history of treatment with at least one medication for ADHD, and passing certain medical tests such as breath alcohol and urine drug screens.\n\nExclusion criteria for the trial include having a diagnosis of ADHD not otherwise specified, receiving adequate benefit from current ADHD medication, having other Axis I disorders or a history of bipolar disorder, substance abuse, or psychotic disorders, having certain medical conditions or taking certain medications, having a BMI outside the range of 18 to 35 kg/m2, and having a history of suicidal ideation or attempts.\n\nOverall, the sample provides information about the phase, disease, ICD-10 codes, drugs, and eligibility criteria for the clinical trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on prostate cancer. The diseases listed in the record include castrate resistant prostate cancer, chemotherapy naive prostate cancer, and prostate cancer. The corresponding ICD-10 codes for these diseases are also provided. The drugs being studied in this trial are pasireotide and everolimus. \n\nThe record also includes the eligibility criteria for participants in the trial. Inclusion criteria include being at least 18 years old, having histological confirmation of prostatic adenocarcinoma, having a PSA level of 2 ng/ml or higher, showing PSA progression or disease progression on imaging studies, being minimally symptomatic, discontinuing certain medications prior to the study, maintaining castrate levels of testosterone, having a Karnofsky Performance Status of 60% or higher, having a life expectancy of at least 3 months, and having adequate hematologic, renal, and liver function.\n\nExclusion criteria include having a currently active second malignancy other than non-melanoma skin cancers, having clinically significant cardiovascular disease, having progressive pulmonary disease, having known CNS disease (except for treated brain metastases), having poorly controlled diabetes mellitus or hypercholesterolemia, currently using chronic steroids, having active gallbladder disease or hepatitis, having high serum creatinine levels, and having prior use of a somatostatin analog or mTOR inhibitor for the treatment of prostate cancer.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is renal cell carcinoma. The trial is looking at the effectiveness of the drug sorafenib (also known as Nexavar or Bay43-9006) compared to a placebo. The eligibility criteria for participants include being over 18 years old, having refractory solid cancer that has failed previous treatments, having at least one measurable tumor, and having a life expectancy of at least 12 weeks. Other criteria include specific laboratory requirements for bone marrow, liver, and renal function, as well as exclusion criteria such as certain types of cancer, cardiac arrhythmia, congestive heart failure, active infections, HIV infection, and recent treatments like chemotherapy or radiotherapy. The sample also mentions exclusion criteria related to organ allograft, previous or concurrent cancer, and previous exposure to a Ras pathway inhibitor. Pregnant or breastfeeding patients are also excluded, and patients with substance abuse or medical or psychological conditions that may interfere with the study are not eligible. Any known or suspected allergies to the investigational agent or any other trial-related agents are also exclusion criteria. Finally, any unstable condition or potential safety risk to the patient that could affect their participation or compliance in the study is also considered.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of hepatitis C. The trial is specifically targeting patients with chronic, compensated hepatitis C genotype 1, who have the IL28B CC genotype and do not have advanced liver disease or cirrhosis. The trial requires participants to use two acceptable methods of birth control during the study and for a certain period after the study. \n\nThe sample also includes exclusion criteria, which are conditions that would disqualify a person from participating in the trial. These include having a non-genotype 1 HCV infection, previous treatment with certain medications for HCV, being HIV positive or co-infected with hepatitis B, having hepatocellular carcinoma or being evaluated for it, currently participating in another study, having certain medical conditions such as diabetes, hypertension, depression, substance abuse, seizure disorder, etc., and having a history of certain diseases or surgeries.\n\nOverall, the sample provides specific details about the phase, diseases, icd-10 codes, drugs, and eligibility criteria for the clinical trial.",
    "The sample from the table is for a clinical trial that is in phase 1/phase 2. The specific disease being studied is acute lymphoblastic leukemia. The corresponding ICD-10 codes for this disease are C91.01, C91.02, and C91.00. The drug being tested in this trial is native l asparaginase. \n\nThe eligibility criteria for this trial include the following inclusion criteria:\n- The subject must be between 1 and 55 years old.\n- The subject must have acute lymphoblastic leukemia or lymphoblastic lymphoma (excluding Burkitt lymphoma) and have relapsed after the first remission (medullary or SNC relapse).\n- Alternatively, the patient can still be refractory to first-line chemotherapy for acute lymphoblastic leukemia.\n- The patient must have given written informed consent, with two parents required for children.\n\nThe exclusion criteria for this trial are not provided in the sample.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is phase 2. The disease being studied is menopause, and it is associated with the ICD-10 codes 'E28.310' and 'E28.319'. The drugs being tested in this trial are 'esterified estrogens 1.25mg and methyltestosterone 2.5mg' and 'esterified estrogens 1.25 mg'. The eligibility criteria for participants in this trial include being hysterectomized, menopausal women between the ages of 30 and 65 years who are experiencing symptoms of estrogen and/or androgen deficiency that are not currently controlled by estrogen therapy.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is colitis, specifically ulcerative colitis. The ICD-10 codes associated with this disease are K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, and K51.811. The drugs being tested in this trial are placebo and anti-ip-10 antibody. The eligibility criteria for participants in this trial include having a clinical diagnosis of moderate to severe ulcerative colitis confirmed by endoscopic and histologic evidence, a Mayo score of 6 or higher with an endoscopic subscore of 2 or higher, and inadequate response or intolerance to conventional therapies. Exclusion criteria include a diagnosis of Crohn's Disease or Indeterminate Colitis, limited UC to the rectum, evidence of fulminant colitis, toxic megacolon, or bowel perforation, current need for a colostomy or ileostomy, and previous total or subtotal colectomy.",
    "The sample is a record from a table that contains information about clinical trials. In this particular record, the trial is in phase 2 and is focused on testicular cancer. The ICD-10 codes associated with this disease are ['E29.0', 'E29.1', 'E29.8', 'E29.9', 'E89.5', 'N50.811', 'N50.812']. The drugs being studied in this trial are paclitaxel, cisplatin, and gemcitabine. The record also includes the eligibility criteria for participants in the trial. The inclusion criteria specify that patients must have a histologically confirmed germ cell tumor with measurable metastatic disease, have been previously treated with standard BEP chemotherapy, be male, be at least 18 years old, have a performance status of 0, 1, 2, or 3, meet certain blood count and bilirubin level requirements, have adequate renal function, and have signed informed consent. The exclusion criteria state that patients with uncontrolled severe infections, serious concomitant systemic disorders, grade 2 or greater peripheral neuropathy, or a second malignancy other than basal or squamous cell skin cancer are not eligible for the trial.",
    "The sample is a phase 2 trial for the treatment of constipation. The trial is focused on patients who have opioid-induced constipation (OIC) and are currently taking a stable daily dose of opioids for chronic noncancer pain. The eligibility criteria include being between the ages of 18 and 75, having a body weight of at least 45 kilograms and a body mass index (BMI) of no more than 40 kilograms per square meter. Participants must also have less than 3 spontaneous bowel movements per week and experience at least one other bowel movement symptom, such as straining, lumpy hard stools, or a sense of incomplete evacuation. They must be willing to discontinue the use of laxatives and stool softeners during the study period, except as allowed by the protocol. \n\nThere are also exclusion criteria, such as being pregnant, having certain abnormal blood test results, recent history of heart attack or unstable angina, active malignancy, taking opioids primarily for fibromyalgia, taking certain medications or substances, having gastrointestinal or pelvic disorders that affect bowel function, and having a history of alcoholism or illicit drug dependence or abuse. Participants must also not have positive results on a urine drug screen indicating illicit drug use, excluding opioids.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is colorectal cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug mentioned is bevacizumab (also known as Avastin). The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include patients with metastatic colon or rectal cancer who have progressed or relapsed after first-line treatment, and women of childbearing potential must use contraception for at least 6 months after the last dose of bevacizumab. Exclusion criteria include patients scheduled for a first-line systemic treatment, those with untreated brain metastases, spinal cord compression, or primary brain tumors, pregnant or lactating women, recent major surgical procedures or significant traumatic injuries, and recent treatment with investigational drugs or participation in other investigational studies.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"urinary bladder, overactive.\" The corresponding ICD-10 code for this disease is \"N32.81.\" The trial involves two drugs, \"uk-369,003\" and \"placebo.\" The eligibility criteria for participants include being male and aged 18 years and above, having a documented clinical diagnosis of overactive bladder with urinary frequency of at least 8 times per 24 hours and experiencing more than 1 urgency episode per 24 hours. The exclusion criteria include having neurological diseases that affect bladder function and having a urinary tract infection.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are leukemia and acute lymphocytic leukemia. The ICDCodes associated with these diseases are provided as well. The drug being tested in this trial is \"velcade\". The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include requirements such as voluntary informed consent, specific birth control methods, certain health parameters, confirmed diagnosis and prior therapy, among others. The exclusion criteria list conditions that would prevent a patient from participating in the trial, such as low platelet or neutrophil count, peripheral neuropathy, heart conditions, hypersensitivity to certain substances, pregnancy or breastfeeding, recent use of other investigational drugs, history of other malignancies, uncontrolled illnesses or infections, and any other conditions that may interfere with the patient's ability to participate or adhere to the study procedures.",
    "The sample is a phase 2 clinical trial for patients with multiple sclerosis. The trial is investigating the effectiveness of the drugs alemtuzumab, fludarabine, and cyclophosphamide in treating the disease. The eligibility criteria for participants include being between the ages of 18-60, having a confirmed diagnosis of multiple sclerosis according to the McDonald's criteria, being HIV negative, having an EDSS score between 3.5-5.5, and being able to provide written consent. Participants must also have shown inflammatory disease despite previous treatment with other disease modifying therapies. Exclusion criteria include a diagnosis of primary progressive MS.",
    "The sample from the table is for a phase 2 trial. The disease being studied is neuropathic pain. The corresponding ICD-10 codes for this disease are E85.1, E85.0, N31.0, N31.1, N31.2, E10.610, and E11.610. The drug being tested is ralfinamide. The eligibility criteria for this trial include being a male or female patient, females being post-menopausal for at least 12 months (or 24 months in India, Poland, and Austria), and being diagnosed with current neuropathic pain by a neurologist. The exclusion criteria are the same as the inclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on colorectal cancer. The ICD-10 codes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being studied in this trial are bevacizumab (brand name Avastin), capecitabine, and irinotecan. The eligibility criteria for this trial include being an adult patient aged 18 or older, having colon or rectal cancer with metastases, and having at least one measurable lesion. The exclusion criteria include having received previous systemic treatment for advanced disease, having undergone radiotherapy within 4 weeks before the study, taking daily aspirin or other medications that can cause gastrointestinal ulceration, and having any other malignancies diagnosed within the last 5 years, except for basal cell cancer or cervical cancer in situ.",
    "The sample is a phase 2 clinical trial for breast cancer. The trial is focused on patients with histologically confirmed invasive breast cancer who have not received any previous treatment. The patients must be eligible for breast-conserving surgery and have a clinical stage of cT1-3, cN0-2 disease with no evidence of metastatic disease. The trial specifically targets patients with HER2-positive primary tumors, which can be confirmed through IHC testing or FISH testing. Patients with inflammatory breast cancer or bilateral breast cancer are excluded, although those who have been treated for cancer in the contralateral breast can be included if there has been at least a 5-year interval since their last systemic treatment. The trial does not specify hormone receptor status.\n\nIn terms of patient characteristics, participants must have a WHO performance status of 0-1 and there are no specific requirements regarding menopausal status. Various blood tests are required, including a white blood cell count of at least 3.5 x 10^9/L, an absolute neutrophil count of at least 1.5 x 10^9/L, and a platelet count of at least 100 x 10^9/L. Other criteria include a hemoglobin level of at least 10 g/dL, specific limits for bilirubin and liver enzyme levels, and a creatinine level of no more than 1.5 mg/dL or a creatinine clearance of at least 60 mL/min. Lung function tests are also required, with a minimum FEV of 55% and spirometry and DLCO levels of at least 50% of normal. Oxygen saturation must be above 88% at rest on room air. Pregnant or nursing individuals are not eligible, and a negative pregnancy test is required. Fertile patients must use effective contraception. There are also restrictions for individuals with known hypersensitivity to certain drugs and those with hypercholesterolemia/hypertriglyceridemia. Patients with uncontrolled infections or other severe and/or uncontrolled medical conditions are excluded. The trial also excludes individuals with a history of HIV seropositivity or any psychological, familial, sociological, or geographical condition that could hinder compliance with the study protocol and follow-up schedule. Patients must be willing to participate in biological investigations and must not be deprived of liberty or placed under guardianship. They must also be affiliated with a Social Security System.\n\nRegarding prior concurrent therapy, patients must meet the disease characteristics mentioned earlier. They must have discontinued other investigational drugs more than 30 days before the screening visit. Additionally, they must have discontinued strong inhibitors or inducers of the isoenzyme CYP3A, such as rifabutin, rifampicin, clarithromycin, ketoconazole, itraconazole, voriconazole, ritonavir, and telithromycin, more than 5 days before randomization. No other concurrent anti-cancer treatments, including chemotherapy, immunotherapy/biological response modifiers, endocrine therapy, or radiotherapy, are allowed during the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the diseases sickle cell anemia and thalassemia. The diseases are identified by their corresponding ICD-10 codes. The drugs being studied are l-glutamine and a placebo. The sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being at least five years old, having a diagnosis of sickle cell anemia or sickle \u00df0-thalassemia, experiencing at least two episodes of painful crises within the past year, and having received continuous treatment with an anti-sickling agent for at least three months. The patient or their legally authorized representative must have given written informed consent, and female patients of child-bearing potential must agree to practice birth control during the study. Exclusion criteria include recent hospitalization for a significant medical condition, untreated diabetes mellitus with high fasting blood sugar, high prothrombin time International Normalized Ratio (INR), low serum albumin, recent receipt of blood products, history of uncontrolled liver disease or renal insufficiency, pregnancy or lactation, recent treatment with experimental anti-sickling medication or treatment (except hydroxyurea), recent treatment with experimental drugs, and any factors that would make it difficult for the patient to comply with the study requirements.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease mentioned is chronic obstructive pulmonary disease (COPD). The ICDCodes associated with this disease are \"J44.9\", \"J44.1\", and \"J44.0\". The drugs being studied in this trial include \"aclidinium 400 \u03bcg / formoterol 12 \u03bcg\", \"aclidinium 400 \u03bcg / formoterol 6 \u03bcg\", \"aclidinium 400 \u03bcg\", \"formoterol 12 \u03bcg\", and \"placebo\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being willing to participate in the study, being aged 40 to 80 years, having a diagnosis of stable, moderate to severe COPD, being a current or former cigarette smoker with a smoking history of at least 10 pack-years, having specific FEV1 values, having post-albuterol/salbutamol FEV1/FVC values below 70%, meeting certain health requirements, and having stable COPD symptoms and FEV1 values. \n\nExclusion criteria include recent hospitalization for a COPD exacerbation, respiratory tract infections or signs of a COPD exacerbation or respiratory infection within 6 weeks before screening, presence of other clinically significant respiratory conditions or asthma, recent use of theophylline, hypertension, chronic use of oxygen therapy, exercise-induced bronchospasm, high body mass index, recent participation in a pulmonary rehabilitation program, cardiovascular conditions, uncontrolled infection from HIV or active hepatitis, symptomatic prostatic hypertrophy or bladder neck obstruction, narrow-angle glaucoma, history of hypersensitivity reaction to certain medications, prolonged QT interval, abnormal clinical laboratory test results or physical examination, concurrent medical conditions that may interfere with the study, and irregular day/night or waking/sleeping cycles.\n\nOverall, this sample provides information about a Phase 2 clinical trial focusing on COPD, the drugs being studied, and the eligibility criteria for participants.",
    "The sample provided is for a phase 2 clinical trial. The diseases being studied in this trial are anemia, chronic kidney disease, and chronic renal failure. The corresponding ICD-10 codes for these diseases are also listed. The drugs being tested in this trial are placebo and peginesatide. \n\nThe eligibility criteria for participants in this trial include being informed about the investigational nature of the study and providing written consent. Participants must be between 18 and 75 years old, with pre-menopausal females needing to have a negative pregnancy test and practice contraception. They must have stage 3 or 4 chronic kidney disease, not requiring dialysis. Hemoglobin levels, serum ferritin levels, transferrin saturation, serum folate levels, and vitamin B12 levels must meet certain criteria. Participants must also meet weight, white blood cell count, and platelet count requirements.\n\nExclusion criteria for this trial include prior treatment with any erythropoiesis stimulating agent, history of pure red cell aplasia, recent red blood cell transfusion, certain hemoglobinopathies, chronic or symptomatic inflammatory diseases, significant infections, febrile illness, uncontrolled secondary hyperparathyroidism, poorly controlled hypertension, recent epileptic seizure, chronic congestive heart failure, high likelihood of early withdrawal or interruption of the study, malignancy (except non-melanoma skin cancer), life expectancy less than 12 months, anticipated elective surgery during the study period, and previous exposure to any investigational agent within a certain timeframe.",
    "The sample is a phase 2 trial for the treatment of various types of glioblastoma multiforme, including gliosarcoma. The trial is specifically for patients with recurrent disease who have shown radiographic evidence of tumor progression. The eligibility criteria include having failed prior radiotherapy, having a Karnofsky performance status of 60-100%, and a life expectancy of more than 8 weeks. Other criteria include specific blood counts and levels, negative pregnancy test, and no uncontrolled significant medical illnesses. The sample also mentions restrictions on concurrent medications and previous treatments.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is lymphoma. The ICDCodes associated with this disease are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drugs being used in the trial are bortezomib and gemcitabine hydrochloride. The eligibility criteria for this trial include specific disease characteristics, patient characteristics, and prior concurrent therapy requirements.",
    "The sample from the table is for a phase 2 clinical trial for the treatment of Hodgkin lymphoma. The sample includes information about the diseases, icd-10 codes, drugs, and eligibility criteria. The disease mentioned in the sample is Hodgkin lymphoma. The icd-10 codes associated with the disease are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drugs being tested in the trial are '12 week stanford v chemotherapy', '4 cycles of vamp chemotherapy', '2 alternating cycles of vamp/cop chemotherapy', and '3 alternating cycles of vamp/cop chemotherapy'. The eligibility criteria include having histologically confirmed previously untreated Hodgkin's disease, being 21 years of age or younger, having Ann Arbor stages IIB-IV, and not having received prior treatment. There are also specific criteria for patients with favorable risk features and unfavorable risk features.",
    "The sample from the table is for a phase 2 trial. The disease being studied is myocardial infraction. The corresponding ICD-10 codes for this disease are I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, and I23.8. The drug being tested is epoetin alfa. The eligibility criteria for inclusion in the trial include having undergone successful primary PCI (TIMI 2/3) for a first acute myocardial infraction, experiencing chest pain suggestive of acute myocardial infraction, having symptom onset less than 12 hours before hospital admission (or less than 24 hours in case of ongoing ischemia), having an ECG with ST-T segment elevation greater than 1 mV in 2 or more leads, and having TIMI flow 0/1 before primary PCI on diagnostic coronary angiography. The exclusion criteria include having hemoglobin levels greater than 10.6 mmol/L, anticipating additional revascularization within 4 months, being in cardiogenic shock, having other serious medical conditions, being pregnant or breastfeeding, having malignant hypertension, having end-stage renal failure (creatinine > 220 micromol/l), having previous treatment with rh-EPO, having received a blood transfusion less than 12 weeks prior to randomization, having polycythemia vera, having a previous acute myocardial infraction, having a concomitant inflammatory or malignant disease, having recent trauma or major surgery, being unwilling to sign informed consent, and having atrial fibrillation.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on various types of breast cancer, including estrogen receptor-negative breast cancer, male breast cancer, progesterone receptor-negative breast cancer, recurrent breast cancer, stage IIIB breast cancer, stage IIIC breast cancer, and stage IV breast cancer. The diseases are identified using ICD-10 codes. The trial involves the use of the drug saracatinib. The eligibility criteria for participants include having histologically or cytologically confirmed breast cancer, having unresectable or locally advanced/metastatic disease, being estrogen receptor-negative and progesterone receptor-negative, having measurable disease, and meeting various other medical and health criteria. The sample also includes exclusion criteria, such as having certain cardiac or lung conditions, unresolved toxicity from previous treatments, and concurrent use of certain medications.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is listed as \"phase 2/phase 3\". The disease mentioned in this sample is \"anaplastic thyroid cancer\". The corresponding ICD-10 codes for this disease are \"C73\", \"D34\", \"D44.0\", and \"Z85.850\". The drugs being used in the trial are \"ca4p\", \"paclitaxel\", and \"carboplatin\". The eligibility criteria for participants in the trial are listed, including requirements such as confirmation of the disease through pathology review, previous treatment history, performance score, and various health parameters. There are also exclusion criteria listed, which include factors such as brain metastasis, hypersensitivity to certain drugs, and certain medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease mentioned is \"myelodysplastic syndrome\". The ICDCodes associated with this disease are \"D46.9\", \"D46.C\", and \"D46.Z\". The drugs being used in this trial are \"antithymocyte globulin (atg)\" and \"prednisone\". \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The patient must have a diagnosis of MDS that meets the International Prognostic Scoring System (IPSS) criteria for low risk, intermediate-1 risk, or intermediate-2 risk.\n- The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.\n- The patient must be willing and able to attend study visits.\n- The patient must be willing to use acceptable forms of contraception prior to study entry and throughout the study.\n\nExclusion Criteria:\n- The patient must not have any serious medical illness that might limit survival to less than 2 years.\n- The patient must not have any other uncontrolled condition or illness.\n- The patient must not have received prior anti-lymphocyte serotherapy.\n- The patient must not have proliferative chronic myelomonocytic leukemia.\n- The patient's MDS must not be caused by radiotherapy, chemotherapy, and/or immunotherapy for cancerous or autoimmune diseases.\n- The patient must not have a previous or current cancer.\n- The patient must not be receiving any other investigational agents.\n- The patient must not have certain abnormal lab values.\n- The patient must not have a history of a grade 2 National Cancer Institute common toxic criteria allergic reaction to rabbit proteins.\n- The patient must not have a psychiatric illness that might interfere with study participation.\n- The patient must not have HIV-1 infection.\n- The patient must not be pregnant or breastfeeding.\n\nThis information provides details about the phase, disease, ICDCodes, drugs, and eligibility criteria for this particular clinical trial sample.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are refractory multiple myeloma, stage I multiple myeloma, stage II multiple myeloma, and stage III multiple myeloma. The corresponding ICDCodes for these diseases are provided as well. The drug being tested in this trial is called \"alvocidib\". \n\nThe eligibility criteria for this trial include a diagnosis of relapsed or refractory multiple myeloma, with a minimum Durie-Salmon stage I at diagnosis. Patients with non-secretory or oligo-secretory MM must have at least 30% bone marrow plasma cells, while patients with secretory MM must have measurable disease defined by certain levels of serum monoclonal protein or urinary M-spike. \n\nPatients must have received at least 1, but no more than 5 prior therapy regimens, with certain conditions regarding the use of corticosteroids and/or thalidomide. The performance status should be ECOG 0-2, or ECOG 0-3 if secondary to neuropathy or acute bone event. Various blood test results should be within certain limits, and there should be no recent myocardial infraction or uncontrolled serious medical conditions or infections. Patients should not have any other active malignancy, should not be pregnant or nursing, and should have a negative pregnancy test. Fertile patients must use effective contraception. \n\nThere are additional criteria related to prior treatments, concurrent therapies, and the use of corticosteroids. For example, patients should not have had prior allogeneic stem cell transplantation, and there should be a certain time gap since the last use of thalidomide, bortezomib, or tipifarnib. Concurrent bisphosphonates are allowed if the patient was on a stable dose before the study entry.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is a combination of phase 1 and phase 2.\n- Diseases: The list of diseases being studied, which in this case includes pancreatic neoplasms and bile duct neoplasms.\n- ICD Codes: The ICD-10 codes associated with the diseases, with the code provided being C25.3 for pancreatic neoplasms.\n- Drugs: The drugs being used in the trial, which include oxaliplatin, capecitabine, and sorafenib.\n- Criteria: The eligibility criteria for participants in the trial, including various medical and demographic requirements.\n\nThe inclusion criteria specify that patients must have locally advanced inoperable or metastatic adenocarcinoma of the pancreas or biliary tract, have not received more than one systemic treatment for their disease, be at least 18 years old, have an ECOG performance status of 0-2, and meet certain organ and marrow function requirements.\n\nThe exclusion criteria state that patients should not be receiving radiation therapy or other systemic cancer therapies, should not have known brain metastases, and should not have a history of allergy to the specified drugs or antiemetics. Other exclusion criteria include uncontrolled intercurrent illnesses, pregnancy or nursing, recent major surgery or traumatic injury, and various other medical conditions or treatments that may affect the patient's ability to participate in the trial.\n\nOverall, this sample provides a snapshot of the information contained in the table, including the phase, diseases, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied are extensive stage small cell lung cancer, limited stage small cell lung cancer, and recurrent small cell lung cancer. The corresponding ICDCodes for these diseases are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being tested in this trial is dasatinib.\n\nThe eligibility criteria for this trial include the following:\n- The patient must have histologically or cytologically confirmed small cell lung cancer (SCLC) of limited or extensive stage.\n- The patient must have progressive or recurrent disease after an initial response to first-line treatment with platinum-based chemotherapy, with or without concurrent definitive radiotherapy to the chest.\n- The patient must have measurable disease, defined as at least one unidimensionally measurable lesion of at least 20 mm by conventional techniques or at least 10 mm by spiral CT scan.\n- Certain types of lesions, such as bone lesions, leptomeningeal disease, ascites, pleural or pericardial effusion, abdominal masses, cystic lesions, and previously irradiated tumor lesions, are not considered measurable.\n- The patient must not have known brain metastases, unless they have been previously treated and are neurologically stable for at least 4 weeks.\n- The patient must have an ECOG performance status of 0-1.\n- The patient must meet certain blood count, bilirubin, creatinine, and AST levels within specified ranges.\n- The patient must not be pregnant or nursing and must have a negative pregnancy test.\n- The patient must not have significant cardiac disease or certain cardiac abnormalities.\n- The patient must have had no more than 1 prior chemotherapy regimen and no prior use of dasatinib or similar compounds.\n- The patient must have had at least 2 weeks since prior definitive or palliative radiotherapy, at least 2 weeks since prior surgery and recovered, and at least 1 week since prior and no concurrent agents with proarrhythmic potential, CYP3A4 inhibitors or inducers, or grapefruit concentrate.\n- The patient must not be receiving concurrent palliative radiotherapy, hormones or other chemotherapeutic agents (except for certain exceptions), combination antiretroviral therapy for HIV-positive patients, or any other concurrent chemotherapeutic or investigational agents.\n- Fertile patients must use effective contraception during and for at least 6 weeks after completion of study therapy.\n\nThis information provides details about the phase, diseases, ICDCodes, drugs, and eligibility criteria for this particular clinical trial sample.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial include doxorubicin and cyclophosphamide (ac) + bevacizumab, docetaxel (t) + bevacizumab, docetaxel, doxorubicin, cyclophosphamide (tac) + bevacizumab, docetaxel, carboplatin, trastuzumab (tch) + bevacizumab, bevacizumab and trastuzumab maintenance therapy, and bevacizumab maintenance therapy. The eligibility criteria for participants include being a woman aged 18 or older, having histologically proven breast cancer, and meeting specific surgical and lymph node criteria. Other criteria include HER2/neu status, cardiac function, hematology evaluation, hepatic function evaluation, and staging work-up. The exclusion criteria include prior systemic anticancer therapy, prior radiation therapy, bilateral invasive breast cancer, pregnancy or lactation, cardiac disease, and other serious illnesses or medical conditions.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on two diseases: lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO). The ICD-10 codes associated with these diseases are N40.2, N40.3, N40.0, and N40.1. The trial involves several drugs, including solifenacin succinate, tamsulosin hydrochloride, placebo to solifenacin, and placebo to tamsulosin. The eligibility criteria for participants include being diagnosed with LUTS and BOO, having a Bladder Outlet Obstruction Index (BOOI) of 20 or higher, and having a total International Prostate Symptom Score (IPPS) of 8 or higher. Exclusion criteria include a history of urinary retention, current urinary tract infection, known history of chronic inflammation or obstruction, history of carcinoma or pelvic radiation therapy, and significant cardiovascular or cerebrovascular diseases within the past 6 months.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is amyotrophic lateral sclerosis (ALSO). The corresponding ICD-10 code for ALSO is G12.21. The drug being tested in this trial is memantine. \n\nThe eligibility criteria for this trial are as follows:\n1. Age between 18 and 85.\n2. Both males and females are eligible.\n3. Patients must have clinically definite ALSO as per the El Escorial criteria.\n4. Patients must have elevated levels of Tau in their cerebrospinal fluid (CSF).\n\nThe exclusion criteria for this trial are as follows:\n1. Patients with forced vital capacity (FVC) below 1.5 L or those who require respiratory assistance.\n2. Patients with a history of liver disease.\n3. Patients with severe renal failure.\n4. Patients with a history of intolerance to Riluzole or Memantine.\n5. Patients with any other co-morbid condition that would make completion of the trial unlikely.\n6. Female patients who are pregnant or breastfeeding, or female patients of childbearing age who are unwilling to use birth control.\n7. Patients who are currently taking any trial medications. Non-trial medications are not a cause for exclusion.\n8. Patients who are unwilling to provide consent for the trial.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is colon cancer. The ICDCodes associated with the disease are C18.2, C18.4, C18.6, C18.7, C18.9, D12.2, and D12.3. The drugs being used in the trial are ngr-htnf, oxaliplatin, and capecitabine. The eligibility criteria for this trial include age (patients must be 18 years or older), previous treatments received, life expectancy, performance status, and various baseline health parameters such as blood counts, liver function, and kidney function. The sample also includes exclusion criteria, which specify conditions that would disqualify a patient from participating in the trial, such as concurrent anticancer therapy, certain cardiac conditions, uncontrolled hypertension, and pregnancy or lactation.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"breast neoplasms\". The corresponding ICD-10 codes for this disease are listed as \"C79.81\", \"D24.1\", \"D24.2\", \"D24.9\", \"D49.3\", \"C44.501\", and \"D48.60\". The drug being studied in this trial is \"sunitinib\". The record also includes eligibility criteria for the trial, such as the requirement of a histologically or cytologically proven diagnosis of breast cancer, the presence of metastatic or locally recurrent disease that is not amenable to resection or radiation therapy, and the presence of at least one measurable lesion as per RECIST criteria. Additionally, there are exclusion criteria, such as the exclusion of patients with inflammatory breast cancer and those who have previously been treated with VEGF inhibitors, unless it was in the adjuvant setting at least 12 months ago.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on studying the effects of certain drugs on patients with chemotherapy-induced nausea and vomiting. The diseases mentioned in the sample are \"nausea and vomiting, chemotherapy-induced\" and \"chemotherapy-induced nausea and vomiting\". The corresponding ICD-10 codes for these diseases are \"D61.810\". The drugs being studied are \"gw679769\", \"dexamethasone\", and \"ondansetron hydrochloride\". \n\nThe sample also includes the eligibility criteria for participants in the trial. The inclusion criteria state that participants must be willing to provide informed consent, have a solid malignant tumor and not have received chemotherapy before, and be scheduled to receive chemotherapy as outlined in the study protocol. The exclusion criteria state that participants must not have received any investigational product within the past 30 days, must not be pregnant or of childbearing potential without using specific barrier methods, must not be scheduled to receive radiation therapy to the abdomen or pelvis within seven days prior to starting the study medication, must not be currently under treatment for a condition that may cause nausea or vomiting, and must not have a history of peptic ulcer disease.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on breast neoplasms and mtor protein. The icd-10 codes associated with these diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being studied in this trial are tamoxifen and everolimus. The eligibility criteria for participants in this trial include being a menopausal female patient aged over 18 years, having histologically proven breast adenocarcinoma, being ER and/or PR positive receptors and HER2 negative, having previously received first or second line of hormonotherapy for metastatic disease, having previously been treated with anti-aromatase in adjuvant and/or in metastatic line, having one or several measurable or evaluable metastatic lesions, having at least one target lesion not previously irradiated, having an ECOG Performance status less than 2, having adequate biological values, and having given consent by signing an informed consent form. There are also exclusion criteria, such as having only local metastatic disease that can be treated by surgery, having uncontrolled brain metastases, pulmonary carcinomatosal lymphangitis, or hepatic metastases, having previous treatment with Tamoxifen unless in adjuvant and terminated more than a year before metastatic relapse, needing immediate local antalgic radiotherapy, having thrombo-embolism disease, having serious concomitant pathology or uncontrolled conditions that could compromise participation in the study, having a history of another malignancy within the past 5 years (with some exceptions), having a history of significant cardiovascular impairment, having any medical or psychiatric condition that would preclude participation, having a known allergy to the study compounds, not being regularly available due to geographical, social, or family reasons, having a history of renal, hepatic, or metabolic pathology that could interfere with metabolism or elimination of the study product, having deficiencies of the upper intestinal tract or malabsorption syndrome, being pregnant, breastfeeding, or using inadequate contraception, being treated with experimental drugs (mTor inhibitor or tyrosin kinase inhibitor), or being treated with molecules that interfere with isoenzyme CYP3A.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of vascular disease, specifically critical lower limb ischemia. The ICD-10 codes associated with these diseases are ['I73.9', 'D57.03', 'D57.213', 'G46.8', 'I73.89']. The drugs being studied in this trial are 'hemospan (mp4ox)' and 'voluven (hes 130/0.4)'. \n\nThe sample also includes the eligibility criteria for the trial. Inclusion criteria include being an adult male or female patient with surgically sterile or post-menopausal status, having a history of pain at rest and/or ulceration, having an ankle systolic BP/Brachial systolic BP Index (ABI) <0.6, and having ankle systolic BP <70 mmHg and/or toe systolic BP <50 mmHg. Patients must have received information about the investigational product and the protocol, and have signed an Informed Consent Form (ICF) approved by the independent Ethics Committee (EC).\n\nExclusion criteria include severe congestive heart failure, any condition that would limit the patient's ability to complete the study, recent acute coronary syndrome, severe dementia or clinically significant psychiatric disorder, untreated or uncontrolled hypertension, smoking or use of nicotine-containing products within the previous 24 hours, systemic rheumatic disease, oral steroid therapy (excluding intermittent inhaler use), chronic hepatic disease, chronic renal disease, expectation of poor patient compliance with the study protocol, scheduled surgical procedure within 7 days, involvement in any other investigational drug or device trial within 30 days, and being a professional or ancillary personnel involved with the study.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2. The diseases being studied are extragonadal germ cell tumor, teratoma, and testicular germ cell tumor. The ICDCodes associated with these diseases are E29.0, E29.1, E29.8, E29.9, E89.5, N50.811, and N50.812. The drugs being used in the trial are carboplatin, cisplatin, etoposide phosphate, and vincristine sulfate. The eligibility criteria for patients participating in the trial include specific disease characteristics, such as nonseminoma germ cell tumor diagnosis and poor prognosis features. Patient characteristics include being male, having a WHO performance status of 0-3, and a glomerular filtration rate above 50 mL/min. Prior concurrent therapy should not include any chemotherapy, except for low-dose chemotherapy to stabilize the disease before the study therapy.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of squamous cell carcinoma of the head and neck (SCCHN). The trial includes a list of ICDCodes, which are specific codes used to classify diseases. The drugs being studied in this trial are bevacizumab, erlotinib, and sulindac. \n\nThe eligibility criteria for this trial are as follows:\n- The patient must have a histologically/cytologically documented SCCHN, excluding salivary gland primary sites.\n- The patient must be 18 years of age or older.\n- The patient must have locoregional and/or metastatic disease that is not suitable for treatment by primary surgical resection or radiotherapy.\n- The patient must have locoregional and/or metastatic disease that has failed to respond to or relapsed from at least one prior chemotherapy or chemoradiotherapy.\n- The patient must have a life expectancy of at least 4 months.\n- The patient must have an ECOG performance status of 0-2.\n- Female patients of child-bearing potential must use effective means of contraception.\n\nThe exclusion criteria for this trial are as follows:\n- The patient must not have had any other malignancy within 5 years, except non-melanomatous skin cancer, or carcinoma in situ of the cervix, bladder, or head and neck.\n- The patient must not be receiving concurrent anticancer therapy other than that of this study.\n- The patient must not have received any anticancer drug within 28 days prior to day 1.\n- The patient must not have received radiotherapy within 28 days prior to day 1.\n- The patient must not have any unresolved toxicity greater than NCI-CTCAE v 3.0 grade 2 from prior systemic anticancer therapy.\n- The patient must not have received any prior therapy that targets the ErbB and/or VEGF pathways.\n- The patient must not be receiving concurrent therapy with any NSAID.\n- The patient must not have a known hypersensitivity characterized by acute bronchospasm, urticaria, and/or rhinitis to NSAIDs, including aspirin.\n- The patient must not have a serum creatinine level greater than 1.5 times the upper limit of normal (ULN).\n- The patient must not have abnormal liver function tests (LFTs) as outlined in the protocol.\n- The patient's blood pressure must not be greater than 150/100mmHg.\n- The patient must not have active unstable angina or a myocardial infraction within the past 6 months.\n- The patient must not have NYHA Grade II or greater congestive heart failure.\n- The patient must not have a history of stroke within the past 6 months.\n- The patient must not have clinically significant active peripheral vascular disease.\n- The patient must not have an absolute neutrophil count less than 1000/mm3 or platelets less than 100,000/mm3.\n- The patient must not have evidence of bleeding diathesis or coagulopathy.\n- The patient must not have a tumor encasing the carotid artery or other major vessel that is at risk for tumor-related hemorrhage.\n- The patient must not have central nervous system or brain metastases.\n- The patient must not have had a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1, or anticipate the need for a major surgical procedure during the course of the study.\n- The patient must not have had minor surgical procedures such as fine needle aspiration or core biopsy within 5 days prior to day 1.\n- The patient must not be pregnant or lactating.\n- The patient must not have a history of abdominal fistula or intra-abdominal abscess within the past 6 months.\n- The patient must not have a history of gastrointestinal ulcer, perforation, or bleeding within the past 6 months.\n- The patient must not have a serious non-healing wound or ulcer or active uncontrolled infection.\n- The patient must not have had a bone fracture within the past 28 days.\n- The patient must not have active substance abuse, defined by substance abuse of alcohol, cocaine, or intravenous drug use within the past 6 months.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the diseases being studied are chronic hepatitis C and hepatitis C virus (HCV) infection. The ICDCodes associated with these diseases are provided as well. The drugs being tested in this trial are abt-267, pegylated interferon (pegIFN), and ribavirin (RBV). The sample also includes the eligibility criteria for participants, including requirements for treatment-naive individuals, specific birth control practices for males, and postmenopausal or surgically sterile status for females. Additionally, the criteria specify that participants must have chronic hepatitis C virus (HCV) genotype-1 infection and documented absence of cirrhosis. The exclusion criteria include restrictions for pregnant or breastfeeding females, recent use of contraindicated medications, and the presence of certain medical conditions or abnormalities in screening laboratory results.",
    "The sample in the table represents a clinical trial in phase 2. The trial focuses on two types of diseases: non-small-cell lung carcinoma and adenocarcinoma. The corresponding ICD-10 codes for these diseases are 'D02.20', 'D02.21', 'D02.22' for non-small-cell lung carcinoma, and 'C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31' for adenocarcinoma.\n\nThe trial involves the use of several drugs, including bevacizumab, carboplatin, paclitaxel, and ag-013736 (axitinib). The eligibility criteria for participants in the trial are as follows:\n\nInclusion Criteria:\n- Advanced non squamous cell, lung cancer\n- No prior treatment for lung cancer except prior adjuvant therapy if last dose was >12 months prior to enrollment\n\nExclusion Criteria:\n- Prior therapy for advanced lung cancer\n- The need for blood-thinners\n- Coughing up blood",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of heart failure. The trial includes patients who meet certain eligibility criteria. The diseases column lists the disease names, and the icdcodes column contains the corresponding ICD-10 codes for the diseases. The drugs column lists the names of the drugs being tested in the trial. The criteria column provides detailed inclusion and exclusion criteria for patient eligibility. These criteria include factors such as age, gender, medical history, physical examination results, laboratory findings, and medication usage.",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is phase 2. The disease being studied is hepatitis C. The ICD-10 codes associated with the disease are B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, and B15.9. The drugs being tested in the trial are ach-0141625 (sovaprevir), placebo, pegylated interferon alpha-2a, and ribavirin. The eligibility criteria for the trial include being 18 years or older, having chronic hepatitis C genotype 1, being treatment naive, and meeting certain requirements for females regarding pregnancy and contraception. There are also exclusion criteria, such as having a BMI over 36 kg/m2, being pregnant or nursing, having coinfection with HBV and/or HIV, and having a history of drug or alcohol dependence. The sample also includes additional exclusion criteria related to medical history, laboratory abnormalities, liver disease, psychiatric disease, malignancy, and other factors.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is lymphoma, and the corresponding ICDCodes are listed as \"S33.110S\", \"S33.111S\", \"S33.120S\", \"S33.121S\", \"S33.130S\", and \"S33.131S\". The drugs being used in the trial are cyclophosphamide, doxorubicin, vincristine, and prednisone. \n\nThe eligibility criteria for this trial include:\n1. Patients with newly diagnosed stage I and II nasal Natural Killer (NK) cell lymphoma.\n2. Adequate blood cell counts (ANC > 1000) at baseline or willingness to accept supportive measures.\n3. Adequate liver function and renal function.\n4. Left ventricular ejection fraction must be at least 50%.\n5. Male patients must use a barrier method of contraception or abstain from heterosexual activity.\n6. Female patients must use two adequate barrier methods of contraception or abstain from heterosexual activity, or be postmenopausal or surgically sterilized.\n7. Female patients of childbearing potential must have a negative serum pregnancy test.\n8. Patients must have the ability to give informed consent.\n\nThe exclusion criteria for this trial include:\n1. Patients with active Hepatitis B and/or Hepatitis C infection.\n2. Patients with active infections requiring specific anti-infective therapy.\n3. Patients known to be HIV positive.\n4. Patients with pre-existing cardiovascular disease requiring ongoing treatment.\n5. Patients with prior exposure to anthracyclines.\n6. Patients who are pregnant or breastfeeding.\n7. Patients with psychiatric illness and/or social situations that would limit compliance with the study medication and requirements.\n8. Prior radiation to the site of current primary disease, if re-treatment would violate known radiation dose tolerance limits for that site.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is sarcoma. The ICD-10 codes associated with the disease are C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, and C92.32. The drugs being used in the trial are cyclophosphamide, dexrazoxane hydrochloride, disaccharide tripeptide glycerol dipalmitoyl, doxorubicin hydrochloride, and vincristine sulfate. \n\nThe eligibility criteria for the trial include having a histologically proven high-risk Ewing's family of tumors, such as Ewing's sarcoma of bone, extraosseous Ewing's sarcoma, or peripheral neuroepithelioma. Patients must also meet certain characteristics, such as having metastatic disease at diagnosis, a primary tumor of the humerus, femur, or trunk, a bulky tumor (greater than 8 cm), and elevated LDH prior to biopsy (at least 900 IU/mL).\n\nOther patient characteristics include being between the ages of 3 and 60, having a certain performance status, and meeting certain hematopoietic, hepatic, renal, cardiovascular, and other criteria. \n\nPrior concurrent therapy is not specified for biologic therapy, chemotherapy, endocrine therapy, radiotherapy, or surgery.",
    "The sample from the table is for a phase 2 clinical trial. The trial is focused on treating patients with leptomeningeal carcinomatosis and non-small cell lung cancer. The diseases are identified by their respective ICD-10 codes. The drug being tested in this trial is erlotinib. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n1. The patient must be over 18 years old.\n2. The patient must have histologically or pathologically proven non-small cell lung cancer.\n3. The patient must have leptomeningeal carcinomatosis confirmed by CSF cytology.\n4. The patient must have an EGFR mutation, including exon 19 deletion or L858R.\n5. The patient's ECOG performance status must be between 0 and 3.\n6. The patient must have an expected life expectancy of at least 4 weeks.\n7. The patient must have signed the informed consent prior to participating in the study.\n8. Chemotherapy-na\u00efve patients are eligible.\n9. Previous use of EGFR TKI is allowed if it was not specifically used for CNS metastases.\n\nThe exclusion criteria for the trial are as follows:\n1. Pregnant or lactating patients are excluded.\n2. Patients of childbearing potential must be tested for pregnancy at baseline or have a negative pregnancy test. Postmenopausal women with at least 12 months of amenorrhea are considered to have non-childbearing potential.\n3. Patients of childbearing potential must be willing to use contraceptive measures during the study.\n4. Patients with a history of another malignant disease within the past 3 years, except for curatively treated basal cell carcinoma of the skin, cervical carcinoma in situ, and early gastric cancer, are excluded.\n5. Patients with active interstitial lung disease, except for simple lymphangitic lung metastasis, are excluded.\n6. Patients with a history of allergic reaction to gefitinib or erlotinib are excluded.\n7. Patients with abnormal laboratory test results, such as low absolute neutrophil counts, low platelet counts, elevated AST and ALT levels, elevated total bilirubin levels, or elevated serum creatinine levels, are excluded.\n8. Patients with serious diseases, such as uncontrolled cardiac arrhythmia, history of myocardial infraction within 6 months, or neurological or psychiatric disorders including dementia or uncontrolled seizure, are excluded.\n9. Patients who refuse to sign the informed consent are excluded.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on breast cancer. The associated ICD-10 codes for the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being studied is taxotere. The eligibility criteria for participants are listed, including requirements such as being female, having locally advanced or primary breast cancer with metastatic disease, negative pregnancy test, normal kidney and liver function, good performance status, age over 18, and no brain or leptomeningeal disease. The exclusion criteria include pregnancy or unwillingness to use contraception, severe underlying chronic illness or disease, and being on other investigational drugs during the study.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is lung neoplasm, specifically inoperable stage IIIA N2 or IIIB NSCLC. The icd-10 codes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being tested in this trial is vinorelbine. \n\nThe inclusion criteria for this trial are as follows: the patient must have histologically or cytologically documented inoperable stage IIIA N2 or IIIB NSCLC, must be previously untreated, must not have malignant pleural effusion, must have a performance status (PS) of 1, and must have a life expectancy of at least 12 weeks. \n\nThe exclusion criteria for this trial are as follows: the patient must not have metastatic disease, must not have small cell lung carcinoma, must not have received prior chemotherapy or radiotherapy, must not have a resecable tumor, must not have any unstable systemic disease, and must not have had any other malignancies within the past 5 years.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"seasonal allergic rhinitis.\" The corresponding ICD-10 code for this disease is \"J30.2.\" The trial involves the use of drugs such as \"act-129968,\" \"cetirizine,\" and a placebo. The eligibility criteria for participants include being between the ages of 18 and 70, having a clinical history of seasonal allergic rhinitis associated with mountain cedar pollen, and having a positive skin prick test to mountain cedar allergen. There are also exclusion criteria, such as having non-allergic rhinitis, respiratory tract infections, chronic respiratory disorders, or recent treatment for seasonal allergic rhinitis.",
    "The sample is a phase 2 trial for breast cancer. The diseases included in the trial are estrogen receptor-positive breast cancer, her2-negative breast cancer, stage ii breast cancer, stage iiia breast cancer, stage iiib breast cancer, and stage iiic breast cancer. The icd-10 codes associated with these diseases are provided. The drugs being tested in the trial are goserelin acetate, letrozole, anastrozole, and chemotherapy. The eligibility criteria for the trial include requirements such as histological confirmation of invasive breast cancer, premenopausal status, negative pregnancy test, specific tumor characteristics (ER+ and HER2 negative), tumor size, mammogram and ultrasound results, clinical staging, age, hormonal treatment cessation, contraception use, ECOG performance status, and normal organ and marrow function. There are also exclusion criteria, such as inflammatory breast cancer, prior treatment for invasive breast cancer, prior DCIS, use of tamoxifen for contralateral DCIS, distant metastasis, refusal to undergo mastectomy or lumpectomy, use of other investigational agents, pregnancy or breastfeeding, concurrent life-threatening illnesses, and prior sentinel lymph node surgery.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is non-small cell lung carcinoma. The corresponding ICD-10 codes for this disease are D02.20, D02.21, and D02.22. The drugs being tested in this trial are pemetrexed and a combination of pemetrexed and pf-3512676. The eligibility criteria for participants include having locally advanced or metastatic NSCLC, measurable disease, and an ECOG performance status of 0 or 1. Participants with known central nervous system metastasis or pre-existing autoimmune or antibody mediated disease are excluded from the trial.",
    "The sample from the table is for a clinical trial in phase 1/phase 2. The trial is focused on head and neck cancer. The ICD-10 codes associated with the disease are C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, and D36.11. The drugs being studied in the trial are cisplatin, fluorouracil, and iressa. The eligibility criteria for the trial include having histologically confirmed primary squamous cell carcinoma of the head and neck region, excluding certain locations like the nasopharynx, paranasal sinuses, and salivary glands. The patient should have locoregionally confined stage III or IV disease, with no evidence of nodal disease below the clavicles and no distant hematogenous metastases. Other patient characteristics include specific performance status, blood cell counts, kidney function, liver function, and absence of certain conditions like pregnancy, severe hypersensitivity to gefitinib, and clinically active interstitial lung disease. The patient should also not have certain medical conditions like unstable angina, clinically apparent jaundice, or active infection. Prior concurrent therapy should not include previous surgery, radiotherapy, chemotherapy, immunotherapy, or epidermal growth factor receptor inhibitors for head and neck cancer. The patient should not have taken investigational drugs within the past 30 days and should not be on concurrent CYP3A4 inducers. Concurrent surgery is allowed as long as gefitinib is not administered 2 weeks before and after the surgery. The patient should not be on concurrent aminoglycoside antibiotics.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being studied is letrozole. The eligibility criteria for participants include being a postmenopausal female, having histologically or cytologically confirmed adenocarcinoma of the breast with locally advanced or metastatic disease, and having a documented elevation of CA 15-3 at the time of diagnosis of metastatic disease. Other criteria include currently receiving letrozole or anastrozole monotherapy, having evidence of hormone sensitivity, and having measurable or evaluable disease according to modified RECIST criteria. There are also exclusion criteria, such as being premenopausal, receiving trastuzumab or biologic therapy within 2 weeks, and having certain types of metastatic disease or severe concomitant conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is prostate cancer. The ICDCodes associated with this disease are \"C61\", \"D29.1\", \"D40.0\", \"Z15.03\", \"Z80.42\", \"Z85.46\", and \"Z12.5\". The drugs being used in the trial are docetaxel, estramustine phosphate sodium, and isotretinoin. The eligibility criteria for this trial include specific disease characteristics, such as histologically confirmed hormone-refractory metastatic prostate cancer, and measurable disease or a prostate-specific antigen level of at least 10 ng/mL. There are also patient characteristics, such as an ECOG performance status of 0-2, estimated life expectancy of at least 6 months, and various blood count and organ function requirements. Prior concurrent therapy requirements include having recovered from prior surgery or radiotherapy, no prior chemotherapy, retinoids, or interferon therapy, and specific time intervals since the last use of flutamide and bicalutamide.",
    "The sample provided is a record from a table that contains information about clinical trials. In this particular record, the trial is in phase 2. The disease being studied is relapsing remitting multiple sclerosis. The corresponding ICD-10 codes for this disease are M94.1, A68.9, A68.0, A68.1, and M35.6. The drugs being tested in this trial are natalizumab, interferon beta 1-a, methylprednisolone, and glatiramer acetate. The eligibility criteria for this trial include having a diagnosis of a relapsing form of MS, previous treatment with natalizumab as per local prescribing information, and other inclusion/exclusion criteria defined by the trial protocol.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the treatment of hepatitis C. The trial involves the drugs bavituximab and pegylated interferon (peg-ifn). The eligibility criteria for participants include being between the ages of 18 and 65, having chronic hepatitis C virus (HCV) genotype 1 infection, and having a HCV RNA level greater than 10,000 IU/mL. Other criteria include no clinically significant abnormalities in hematology, coagulation, or chemistry variables, negative urine pregnancy test for female patients, and the ability to provide informed consent. The exclusion criteria include previous interferon-based antiviral therapy for chronic HCV infection, previous treatment with known immunogenic drugs, and concomitant human immunodeficiency (HIV) or hepatitis B virus (HBV) infection, among others.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is divided into different phases, and in this case, it is a combination of phase 1 and phase 2. The diseases being studied in this trial are \"primary erythromelalgia\" and \"inherited erythromelalgia.\" The diseases are also associated with specific ICD-10 codes, with the code \"I73.81\" being linked to these diseases. The trial involves testing the effectiveness of two drugs, namely \"xpf-001\" and \"placebo.\" \n\nThe eligibility criteria for participants in this trial include being between 18 and 75 years old, having inherited erythromelalgia, experiencing moderate pain caused by erythromelalgia (with a pain score of 4 out of 10), being generally healthy (except for the pain), and not being pregnant or breastfeeding. Participants are required to stop taking their usual pain medications for 9 days. \n\nThe role of participants in the trial includes an outpatient screening visit, a 9-day/8-night in-patient treatment visit at Nijmegen Medical Center (where they will be closely monitored), a follow-up phone call after returning home, taking the investigational medication daily, and recording their daily pain levels during their stay at the Medical Center. \n\nThere are also exclusion criteria that would disqualify individuals from participating in the trial. These include having another source of pain from different conditions, receiving professional psychological support for dealing with inherited erythromelalgia, recent treatment for significant depression, having active HIV, Hepatitis B or C, using prescription or over-the-counter medication between check-in and discharge, being pregnant or lactating without adequate contraception, having alcoholism or substance abuse issues, having a history of major psychiatric disturbance, being unwilling or unable to comply with dietary and activity restrictions, having any other condition or finding that may pose undue risk for participation, and using any other investigational drug in the 60 days prior to dosing.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating lymphoma. The ICD-10 codes associated with the disease are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drugs being used in the trial are cyclophosphamide, doxorubicin hydrochloride, prednisolone, and vincristine sulfate. The eligibility criteria for the trial include having grade 1, 2, or 3 follicular non-Hodgkin lymphoma, being in stage II, III, or IV of the disease, and having CD20-positive disease. Other criteria include having specific symptoms, meeting certain laboratory values, and not having certain medical conditions. The patient must also meet certain requirements regarding their performance status, life expectancy, blood counts, and other factors. The sample does not provide information about prior concurrent therapy, except that there should be at least 4 weeks since prior investigational drugs and no prior radioimmunotherapy.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on HIV infections. The trial is specifically looking at the effectiveness of various drugs in treating HIV. The eligibility criteria for participants are listed, including being HIV infected, having no other available treatment options, specific measurements of CD4% and viral load, previous exposure to certain drugs, resistance to previous treatment, ability to swallow study medications, and willingness to use contraception. The exclusion criteria are also listed, which include previous exposure to a specific drug, certain laboratory abnormalities, allergies to any of the study drugs, active opportunistic infections or serious bacterial infections, undergoing chemotherapy for active cancer, requiring certain medications, abnormal kidney function, having other clinically significant diseases, and being pregnant or breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is prostate cancer. The icd-10 codes associated with this disease are 'C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', and 'Z12.5'. The drugs being used in the trial are 'zometa', 'zometa', and 'zometa'. The eligibility criteria for this trial include having a histologic diagnosis of adenocarcinoma of the prostate, specific serum PSA values, evidence of metastatic disease, and an ECOG performance status of less than 2. There are also exclusion criteria listed, such as prior treatment with certain medications, evidence of immunosuppression, and current or recent use of specific drugs.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the trial is in phase 2 and focuses on the disease psoriasis. The ICD-10 codes associated with psoriasis are ['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50']. The trial involves two drugs, act-128800 and placebo. The eligibility criteria for participants include being adult males and females aged 18 to 60 with moderate to severe chronic plaque psoriasis who require systemic treatment. Exclusion criteria include having other forms of psoriasis, being currently treated for autoimmune disorders other than psoriasis, having ongoing bacterial, viral, or fungal infections, and having a history or presence of malignancy. There may be additional inclusion and exclusion criteria related to medical conditions and concomitant treatments.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is Crohn's disease. The ICDCodes associated with Crohn's disease are listed as ['K50.90', 'K50.913', 'K50.914', 'K50.911', 'K50.912', 'K50.918', 'K50.919']. The drug being used in the trial is a vehicle control. \n\nThe eligibility criteria for this trial include being between the ages of 18-75, providing informed consent, being able to adhere to the study visit schedule and other protocol requirements, having a minimum weight of 50 kg, and having a negative urine pregnancy test for females of childbearing potential. Additionally, sexually active females of childbearing potential must agree to use two forms of contraception, and males must agree to use barrier contraception. \n\nOther criteria include having inflammatory Crohn's disease for at least 6 months prior to treatment and confirming ongoing disease activity through colonoscopy or another method. The subject must also have a CDAI score between 220 and 450 and must have failed or had an inadequate response to a previous treatment. \n\nExclusion criteria include any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent participation in the study. Additionally, any condition or laboratory abnormality that would place the subject at unacceptable risk is also an exclusion criterion. \n\nA female of childbearing potential is defined as a sexually mature woman who has not undergone a hysterectomy or bilateral oophorectomy and has not been naturally postmenopausal for at least 24 consecutive months.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on esophageal cancer. The trial includes patients with histologically confirmed adenocarcinoma of the esophagus or gastroesophageal junction. The tumor must be newly diagnosed and surgically resectable, with a primary esophageal tumor measuring less than 20 cm below the incisors and extending no more than 2 cm into the cardia. The stage of the tumor should be T2-3, N0-1, M0-1a, as determined by imaging studies and biopsy. The presence of any suspicious metastatic lesions must be confirmed through biopsy. The trial excludes patients with CNS metastasis and those with severe hypersensitivity to gefitinib or any of its excipients. Patients with severe or uncontrolled systemic diseases are also excluded. Other exclusion criteria include clinically active interstitial lung disease, preexisting peripheral neuropathy greater than grade 1, incomplete healing from prior major surgery, prior chemotherapy, radiotherapy, or surgery for this cancer, and concurrent use of certain medications. The sample also includes inclusion and exclusion criteria related to various laboratory findings and pregnancy status.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on Alzheimer's disease. The ICD-10 codes associated with the disease are G30.8, G30.9, G30.0, and G30.1. The drugs being studied are sb-742457, donepezil, and a placebo. The sample also includes the eligibility criteria for participants. Inclusion criteria include providing informed consent, having a clinical diagnosis of mild-to-moderate Alzheimer's disease, having a regular caregiver, and meeting certain requirements for female subjects of child-bearing potential. Exclusion criteria include having a diagnosis of vascular dementia, having any other CNS disorder that could be a cause of dementia, having a history of seizures or head trauma, having certain abnormal ECG, blood pressure, or laboratory values, having photosensitivity, and having previous exposure to SB-742457 or taking certain medications that may impact the study outcomes.",
    "The sample is a record from a table that contains information about clinical trials. It is for a phase 2 trial and the diseases being studied are \"de novo myelodysplastic syndromes\", \"previously treated myelodysplastic syndromes\", and \"secondary myelodysplastic syndromes\". The corresponding ICD-10 codes for these diseases are \"D46.Z\", \"D46.9\", \"C94.6\", and \"D46.C\". The drug being tested in this trial is \"belinostat\". The eligibility criteria for participants in this trial include having histologically confirmed myelodysplastic syndromes, meeting certain criteria for bone marrow blasts, having an ECOG performance status of 0-2, and meeting various other medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is Alzheimer's disease. The ICDCodes associated with the disease are \"G30.8\", \"G30.9\", \"G30.0\", and \"G30.1\". The drug being used in the trial is \"leuprolide acetate\". \n\nThe eligibility criteria for this trial include:\n- Patients must be able to provide consent or have a legally authorized representative provide consent.\n- Only male patients are eligible.\n- Patients must be 65 years of age or older.\n- Patients must have a diagnosis of probable Alzheimer's disease according to specific criteria.\n- Patients must be taking a drug for the treatment of Alzheimer's disease or have never taken such a drug.\n- Patients must be taking or have stopped taking other drugs or substances with cognition-enhancing properties.\n- Patients must have a specific Mini Mental State Examination (MMSE) score.\n- Patients must have undergone a brain imaging study confirming the diagnosis of Alzheimer's disease.\n- Patients must have a specific Rosen Modified Hachinski score.\n- Patients must be fluent in English or Spanish and have completed at least 6 years of education.\n- Patients must live at home or in a congregate living facility and have a caregiver who sees them regularly.\n- Patients must have a specific Hamilton Depression Scale (HamD) score.\n- Patients must have specific DEXA scan results or be receiving treatment for osteoporosis/osteopenia.\n- Patients must not have significant medical conditions indicated by screening laboratory test values.\n\nThe exclusion criteria for this trial include:\n- Female patients are not eligible.\n- Patients younger than 65 years of age are not eligible.\n- Patients with significant neurological or psychiatric diseases other than Alzheimer's disease are not eligible.\n- Patients with current significant systemic illness or symptoms of organ failure are not eligible.\n- Patients with specific screening ECG results or PSA test results are not eligible.\n- Patients receiving testosterone are not eligible.\n- Patients taking a drug for the treatment of Alzheimer's disease for less than 90 days prior to baseline are not eligible.\n- Patients who have never received cholinesterase inhibitor treatment or are likely to start or resume such treatment during the study are not eligible.\n- Patients who have started or changed the dosage of certain drugs within 60 days prior to the screening visit are not eligible.\n- Patients taking specific medications or with specific medical conditions are not eligible.\n- Patients who have taken other investigational drugs within a certain timeframe are not eligible.\n- Patients taking medications known to affect serum gonadotropin concentrations are not eligible.\n- Patients with specific screening HamD scores or a history of substance abuse or dependence are not eligible.\n- Patients who have donated blood within a certain timeframe or have a history of certain cancers or medical conditions are not eligible.\n- Patients with specific bladder or esophagus abnormalities or sleep apnea are not eligible.",
    "The sample from the table represents a phase 2 clinical trial. The diseases being studied in this trial are leukemia, lymphoma, and lymphoproliferative disorder. The corresponding ICD-10 codes for these diseases are provided as well. The drug being tested in this trial is everolimus. The eligibility criteria for participants include having biopsy-proven relapsed or refractory lymphoma, previously treated disease, and measurable disease as defined by CT scan or MRI. Other patient characteristics, such as performance status, blood counts, liver and kidney function, and pregnancy status, are also specified. The sample also includes information on prior concurrent therapy and the exclusion of other active malignancies or serious non-malignant diseases.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on Crohn's disease. The diseases column specifies that the trial is targeting Crohn's disease. The icdcodes column provides a list of ICD-10 codes associated with Crohn's disease. The drugs column lists the drugs being used in the trial, including placebos for metronidazole and ciprofloxacin, as well as the actual drugs themselves. The criteria column outlines the eligibility criteria for the trial, including inclusion and exclusion criteria. The inclusion criteria include being 16 years or older, having a diagnosis of Crohn's disease for more than 1 month, having specific CDAI scores, and having Crohn's disease involving any portion of the colon. The exclusion criteria include being pregnant or breastfeeding, having allergies or contraindications to the drugs being used, experiencing complications of Crohn's disease, having certain medical conditions, and having received specific treatments or therapies within certain timeframes.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for participating in the trial.\n\nIn this specific sample, the phase of the trial is phase 2. The diseases being studied include \"brenner tumor,\" \"fallopian tube cancer,\" \"ovarian clear cell cystadenocarcinoma,\" \"ovarian endometrioid adenocarcinoma,\" \"ovarian mucinous cystadenocarcinoma,\" \"ovarian serous cystadenocarcinoma,\" \"ovarian undifferentiated adenocarcinoma,\" \"stage iii ovarian epithelial cancer,\" and \"stage iv ovarian epithelial cancer.\" The corresponding ICD-10 codes for these diseases are also provided.\n\nThe drugs being used in the trial are \"paclitaxel,\" \"carboplatin,\" and \"erlotinib.\" The eligibility criteria for participating in the trial are listed under \"criteria\" and include various requirements such as specific histologic diagnoses, timing of chemotherapy initiation, performance status, blood counts, liver and kidney function, absence of certain medical conditions, and the ability to understand and sign an informed consent document.\n\nThe sample also includes exclusion criteria, which specify conditions under which patients would not be eligible to participate in the trial. These include recent chemotherapy, use of other investigational agents, known brain metastases, history of allergic reactions to certain compounds, uncontrolled illnesses, pregnancy or breastfeeding, and HIV-positive patients receiving combination anti-retroviral therapy.\n\nOverall, this sample provides a detailed description of a specific clinical trial, including the phase, diseases being studied, drugs used, and eligibility criteria for participation.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being studied is called rad 001. The eligibility criteria for participants are listed, including requirements such as having an Eastern Cooperative Group (ECOG) performance status of 2 or lower, being at least 18 years old, having measurable disease according to RECIST criteria, and meeting certain health criteria for bone marrow, liver, kidney, and diabetes control. The exclusion criteria are also listed, which include not currently receiving or having received anticancer therapies within the past 4 weeks, not having recovered from major surgery, not having received any investigational drugs within the past 4 weeks, and having certain medical conditions or diseases that could affect participation in the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is Alzheimer's disease. The ICDCodes associated with this disease are G30.8, G30.9, G30.0, and G30.1. The drug being used in the trial is rosiglitazone. \n\nThe eligibility criteria for this sample include:\n- The subject must have successfully completed the 12 Month Visit of a previous treatment without any tolerability issues.\n- Female subjects must be post-menopausal, surgically sterile, or using effective contraceptive measures.\n- The subject must be willing to participate in the extension study and have provided written informed consent.\n- The caregiver of the subject must also provide written informed consent.\n\nThe exclusion criteria for this sample include:\n- The subject has experienced a serious adverse experience or clinically significant laboratory abnormality during a previous treatment that is ongoing.\n- The investigator feels that the subject is unsuitable for inclusion in the study based on health, compliance, caregiver availability, or other reasons.\n- The subject has experienced a significant cardiovascular event during a previous treatment, unless a thorough cardiovascular evaluation confirms that the subject is clinically stable.\n- The subject has initiated treatment with certain medications for cognitive symptoms/Alzheimer's disease at the end of a previous treatment.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of diabetic macular edema. The table includes columns for the phase, diseases, icd-10 codes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase is phase 2, the disease is diabetic macular edema, and the icd-10 codes associated with the disease are provided. The drugs being studied are ranibizumab. The eligibility criteria for participants are listed, including age, diagnosis of diabetes mellitus, specific HbA1c levels, confirmation of diagnosis through imaging, specific visual acuity requirements, and other factors. \n\nThere are also exclusion criteria listed, such as recent treatments or surgeries, certain ocular disorders, uncontrolled glaucoma or diabetes, and other medical conditions that may pose a risk. The sample also includes additional information about the trial, such as the need for contraception for female participants and the inability to participate in other medical investigations or trials simultaneously.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is lung cancer. The ICD-10 codes associated with the disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are celecoxib and docetaxel. The eligibility criteria for participants in the trial are listed, including specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is colorectal cancer. The ICD-10 codes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are cetuximab and lenalidomide. The eligibility criteria for participants in the trial are listed, including requirements such as having metastatic colorectal adenocarcinoma, confirmed K-RAS mutant tumor, disease progression on specific regimens, and a certain performance status. There are also exclusion criteria listed, such as recent use of certain treatments, previous treatment with specific drugs, and certain medical conditions.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease being studied is photosensitive epilepsy. The ICDCodes associated with this disease are G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, and G40.801. The drugs being used in the trial are jnj-26489112 and placebo. The eligibility criteria for participants include factors such as gender, age, BMI, diagnosis of idiopathic photosensitive epilepsy, and various medical conditions or medications that would exclude someone from participating in the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on bladder cancer. The ICD-10 codes associated with the disease are 'D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', and 'D41.4'. The trial involves the use of drugs such as cisplatin, doxorubicin hydrochloride, methotrexate, and vinblastine sulfate. The eligibility criteria for participants include having biopsy-proven muscle invasion of transitional cell carcinoma of the bladder, being suitable for resection without any visible or palpable tumor mass, and meeting certain staging criteria. Other criteria include specific age, performance status, hematopoietic, hepatic, renal, and cardiovascular conditions. The sample also includes information about prior concurrent therapies, such as biologic therapy, chemotherapy, endocrine therapy, radiotherapy, and surgery.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease mentioned is \"myelodysplastic syndromes\". The ICDCodes associated with the disease are \"D46.9\", \"D46.C\", and \"D46.Z\". The drug mentioned is \"metoclopramide\". The eligibility criteria for this trial include specific conditions such as being in the low or intermediate-1 risk group according to the IPSS (International Prognostic Scoring System), being off all other treatments for at least 4 weeks, having anemia with hemoglobin less than 11g/dL, having an absolute reticulocyte count less than 60,000/microliter, having an absolute neutrophil count greater than 200/microliter, having a platelet count greater than 10,000/microliter, being between the ages of 18 and 72, having an ECOG (Eastern Cooperative Oncology Group) performance status less than or equal to 2, and having the ability to understand the investigational nature of the protocol and provide informed consent. The exclusion criteria include being in the high IPSS risk group, having secondary MDS (myelodysplastic syndromes), having a previous history of dystonic reaction and/or anaphylactic reaction to metoclopramide, having a history of certain medical conditions or disorders, being currently pregnant or unwilling to use contraception, having concomitant drug therapy with high risks of extrapyramidal side effects, having received metoclopramide therapy 4 months prior to study enrollment, and having hyperprolactinemia prior to study implementation.",
    "The sample provided is a record from a table that contains information about a clinical trial. The record includes the following details:\n\n- Phase: The phase of the trial is Phase 2.\n- Diseases: The disease being studied in this trial is hepatocellular carcinoma.\n- ICD Codes: The ICD-10 codes associated with the disease are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8.\n- Drugs: The drugs being used in the trial are infusional 5-fluorouracil and sorafenib (bay 43-9006).\n- Criteria: The eligibility criteria for participants in the trial are listed, including age, histological or cytological evidence of HCC, ECOG Performance Status, life expectancy, tumor stage, previous treatments, and various laboratory requirements. The exclusion criteria are also provided, which include certain medical conditions, previous and concomitant therapies, pregnancy or breastfeeding, substance abuse, and any condition that could jeopardize the patient's safety or compliance in the study.\n\nOverall, this record provides specific information about the phase, disease, drugs, and eligibility criteria for a clinical trial focused on hepatocellular carcinoma.",
    "The sample is a phase 2 trial for pancreatic cancer. The eligibility criteria for this trial include being an adult patient aged 18 years or older, having locally advanced-unresectable or metastatic pancreatic cancer confirmed through histological or cytological documentation, having measurable disease according to RECIST, and having failed at least one prior chemotherapy regimen or being deemed unsuitable for chemotherapy. Additionally, patients must have an ECOG performance status of 0-2. \n\nThe exclusion criteria for this trial include having local or locally advanced-resectable pancreatic cancer, having any other malignancies within the last 5 years (except for adequately treated cancer in situ of the cervix or basal or squamous cell skin cancer), and having undergone major surgery within 2 weeks prior to randomization. \n\nThe drugs being tested in this trial are erlotinib and placebo.",
    "The sample provided is for a phase 2 clinical trial for the treatment of melanoma (skin cancer) using the drug abt-510. The eligibility criteria for patients participating in the trial are as follows:\n\nDisease Characteristics:\n- Patients must have histologically confirmed malignant melanoma.\n- Patients must have stage IV disease.\n- Patients must not have any known potentially curative standard therapy available that can extend life expectancy.\n- Patients must have measurable disease.\n- Patients must not have a history of or current central nervous system (CNS) metastases.\n- Patients must not have known, presently active carcinomatous meningitis.\n\nPatient Characteristics:\n- Patients must have an ECOG performance status of 0-2.\n- Patients must have a life expectancy of at least 6 months.\n- Patients must have an absolute neutrophil count (ANC) of at least 1,500/mm\u00b3.\n- Patients must have a platelet count of at least 100,000/mm\u00b3.\n- Patients' alkaline phosphatase levels must be \u2264 3 times the upper limit of normal (ULN).\n- Patients' AST levels must be \u2264 3 times the ULN.\n- Patients' creatinine levels must be \u2264 2.5 times the ULN.\n- Patients' hemoglobin levels must be \u2265 9.0 g/dL.\n- Patients' prothrombin time must be normal.\n- Patients must be willing to return to Mayo Clinic Rochester, Jacksonville, or Scottsdale for follow-up.\n- Patients must be able to self-administer the subcutaneous injections of the drug or have a caregiver who can reliably administer them.\n- Patients must not be pregnant or nursing.\n- Patients must have a negative pregnancy test.\n- Fertile patients must use effective contraception.\n- Patients must not have any uncontrolled or current infection.\n- Patients must not have New York Heart Association class III-IV heart disease.\n- Patients must not have a recent history of (within the past 12 weeks) or current cancer-related bleeding event.\n- Patients must not have a recent history of (within the past 4 weeks) or current noncancer-related clinically significant bleeding event.\n- Patients must not have uncontrolled hypertension.\n- Patients must not have a history of stroke or other CNS bleeding events (e.g., aneurysms).\n\nPrior Concurrent Therapy:\n- Patients must have had at least 4 weeks since their last chemotherapy treatment and must have recovered (6 weeks for mitomycin C or nitrosoureas).\n- Patients must have had at least 4 weeks since their last immunotherapy, biologic therapy, radiotherapy, or surgery.\n- Patients must not be receiving concurrent anticoagulation therapy or antiplatelet therapy.\n- Patients must not be receiving any other concurrent antineoplastic agents (e.g., cytotoxic chemotherapy, immunotherapy, radiotherapy, or investigational therapy), except for local radiotherapy for supportive reasons involving a small radiation field.",
    "The sample is a phase 2 trial for patients with myelodysplastic syndromes (MDS) and leukemia. The trial is testing the effectiveness of the drug azacitadine and hematopoietic growth factors. The eligibility criteria include having a diagnosis of MDS or certain types of leukemia, meeting specific criteria related to anemia, thrombocytopenia, and neutropenia, and not having certain medical conditions or prior treatments. Patients must also meet certain patient characteristics such as performance status, life expectancy, and normal levels of certain blood markers. Prior concurrent therapy is also specified, including no prior use of azacitadine or decitabine and no other concurrent treatment for MDS or hematopoietic growth factors.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is rectal cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being used in the trial is intensified preoperative chemotherapy. \n\nThe eligibility criteria for this trial are as follows:\n- Patients must be male or female with histologically proven adenocarcinoma of the rectum (tumor located below the peritoneum).\n- The disease must be T3/4 or any node positive (clinical stage according to the TNM classification system).\n- There should be no evidence of metastatic disease.\n- The disease must be considered either resectable at the time of entry or thought to become resectable after preoperative chemoradiation.\n- Patients must be 18 years or older.\n- WHO Performance Status should be between 0-2.\n- No prior radiotherapy, chemotherapy, or any targeting therapy for rectal cancer.\n- Adequate hematological, hepatic, and renal function, as well as the ability to swallow tablets, are required.\n- Patients must provide signed informed consent.\n- Patients must be willing and able to comply with the protocol for the duration of the study.\n\nThe exclusion criteria for this trial are as follows:\n- Malignancy of the rectum other than adenocarcinoma.\n- Any unrested synchronous colon cancer.\n- Other co-existing malignancy or malignancy within the past 5 years, except for adequately treated in situ carcinoma of the cervix or basal cell carcinoma of the skin.\n- Significant heart disease, including uncontrolled hypertension despite medication, NYHA class III or IV heart disease, unstable angina, or myocardial infraction within the past 1 year prior to the study entry, and a history of significant ventricular arrhythmia requiring treatment.\n- Pregnant or lactating patients.\n- Females with a positive or no pregnancy test, unless childbearing potential can be otherwise excluded (amenorrheic for at least 2 years, hysterectomy, or oophorectomy).",
    "The sample is from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is hypertension. The ICD-10 codes associated with the disease are I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, and I10. The drugs being tested in the trial are irbesartan, placebo, and ps433540. The eligibility criteria for the trial include age between 18 and 70, specific blood pressure ranges, and requirements for contraception for women of child-bearing potential. The exclusion criteria include various serious disorders, history of certain medical conditions, and specific cardiac conditions.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of myelodysplastic syndrome, a type of blood disorder. The ICD-10 codes associated with this disease are 'D46.9', 'D46.C', and 'D46.Z'. The drugs being studied in this trial are decitabine. \n\nThe sample also includes the eligibility criteria for patients to be enrolled in the study. These criteria include being 18 years or older, signing an informed consent form, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and having adequate renal and hepatic function. Female patients need to have a negative pregnancy test and both men and women must use contraception during the study. Patients with low or intermediate-1 risk myelodysplastic syndrome according to the International Prognostic Scoring System (IPSS) classification are eligible.\n\nThe sample also lists the exclusion criteria, which include being pregnant or nursing, having received prior therapy with decitabine or azacitidine, receiving growth factor support or lenalidomide in the 30 days prior to the first dose of decitabine, or having received an investigational agent 30 days prior to the first dose of decitabine. Patients with active, uncontrolled, systemic infection or any severe concurrent disease that would make them inappropriate for study entry are also excluded.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 2. The disease being studied is \"infections, urinary tract.\" The ICD-10 codes associated with the disease are \"P39.3, N39.0, O86.20, O86.29, N99.531, O03.38, N99.521.\" The drugs being used in the trial are \"gsk2251052\" and \"imipenem-cilastatin.\" The eligibility criteria for participants include being at least 18 years old, practicing contraception, and having specific symptoms and medical conditions related to urinary tract infections. There are also exclusion criteria, such as having certain infections or medical conditions, being pregnant or nursing, and having a history of hypersensitivity to certain antibiotics.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating renal cell carcinoma and neoplasm metastases. The diseases are identified by their respective ICD-10 codes. The drugs being studied are gemcitabine and sunitinib. The eligibility criteria for participants are listed, including specific requirements related to the disease, measurable lesions, age, performance status, previous treatments, and various medical conditions. There are also exclusion criteria that outline factors that would disqualify someone from participating in the trial, such as prior treatment with the drugs being studied, certain medical conditions, and pregnancy or breastfeeding.",
    "The sample provided is for a phase 2 clinical trial for breast cancer. The trial is specifically for patients with metastatic breast adenocarcinoma (stage IV) who have not received any prior chemotherapy. The eligibility criteria include having a performance status of 0-2, HER-2 overexpression, measurable disease not in a prior irradiation field, and adequate bone marrow, liver, renal, and cardiac function. Patients must also have a paraffin block from the primary tumor available in the research lab. Exclusion criteria include being pregnant or nursing, having certain concurrent medications, having uncontrolled brain metastatic disease, and having a history of allergic reaction to docetaxel. Patients with other concurrent uncontrolled illnesses or invasive malignancies within the past 5 years (except for certain types of skin and cervical cancers) are also excluded.",
    "The sample is a phase 2 trial for the treatment of migraine. The trial focuses on patients who have been diagnosed with migraine with or without aura, and have experienced 2-8 moderate to severe migraine headaches per month. The trial excludes patients who have received any investigational drug within the past 30 days, have more than 15 headache days per month, have known allergies or hypersensitivity to the drug ketorolac or its components, have allergies to aspirin or other NSAIDs, are currently receiving other NSAIDs or aspirin, or have a medical history that would prevent the use of NSAIDs. The trial involves the use of the drug ketorolac tromethamine, as well as a placebo.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is hypertension. The ICD-10 codes associated with this disease are 'I15.0', 'I97.3', 'K76.6', 'P29.2', 'G93.2', 'H40.053', and 'I10'. The drugs being tested in this trial are eplerenone and losartan. The eligibility criteria for inclusion in the trial include having a history of mild to moderate hypertension or newly diagnosed hypertension with specific blood pressure ranges. Participants must also have withdrawn from any previous antihypertensive medications. Exclusion criteria include having secondary hypertension or severe/malignant hypertension, as well as being unable to withdraw from certain medications that affect blood pressure. Additionally, there are specific restrictions on the use of certain medications within 24 hours prior to a clinic visit.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is divided into different phases, and in this case, it is a combination of phase 1 and phase 2. The trial focuses on the treatment of type 2 diabetes mellitus. The diseases column specifies the disease being studied, and the icdcodes column provides the corresponding ICD-10 codes for the disease.\n\nThe drugs column lists the names of the drugs being used in the trial, which in this case are \"efb0027 (metformin delayed release)\" and \"efb0026 (metformin immediate-release)\". The criteria column contains the eligibility criteria for participants in the trial.\n\nThe inclusion criteria include age requirements, specific HbA1c levels for different treatment regimens, serum creatinine and creatinine clearance levels, body mass index (BMI) range, gender-specific requirements, physical examination results, understanding and willingness to adhere to the protocol, stable thyroid medication dose, and normal thyroid-stimulating hormone (TSH) levels.\n\nThe exclusion criteria include various medical conditions that could affect participation, recent adjustments to chronic medication, use of medications affecting gastric pH, recent major surgery or blood transfusion, significant weight change, abnormal laboratory test results, unsuitability for the study based on physical, psychological, or historical findings, drug or alcohol abuse, recent blood donation, recent use of insulin, recent use of GLP-1 receptor agonists and/or thiazolidinedione treatment, intolerance to metformin, recent use of investigational drugs, known allergies or hypersensitivity to study treatment components, employment by Elcelyx Therapeutics, Inc., and excessive tobacco use.\n\nOverall, this sample provides specific details about the phase, diseases, icd codes, drugs, and eligibility criteria for participants in a clinical trial focused on type 2 diabetes mellitus.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is ovarian cancer. The ICDCodes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are bortezomib and pegylated liposomal doxorubicin. The eligibility criteria for participants include having a confirmed diagnosis of ovarian carcinoma, progressive or recurrent disease, specific disease measurability requirements, a maximum of 2 prior chemotherapies, ECOG performance status grade 0 or 1, age between 18 and 75 years, adequate hematological, liver, and renal function, a life expectancy of at least 3 months, specific requirements for prior anthracycline treatment, normal LVEF (left ventricular ejection fraction), and signed informed consent. The exclusion criteria include recent participation in other treatments or studies, pre-existing peripheral neuropathy above Grade 1, presence of cirrhosis or active/chronic hepatitis, serious cardiac, neurological, or psychiatric disorders, uncontrolled intercurrent illness or conditions that may interfere with the study, symptomatic brain metastases or leptomeningeal disease, pregnancy or lactation, active infection, and known allergies to mannitol, boron, or liposomally formulated drugs.",
    "The sample from the table represents a clinical trial with a phase 2/phase 3 design. The trial focuses on patients with transient ischemic attack (TIA) or stroke. The diseases are further specified with ICD-10 codes. The drugs being studied in the trial are aspirin, clopidogrel, and simvastatin. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n- Patients must have TIA or minor acute ischemic stroke with a NIHSS score of less than 4 at the time of randomization.\n- Patients must not be candidates for acute thrombolysis or other acute intervention that is considered the current standard of care.\n- Patients must be aged 40 years or older.\n- Patients must have weakness or language disturbance at the time of TIA/minor stroke, and the duration of neurological deficit (TIA) must be greater than 5 minutes.\n- Patients can be randomized within 24 hours of symptom onset, defined by the \"last seen well\" principle.\n- Patients must provide written, informed consent to participate in the trial.\n\nThe exclusion criteria for the trial are as follows:\n- Patients with pure sensory symptoms, pure vertigo or dizziness, pure ataxia, or pure visual loss.\n- Patients for whom thrombolysis or other acute intervention is indicated as the current standard of care.\n- Patients who are currently on statin therapy, antiplatelet therapy (excluding aspirin), long-term non-steroidal anti-inflammatory drugs (NSAIDs, but not COX inhibitors), or anticoagulation.\n- Patients who, in the opinion of the site Investigator, should be commenced on statin therapy.\n- Patients with neurological deficit due to intracranial hemorrhage, tumor, infection, or any finding not consistent with acute brain ischemia as the cause of presenting symptoms.\n- Patients with a presumed cardiac source of embolus (e.g., atrial fibrillation, prosthetic cardiac valve, known/suspected endocarditis).\n- Patients with a concomitant acute coronary syndrome (acute myocardial infraction or unstable angina).\n- Patients with a Modified Rankin Score of 3 or more (pre-morbid historical assessment).\n- Patients in whom the qualifying event was due to a complication of cerebral angiography, a revascularization procedure, or trauma.\n- Patients with uncontrolled hypertension at baseline (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg), or malignant hypertension defined by brain plus acute organ involvement due to acute hypertension.\n- Women who are breastfeeding or pregnant. Women of childbearing potential must have a negative pregnancy test prior to randomization and must plan on not becoming pregnant during the study while practicing a suitable method of birth control.\n- Patients with evidence of contraindication for the use of Trial Medication, such as serious systemic bleeding precluding antiplatelet therapy, hypersensitivity to aspirin, clopidogrel, or statins, renal insufficiency, hepatic dysfunction, thrombocytopenia, neutropenia, or bleeding diathesis or coagulopathy.\n- Patients with a life expectancy of less than 90 days.\n- Patients who have participated in another clinical therapeutic trial (drug or device) either concurrently or within the previous 30 days, or have previously participated in the FASTER trial.\n- Patients with geographical or other factors that make follow-up impractical or evaluation of outcome events impossible, such as severe dementia. However, patients who could and are willing to complete their follow-up at a participating center may still be randomized.",
    "The sample is from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is phase 2. The diseases being studied are \"graft versus host disease\" and \"hematologic malignancies\". The corresponding ICD-10 codes for these diseases are provided. The drugs being tested are \"palifermin\", \"placebo\", and \"methotrexate\". The eligibility criteria for the trial are listed under \"criteria\" and include requirements such as having hematologic malignancies, having a 6/6 HLA-matched family member or unrelated donor for stem cell support, and having a Karnofsky Performance Status of at least 70%. There are also exclusion criteria listed, such as having certain types of cancer, previous bone marrow or stem cell transplantation, and inadequate organ function.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are colorectal cancer and metastatic cancer. The ICDCodes associated with these diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are fluorouracil, leucovorin calcium, and oxaliplatin. The eligibility criteria for this trial include specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions. The criteria cover various aspects such as disease history, liver metastases, measurable disease, age, performance status, hematopoietic, hepatic, renal, cardiovascular, gastrointestinal, and other factors. The sample also includes information about prior concurrent therapies, including biologic therapy, chemotherapy, endocrine therapy, radiotherapy, surgery, and other treatments.",
    "The sample is a phase 2 trial for chronic obstructive pulmonary disease (COPD). The trial is testing two drugs, \"pt001 mdi\" and \"ipratropium bromide hfa inhalation aerosol\". The eligibility criteria for participants include being between 40-80 years old, having a clinical history of COPD with airflow limitation, being a current or former smoker with at least a 10 pack-year history, and having specific measurements of lung function. There are also exclusion criteria, such as being pregnant or lactating, having a primary diagnosis of asthma, or having certain medical conditions. The sample includes both key inclusion and exclusion criteria, as well as a mention of other criteria defined in the protocol.",
    "The sample is a phase 2 trial for patients with type 2 diabetes mellitus. The trial is focused on evaluating the effectiveness of different insulin drugs. The inclusion criteria for participants include being 18 years or older, having type 2 diabetes treated with insulin for at least 12 months, having a BMI between 23.0 and 45.0 kg/m^2, having a HbA1C level between 7.0 and 8.5%, having a fasting C-peptide level below 0.6 ng/mL, being willing to use insulin glargine twice a day as basal insulin throughout the study, and avoiding the use of insulin infusion pumps or unblinded continuous glucose monitoring. The exclusion criteria include having allergies to any study drug components, exclusive use of pre-mixed insulins, recent use of certain diabetes medications, use of drugs that could interfere with the study results or insulin action, and a history of recurrent severe hypoglycemia or hypoglycemic unawareness.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on patients with metastatic breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are g-csf, trastuzumab, vinorelbine, and a saline placebo. \n\nThe eligibility criteria for this trial include the requirement of pathological confirmation of breast carcinoma, documented clinical or radiological assessment of metastatic breast cancer, and HER-2/neu overexpression. Patients must be at least 18 years old and have a Karnofsky performance status of 60% or higher. Adequate hepatic, renal, and hematologic function is also required. Prior treatment with trastuzumab is allowed, and patients must have adequate cardiac function. Premenopausal women need to have a negative pregnancy test and use contraception. Patients with a history of brain metastases are allowed if they are clinically stable. Written informed consent is required from all patients.\n\nThe exclusion criteria for this trial include no recent treatment with chemotherapy or trastuzumab, prior therapy with vinorelbine, known hypersensitivity to trastuzumab or certain proteins, history of unstable angina or heart failure, recent myocardial infraction, pregnancy, and known hypersensitivity to certain proteins.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is non-small cell lung cancer. The corresponding ICD-10 codes for this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being tested in this trial are cisplatin, docetaxel, and pegfilgrastim. \n\nThe eligibility criteria for this trial include patients with documented stage III NSCLC (IIIA or IIIB) who are considered appropriate for treatment with chemotherapy, radiation, or surgery. The disease must be measurable or evaluable, and patients must not have received prior chemotherapy or radiotherapy for lung cancer. Brain metastases are not allowed, and patients must have a performance status of 0-2. Patients must be at least 18 years old and provide informed consent. Certain blood counts and liver and kidney function tests must be within specified ranges. Peripheral neuropathy must be grade 1 or lower.\n\nExclusion criteria for this trial include known sensitivity to certain products, recent use of IV systemic antibiotics, known HIV infection, recent use of lithium or cytokines, concurrent use of other investigational drugs, history of myelodysplastic syndrome, pregnancy, nursing, or unprotected sex, unavailability for follow-up assessment, inability to comply with protocol procedures, and a history of severe hypersensitivity reaction to Taxotere\u00ae or other drugs formulated with polysorbate 80.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is cytomegalovirus infections. The corresponding ICD-10 code for this disease is P35.1. The drug being tested in this trial is a placebo. The eligibility criteria for participants include obtaining informed consent, being 18 years of age or older, awaiting a liver or kidney transplant, having a negative pregnancy test for female patients of childbearing potential, and agreeing to use an effective barrier method of birth control. Additionally, the trial requires HLA type compatibility with tetramer assays for CMV seropositives (specifically A2, A24, B7, B8, B35), while seronegatives of any HLA type are eligible. Exclusion criteria include being unable or unwilling to provide informed consent, being pregnant or breastfeeding, participating in another clinical trial of a vaccine or systemic drug within the past 4 weeks, having a systemic hypersensitivity to the vaccine components, receiving blood or blood-derived products in the past 3 months (except albumin), having current thrombocytopenia or bleeding disorder contraindicating IM vaccination, having HLA type incompatibility with tetramer assays for CMV seropositives, requiring emergency transplant for fulminant liver failure, and being known to be HIV positive.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is head and neck cancer. The ICDCodes associated with this disease are C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, and D36.11. The drug being tested is perifosine. The eligibility criteria for this trial include specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions. The disease characteristics include histologically or cytologically confirmed squamous cell cancer of the head and neck, metastatic or recurrent disease that is not amenable to surgery or radiotherapy, and the presence of unidimensionally measurable disease. The patient characteristics include being 18 years or older, having an ECOG performance status of 0-2 or a Karnofsky performance status of 60-100%, having a life expectancy of more than 3 months, and meeting certain hematopoietic, hepatic, renal, and cardiovascular requirements. The prior concurrent therapy restrictions include limitations on biologic therapy, chemotherapy, radiotherapy, and other concurrent treatments.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is idiopathic pulmonary fibrosis. The corresponding ICD-10 code for this disease is J84.112. The drugs being tested in the trial are placebo and bibf 1120. The eligibility criteria for inclusion in the trial include a diagnosis of idiopathic pulmonary fibrosis according to the American Thoracic Society/European Respiratory Society guideline, a forced vital capacity (FVC) of 50-90%, a diffusing capacity for carbon monoxide (DLCO) of 30-79%, and being on a steady dose of pirfenidone for at least 3 months for patients already taking it. The exclusion criteria include elevated levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), elevated bilirubin levels, relevant airways obstruction, continuous oxygen supplementation, active infection, treatment with certain medications, and patients who are expected to undergo lung transplantation, have rapidly deteriorating disease, or have a life expectancy less than 3 months.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of hepatitis C virus. The trial includes patients with chronic genotype 1, 2, or 3 HCV infection who have not received previous treatment with HCV antiviral medications. The patients must be between the ages of 18 and 70 and have a body mass index (BMI) between 18 and 36 kg/m2. They must also have a non-cirrhotic fibrosis classification based on a liver biopsy taken within the past 3 years. The patients should not start any new exercise regimens during the first 3 months of the study. Other inclusion criteria include specific blood glucose and glycosylated hemoglobin levels, as well as hypertension managed effectively on a stable regimen. Exclusion criteria include breastfeeding, lack of willingness to use contraception, positive tests for HBsAg, anti-HBc IgM Ab, or anti-HIV Ab, history of other chronic liver diseases, recent use of herbal/natural remedies with antiviral activity, and various medical conditions and medication use.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is chronic lymphocytic leukemia. The ICD-10 codes associated with this disease are C91.11, C91.12, and C91.10. The drug being tested is a combination of valproic acid and fludarabine. \n\nThe eligibility criteria for this trial include having active CLL, having received at least one prior therapy for CLL with a nucleoside analogue, and having an ECOG performance status of 2 or less. \n\nThe exclusion criteria for this trial include being pregnant or breastfeeding, having a history of autoimmune cytopenias, having low platelet count or low absolute neutrophil count, having hepatic disease or elevated AST/ALT levels, having low creatinine clearance, having a history of pancreatitis, taking drugs that affect VPA protein binding or metabolism, having active infection, HIV, or active viral hepatitis, having active secondary malignancy or central nervous system involvement with CLL, and being diagnosed with a more aggressive lymphoproliferative disorder such as Richter's transformation.",
    "The sample from the table is for a clinical trial that is in phase 2/phase 3. The trial is focused on colorectal cancer. The ICD-10 codes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being studied in the trial are cpt-11 and ts-1, as well as cpt-11, 5-fu, and l-lv. The eligibility criteria for participants include having histologically confirmed colorectal cancer, being locally advanced and/or metastatic, having received prior chemotherapy as first-line treatment, not having received prior irinotecan administration, being able to take oral medication, being between the ages of 20 and 75, having a performance status of 0 or 1 (ECOG), having a white blood cell count between 3,000 and 12,000/mm^3, having a platelet count of at least 100,000/mm^3, having AST and ALT levels below or equal to 100 IU/L, having a creatinine level below or equal to 1.2 mg/dL, and having a bilirubin level below or equal to 1.5 mg/dL. The exclusion criteria include having received prior radiotherapy for colorectal cancer, having had other malignancies in the past 5 years, and having a serious illness or medical condition.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied include anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, hepatosplenic t-cell lymphoma, peripheral t-cell lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult t-cell leukemia/lymphoma, and recurrent cutaneous t-cell non-hodgkin lymphoma. The corresponding ICDCodes for these diseases are also provided. The drug being used in the trial is sorafenib tosylate. The eligibility criteria for participants are listed, including requirements such as confirmed diagnosis of recurrent de novo or transformed diffuse large B cell lymphoma, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, measurable disease, previous treatment failure, specific blood count and liver function requirements, and exclusion criteria such as CNS involvement, previous treatment with sorafenib or similar drugs, and certain medical conditions or medications.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on two diseases: foot ulcer, diabetic and diabetes complications. The corresponding ICD-10 codes for these diseases are ['E10.9', 'E11.9', 'E13.9', 'E10.8', 'E11.8', 'E13.8', 'E08.9']. The trial involves two drugs, namely 'mre0094' and 'vehicle gel'. The eligibility criteria for participants are listed, including having type 1 or type 2 diabetes mellitus, nerve problems in their feet, a large ulcer or multiple ulcers on the bottom surface of their foot for at least 3 weeks, ability to apply the study drug to the ulcer or have a caregiver do it, and being able to visit the doctor regularly during the 4\u00bd month study. There are also exclusion criteria, such as having an ulcer caused by poor blood flow or infection, inability to wear an off-loading device to relieve pressure on the ulcer, and having certain other diseases or using certain types of drugs.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 2 and focuses on diseases related to neoplasm metastasis and palliative care. The ICD-10 codes associated with these diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, and Z51.5. The drugs being studied in this trial are tanezumab 10 mg iv and an IV placebo for tanezumab. The eligibility criteria for this trial include having prostate cancer, breast cancer, renal cell carcinoma, or multiple myeloma that has spread to the bone and is causing moderate to severe bone pain, as well as requiring daily opioid medication. There are also exclusion criteria, such as not having bone pain caused by cancer, recent chemotherapy or radiotherapy, a history of osteoarthritis or rheumatoid arthritis, or significant trauma to a major joint within the past year.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is hormone refractory prostate cancer. The icd-10 codes associated with this disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drugs being used in the trial are picoplatin and docetaxel. The eligibility criteria for participants in this trial include having histologically or cytologically confirmed adenocarcinoma of the prostate, radiologic evidence of metastatic disease, disease progression or recurrence, receiving androgen ablation therapy, adequate hormonal therapy, specific age requirements, ECOG performance score, stable levels of pain, life expectancy, specific time intervals since prior treatments, certain blood count and liver function requirements, and agreement to use birth control methods. The exclusion criteria include prior treatment with certain agents, evidence of brain or leptomeningeal metastases, symptomatic peripheral neuropathy, history of other cancers within the past 5 years, hypersensitivity to certain drugs, prior radiotherapy affecting a significant portion of the bone marrow, uncontrolled intercurrent illness, serious medical or psychiatric illness that could interfere with the study treatment, and history of serious cardiac disease.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on lung cancer. The ICD-10 codes associated with the disease are ['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']. The drugs being studied in this trial are cisplatin and etoposide. The eligibility criteria for participants in this trial are listed, including specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions.",
    "The sample is a phase 2 trial for the treatment of schizophrenia. The table includes information about the phase, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is phase 2, and the disease being studied is schizophrenia. The icd-10 codes associated with schizophrenia are listed as ['F20.0', 'F20.1', 'F20.2', 'F20.3', 'F20.5', 'F20.89', 'F20.9']. The drugs being tested in this trial are armodafinil and placebo. The eligibility criteria include having a diagnosis of schizophrenia according to DSM-IV-TR criteria, being clinically stable for at least 8 weeks, and having received treatment with specific antipsychotic medications for at least 6 weeks. Other criteria include being in good health, using contraception if a woman of childbearing potential, and being willing to comply with study restrictions. Exclusion criteria include having other Axis I disorders, movement disorders, significant medical conditions, previous use of modafinil or armodafinil, and being pregnant or lactating.",
    "The sample is a phase 2 clinical trial for patients with advanced non-small cell lung cancer. The trial is testing the effectiveness of two drugs, erlotinib and docetaxel, in treating the disease. The eligibility criteria for the trial include being between the ages of 18 and 75, having histologically confirmed metastatic NSCLC, and not having been previously treated with anticancer drugs for advanced disease. Other criteria include having an ECOG performance status of 0-1, a life expectancy of at least 12 weeks, and the ability to take oral medication. The sample also includes exclusion criteria, such as prior exposure to agents directed at the HER axis, prior chemotherapy for advanced disease, and unstable systemic diseases that contraindicate the use of the study medications.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is ovarian cancer. The ICD-10 codes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being tested in the trial are vintafolide and pegylated liposomal doxorubicin (PLD). The eligibility criteria for the trial include signing an informed consent form, being at least 18 years old, having confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, having platinum-resistant ovarian cancer, having a measurable lesion on a radiological evaluation, having had prior debulking surgery, having received prior platinum-based chemotherapy but not more than 2 prior systemic cytotoxic regimens, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, having recovered from prior cytotoxic therapy-associated acute toxicities, and having adequate organ function. The exclusion criteria include having a tumor of low-malignant potential, prior exposure to PLD or anthracycline therapy, prior exposure to FR-targeted therapy, prior therapy with mouse antibodies or vinorelbine, prior abdominal or pelvic radiation therapy, recent history of abdominal surgery or peritonitis, serious comorbidities, pregnancy, concurrent malignancy or history of other cancer within the last 5 years, symptomatic central nervous system metastasis, and concurrent use of investigational therapies.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is ulcerative colitis, which is identified by the ICD-10 codes K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, and K51.811. The drugs being tested in this trial are aeb071 and placebo. \n\nThe eligibility criteria for this trial include being between the ages of 18-75, both males and females. Female subjects of childbearing potential must be using two methods of contraception. Participants must have active, moderate to severe disease and have had a poor response to or no toleration of conventional therapy such as steroids or mesalamine. Good communication with the investigator, understanding and compliance with the study requirements, and written informed consent are also required.\n\nExclusion criteria for this trial include allergy to the drug, very low or high body weight, ongoing treatment with specific other medications (such as antibiotics), diagnosis of primary sclerosing cholangitis, renal impairment, toxic megacolon, presence or history of specific other diseases, cancer, cardiac abnormalities, abnormal laboratory findings, history of alcohol or drug abuse, pregnant or breastfeeding women, and positive HIV, Hepatitis B, or Hepatitis C test results.\n\nIt is important to note that there may be additional inclusion/exclusion criteria defined by the protocol of the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a phase 2 trial for the treatment of various types of brain tumors, including adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, and recurrent adult brain tumor. The trial is investigating the use of a drug called vorinostat.\n\nThe eligibility criteria for this trial include having a confirmed grade 4 astrocytoma (glioblastoma multiforme) at primary diagnosis or recurrence, measurable or evaluable disease as determined by MRI or CT scan, a performance status of ECOG 0-2, specific blood cell counts within normal ranges, normal liver function, normal kidney function, no recent heart conditions or arrhythmias, not being HIV positive, not being immunocompromised (unless due to corticosteroid use), no known hypersensitivity to the study drug, no uncontrolled infection, not being pregnant or nursing, negative pregnancy test, and using effective contraception during and after the study treatment.\n\nAdditional criteria include not having any other malignancy or severe disease that would prevent participation in the study, allowing prior adjuvant chemotherapy, a specific time period since the last chemotherapy or small molecule cell cycle inhibitor, allowing concurrent use of corticosteroids if the dose has been stable for at least 1 week, a specific time period since prior radiotherapy, and a specific time period since prior stereotactic radiosurgery or interstitial brachytherapy unless certain criteria are met.\n\nIt is also mentioned that evidence of tumor progression by MRI or CT scan after radiotherapy is required, and a specific time period since prior valproic acid is necessary.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on the disease of hypertension. The ICD-10 codes associated with this disease are ['I15.0', 'I97.3', 'K76.6', 'P29.2', 'G93.2', 'H40.053', 'I10']. The drugs being studied in the trial are olmesartan medoxomil and placebo. The record also includes the eligibility criteria for the trial. The inclusion criteria state that the patient's seated systolic blood pressure (SeSBP) should be above the 95th percentile for their gender and height-for-age, or above the 90th percentile if the patient is diabetic, has glomerular kidney disease, or has a family history of hypertension. The patient should also test negative for hepatitis B, hepatitis C, and HIV. The exclusion criteria include not having any serious conditions that could interfere with the trial's results or the patient's well-being, known sensitivity to olmesartan medoxomil, taking prohibited medication, consuming more than 180 mg of caffeine daily, having malignant hypertension, a history of congestive heart failure, cardiomyopathy, or obstructive valve disease, having a renal transplant within the previous 6 months, and having severe nephritic syndrome not in remission.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is prostate cancer. The ICDCodes associated with the disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drugs mentioned in the sample are aminoglutethimide, ketoconazole, and therapeutic hydrocortisone. The eligibility criteria include specific disease characteristics, patient characteristics, and prior concurrent therapy details.",
    "The sample from the table represents a clinical trial for the treatment of melanoma, specifically advanced or metastatic melanoma. The trial is in phase 1/phase 2. The diseases being studied are melanoma and advanced melanoma. The corresponding ICD-10 codes for these diseases are provided. The drug being tested is a combination of gleevec and temozolomide. \n\nThe eligibility criteria for participants in the trial include having histologically confirmed melanoma that is metastatic or unresectable, with no available curative or palliative treatments. Prior chemotherapy, immunotherapy, radiation therapy (Phase I portion only), cytokine, biologic, or vaccine therapy is allowed, but not prior treatment with temozolomide. Other criteria include having measurable disease, an ECOG performance status of 2 or lower, and a life expectancy of more than 3 months.\n\nExclusion criteria for the trial include no prior treatment with temozolomide or imatinib mesylate, organ allografts, prior radiotherapy or intratumor injection therapy to target indicator lesions unless there has been progression or development of measurable disease outside the treatment area. Other exclusion criteria include pregnancy or lactation, history of second cancer, known hypersensitivity to temozolomide or imatinib, and use of any experimental therapy within 3 weeks prior to enrollment.",
    "The sample is a phase 2 trial for patients with ovarian carcinoma and peritoneal neoplasms. The trial is testing the effectiveness of the drug combination docetaxel and gemcitabine. The eligibility criteria for the trial include having a histologically proven diagnosis of epithelial ovarian cancer, platinum-resistant disease, measurable or evaluable disease, being at least 18 years old, having a GOG performance status of 2 or less, and meeting certain blood test requirements. The sample also lists exclusion criteria, such as prior treatment with gemcitabine or docetaxel, certain medical or psychiatric conditions, and peripheral neuropathy of grade 2 or higher.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and includes information about the diseases being studied, the corresponding ICD-10 codes, the drug being tested, and the eligibility criteria for participants.\n\nIn this particular trial, the diseases being studied are breast neoplasms and neoplasms in general. The ICD-10 codes associated with these diseases are provided as well. The drug being tested is neratinib.\n\nThe eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having a pathologic diagnosis of breast cancer and being at stage IIIB, IIIC, or IV. Progression following standard doses of Herceptin is also required for participants in Arm A. Over-expression of HER2, availability of tumor tissue for analysis, and at least one measurable lesion are additional inclusion criteria.\n\nExclusion criteria include prior treatment with Herceptin for participants in Arm B, having had more than 4 prior cytotoxic chemotherapy regimens, having bone or skin as the only site of measurable disease, inadequate cardiac function, recent major surgery or cancer therapy, active central nervous system metastases, pregnancy or breastfeeding, and inability to swallow the HKI-272 capsules.\n\nOverall, this sample provides a snapshot of a phase 2 clinical trial focusing on breast neoplasms and neoplasms, with neratinib as the drug being tested, and specific eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a phase 2 trial for pancreatic cancer. The diseases column specifies that the trial is focused on pancreatic cancer. The icdcodes column provides the ICD-10 code for the disease, which in this case is C25.3. The drugs column lists the drugs being used in the trial, which are erlotinib hydrochloride and gemcitabine hydrochloride. The criteria column contains the eligibility criteria for patients participating in the trial. It includes disease characteristics such as histologically confirmed pancreatic adenocarcinoma, locally advanced or metastatic disease, and the absence of endocrine tumor or lymphoma of the pancreas. The patient characteristics include specific requirements for performance status, life expectancy, blood counts, liver function, kidney function, and other factors. The prior concurrent therapy section outlines the restrictions on previous treatments and concurrent therapies during the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on hormone-resistant and recurrent prostate cancer. The diseases column lists the names of the diseases being studied, while the icdcodes column provides the corresponding ICD-10 codes for those diseases. The drugs column lists the drug being tested, which in this case is saracatinib. The criteria column contains the eligibility criteria for participants in the trial, including requirements related to the stage and progression of the disease, previous treatments, medical conditions, and laboratory values. The sample also includes exclusion criteria, which outline conditions that would disqualify a patient from participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a phase 2 trial for the treatment of migraines. \n\nThe phase of the trial is specified as phase 2. The diseases being studied are listed as 'migraine', 'migraine headache', 'migraine disorders', 'migraine with aura', and 'migraine without aura'. The corresponding ICD-10 codes for these diseases are also provided.\n\nThe drugs being tested in this trial are 'ast-726 low dose', 'ast-726 high dose', and 'ast-726 placebo'. \n\nThe eligibility criteria for participants in this trial are outlined in the 'criteria' section. The primary inclusion criteria include having migraine headaches according to International Headache Society guidelines, having had migraines for at least 6 months, and experiencing a certain frequency of migraine attacks. The primary exclusion criteria include having a high frequency of headaches, recent use of certain migraine medications, and failure in previous clinical studies for migraine prevention.\n\nThis sample provides a snapshot of the information stored in the table for this particular trial.",
    "The sample from the table is for a clinical trial in phase 2/phase 3. The trial focuses on the disease \"ocular hypertension\" and the corresponding ICD-10 codes are \"H40.053\", \"H40.051\", \"H40.052\", and \"H40.059\". The drug being tested is \"bimatoprost\". The eligibility criteria for inclusion in the trial are a clinical diagnosis of glaucoma or ocular hypertension in both eyes, and the patient must require an IOP-lowering drug in both eyes. The exclusion criteria are uncontrolled medical conditions and ocular seasonal allergies within the past 2 years.",
    "The sample is a phase 2 trial for the treatment of hepatitis C virus (HCV). The trial includes patients with HCV genotype 1a or 1b, both males and females who are at least 18 years old. The HCV RNA level should be equal to or greater than 10,000 IU/mL. Participants with compensated cirrhosis are allowed, but advanced fibrosis (F3/F4) is limited to approximately 35% of the total treated population, with a minimum of 20% F4 patients. Patients without cirrhosis should have had a liver biopsy within 3 years prior to enrollment, while those with cirrhosis can have any prior liver biopsy.\n\nThere are several exclusion criteria, including a history of liver or any other transplant, evidence of a medical condition contributing to chronic liver disease other than HCV infection, current or known history of cancer (except for certain types), evidence of decompensated liver disease, HIV or hepatitis B virus infection, gastrointestinal disease that affects drug absorption, uncontrolled diabetes or hypertension, prior exposure to an HCV direct-acting agent, and criteria that would exclude the patient from receiving ribavirin.\n\nThere are also specific laboratory criteria that need to be met, such as absolute neutrophil count, platelet count, hemoglobin levels, alanine aminotransferase levels, total bilirubin levels, international normalized ratio, QTcF or QTcB values, creatinine clearance, alpha fetoprotein levels, and albumin levels.",
    "The sample from the table is for a clinical trial in phase 2/phase 3. The trial is focused on Parkinson's disease. The ICD-10 code for Parkinson's disease is 'G20'. The trial involves two drugs, namely pramipexole immediate release and pramipexole extended release. The eligibility criteria for the trial are as follows:\n\nInclusion criteria:\n1. Male or female patients diagnosed with Parkinson's disease, including juvenile Parkinsonism, with onset at the age of forty or younger.\n2. Patients with a modified Hoehn and Yahr scale of II to IV during \"on\" time.\n3. Patients who have been on a stable dose of L-DOPA (either standard L-DOPA or L-DOPA with dopa-decarboxylase inhibitor) for at least 4 weeks before the baseline visit.\n4. Patients experiencing therapeutically problematic issues or status based on L-DOPA therapy, such as wearing-off phenomena, no on/delayed on, dystonia at off time, on-off phenomena, freezing phenomena at off time, sub-optimal dose of L-DOPA due to side effects or therapeutic strategy.\n\nExclusion criteria:\n1. Patients with atypical parkinsonian syndromes caused by drugs, metabolic disorders, encephalitis, or degenerative diseases.\n2. Patients with dementia, as indicated by a Mini-Mental State Examination (MMSE) score <24 at the screening visit.\n3. Patients with any psychiatric disorder according to DSM-IV criteria that could hinder compliance or completion of the trial or put the patient at risk.\n4. Patients with a history of psychosis, except for drug-induced hallucinations if the investigator determines that participation in the trial would not pose a significant risk.\n5. Patients with clinically significant ECG abnormalities at the screening visit, as determined by the investigator.\n6. Patients with clinically significant hypotension or symptomatic orthostatic hypotension at the screening or baseline visit.\n7. Patients with any other clinically significant disease, whether treated or not, that could put the patient at risk or hinder compliance or completion of the trial.\n8. Pregnant or breastfeeding individuals.\n9. Sexually active females of childbearing potential who are not using a medically approved method of birth control.\n10. Patients with serum levels of AST, ALT, alkaline phosphatases, or bilirubin exceeding 2 times the upper limits of normal.\n11. Patients with a creatinine clearance <50 mL/min.\n12. Patients with complications or signs of malignant tumors or those within 5 years after treatment.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on the disease \"seizures\". The associated ICD-10 codes for this disease are \"G40.89\", \"R56.1\", \"F44.5\", \"G40.501\", \"G40.509\", \"G40.111\", and \"G40.119\". The trial involves two drugs: \"levetiracetam 1 g iv + lorazepam 2 mg iv\" and \"placebo + lorazepam 3 mg iv\". The eligibility criteria for this trial include the inclusion criteria of having a seizure and the exclusion criteria of being pregnant, having renal failure, or hepatic impairment.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 2. The disease being studied is diabetes mellitus, type 2. The ICD-10 codes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being used in the trial are tak-875, glimepiride, and placebo. The eligibility criteria for participants in the trial are listed, including requirements related to diabetes diagnosis, medication use, glucose levels, body mass index, and other factors. There are also exclusion criteria listed, which specify conditions or factors that would disqualify a participant from the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on gastric cancer. The ICD-10 codes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being studied in this trial are cisplatin, fluorouracil, leucovorin calcium, and paclitaxel. \n\nThe eligibility criteria for participants in this trial include having histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction, localized cancer that is potentially curable by surgery, no metastatic cancer to the ovaries, being 18 years or older, having an ECOG performance status of 0-2, having a white blood cell count of at least 4,000 cells/mm3, a platelet count of at least 150,000/mm3, a bilirubin level less than 2 mg/dL, a creatinine level no greater than 1.5 mg/dL, a creatinine clearance greater than 50 mL/min, a caloric intake of at least 1500 kcal/day, no prior history of cancer within the past 5 years except for basal cell carcinoma of the skin or in situ carcinoma of the cervix, no prior radiation therapy except for skin cancer, and fertile patients must use adequate contraception.\n\nThe exclusion criteria for this trial include prior chemotherapy, clinically significant auditory impairment, significant heart disease, and being pregnant or lactating.",
    "The sample from the table represents a clinical trial study for a specific phase of the trial (phase 1/phase 2). The diseases being studied are alveolitis and systemic sclerosis. The corresponding ICD-10 codes for these diseases are provided as well. The drugs being investigated in the trial are imatinib. \n\nThe sample also includes the eligibility criteria for the trial. Inclusion criteria include fulfilling the criteria for systemic sclerosis, being at least 18 years old, having a forced vital capacity (FVC) less than 85% of predicted, being able to complete a 6-minute walk test with a walking distance of at least 150 meters, experiencing dyspnea on exertion, having a disease duration of \u2264 10 years, and showing evidence of alveolitis. Female patients of childbearing potential must have a negative pregnancy test. Written voluntary informed consent is also required.\n\nExclusion criteria include having severe or irreparable lung disease, significant airflow obstruction, clinically significant abnormalities on high-resolution computed tomography (HRCT) not related to systemic sclerosis, clinically significant pulmonary hypertension, persistent unexplained hematuria, history of persistent leukopenia, neutropenia, or thrombocytopenia, clinically significant anemia, elevated serum creatinine, pregnancy or breastfeeding, failure to use reliable contraception, active infection, unreliability or drug abuse, presence of any chronic debilitating illness other than systemic sclerosis, smoking within the past 6 months, abnormal liver function tests, previous use of high-dose prednisone, use of other disease-modifying medications, recent primary malignancy, severe cardiac problems, severe or uncontrolled medical disease, chronic liver disease, and known diagnosis of HIV infection. The use of contraindicated medications at baseline is also not allowed.\n\nThis sample provides a detailed description of the phase, diseases, drugs, and eligibility criteria for the clinical trial study.",
    "The sample is a phase 2/phase 3 clinical trial for the treatment of restless legs syndrome (RLS). The trial is looking at the effectiveness of the drugs rasagiline and placebo (sugar pill) in treating moderate to severe symptoms of RLS. The eligibility criteria for participants include being at least 18 years old, diagnosed with idiopathic RLS (without evidence of secondary causes), having a score of 15 or greater on the International RLS Study Group Rating Scale, and not currently receiving treatment for RLS (with a required 30-day washout period for participants on certain therapies). Participants must also be on a stable dose of specific antidepressants and meet certain contraceptive requirements if female. The exclusion criteria include having signs consistent with a secondary cause of RLS, history of unresponsiveness to dopaminergic RLS treatment, recent use of certain medications, allergies or adverse reactions to rasagiline or tyramine-containing foods, and use of contraindicated drugs or supplements. Participants should not be scheduled for elective surgery and should not have active medical or psychiatric illnesses that would require changes to treatment or jeopardize their ability to remain in the study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and is focused on the disease \"rheumatoid arthritis\". The ICD-10 codes associated with this disease are ['M06.9', 'M05.9', 'M06.08', 'M06.00', 'M06.011', 'M06.012', 'M06.019']. The drugs being studied in this trial are \"sarilumab\", \"placebo (for sarilumab)\", \"methotrexate\", and \"folic acid\". The eligibility criteria for participants in this trial include a diagnosis of rheumatoid arthritis lasting at least 3 months, active disease symptoms, and specific requirements related to joint tenderness, joint swelling, and high sensitivity C-reactive protein levels. There are also additional criteria for a specific part of the trial (Part B) related to bone erosion, Cyclic Citrullinated Peptide (CCP) positivity, and Rheumatoid Factor (RF) positivity. The exclusion criteria include age restrictions, recent use of certain medications, non-response to prior treatments, and recent use of glucocorticoids. It is important to note that the provided information may not include all relevant considerations for potential participants in the clinical trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on colorectal cancer. The ICD-10 codes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being studied in this trial are capecitabine and oxaliplatin. The eligibility criteria for participants include having histologically confirmed adenocarcinoma of the colon or rectum, having unresectable, metastatic, or recurrent disease, and not being amenable to potentially curative treatment. Other criteria include specific performance status, hematopoietic, hepatic, renal, cardiovascular, gastrointestinal, immunologic, and other health requirements. Prior concurrent therapies are also listed, including biologic therapy, chemotherapy, endocrine therapy, radiotherapy, surgery, and other treatments.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being studied in this trial are celecoxib and letrozole. The eligibility criteria for participants include having histologically or cytologically confirmed adenocarcinoma of the breast, locally advanced or metastatic disease, measurable disease (excluding bone disease only), and being estrogen receptor- or progesterone receptor-positive. Other criteria include age 18 and over, female sex, postmenopausal status, ECOG performance status of 0-2, a life expectancy of at least 3 months, specific hematopoietic, hepatic, and renal parameters, and no prior allergic reactions or medical conditions that would prevent participation. The record also specifies prior concurrent therapies that are not allowed, such as certain chemotherapy, endocrine therapy, radiotherapy, and medications like fluconazole or lithium.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on breast cancer, specifically recurrent or stage IV breast cancer. The trial is testing the drug pazopanib hydrochloride. The eligibility criteria for participants include having no prior treatment with bevacizumab, having confirmed invasive breast carcinoma, having measurable disease, and not being eligible for hormonal therapy or trastuzumab treatment. Other criteria include having no known brain metastases, having a good performance status, having a life expectancy of more than 12 weeks, and meeting certain blood count and liver function requirements. Participants should also not have certain medical conditions or be taking certain medications. The trial excludes pregnant or nursing individuals and requires the use of effective contraception for fertile participants. Participants should have had at least 4 weeks since prior chemotherapy, radiotherapy, or surgery. The sample also includes additional criteria related to cardiac health, prior treatments, and concurrent medications.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"rheumatoid arthritis\". The associated ICD-10 codes for this disease are ['M06.9', 'M05.9', 'M06.08', 'M06.00', 'M06.011', 'M06.012', 'M06.019']. The drugs being studied in this trial are 'mlta3698a', 'adalimumab', 'leflunomide', 'methotrexate', and 'placebo'. The eligibility criteria for participants in this trial include having a diagnosis of rheumatoid arthritis for at least 6 months, testing positive for rheumatoid factor or anti-cyclic citrullinated peptide (CCP) antibody, having active disease based on certain criteria, having a previous inadequate response to a disease-modifying anti-rheumatic drug (DMARD), and meeting other specific requirements. There are also exclusion criteria, such as being pregnant or planning to become pregnant, having certain abnormal laboratory values or medical conditions, and having a history of certain diseases or treatments.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 2. The disease being studied is \"geographic atrophy.\" The corresponding ICDCodes for this disease are \"K14.1.\" The drugs being used in the trial are \"al-78898a\" and \"sham injection.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include the ability to provide informed consent, a diagnosis of bilateral geographic atrophy confirmed within 14 days prior to randomization, specific visual acuity requirements, and other criteria defined by the protocol. \n\nExclusion criteria include a history or current evidence of exudative (\"wet\") AMD in the study eye, other retinal diseases, ophthalmologic conditions that interfere with examination or imaging, glaucoma or ocular hypertension, conditions requiring surgery during the study period, ocular or periocular infection, history of uveitis or endophthalmitis, recent intraocular or periocular surgery or injection, participation in other clinical studies or use of experimental treatments, certain medical or psychiatric conditions, women of childbearing potential without effective birth control, known allergies or hypersensitivity to certain substances, and other criteria defined by the protocol.",
    "The sample from the table is for a phase 2 trial. The disease being studied is depressive disorder, and the associated ICD-10 codes are F25.1, F33.0, F33.1, F33.9, F32.0, F32.1, and F32.9. The drugs being tested in the trial are gsk372475, venlafaxine, and a placebo. The eligibility criteria for inclusion in the trial include having a major depressive episode associated with major depressive disorder, a duration of the current episode between 12 weeks and 2 years, symptoms of decreased energy, pleasure, and interest, and being a female subject who agrees to use acceptable methods of birth control throughout the study. The exclusion criteria include having a current diagnosis of panic disorder or symptoms of generalized anxiety or panic attacks that could interfere with the trial, symptoms of the major depressive episode being better accounted for by another diagnosis, a diagnosis of bipolar disorder, schizophrenia, other psychotic disorders, borderline or antisocial personality disorder, or dementia, starting psychotherapy within 3 months prior to the screening, receiving electroconvulsive therapy or transcranial magnetic stimulation within 6 months prior to the screening, receiving psychoactive drugs within 4 weeks of randomization, testing positive on a urine drug screen or blood alcohol test, being at risk of suicide or having a previous suicide attempt or family history of suicide attempt, testing positive on a pregnancy test, having a history of seizure disorder, myocardial infraction within the past year, or an unstable medical condition, and failing to respond to an adequate course of pharmacotherapy with at least 2 different antidepressants.",
    "The sample is a phase 2 trial for the treatment of leukemia. The specific disease being targeted is acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). The trial is not applicable to M3 AML cases. The eligibility criteria include being in the first or second relapse, or being refractory to initial induction therapy. Patients must not have symptomatic CNS involvement and must meet certain patient characteristics such as having an ECOG performance status of 2 or lower, specific levels of creatinine, bilirubin, AST, and ALT, and not being pregnant or nursing. Prior concurrent therapy is allowed as long as it has been at least 1 week since the therapy and the patient has recovered. However, concurrent chemotherapy, corticosteroids (unless used for diseases other than leukemia), palliative radiotherapy, and certain growth factors are not allowed.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"diabetes mellitus, type 2\". The associated ICD-10 codes for this disease are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']. The trial involves the use of two drugs, \"ly2605541\" and \"insulin glargine\". The eligibility criteria for participants are listed, including requirements such as having type 2 diabetes for at least 1 year, being at least 18 years old, and using specific medications for a certain period of time. Other criteria include specific ranges for hemoglobin A1c, body mass index (BMI), and the ability to prepare and inject insulin. Women of childbearing potential must test negative for pregnancy and agree to use birth control during the trial. The exclusion criteria list factors that would disqualify potential participants, such as recent use of certain medications, participation in weight loss programs, or certain medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is asthma. The ICDCodes associated with asthma are listed as ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The drugs being tested in this trial include 'formoterol fumarate dpi', 'mometasone furoate/formoterol fumarate mdi (ex-actuator) without spacer', 'mometasone furoate/formoterol fumarate mdi (ex-actuator) with spacer', 'placebo mdi with spacer', 'placebo mdi without spacer', and 'mometasone furoate dpi'. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having a diagnosis of asthma for at least 6 months, having taken an Inhaled Corticosteroid (ICS) for at least 3 months prior to the screening visit, and meeting certain FEV1 (Forced Expiratory Volume in 1 second) requirements. Exclusion criteria include recent severe asthma exacerbation or hospitalization, requiring ventilator support, certain FEV1 decreases, excessive use of short-acting beta-2 agonists or nebulized treatments, and experiencing clinical deterioration in asthma.\n\nOverall, this sample provides specific details about the phase, disease, ICDCodes, drugs, and eligibility criteria for a clinical trial focused on asthma.",
    "The sample is a phase 2 clinical trial that focuses on various diseases, including cervical cancer, endometrial cancer, fallopian tube cancer, neurotoxicity, ovarian cancer, primary peritoneal cavity cancer, and sarcoma. The diseases are identified by their corresponding ICD-10 codes. The proposed treatment for these diseases is a combination of cisplatin and paclitaxel, and the eligibility criteria include being ineligible for a higher priority GOG protocol. \n\nThe patient characteristics required for participation in the trial include a specified age range, a performance status of GOG 0-3, and no specified life expectancy. Hematopoietic requirements include a minimum white blood cell count, granulocyte count, and platelet count. Hepatic requirements include a maximum bilirubin level and AST and alkaline phosphatase levels. Renal requirements include a maximum creatinine level. Cardiovascular requirements include no hypertension that cannot be discontinued for 24 hours during chemotherapy treatment. Other criteria include no history of neuropathy, no significant infection, no prior malignancy within the last 12 months, and no physical disabilities that would prevent vibration perception threshold testing.\n\nPrior concurrent therapy restrictions include no prior chemotherapy, no prior radiotherapy except for cervical carcinoma, and no specified requirements for biologic or endocrine therapy. Surgery requirements are not specified.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, the disease is \"neuralgia, postherpetic,\" the ICDCodes is ['B02.22'], the drug is \"levetiracetam,\" and the eligibility criteria are provided in the inclusion and exclusion sections. The inclusion criteria include being a male or female outpatient over 18 years old, suffering from neuralgia for at least 3 months after healing from acute herpes zoster skin rash, having a certain level of pain intensity, and having an estimated creatinine clearance of at least 50 ml/min. The exclusion criteria include receiving professional psychological support for coping with postherpetic neuralgia, previous neurolytic or neurosurgical therapy for postherpetic neuralgia, having a known co-existent source of pain or painful peripheral neuropathy, having a significant neurological disorder other than the study disease, having conditions associated with immunosuppressive states, and having clinically significant major depression.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of glaucoma and ocular hypertension. The trial involves testing three different drugs: latanoprost 0.005%, ar-12286 ophthalmic solution 0.5%, and timolol maleate ophthalmic solution 0.5%. The eligibility criteria for participants include being 18 years of age or older, having a diagnosis of open angle glaucoma or ocular hypertension, and currently using a prostaglandin analogue for at least one month. The inclusion criteria also specify certain intraocular pressure levels and visual acuity requirements. The exclusion criteria include previous participation in a study of AR-12286, high intraocular pressure, history of certain eye conditions, hypersensitivity to certain medications, recent ocular trauma or surgery, and other factors that may interfere with the study. The sample also includes systemic exclusion criteria and restrictions for women of childbearing potential.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on prostate cancer. The diseases listed include prostate adenocarcinoma, prostate carcinoma, recurrent prostate carcinoma, stage III prostate cancer, and stage IV prostate cancer. The corresponding ICD-10 codes for these diseases are also provided. The drugs being studied in the trial are bicalutamide, flutamide, goserelin acetate, ipilimumab, and leuprolide acetate. The eligibility criteria for the trial are listed, including requirements for histologically confirmed adenocarcinoma of the prostate, specific PSA levels, organ function, performance status, and ability to understand and sign informed consent. The exclusion criteria are also listed, which include pre-existing medical conditions, recent usage of immune-suppressive medication, prior treatments, and other concurrent malignancies.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and includes information about the diseases being studied, the corresponding ICD-10 codes, the drug being tested, and the eligibility criteria for participants.\n\nIn this particular sample, the phase of the trial is phase 2. The diseases being studied are \"extrahepatic bile duct cancer,\" \"gallbladder cancer,\" and \"liver cancer.\" The corresponding ICD-10 codes for these diseases are \"C24.0,\" \"D13.5\" for extrahepatic bile duct cancer, \"C23,\" \"D37.6\" for gallbladder cancer, and \"D13.4,\" \"Z85.05,\" \"C22.8,\" \"C78.7,\" \"C22.9,\" \"D37.6\" for liver cancer. The drug being tested is \"becatecarin.\"\n\nThe eligibility criteria for participants include a diagnosis of advanced hepatobiliary carcinoma that is not amenable to conventional surgery, measurable disease, and no known brain metastases. The patient must be 18 years or older with an ECOG performance status of 0-2 and a life expectancy of at least 12 weeks. Hematopoietic requirements include a white blood cell count of at least 3,000/mm^3, a granulocyte count of at least 1,500/mm^3, a platelet count of at least 100,000/mm^3, and a hemoglobin level greater than 10 g/dL. Hepatic requirements vary depending on the cohort, with bilirubin levels needing to be less than 3 mg/dL overall. Renal requirements include normal creatinine levels or a creatinine clearance of at least 60 mL/min. Cardiovascular criteria state that the patient should not have New York Heart Association class III or IV heart disease. Other requirements include not being pregnant or nursing, having a negative pregnancy test, and using effective contraception if fertile. \n\nThe record also includes information about prior concurrent therapy, specifying that there should be no prior chemotherapy for cholangiocarcinoma or hepatobiliary carcinoma, and no concurrent combination antiviral therapy for HIV-positive patients. The use of biologic therapy, endocrine therapy, radiotherapy, and surgery is not specified in this sample.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on cervical cancer. The ICD-10 codes associated with the disease are ['M50.20', 'M50.21', 'M50.30', 'M50.31', 'M50.80', 'M50.81', 'M50.90']. The drugs being studied in this trial are bevacizumab and carboplatin. The eligibility criteria for participants are listed, including specific tumor characteristics, negative para-aortic nodes, adequate bone marrow and renal function, and a Zubrod Performance Status of 0 or 1. There are also exclusion criteria, such as certain tumor stages, previous radiation or chemotherapy, and various medical conditions. The sample also includes specific exclusion criteria for bevacizumab and carboplatin.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied include \"epilepsy, cryptogenic\", \"epilepsy, partial\", \"seizure disorder\", \"autoimmune diseases, nervous system\", and \"limbic encephalitis\". The ICDCodes associated with these diseases are \"['G40.111', 'G40.119', 'G40.211', 'G40.219', 'G40.101', 'G40.109', 'G40.201']\". The drug being tested is \"ivig\". The eligibility criteria for this trial include a diagnosis of uncontrolled epilepsy with at least two seizures a month for three consecutive months, age between 18 and 50, clinical semiology or EEG consistent with partial onset epilepsy, refractory to two or more main-line anti-epileptic drugs, ability to keep a seizure diary, and normal brain MRI (3 Tesla, seizure protocol) with the exception of hippocampal sclerosis. The exclusion criteria include a history of certain medical conditions or illnesses such as severe prematurity, neonatal distress, febrile seizures, traumatic brain injury, stroke, brain tumor, meningitis, encephalitis, neurocutaneous syndromes, or intracranial metal objects. Additionally, individuals with evidence of psychogenic epilepsy, history of convulsive status epilepticus, history of primary generalized epilepsy in a first-degree relative, or known serious medical illness are also excluded from the trial.",
    "The sample is a phase 2 trial for HIV infections. The trial is testing the effectiveness of a combination of drugs including raltegravir potassium, darunavir/ritonavir, etravirine, and an optimized background regimen. The eligibility criteria for participants include being 18 years or older, having documented HIV-1 infection, a history of virological failure on NNRTIs, and being on a combination antiretroviral therapy for at least 8 weeks prior to the screening visit. Participants should also be naive to darunavir, etravirine, and integrase inhibitors. The plasma viral load at the screening visit should be over 1000 copies/ml, with no CD4 restriction. Genotypic resistance testing is required, specifically looking for protease inhibitor mutations and reverse transcriptase mutations. There are also exclusion criteria, such as non-effective barrier contraception in women of childbearing potential, pregnancy or breastfeeding, opportunistic infection at the acute phase, and various medical conditions or allergies. Participants should not be receiving experimental agents with an exclusion period for participation in other studies.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on heart-related diseases such as heart failure, myocardial ischemia, and angina pectoris. The diseases are associated with specific ICD-10 codes. The trial involves several drugs, including ck-1827452 in different forms and a placebo. The eligibility criteria for participants are listed, including requirements such as being at least 18 years old, having a documented history of ischemic heart disease, experiencing exercise-induced angina, and having specific cardiac measurements and conditions. There are also exclusion criteria, which include having certain medical conditions, abnormal blood pressure levels, recent cardiac events or procedures, and other factors that may limit exercise capacity or indicate impaired organ function. Additionally, there are restrictions related to prior use of investigational drugs or devices, weight, body temperature, and laboratory abnormalities. The sample also mentions that the patient should not have received prior treatment with CK-1827452.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is metastatic colorectal cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs used in this trial are capecitabine, oxaliplatin, and bevacizumab. The eligibility criteria for this trial include having a histologically proven diagnosis of colorectal adenocarcinoma, presence of metastatic disease in the liver only, absence of extrahepatic metastases, and liver-only metastases determined to be unresectable. Other criteria include no previous treatment for metastatic colorectal cancer, feasibility of surgery with curative intent, and adequate medical fitness to undergo neoadjuvant treatment and surgery. Additionally, patients should not have pre-existing liver dysfunction of Childs Pugh Grade B or greater.",
    "The sample from the table is for a phase 2 clinical trial. The trial focuses on the treatment of autistic disorders, including autistic disorder, Asperger syndrome, and autism spectrum disorder. The trial uses the drug aripiprazole. The eligibility criteria for participants include being between 30 months and 17 years 11 months old, having a diagnosis of autism or related disorders, having a guardian who can provide consent, and being seizure-free if on anticonvulsants. The sample also lists exclusion criteria, such as not having Rett's syndrome or Child Disintegrative Disorder, not having taken certain psychotropic medications within 2 weeks, not having previously participated in a trial with aripiprazole, and not being pregnant or nursing. Additionally, participants should not have epilepsy or another significant chronic medical illness.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, the disease is uterine cancer, the ICDCodes are C57.4 and D28.2, the drug is celecoxib, and the eligibility criteria are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include age requirement, specific histologic types of uterine cancer, disease stage, negative pregnancy test, performance status, and informed consent. The exclusion criteria include hypersensitivity to celecoxib, previous usage of NSAIDs or aspirin, peptic ulcer disease, advanced renal disease, and impairment of hepatic, renal, or hematologic function.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"multiple myeloma\" and \"multiple myeloma in relapse\". The corresponding ICDCodes for these diseases are \"C90.01\", \"C90.02\", and \"C90.00\" for the first disease, and \"C90.02\" for the second disease. The drugs being used in the trial are \"perifosine\", \"bortezomib\", and \"dexamethasone\". The eligibility criteria for this trial include various conditions and requirements such as previous diagnosis of multiple myeloma, specific diagnostic criteria, relapsed or refractory disease, previous treatment with bortezomib, age requirement, performance status, ability to adhere to the study schedule, and signing an informed consent document. There are also exclusion criteria listed, which include certain medical conditions, medication history, laboratory abnormalities, pregnancy or breastfeeding, and plasma cell leukemia at the time of study entry.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of posttraumatic stress disorder (PTSD). The trial involves the use of the drugs nepicastat and placebo. The eligibility criteria for participants include having a diagnosis of PTSD, being free of substance use disorders, not taking psychotropic medication for two weeks prior to randomization, and having normal physical and laboratory results. Women of childbearing potential must be using approved methods of birth control. The age range for participants is 19 to 65 years. The exclusion criteria include a history of bipolar disorder, schizophrenia, or cognitive disorders, active suicidal or homicidal thoughts, psychotic symptoms that impair the ability to give informed consent, unstable medical conditions, contraindications to nepicastat, plans to become pregnant or breastfeed during the study, current or pending incarceration, and terminal illness.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of nasal polyposis and asthma. The diseases column lists the names of the diseases being studied, while the icdcodes column contains the corresponding ICD-10 codes for those diseases. The drugs column lists the names of the drugs being tested, which in this case are omalizumab and placebo. The criteria column provides the eligibility criteria for participants in the trial.\n\nThe inclusion criteria state that subjects must be at least 18 years old, have a diagnosis of bilateral nasal polyps that have recurred after surgical resection or are grades 3 or 4 in both nares, and have a diagnosis of asthma for more than 2 years. Subjects must also be in good health, willing to give informed consent, adhere to visit schedules and medication restrictions, and perform daily diary entries. They must be free of any upper respiratory tract infection within two weeks prior to inclusion, and their clinical laboratory tests must be within normal limits or clinically acceptable.\n\nFor female subjects of childbearing potential, they must use a medically acceptable form of birth control, and a negative urine pregnancy test is required prior to treatment. Male subjects must also use an adequate form of birth control. The exclusion criteria include being pregnant, breastfeeding, or premenarcheal for women, being younger than 18 years old, having a history of systemic reactions to the study medication, and having certain medical conditions or infections. Additionally, subjects must not have a history of cancer, HIV, or hepatitis B or C, and they must not have had an acute asthmatic attack requiring hospital admission within the four weeks prior to screening. Specific immunotherapy should not have been received within the previous three months.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is asthma. The ICD-10 codes associated with the disease are 'J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', and 'J45.40'. The drugs being tested in the trial are 'bi671800', 'fluticasone placebo', 'fluticasone', 'bi 671800 placebo'. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n1. Participants must provide signed informed consent consistent with ICH-GCP.\n2. Participants must have a three-month history of reversible asthma (12% with 200 mL) according to GINA guidelines, with spirometry results at randomization showing FEV1 between 60% and 85%.\n3. Participants must not have used ICS (inhaled corticosteroids) in the three months prior to screening.\n4. Participants must have been diagnosed with asthma before the age of 40.\n5. Participants must have an ACQ (Asthma Control Questionnaire) score of at least 1.5 at randomization.\n6. Participants must be between 18 and 65 years old.\n7. Participants must be non-smokers or ex-smokers with a history of less than 10 pack years, and must have a negative cotinine screen.\n8. Participants must be able to perform PFT (Pulmonary Function Test).\n\nThe exclusion criteria for the trial are as follows:\n1. Participants with significant diseases other than asthma or allergic rhinitis.\n2. Participants with hepatic transaminases or total bilirubin levels greater than 1.5 times the upper limit of normal (ULN).\n3. Participants who have been hospitalized for asthma or asthma-related intubation within the past 3 months.\n4. Participants with uncontrolled asthma.\n5. Participants who have had a respiratory tract infection or exacerbation within the past 4 weeks.\n6. Participants with FEV1 less than 40%, who have used more than 12 puffs of SABA (Short-Acting Beta Agonist) on more than two consecutive days, or who have experienced an asthma exacerbation during the run-in period.\n7. Participants who are already participating in another interventional study.\n8. Pregnant or nursing women.\n9. Women of childbearing potential who are not using appropriate methods of birth control as defined by the protocol.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is non-small-cell lung carcinoma. The corresponding ICD-10 codes for this disease are D02.20, D02.21, and D02.22. The drug being tested in this trial is erlotinib. \n\nThe eligibility criteria for this trial include having histologically or cytologically confirmed stage IIIB or IV NSCLC that has been treated with 1-2 platinum- or taxane-containing regimens. The patient must also have measurable disease and may have had prior surgery and external beam radiation. Additionally, the trial is specifically looking for African American participants who are 18 years or older.\n\nThe exclusion criteria for this trial include having known brain metastases, prior treatment with EGFR targeting therapies, and being pregnant or lactating.",
    "The sample is a phase 2 clinical trial for the treatment of melanoma (skin cancer). The trial is open to patients with metastatic or unresectable melanoma. The eligibility criteria include having histologically or cytologically confirmed melanoma, measurable disease according to RECIST criteria (with cutaneous lesions measuring at least 1 cm), and completion of radiotherapy for brain metastases if clinically indicated at the time of diagnosis. \n\nThe patient characteristics required for participation in the trial include an ECOG performance status of 0-1, specific blood cell counts within normal ranges, normal kidney and liver function, and no concurrent serious illnesses. Patients must not be pregnant or nursing, must have a negative pregnancy test, and fertile patients must use effective contraception. HIV positivity is also not allowed.\n\nRegarding prior concurrent therapy, patients must have recovered from all previous treatments. Prior radiotherapy is allowed, but there must be radiographic evidence of progression for any lesion that has received radiotherapy to be considered measurable disease. Prior use of temozolomide or sorafenib tosylate is also allowed. There must be at least a 4-week interval since the last chemotherapy or active immunotherapy treatment, and no other concurrent investigational anticancer therapy is allowed. Certain medications, such as cytochrome P450 enzyme-inducing antiepileptic drugs, rifampin, and St. John's wort, are not allowed to be taken concurrently with the trial drugs.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is phase 2. The disease mentioned is \"diabetes mellitus, type 2\" and its corresponding icd-10 codes are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']. The drugs being tested are 'pf-00734200 30 mg qd', 'pf-00734200 20 mg qd', and 'placebo'. The eligibility criteria state that the trial is open to men and women between the ages of 18 and 80 with poorly controlled Type 2 diabetes. However, individuals with Type 1 or secondary forms of diabetes and those currently using insulin are excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied are myalgia, hypercholesterolemia, and hyperlipidemia. The corresponding ICDCodes for these diseases are ['E78.01', 'E78.00', 'Z83.42'] for hypercholesterolemia and ['E78.2', 'E78.49', 'E78.5'] for hyperlipidemia. The drugs being used in the trial are ppd10558, atorvastatin, and placebo.\n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include a diagnosis of primary hypercholesterolemia (Fredrickson types IIa or IIb), a history of statin-associated myalgia, specific LDL-C and triglyceride levels, certain hemoglobin values, and agreement to stop other antihyperlipidemic agents and Coenzyme Q10 supplements. Exclusion criteria include a history of chronic pain, chronic use of pain medications, vitamin D insufficiency, abnormal thyroid function, history of rhabdomyolysis, liver disease, renal dysfunction, nephrotic-range proteinuria, high HbA1C and CK levels, congestive heart failure, recent cardiovascular events, pregnancy or breastfeeding, history of cancer, and positive test results for certain infections.\n\nOverall, this sample provides a snapshot of a clinical trial in Phase 2, focusing on the diseases myalgia, hypercholesterolemia, and hyperlipidemia, and the drugs being tested, along with the specific eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of multiple myeloma, a type of cancer. The ICD-10 codes associated with the disease are C90.01, C90.02, and C90.00. The drug being studied is palonosetron. \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include providing written informed consent, being at least 18 years old, having histologically confirmed multiple myeloma, having a Karnofsky index of at least 50%, and being scheduled to receive a regimen containing melphalan followed by autologous stem cell transplant. Mild to moderate hepatic, renal, or cardiovascular impairment may be allowed at the discretion of the investigator. Women of childbearing potential must use reliable contraceptive measures and have negative pregnancy tests.\n\nExclusion criteria include inability or unwillingness to understand or cooperate with the study procedures, recent use of investigational drugs, recent use of drugs with potential antiemetic efficacy, ongoing vomiting or significant nausea, contraindications to 5-HT3 receptor antagonists, and recent or planned radiotherapy.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating metastatic melanoma and skin cancer. The diseases are represented by their respective ICD-10 codes. The drugs being used in the trial are cyclophosphamide and fludarabine phosphate. The record also includes the eligibility criteria for participants in the trial, which are listed under \"INCLUSION CRITERIA\" and \"EXCLUSION CRITERIA\". The criteria include factors such as age, previous treatments, medical conditions, and laboratory values. The purpose of this record is to provide detailed information about the trial and the requirements for potential participants.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is Parkinson's disease. The corresponding ICD-10 code for Parkinson's disease is G20. The drugs being used in the trial are preladenant and a placebo tablet to match preladenant. The eligibility criteria for participants in this trial include having a diagnosis of idiopathic PD based on specific criteria, having received prior therapy with L-dopa for more than 1 year, being on a stable dopaminergic treatment regimen for at least 4 weeks, and meeting certain Hoehn and Yahr stage requirements. Participants must also be experiencing motor fluctuations and a minimum of 2 hours/day of \"off\" time, as well as being capable of maintaining an accurate symptom diary. There are additional criteria related to laboratory tests, physical examination results, adherence to dose and visit schedules, and contraception for females of child-bearing potential. The exclusion criteria include not having drug-induced or atypical parkinsonism, cognitive impairment, bipolar disorder, schizophrenia, or other psychotic disorder. Participants must not have had surgery for PD, untreated major depressive disorder, or be at imminent risk of self-harm or harm to others. They must not have previously participated in studies using preladenant, have allergies/sensitivity to preladenant or its excipients, or have used any investigational drugs or participated in any other clinical trial within 90 days of screening.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease asthma. The ICD-10 codes associated with asthma are provided. The trial involves two drugs, \"gw642444m\" and \"placebo\". The eligibility criteria for participants are listed, including age requirements, gender eligibility, and contraceptive methods for female participants. The criteria also specify that participants must have a documented clinical history of persistent asthma and demonstrate current reversible airways disease. Additionally, participants must be using an inhaled corticosteroid at a stable dose. The sample also includes exclusion criteria, such as recent exacerbation of asthma, history of life-threatening asthma, and recent hospitalization for asthma. Other excluded conditions and diseases are listed, including cardiovascular, renal, and immunological conditions. Adverse reactions to certain drugs and non-compliance with study requirements are also grounds for exclusion. The sample concludes with restrictions on alcohol and tobacco use, recent use of certain medications, and a list of medications that should not have been taken within 14 days of the trial.",
    "The sample from the table represents a phase 2 clinical trial. The trial focuses on chronic lymphocytic leukemia (CLL) and stage 0 CLL, stage I CLL, stage I small lymphocytic lymphoma, stage II CLL, stage II small lymphocytic lymphoma, stage III CLL, stage III small lymphocytic lymphoma, stage IV CLL, and stage IV small lymphocytic lymphoma. The corresponding ICD-10 codes for these diseases are provided as well. The drugs being studied in the trial are cyclophosphamide and pentostatin. The eligibility criteria for participants include specific diagnostic criteria for CLL or SLL, previous untreated status, and indications for chemotherapy. Additional criteria include specific laboratory values, performance status, willingness to provide blood samples, and ability to adhere to the study requirements. The exclusion criteria include certain comorbid conditions, pregnancy or nursing, lack of contraception use, other active primary malignancy, recent radiation therapy or major surgery, current use of corticosteroids (except for low doses for non-hematologic conditions), and active hemolytic anemia requiring treatment.",
    "The sample from the table is for a phase 2 trial. The disease being studied is epilepsy, and the corresponding ICD-10 codes for epilepsy are provided. The drug being tested is clonazepam. The eligibility criteria for this trial include a diagnosis of refractory epilepsy and the absence of nasal conditions that would prevent the use of an intranasal product. The exclusion criteria include having a clinically significant unstable medical abnormality and currently or regularly taking clonazepam.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The phase column indicates the phase of the trial, which can be phase I, phase II, or phase III. The diseases column lists the names of diseases being studied in the trial. The icdcodes column contains the corresponding ICD-10 codes for each disease. The drugs column lists the names of drugs being used in the trial. The criteria column provides the eligibility criteria for participating in the trial.\n\nIn the given sample, the phase is described as \"phase 1/phase 2\". The diseases being studied include leukemia, lymphoma, neuroblastoma, immunodeficiencies, and anemia. The corresponding ICD-10 codes for these diseases are also provided. The drugs being used in the trial include alemtuzumab, melphalan, busulfan, phenytoin, fludarabine, cyclophosphamide, horse antithymocyte globulin, rabbit antithymocyte globulin, and thiotepa. The eligibility criteria are listed, including requirements for adequate renal function, liver function, cardiac function, and pulmonary function. The exclusion criteria include being pregnant or breastfeeding and having an uncontrolled infection at the time of study entry.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is thyroid neoplasms. The ICD-10 codes associated with the disease are C73, D34, D44.0, and Z85.850. The drug being tested is vandetanib. \n\nThe inclusion criteria for the trial are as follows:\n- The patient must have a previously confirmed histological diagnosis of locally advanced or metastatic papillary or follicular thyroid carcinoma, without an anaplastic component. A tumor sample must be available for centralized exploratory analysis.\n- The patient must have one or more measurable lesions, with a size of at least 1 cm in the longest diameter by spiral CT scan or 2 cm with conventional techniques.\n- The patient must have progressive disease following RAI131 treatment or be unsuitable for RAI131 after surgery.\n- The patient's serum TSH level must be less than 0.5mU/L.\n\nThe exclusion criteria for the trial are as follows:\n- The patient must not have undergone major surgery within 4 weeks before randomization.\n- The patient must not have received chemotherapy within the last 4 weeks prior to randomization.\n- The patient must not have received RAI131 therapy within 3 months if they have radioiodine uptake.\n- The patient must not have received radiation therapy within the last 4 weeks prior to randomization, except for palliative radiotherapy.\n- The patient's serum bilirubin level must not be greater than 1.5 times the upper limit of the reference range.\n- The patient's creatinine clearance must not be less than 30 ml/min (calculated by Cockcroft-Gault formula).\n- The patient's ALT, AST, or ALP levels must not be greater than 2.5 times the upper limit of the reference range, or greater than 5.0 times the upper limit of the reference range if related to liver metastases.\n- The patient must not have had a clinically significant cardiovascular event, superior vena cava syndrome, NYHA classification of heart failure greater than II within 3 months before entry, or presence of cardiac disease that increases the risk of ventricular arrhythmia according to the investigator's opinion.\n- The patient must not have a history of symptomatic arrhythmia or require treatment for arrhythmia, except for controlled atrial fibrillation.\n- The patient must not have congenital long QT syndrome or have a first-degree relative who experienced unexplained sudden death under 40 years of age.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on prostate cancer. The ICD-10 codes associated with the disease are ['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']. The drugs being used in the trial are carboplatin and paclitaxel. The eligibility criteria for participants are listed, including requirements such as a histologic or cytologic diagnosis of prostate carcinoma, progressive metastatic prostate cancer despite castration therapy, and a serum testosterone level below 50 ng/ml. There are also exclusion criteria, such as low platelet count, low hemoglobin, and certain organ system illnesses that could interfere with the study. The sample also mentions that prior investigational therapy within 4 weeks of treatment is not allowed, and peripheral neuropathy above grade 1 is an exclusion criterion.",
    "The sample from the table represents a phase 2 trial. The diseases being studied are recurrent non-small cell lung carcinoma, stage IIIB non-small cell lung cancer AJCC v7, and stage IV non-small cell lung cancer AJCC v7. The corresponding ICD-10 codes for these diseases are D02.20, D02.21, D02.22, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are pemetrexed disodium and sunitinib malate. The eligibility criteria for the trial include histologic or cytologic documentation of NSCLC, stage IIIB/IV with evidence of disease progression following first-line therapy, specific tumor site and characteristics, limitations on prior chemotherapy regimens, specific timeframes for prior treatments, restrictions on previous inhibitors of VEGF receptor, and prior use of pemetrexed. Patients must have measurable or non-measurable disease, meet certain performance status criteria, and meet specific medical and health history requirements. Certain medical conditions and medications are not allowed for participation in the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of urinary bladder cancer. The trial includes patients with unresectable urothelial carcinoma of the bladder or upper urinary tract. The eligibility criteria include having a wild-type HRAS, being over 18 years old, having a general condition score of ECOG 0-1, and having a life expectancy of at least 12 weeks. Female participants must have a negative pregnancy test and use effective contraception, while male participants must use adequate contraception for up to 3 months after discontinuation of panitumumab therapy. The trial is for patients with locally advanced or metastatic disease, and they must have at least one measurable lesion detectable in CT or MRI. The participants must also meet certain hematological, hepatic, renal, and metabolic function parameters. There are also exclusion criteria, such as having an HRAS mutation, absence of any of the inclusion criteria, dialysis-dependence following nephrectomy, and presence of cerebral tumors or metastases. Other exclusion criteria include significant cardiovascular disease, uncontrolled hypertension, history of interstitial lung disease, thrombotic or embolic events, significant neurological or psychiatric disorders, serious inflammatory eye conditions, pulmonary, hematopoietic, hepatic or renal disorders, poorly controlled diabetes mellitus, serious bacterial or fungal infections, chronic hepatitis B or C, HIV infection, autoimmune disease, allergic reaction to the medications used, status post organ transplantation, status post autologous bone marrow transplantation or stem cell transplantation in the previous 4 months, manifest secondary malignancy or other form of cancer in the previous 5 years, pregnancy or breastfeeding, and not willing to use highly effective methods of contraception during and after treatment. The sample also mentions that the patient should not have had prior systemic therapy with cytostatics or immunotherapeutic agents, concurrent use of other anticancer treatments, intravesical chemotherapy or radiotherapy in the previous 4 weeks, or previous radiotherapy that included all lesions to be used for the evaluation of tumor response. Lastly, patients in a closed institution according to an authority or court decision are also excluded from the trial.",
    "The sample from the table is for a phase 2 trial. The disease being studied is breast neoplasms. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being tested in the trial are lapatinib and pazopanib. The eligibility criteria for the trial include specific information about warnings, precautions, contraindications, and adverse events related to the investigational products. Patients must meet certain criteria related to the diagnosis of Inflammatory Breast Cancer (IBC), including a history of invasive breast cancer, current photographs demonstrating evidence of IBC, and evaluation of ErbB2 overexpression. Other criteria include disease progression or relapse following treatment for invasive breast cancer, adequate organ function, and written informed consent. There are also exclusion criteria, such as recent treatment with cancer therapy, ongoing toxicity from prior therapy, and certain medical conditions that could interfere with the patient's safety or compliance with the study procedures.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the treatment of lymphoma. The diseases column specifies that the trial is targeting aggressive non-Hodgkin's lymphoma, including subtypes such as diffuse large B-cell, mantle cell, high-grade B-cell, Burkitt's, or Burkitt-like, and anaplastic large cell (B-cell phenotype only).\n\nThe icdcodes column contains a list of ICD-10 codes associated with the diseases mentioned. In this case, the codes are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S'].\n\nThe drugs column lists the medications used in the trial, which include cyclophosphamide, doxorubicin hydrochloride, prednisone, and vincristine sulfate.\n\nThe criteria column provides eligibility criteria for patients participating in the trial. It includes disease characteristics such as histological confirmation of the specified lymphoma subtypes, specific stages of the disease, CD20 expression, and adverse prognostic factors. The patient characteristics include age, performance status, and other medical conditions. The prior concurrent therapy section specifies restrictions on previous treatments, including no prior monoclonal antibody therapy or chemotherapy for lymphoma.\n\nOverall, this sample record provides detailed information about the phase 2 clinical trial for lymphoma, including the specific diseases targeted, drugs used, and eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is prostate cancer. The ICDCodes associated with this disease are ['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']. The drug being tested is enzastaurin. \n\nThe eligibility criteria for this trial include being alive for at least 12 weeks, being at least 18 years old, living close enough to the doctor's office for required visits, not having received chemotherapy for prostate cancer (for cohort 1), having evidence of androgen-independent PSA-progressive disease without metastatic disease, not having received prior systemic chemotherapy for prostate cancer, having had one prior docetaxel-based chemotherapy regimen (for cohort 2), having evidence of metastatic prostate cancer with bone or soft tissue disease (for cohort 2), and having evidence of docetaxel-resistant, androgen-independent metastatic prostate cancer with bone or soft tissue disease.\n\nThere are also exclusion criteria, which include being unable to swallow pills, having another illness besides prostate cancer, having taken another experimental drug within the last 30 days, having a serious heart condition, and receiving another anti-cancer therapy.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on breast neoplasms. The trial includes participants who meet specific eligibility criteria. These criteria include being a woman aged 18 to 70 years with histologically proven breast cancer and having undergone surgery for breast cancer within the past 60 days. Participants must have had definitive surgical treatment and either be lymph node positive or high risk lymph node negative. The trial also requires participants to have known HER2/neu status and estrogen and progesterone receptor status. Other criteria include having a normal cardiac function, specific hematology criteria, and completing staging work-up within a certain timeframe. Participants must also meet certain exclusion criteria, such as not having prior systemic anticancer therapy, not being pregnant or lactating, and not having certain cardiac diseases or other serious illnesses. The sample also includes additional exclusion criteria and criteria related to previous or concurrent treatments, gender, hypersensitivity, surgical procedures, involvement in the study staff, mental condition, and likelihood of compliance with the protocol.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the treatment of multiple myeloma, a type of cancer. The trial is specifically for patients who have relapsed or progressive disease after at least one prior therapy. The eligibility criteria for the trial include having measurable disease, a performance status of less than 2, certain blood counts and kidney function within normal ranges, and adequate liver function. The trial is open to both male and female adults who are at least 18 years old. Female participants must either be post-menopausal, surgically sterilized, or willing to use a reliable method of birth control during the study. Male participants must also agree to use contraception during the study. The sample also includes a list of exclusion criteria, which are conditions or factors that would disqualify a person from participating in the trial. These include certain blood counts and kidney function outside of normal ranges, a history of significant heart conditions, hypersensitivity to the drug being tested, recent chemotherapy or radiotherapy, pregnancy or breastfeeding, recent use of other investigational drugs, and certain medical or psychiatric conditions that could interfere with participation. The sample also includes additional exclusion criteria related to specific medical conditions and treatments.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and the diseases being studied are breast cancer and breast neoplasms. The corresponding ICD-10 codes for these diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are pemetrexed and gemcitabine. The eligibility criteria for participants in this trial include having received prior chemotherapy with Taxol or Taxotere, having had less than 3 different chemotherapy treatments for metastatic disease, and having received prior treatment with hormonal and/or radiation therapy. Inclusion criteria also require that the disease can be measured and that the participant is able to take care of their personal hygiene. Exclusion criteria include not being pregnant or breastfeeding, having cancer that has spread to the brain, having received treatment with Gemcitabine or Pemetrexed, being unable to take folic acid or Vitamin B12, and having received treatment for another cancer within the last 5 years.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is attention-deficit/hyperactivity disorder (ADHD), and the corresponding ICDCodes for this disease are ['F90.2', 'F90.8', 'F90.9', 'F90.0', 'F90.1']. The drugs being tested in this trial are 'abt-089', 'atomoxetine', and 'placebo'. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having voluntarily signed an informed consent form, meeting diagnostic criteria for ADHD, being in first grade or higher in a school setting 3 days/week, being in good health based on medical history and examination, weighing at least 37 pounds (17 kg), having a negative urine pregnancy test (for female subjects of childbearing potential), and being reliable to keep required appointments for clinic visits and tests.\n\nExclusion criteria include not functioning at an age-appropriate level intellectually, having a current or past diagnosis of bipolar disorder, psychosis, autism, Asperger's syndrome, or pervasive developmental disorder, having a current diagnosis of obsessive-compulsive disorder, eating disorder, anxiety disorder, or depressive disorder requiring treatment, having a history of significant allergic reaction to any drug, requiring ongoing treatment with any psychiatric medication, having a serious medical condition, seizure disorder (except febrile seizures as an infant), or a history of substance abuse or dependence.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is type 1 diabetes mellitus. The corresponding ICD-10 codes for this disease are E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, and E10.44. The drug being tested in this trial is pramlintide acetate. The eligibility criteria for participants in this trial include being diagnosed with type 1 diabetes mellitus for at least 1 year, being on a stable regimen of multiple daily injections of insulin or continuous subcutaneous insulin infusion for at least 2 weeks, having an HbA1c level between 6.0% and 10.0%, and having a body weight of at least 50 kg. The exclusion criteria include currently being treated with certain medications, having previously been treated with Symlin/pramlintide, and having received any investigational drug within 1 month of screening.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2, and the disease being studied is esophageal cancer. The ICDCodes associated with this disease are \"K22.2\", \"K22.81\", \"Q39.4\", \"P78.83\", \"I85.00\", \"I85.01\", and \"I85.10\". The drugs being used in the trial are antineoplaston a10 and antineoplaston as2-1.\n\nThe eligibility criteria for this trial include the following disease characteristics: histologically confirmed adenocarcinoma of the esophagus that is unlikely to respond to existing therapy and for which no curative therapy exists. The patient must have measurable disease by MRI or CT scan.\n\nIn terms of patient characteristics, the trial requires participants to be 18 years or older with a Karnofsky performance status of 60-100%. The patient must have a life expectancy of at least 2 months. Hematopoietic requirements include a white blood cell count of at least 2000/mm3 and a platelet count of at least 50,000/mm3. Hepatic requirements include no hepatic failure, bilirubin levels not greater than 2.5 mg/dL, and SGOT and SGPT levels not greater than 5 times the upper limit of normal. Renal requirements include a creatinine level not greater than 2.5 mg/ml and no history of renal conditions that contraindicate high dosages of sodium. Cardiovascular requirements include no chronic or congestive heart failure, no uncontrolled hypertension, and no other cardiovascular conditions that contraindicate high dosages of sodium. Pulmonary requirements include no serious lung disease, such as severe chronic obstructive pulmonary disease.\n\nOther eligibility criteria include not being pregnant or nursing, fertile patients must use effective contraception during and for 4 weeks after study participation, no medical illness, psychiatric illness, or non-malignant systemic disease that would preclude study treatment, and no active infection.\n\nIn terms of prior concurrent therapy, the trial requires at least 4 weeks since prior immunotherapy and recovery, at least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovery, concurrent steroids are allowed for endocrine therapy, at least 8 weeks since prior radiotherapy (except in patients with multiple tumors who have received radiotherapy to some of their tumors) and recovery, and recovery from prior surgery. Other requirements include no prior antineoplaston therapy and prior cytodifferentiating agents are allowed.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease is schizophrenia. The ICDCodes associated with schizophrenia are ['F20.0', 'F20.1', 'F20.2', 'F20.3', 'F20.5', 'F20.89', 'F20.9']. The drugs being tested in this trial are 'mk-8435 (org 25935) 4-8 mg', 'placebo', and 'mk-8435 (org 25935) 12-16 mg'. The eligibility criteria for participants in this trial include being diagnosed with non-first episode schizophrenia, receiving stable treatment with specific antipsychotic medications, being clinically stable for 3 months prior to the study, having specific scores on the Positive and Negative Symptoms Scale (PANSS), and meeting various exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 2 and focuses on the disease \"arthritis, rheumatoid.\" The associated ICD-10 codes for this disease are ['M06.9', 'M05.9', 'M06.08', 'M06.00', 'M06.011', 'M06.012', 'M06.019']. The trial involves two drugs: 'mk0812' with a duration of treatment of 12 weeks, and a comparator drug described as 'placebo (unspecified)' with a duration of treatment also set at 12 weeks. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include having a diagnosis of rheumatoid arthritis for at least 6 months, being over 16 years old at the time of diagnosis, and having active rheumatoid arthritis with a minimum level of disease activity. Exclusion criteria include being mentally or legally incapacitated, having significant emotional problems, or a history of psychosis. Additionally, patients with clinically significant diseases in various systems, uncontrolled blood pressure, or who are pregnant or breastfeeding are also excluded from the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of pain. The associated ICD-10 codes for the disease are ['N50.82', 'R07.2', 'R07.82', 'R10.13', 'R10.33', 'R14.1', 'R52']. The drugs being studied are 'namisol' and 'diazepam/placebo'. The sample also includes the eligibility criteria for the trial, including age requirements, specific medical conditions, and the ability to comply with the trial procedures. It also lists the exclusion criteria, which are conditions or factors that would disqualify a patient from participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in phase 2/phase 3, focusing on small cell lung cancer. The associated ICD-10 codes for this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The trial compares the effectiveness of two drug combinations: carboplatin plus irinotecan versus carboplatin plus etoposide. The eligibility criteria for participants include having cytological or histological proven stage I or II small cell lung cancer at first diagnosis, no prior chemotherapy, measurable tumor disease, and a Karnofsky performance score of 70. The exclusion criteria include having a second malignancy (except for basal cell carcinoma or carcinoma in situ of the cervix uteri), NYHA class III heart failure, and chronic diarrhea or obstructive bowel syndrome.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"benign prostatic hyperplasia,\" and its corresponding ICDCodes are \"N40.0\" and \"N40.1.\" The drugs being studied are \"prx302\" and \"placebo.\" The eligibility criteria for this trial include various factors such as lower urinary tract symptoms (LUTS) attributed to BPH for at least 6 months, written informed consent, IPSS score of 12 or higher, prostate volume between 30-100 mL, maximum urine flow (Qmax) between 4-15 mL/sec, refractory, intolerant or refused use of alpha-blockers and/or 5 alpha-reductase inhibitors, unwillingness or inability to undergo conventional surgical or minimally invasive treatments, and blood PSA values less than 10 ng/mL. The exclusion criteria include inability to void at least 125 mL of urine, post-void residual (PVR) volume greater than 200 mL, presence or history of certain conditions that could interfere with the study results or endanger the subject, and use of certain prescribed medications that could interfere with the study results.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease asthma. The ICD-10 codes associated with asthma are provided. The trial involves the use of two drugs: levalbuterol hfa mdi followed by racemic albuterol hfa mdi. The eligibility criteria for participants are listed, including age requirements, a documented diagnosis of asthma, good overall health, and the ability of the subject's parent or legal guardian to complete diary cards and understand dosing instructions. The exclusion criteria are also listed, which include pregnancy, recent participation in another clinical trial, and various medical conditions or history that may affect the subject's eligibility.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is breast cancer, and the corresponding ICDCodes are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being studied are fulvestrant, mk-0646, and dasatinib. The eligibility criteria for this trial include various factors such as confirmed diagnosis of metastatic hormone receptor-positive HER2-negative breast cancer, prior endocrine therapy for metastatic disease, specific laboratory values, age requirement, performance status, ability to understand and consent to the study, postmenopausal status, and consent for biopsies. The exclusion criteria include factors such as history of prior malignancies, uncontrolled medical diseases, certain medications, brain metastasis, pleural or pericardial effusion, bone-only metastases, and patients for whom endocrine therapy is not appropriate.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied are hematological malignancies, myelodysplastic syndrome, leukemia, and lymphoma. The corresponding ICDCodes for these diseases are also provided. The drugs being used in the trial are mycophenolate mofetil (mmf), thymoglobulin, and sirolimus. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include patients with high-risk hematological malignancies, those with induction failure or relapse, and patients who are not eligible for higher priority protocols. Other criteria include age range, bilirubin and SGPT levels, and creatinine levels. \n\nExclusion criteria include restrictions on certain regimens and prior treatments, HIV seropositivity, uncontrolled infection, pregnancy, inability to sign consent, and past recipients of stem cell transplants. \n\nOverall, this sample provides specific details about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial.",
    "The sample from the table represents a phase 2 clinical trial for non-squamous cell non-small cell lung cancer (NSCLC) patients with stage IIIA (N2) disease. The trial aims to evaluate the effectiveness of a combination of drugs including gemcitabine, cisplatin, bevacizumab, and etoposide. \n\nThe eligibility criteria for the trial include having histologically or cytologically confirmed non-squamous cell NSCLC, measurable disease, and stage IIIA (N2) disease. Patients should not have received any prior treatment for lung cancer and must be at least 18 years old with a life expectancy of more than 3 months. They should also have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 and adequate pulmonary and cardiovascular function to tolerate surgical resection.\n\nOther criteria include specific laboratory values such as serum creatinine, hemoglobin, absolute neutrophil count, aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT), and total bilirubin levels. Patients should also have a left ventricular ejection fraction (LVEF) greater than 40 percent and no pulmonary hypertension or unstable angina.\n\nExclusion criteria for the trial include having squamous cell cancer or mixed tumors with small cell elements, tumors in close proximity to major vessels or cavitation, history of hemoptysis, metastatic disease, uncontrolled or labile hypertension, and certain cardiovascular conditions. Other exclusion criteria include psychiatric or neurologic illnesses, serious illnesses or medical conditions, active infection, receiving other investigational agents, history of malignancy within the last five years (except for certain cases), and being on therapeutic anticoagulation or chronic daily treatment with aspirin.\n\nAdditional exclusion criteria include breastfeeding, history of stroke or transient ischemic attack, history of pulmonary embolism or deep venous thrombosis, severe hypersensitivity reaction to certain drugs, recent major surgical procedures or traumatic injuries, history of abdominal fistula or gastrointestinal perforation, non-healing wound or ulcer, coagulopathic disorder or hemorrhagic diathesis, existing ototoxicity, pregnancy, high urine protein to creatinine ratio, being HIV-positive or having active hepatitis B/C, and serious illness that may interfere with protocol adherence.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 2. The diseases being studied are breast cancer and ovarian cancer. The ICDCodes associated with these diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60 for breast cancer, and C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2 for ovarian cancer. The drugs being used in the trial are bevacizumab, fludarabine, melphalan, and thymoglobulin.\n\nThe eligibility criteria for this trial include:\n1. Age requirement: Participants must be between 18 and 65 years old.\n2. Disease requirement: Participants must have either metastatic breast cancer that has responded to pre-transplant therapy, low-grade advanced ovarian cancer, or high-grade advanced ovarian cancer that has responded to pre-transplant therapy.\n3. Zubrod performance status: Participants must have a Zubrod performance status of 1 or less.\n4. Donor requirement: Participants must have an HLA-matched related or unrelated donor who is willing and able to donate peripheral blood stem cells or bone marrow and/or lymphocytes.\n5. Prior treatment requirement: Participants with metastatic renal cell carcinoma must have had two prior treatments, including targeted therapy. Participants with breast or ovarian cancer must have had one prior treatment, including chemotherapy.\n6. Adequate major organ functions: Participants must have adequate major organ functions.\n7. Informed consent: Participants must have signed informed consent.\n8. Cardiac requirement: Participants must have a left ventricular ejection fraction of 45% or higher. Cardiology clearance is needed for patients with a lower ejection fraction or symptomatic cardiac disease.\n9. Pulmonary requirement: Participants must have a forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and carbon monoxide diffusing capacity (DLCO) of 50% or higher of the predicted value. Pulmonary clearance is needed for patients with values lower than 50% or any symptomatic pulmonary disease.\n10. Renal requirement: Participants must have a serum creatinine level of 2.0 mg/dL or lower, or a creatinine clearance of more than 40 mL/min.\n11. Liver requirement: Participants must have a serum bilirubin level of 1.5 mg/dL or lower, and a serum glutamic-pyruvic transaminase (SGPT) level of 3 times the upper limit of normal or lower.\n\nThe exclusion criteria for this trial include:\n1. Prior history of allogeneic stem cell transplantation.\n2. Severe limitation of life expectancy due to concomitant illness.\n3. Clinically significant active infections.\n4. HIV infection.\n5. Chronic active hepatitis.\n6. Pregnancy or lactation.\n7. Presence of multiple brain metastasis or prior history of multiple brain metastasis, unless the patient has had complete surgical resection or stereotactic radiation therapy with no recurrence or brain edema for at least 6 months.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is phase 2. The disease being studied is coronary artery disease. The corresponding ICD-10 codes for this disease are I25.10, I25.110, I25.119, I25.111, and I25.118. The drugs being used in the trial are reg1 and unfractionated heparin. \n\nThe sample also includes the eligibility criteria for the trial. The inclusion criteria state that the trial is open to both males and females who are scheduled for non-urgent elective PCI (percutaneous coronary intervention) and have not been treated with UHF (unfractionated heparin) prior to PCI. The subject must be able to give informed consent and comply with the protocol. They must also have a negative urine pregnancy test or have documented surgical sterilization or be menopausal.\n\nThe exclusion criteria list factors that would disqualify a subject from participating in the trial. These include having a weight over 120 kg, recent acute coronary syndrome with elevated cardiac markers or ST segment depression at rest, evidence of clinical instability, angiographic high-risk, contraindication to anticoagulation or increased risk of bleeding, use of prohibited medications or investigational drugs prior to the study, clinically significant abnormal laboratory findings, planned use of a femoral sheath greater than a certain size, known allergy or intolerance to drugs mandated by the study, use of devices other than angioplasty balloons and coronary stents, history of licit drug abuse or illicit drug use or current evidence of such abuse, any other factor that the Investigator feels would put the subject at increased risk if participating in the protocol, lactation, currently enrolled in this or another clinical trial (with some exceptions), and participation in an investigational drug or device trial in the past 30 days.",
    "The sample from the table represents a phase 2 clinical trial for liver cancer. The trial is focused on patients with hepatocellular carcinoma (HCC) that is either localized, unresectable, or metastatic. The patients must have a Child-Pugh class A or mildly decompensated Child-Pugh class B liver dysfunction. The disease must be classified as stage B or C according to the Barcelona Clinic Liver Cancer (BCLC) staging classification.\n\nThe eligibility criteria for the patients include having measurable disease, with at least one site of disease that can be measured using CT or MRI scans. Patients with locally advanced disease who are candidates for radical surgery are not eligible. Patients with fibrolamellar HCC or mixed cholangiocarcinoma/HCC are also excluded. Additionally, patients should not have clinical symptoms or a history of CNS metastases or leptomeningeal disease.\n\nThe patient characteristics required for participation in the trial include a WHO performance status of 0-1, hemoglobin levels of at least 90 g/L, neutrophil count of at least 1.5 x 10^9/L, platelet count of at least 75 x 10^9/L, creatinine clearance of at least 40 mL/min, ALT levels within 5 times the upper limit of normal, INR levels within 2, and urine dipstick for proteinuria of 1+ or protein spot urine less than 0.6 g/L. Pregnant or nursing patients are not eligible, and fertile patients must use effective contraception during and after the study therapy.\n\nThere are additional criteria related to the patient's medical history, including no prior malignancy within the past 5 years (except for adequately treated carcinoma in situ of the cervix or localized nonmelanoma skin cancer), no history of hemorrhagic or thrombotic cerebrovascular events within the past 12 months, and no documented variceal hemorrhage within the past 3 months. The patient should not require anticoagulant therapy, except for low-dose anticoagulants for maintenance of central venous access or prevention of deep vein thrombosis.\n\nThe patient should not have a history or presence of clinically significant acute or unstable cardiovascular, cerebrovascular, renal, gastrointestinal, pulmonary, endocrine, central nervous system, or immunological disorders (except for the presence of hepatitis B or C virus or cirrhosis) within the past 6 months. Other exclusions include no encephalopathy, no known HIV infection, no active infection requiring IV antibiotics, and no arterial hypertension above 150/100 mm Hg despite therapy.\n\nThe patient should not have ongoing cardiac dysrhythmias of NCI CTCAE grade 2 or higher, atrial fibrillation of any grade, prolongation of QTc > 500 msec on screening ECG, or a history of familial long QT syndrome. Repeated paracentesis (more than 1 per month) and psychiatric disorders that preclude understanding of trial-related topics or interfere with compliance for oral drug intake are also exclusion criteria. Patients should not consume grapefruit, grapefruit juice, or products containing bitter oranges.\n\nThe patient should be able to take oral medications, have completed a baseline quality of life questionnaire, and be compliant and geographically proximal for follow-up.\n\nRegarding prior concurrent therapy, patients should not have received prior systemic anticancer treatment for this disease. However, certain prior therapies are allowed if previously treated lesions remain separate from those to be measured in the current trial and prior treatment was completed within the past 4 weeks. Prior organ transplantation, concurrent estrogen-containing supplementary therapy, full-dose anticoagulation with coumarin derivatives, concurrent elective major surgery, and concurrent radiotherapy (except for concurrent analgesic radiotherapy of non-target lesions) are not allowed.\n\nPatients should not have concurrent or anticipated need for certain CYP3A4 inhibitors or inducers, unless medically necessary and no substitutes are available. Concurrent strong CYP3A4 inducers are also not allowed. Other exclusions include concurrent use of other experimental drugs or anticancer therapy, treatment in another clinical trial within the past 30 days, use of other investigational drugs, chronic systemic steroids or other immunosuppressive agents, and concurrent use of angiotensin-converting enzyme inhibitors (ACE-I).\n\nThis description provides an overview of the sample from the table, including the phase of the trial, the disease being studied, the eligibility criteria, and the prior concurrent therapy restrictions.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on lung cancer, specifically small cell lung cancer. The associated ICD-10 codes for the disease are provided. The trial involves the use of two drugs, topotecan and carboplatin. The eligibility criteria for participants are listed, including requirements for contraception, absence of active infection, expected life expectancy of at least 3 months, no prior chemotherapy for small cell lung cancer, and a performance status of ECOG 0-1. Adequate hematologic, renal, and hepatic function are also required. The sample includes detailed instructions for calculating creatinine clearance and specific criteria for renal and hepatic function. The minimum age for participation is 18 years old, and written informed consent is necessary. The sample also includes criteria for the diagnosis of extensive small cell lung cancer and the presence of measurable disease. Exclusion criteria are listed, including concurrent or planned treatments for SCLC, severe medical problems, concurrent or previous malignancies, brain or leptomeningeal metastases, uncontrolled infection, ongoing or previous tumors other than lung cancer, and other medical conditions that would limit compliance or pose extreme risk. The sample concludes with additional exclusion criteria related to previous use of investigational drugs, pregnancy or lactation, refusal to practice adequate birth control, allergic reactions to related chemicals, and pre-existing heart disease.",
    "The sample from the table represents a clinical trial for a contraceptive patch. The trial is a combination of phase 1 and phase 2. The specific disease being studied is contraception. The ICD-10 codes associated with this disease are Z92.0, Z30.012, and Z30.09. The drugs being tested in the trial are different variations of a levonorgestrel patch, based on the participant's body mass index (BMI). \n\nThe eligibility criteria for participants include being in good general health, being between the ages of 18-44, having an intact uterus with at least one ovary, and having had a recent Pap test or undergoing one at screening. Other criteria include having a cervical mucus score above 7, regular menstrual cycles, and either being abstinent or using appropriate contraception methods. Participants must also be willing to comply with the study protocol, live within the study site catchment area, and sign an informed consent form.\n\nExclusion criteria include contraindications for using combined hormonal contraceptives, known hypersensitivity or contraindication to progestins, known or suspected pregnancy, prior hysterectomy or bilateral oophorectomy, history of drug or alcohol abuse, undiagnosed abnormal genital bleeding, undiagnosed vaginal discharge or lesions, uncontrolled thyroid disorder, history or presence of dermal hypersensitivity, and various other medical conditions and factors. Women with a BMI of 40 kg/m2 or higher are also excluded from the trial.\n\nOverall, the sample provides detailed information about the phase, disease, drugs, and eligibility criteria for the clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"metastatic pancreatic adenocarcinoma.\" The associated ICD-10 codes for this disease are ['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']. The drugs being studied in this trial are 'co-1.01' and 'gemcitabine'. The eligibility criteria for participants are listed, including requirements such as having metastatic pancreatic ductal adenocarcinoma, previous adjuvant chemotherapy/radiotherapy, and a performance status (ECOG) of 0 or 1. There are also exclusion criteria, such as prior palliative chemotherapy for pancreatic cancer and symptomatic brain metastases. The record provides detailed information about the inclusion and exclusion criteria for potential participants in the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on pancreatic cancer. The trial is open to patients with newly diagnosed or previously treated metastatic disease or unresectable disease. Patients with CNS or brain metastases are not eligible. \n\nThe patient characteristics include being over 18 years old, having an ECOG performance status of 0-1, and a life expectancy of more than 3 months. Hematopoietic requirements include an absolute neutrophil count > 1,500/mm^3, WBC > 3,000/mm^3, platelet count > 100,000/mm^3, and hemoglobin \u2265 9 g/dL. There should be no evidence of bleeding diathesis or coagulopathy.\n\nFor hepatic requirements, the bilirubin level should be < 2 mg/dL, AST or ALT should be < 2.5 times the upper limit of normal (ULN) (5 times ULN if liver metastases are present), and INR should be < 1.5 (except for patients receiving full-dose warfarin).\n\nRenal requirements include a creatinine level < 1.5 mg/dL, no proteinuria or urine protein < 500 mg by 24-hour urine collection, and no clinically significant impairment of renal function.\n\nCardiovascular criteria include no uncontrolled hypertension (blood pressure > 160/110 mm Hg on medication), no New York Heart Association class II-IV congestive heart failure, no unstable symptomatic arrhythmia requiring medication (except for chronic atrial arrhythmia), no clinically significant grade II-IV peripheral vascular disease, and no arterial thromboembolic event within the past 6 months.\n\nOther requirements include not being pregnant or nursing, having a negative pregnancy test, using effective contraception for fertile patients, having no other serious systemic disease, no significant traumatic injury within the past 28 days, no serious non-healing wound, ulcer, or bone fracture, and no history of other diseases or clinical findings that would prevent study participation.\n\nThe prior concurrent therapy section specifies that there are no requirements for biologic therapy, chemotherapy, endocrine therapy, or radiotherapy. Regarding surgery, there should be more than 28 days since prior major surgery or open biopsy, more than 7 days since prior fine needle aspirations or core biopsies, and no concurrent major surgery. Other requirements include more than 4 weeks since prior and no concurrent participation in any other experimental drug study, and more than 12 months since prior adjuvant therapy. There should be no prior systemic therapy for metastatic disease.",
    "The sample from the table is for a phase 2 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH). The eligibility criteria for participants include being adults between the ages of 18 and 70 with NASH, having abnormal aminotransferase levels on multiple occasions, having histologic evidence of steatohepatitis on a recent liver biopsy, not consuming excessive alcohol, having compensated liver disease and normal blood cell counts, having normal thyroid-stimulating hormone levels, excluding other liver diseases, having a hemoglobin A1C below 10.0% if diabetic, having a normal alpha-fetoprotein level or a negative ultrasound for hepatocellular carcinoma, practicing adequate contraception for sexually active females of childbearing potential, practicing acceptable contraception for sexually active males, and providing written informed consent.\n\nThe exclusion criteria include recent treatment with certain drugs for NASH, evidence of decompensated liver disease, pre-existing medical conditions that could interfere with participation, pregnancy or breastfeeding, unwillingness to use contraception during treatment, previous malignant disease within the past two years (excluding non-melanoma skin cancer), substance abuse, lactose intolerance, and any other conditions that the investigator deems unsuitable for enrollment or that could interfere with the protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is \"diabetes mellitus, type 1\" and its corresponding ICDCodes are ['E10.65', 'E10.9', 'E10.21', 'E10.36', 'E10.41', 'E10.42', 'E10.44']. The drugs being used in the trial are 'insulin lispro', 'recombinant human hyaluronidase ph20', 'insulin aspart', and 'insulin glulisine'. \n\nThe eligibility criteria for this trial include being male or female aged 18 years or older, having type 1 diabetes mellitus treated with insulin for at least 12 months, having a body mass index (BMI) between 18.0 and 40.0 kg/m^2, having a hemoglobin A1C (HbA1C) level between 6.7% and 8.2%, having a fasting C-peptide level below 0.6 ng/mL, being willing to use insulin glargine twice daily as basal insulin throughout the study, and agreeing to avoid using an insulin infusion pump or unblinded continuous glucose monitoring (CGM) during the study.\n\nThe exclusion criteria for this trial include having a known or suspected allergy to any component of the study drugs, having used pramlintide within 30 days of screening, using drugs that could interfere with the interpretation of study results or have clinically relevant interference with insulin action, glucose utilization, or recovery from hypoglycemia during the study or within 30 days of screening, and having recurrent severe hypoglycemia or hypoglycemic unawareness as judged by the investigator.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being studied in this trial are igf-1r inhibitor osi-906, erlotinib hydrochloride, goserelin, and letrozole. The eligibility criteria for participants in this trial include having histologically confirmed invasive breast carcinoma, stage IV disease, and no locally recurrent resectable disease. Other criteria include hormone receptor status, pre- or post-menopausal status, specific performance status, life expectancy, blood counts, kidney and liver function, pregnancy status, ability to swallow medication, and absence of certain medical conditions. The sample also includes information about prior therapy and concurrent treatments that are not allowed.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on two diseases: systemic scleroderma and pulmonary hypertension. The diseases are identified by their corresponding ICD-10 codes. The trial involves the use of two drugs: bosentan and placebo. The eligibility criteria for participants include being over 18 years old, having NYHA functional Class I/II symptoms, and providing informed consent. Participants must also meet specific requirements related to right heart catheterization and exercise echocardiogram studies. There are exclusion criteria as well, such as having established resting pulmonary hypertension, congestive heart failure, diastolic dysfunction, or severe liver disease. Additionally, pregnant individuals or those unable to adequately walk/exercise are not eligible for the trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is phase 2, and the disease mentioned is major depressive disorder. The icd-10 code associated with this disease is \"['F33.0', 'F33.1', 'F33.9', 'F32.0', 'F32.1', 'F32.9', 'F33.40']\". The drug mentioned is glyx-13. The sample also includes the eligibility criteria for the trial, including inclusion and exclusion criteria. Inclusion criteria include a diagnosis of major depressive disorder consistent with DSM-IV-TR, a current episode lasting more than 8 weeks, a Hamilton Depression score greater than or equal to 21, and less than a 25% reduction in depression during the current episode assessed by ATRQ. Exclusion criteria include an axis diagnosis of other psychiatric disorders, experiencing hallucinations, delusions, or other psychotic symptomatology, and undergoing ETC during the current episode.",
    "The sample from the table is a clinical trial for patients with metastatic breast cancer. The trial is a combination of phase 1 and phase 2. The diseases column specifies the disease being studied, which in this case is metastatic breast cancer. The icdcodes column provides the ICD-10 codes associated with the disease. The drugs column lists the drugs being used in the trial, including dasatinib, trastuzumab, and paclitaxel. The criteria column contains the eligibility criteria for participating in the trial, including requirements such as histologically confirmed breast cancer with documented metastasis, HER2 overexpression, performance status, previous therapies, organ function, ability to take oral medication, and concomitant medications. The exclusion criteria are also listed, which include factors such as pregnancy, central nervous system metastases, medical history, allergies, prohibited treatments, and other exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 2. The diseases being studied are pulmonary hypertension, lung disease, sickle cell disease, cardiac transplant, and lung transplant. The corresponding ICDCodes for these diseases are also provided. The drug being tested is inhaled nitric oxide. The eligibility criteria for this trial include specific conditions for inclusion and exclusion. Inclusion criteria involve patients with pulmonary arterial hypertension or chronic lung disease with severe gas exchange impairment. Exclusion criteria include patients who are unable to manage safe administration of home nitric oxide therapy, as well as pregnant or nursing women.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is allergic rhinitis. The corresponding ICD-10 codes for this disease are 'J30.89', 'J30.9', 'J30.2', 'J30.1', 'J30.5', and 'J30.81'. The drugs being tested in this trial are 'sparc1203' and 'placebo'. The eligibility criteria for inclusion in the trial are being a male or female patient between the ages of 18 and 65 with a history of seasonal allergic rhinitis and a positive skin prick test. The exclusion criteria include having a history or presence of perennial allergic rhinitis, having had a respiratory tract infection within 2 weeks prior to Visit 2, having significant pulmonary disease other than allergic rhinitis or mild asthma controlled by beta-2-agonists alone, and having received immunizations or vaccinations within 4 weeks prior to Visit 1.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are myelodysplastic syndromes, acute myeloid leukemia, and leukemia. The corresponding ICDCodes for these diseases are provided as well.\n\nThe drugs being used in the trial are oxaliplatin, fludarabine, and cytarabine. The eligibility criteria for participants in this trial include having a confirmed diagnosis of relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome, a performance status of 0-2 on the Zubrod scale, specific levels of serum creatinine and bilirubin, and written informed consent.\n\nThere are also exclusion criteria, such as not having untreated or uncontrolled life-threatening infections, intolerance to the specified drugs, pregnancy or lactation, recent chemotherapy or radiation therapy, and other medical conditions that may interfere with a patient's ability to participate in the study or interpret the results.",
    "The sample provided is a record from a clinical trial database. It represents a phase 2 trial for breast cancer. The trial is evaluating the effectiveness of the drugs everolimus and fulvestrant in postmenopausal women with metastatic or locally advanced breast cancer. The eligibility criteria for participants include being postmenopausal, having histologically confirmed invasive breast cancer, and having estrogen receptor and/or progesterone receptor positive disease. Other criteria include measurable or evaluable disease, failure of aromatase inhibitor therapy within the previous 6 months, and not having received chemotherapy, radiation therapy, or surgery within 4 weeks prior to enrollment. The sample also includes exclusion criteria such as severe hypersensitivity to everolimus or similar drugs, premenopausal status, and the presence of other coexisting malignancies. The sample provides detailed inclusion and exclusion criteria, as well as information on organ function requirements and other medical considerations.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"chronic graft-versus-host disease\" (cGVHD). The associated ICD-10 codes for this disease are \"D89.811\" and \"D89.812\". The drug being studied in this trial is \"bortezomib\". \n\nThe record also includes eligibility criteria for participants. Inclusion criteria include being at least 18 years old, having a diagnosis of steroid-refractory cGVHD, not having received previous treatment with Bortezomib for cGVHD, having an ECOG performance status of less than 3, and meeting certain medical requirements such as total bilirubin levels, life expectancy, and contraception methods for females and males.\n\nExclusion criteria include having certain medical conditions or abnormalities such as low platelet count, low neutrophil count, low creatinine clearance, high total bilirubin levels, peripheral neuropathy, recent myocardial infraction or heart failure, hypersensitivity to bortezomib, being pregnant or breastfeeding, recent use of other investigational drugs, serious medical or psychiatric illness, primary malignancy not in remission, recent diagnosis or treatment of another malignancy, and recent radiation therapy.\n\nOverall, this record provides specific details about the phase 2 trial, the disease being studied, the drug being tested, and the eligibility criteria for participants.",
    "The sample is from a table that contains information about clinical trials. In this specific sample, the trial is in phase 2 and is focused on Huntington's disease and chorea. The ICD-10 codes associated with these diseases are provided. The trial involves the drugs \"afq056\" and \"placebo\". The eligibility criteria for participants are listed, including requirements related to the disease diagnosis, medication history, and contraception use. There are also exclusion criteria, such as cognitive impairment and certain medical conditions. Additional inclusion/exclusion criteria may apply as defined by the protocol.",
    "The sample is a phase 2 trial that focuses on patients with prostate cancer and fatigue. The trial aims to evaluate the effectiveness of methylphenidate hydrochloride in treating fatigue in these patients. The eligibility criteria for inclusion in the trial include being between the ages of 18 and 85, having histologically confirmed prostate cancer, currently receiving LHRH-agonist therapy for more than 6 months with measurable fatigue, and having a stable or decreasing serum PSA level. Other criteria include having adequate liver and renal function, being able to swallow and retain oral medication, having a life expectancy of at least 1 year, and being able to read and write in English. Exclusion criteria include having a current or previous malignancy (except for superficial bladder cancer or non-melanoma skin cancer), previous chemotherapy within the last 5 years, anemia, recent myocardial infraction, unstable serious co-existing medical conditions, severe depression, history of motor tics or seizures, infection with HIV, HBV, or HCV, evidence of drug or alcohol abuse, known hypersensitivity to methylphenidate, or any other contraindications to methylphenidate use.",
    "The sample from the table is a clinical trial for phase 2/phase 3 of a drug called \"1st line chemotherapy\" for the treatment of non-small cell lung carcinoma. The trial is specifically targeting patients with stage IIIb \"wet\" or stage IV disease who have not received prior systemic therapy for advanced disease, except for adjuvant treatment. The inclusion criteria include histologically confirmed non-small cell lung carcinoma, MUC1 antigen expression on the tumor, at least one measurable lesion, and adequate hematological, hepatic, and renal function. The patients should also have a performance status of 0 or 1 on the ECOG scale and a minimum estimated life expectancy of 4 months. Exclusion criteria include concomitant brain metastases, previous history of other malignancy (except basal cell carcinoma and intra-epithelial cervical cancer), previous systemic therapy for advanced non-small cell lung cancer, and certain medical disorders. Other exclusion criteria include major surgery within 4 weeks prior to the trial, organ allograft, allergy to eggs, participation in another experimental protocol, pregnancy or breastfeeding, inadequate protection against pregnancy, history of substance abuse, and inability or unwillingness to comply with the protocol requirements.",
    "The sample from the table is for a phase 2 trial. The disease being studied is atrial fibrillation. The ICD-10 codes associated with this disease are 'I48.0', 'I48.21', 'I48.91', 'I48.11', 'I48.19', and 'I48.20'. The drugs being tested in this trial are azd1305 and placebo. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- The patient must have documented atrial fibrillation but must be in stable sinus rhythm for at least 2 hours and a maximum of 28 days.\n- The patient must be in sinus rhythm at the time of randomization.\n\nExclusion Criteria:\n- The patient must not have a haemodynamically unstable condition, as judged by the investigator. This includes systolic blood pressure below 100 mmHg or above 180 mmHg, or diastolic blood pressure above 105 mmHg at the time of randomization.\n- The patient must not have a personal or family history of Torsades de Points (TdP), any other polymorphic ventricular tachycardia (PVT), sustained ventricular tachycardia, long QT syndrome, and/or Brugada syndrome.\n- The patient must not have sinus bradycardia (less than 50 beats per minute) at the time of randomization.\n- The patient must not have a QTc (Fridericia) interval longer than 450 ms, measured in sinus rhythm at the time of randomization.\n- The patient's serum potassium levels must not be below 3.8 or above 5.0 mmol/L, or plasma potassium levels must not be below 3.6 or above 5.0 mmol/L.\n- The patient's QRS duration must not be longer than 120 ms at the time of randomization.\n- The patient must not be using any antiarrhythmic drug class I and/or III, digitalis glycoside, QT prolonging drug, drug that inhibits CYP3A4, or St John's Wort.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease of asthma. The ICD-10 codes associated with the disease are ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The trial involves testing several drugs, including 'formoterol fumarate in the pressair dpi, low dose', 'formoterol fumarate in the pressair dpi, high dose', 'foradil aerolizer, low dose', 'foradil aerolizer, high dose', and a placebo. \n\nThe eligibility criteria for the trial are as follows:\n- Patients must have mild-to-moderate asthma for at least 6 months prior to the start of the trial.\n- Patients must have been on a stable dose of Inhaled Corticosteroids (ICS) for at least 30 days before the trial.\n- Spirometry tests must show that the patient's highest FEV1 (forced expiratory volume in 1 second) is between \u2264 85% and \u2265 60% of the predicted value for their age, height, and gender.\n- Patients must show reversibility with an increase in FEV1 of 12% and 200 mL after taking 360 \u00b5g of albuterol.\n- The highest pre-dose FEV1 at specific visits must be within 25% of the qualifying FEV1 at the start of the trial.\n\nThere are also exclusion criteria, which include:\n- Patients with any clinically significant respiratory conditions other than mild to moderate asthma, such as COPD, active tuberculosis, or a history of interstitial lung disease.\n- Patients who have had a severe asthma exacerbation requiring hospitalization in the previous 12 months.\n- Patients who are unable to withhold the use of inhaled short-acting beta-agonist (SABA) for at least 6 hours before a visit.",
    "The sample provided is a phase 2 clinical trial for breast cancer. The trial is specifically targeting individuals who are at an increased risk for breast cancer. The eligibility criteria include having a histologically confirmed lobular carcinoma in situ (LCIS) treated by local excision only or having a composite increased breast cancer risk of at least 1.67% over 5 years based on various factors such as age, family history, prior breast biopsies, atypical hyperplasia of the breast, age at first live birth, nulliparity, race, and age at onset of menarche.\n\nThe trial excludes individuals with prior or suspected invasive breast cancer or ductal carcinoma in situ, as well as those with clinical evidence of malignancy by physical examination or suspicious/malignant lesions on recent mammograms. Participants must have a normal gynecologic examination and hormone receptor status is not specified.\n\nOther patient characteristics include being female, aged 35 and over, and having a performance status of ECOG 0-2. There are no specific requirements for life expectancy or renal function. Hematopoietic and hepatic functions should be normal, and there should be no active bleeding disorder or liver function abnormalities.\n\nRegarding prior medical history, individuals should not have had prior deep-vein thrombosis, cerebral vascular accident, or transient ischemic attack. They should also not have had prior pulmonary embolus except for a single occurrence related to lower extremity trauma. Other exclusions include having saline or silicone breast implants, known allergy to tamoxifen, macular degeneration, malignancy within the past 5 years (except for basal cell or squamous cell skin cancer or carcinoma in situ of the cervix), nonmalignant disease that would prevent tamoxifen administration, psychiatric conditions that would affect informed consent or study compliance, pregnancy or nursing, and a negative pregnancy test. Fertile patients must use effective nonhormonal contraception during and for 3 months after study participation.\n\nIn terms of prior concurrent therapy, participants should not have received prior systemic adjuvant chemotherapy or tamoxifen, raloxifene, or other selective estrogen-receptor modulators. There should be at least a 3-month gap since the use of estrogen or progesterone replacement therapy, oral contraceptives, androgens, luteinizing hormone-releasing hormone analogs, prolactin inhibitors, antiandrogens, or steroids. Concurrent nonhormonal medications are allowed, but warfarin or cholestyramine should not be used. Participants should not have undergone prior bilateral prophylactic mastectomy or mastectomy for LCIS, and they should not be currently participating in any other cancer prevention study.\n\nIt is worth noting that patients who were treated with placebo in a previous trial (protocol NSABP-P-1) are eligible for this trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease called Friedreich's Ataxia. The ICD-10 code for this disease is G11.11. The trial involves two drugs, namely \"lu aa24493\" and \"placebo\". The eligibility criteria for participants are listed, including the requirement of a genetic test showing more than 400 GAA nucleotide triplet repeats on the shorter frataxin allele, specific sub-scores for the SARA (Stance) and SARA (Gait) assessments, and being 18 years or older. Female participants must agree not to become pregnant during the study and use appropriate protection or be unable to bear children. The exclusion criteria include unstable illnesses unrelated to Friedreich's Ataxia, disallowed medications, serious underlying diseases, abnormal vital signs, abnormal laboratory blood results, recent treatment with idebenone or erythropoietin, abnormal ECG, recent blood donation or receipt, participation in another clinical trial within the past 30 days, pregnancy or breastfeeding, history of drug allergies or hypersensitivities, and current or recent disorder related to drug or alcohol abuse.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is \"Waldenstr\u00f6m's macroglobulinemia.\" The corresponding ICDCodes for this disease is \"C88.0.\" The drug being tested is \"perifosine.\" \n\nThe eligibility criteria for this trial include:\n- Age of the participant must be 18 years or older.\n- Participants must have received prior therapy for their Waldenstr\u00f6m's macroglobulinemia and have relapsed or refractory disease. There is no limit on the number of prior therapies.\n- Measurable disease is required, which is defined as the presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level of more than 2 times the upper limit of each institution's normal value, and over 10% of lymphoplasmacytic cells in the bone marrow.\n- ECOG Performance Status (PS) must be 0, 1, or 2.\n- Various laboratory values must meet certain criteria, such as ANC (Absolute Neutrophil Count) and PLT (Platelet Count) levels.\n- Other criteria include specific values for total bilirubin, AST (Aspartate Aminotransferase), and creatinine levels.\n- Participants must be able to provide informed consent and have a life expectancy of at least 12 weeks.\n\nThe exclusion criteria for this trial include:\n- Uncontrolled infection.\n- Presence of other active malignancies.\n- Central Nervous System (CNS) involvement.\n- Recent use of cytotoxic chemotherapy, biologic therapy, or corticosteroids.\n- Concurrent use of other chemotherapy, immunotherapy, radiotherapy, or investigational therapies.\n- Pregnancy or nursing.\n- Men or women of childbearing potential who are unwilling to use adequate contraception.\n- Known HIV positive status.\n- Recent radiation therapy.\n\nThis sample provides a detailed description of the eligibility criteria for participants in this particular clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on non-small cell lung cancer. The ICD-10 codes associated with the disease are ['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']. The drug being studied in the trial is dasatinib. The eligibility criteria for participants in the trial are listed, including requirements for histological documentation of the cancer, prior treatment regimens, organ function, age, and other medical conditions. There are also exclusion criteria, such as previous or concomitant malignancy, prior treatment with dasatinib or other agents that inhibit Src, and certain cardiac conditions.",
    "The sample provided is for a phase 2 clinical trial focused on the disease gastroparesis. The trial involves testing multiple drugs, including \"velusetrag dose 1,\" \"velusetrag dose 2,\" \"velusetrag dose 3,\" and a placebo. The eligibility criteria for participants include experiencing symptoms of gastroparesis for at least 3 months, having a body mass index (BMI) between 18 and 35 kg/m2, a Gastroparesis Cardinal Symptom Index (GCSI-2W) composite score between 2 and 4, and delayed gastric emptying. The sample also lists exclusion criteria, such as recent severe gastroenteritis, history of gastric surgery, recurrent vomiting, recent hospitalization for gastroparesis or diabetes complications, uncontrolled thyroid dysfunction, and high levels of glycosylated hemoglobin or glucose for diabetic participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are anemia and kidney disease. The ICDCodes associated with these diseases are D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9 for anemia, and I12.9, N18.9, Q61.9, I12.0, D63.1, N18.1, N18.5 for kidney disease.\n\nThe drug being tested in this trial is akb-6548. The eligibility criteria for participants in this trial include being between 18 and 79 years of age, having Chronic Kidney Disease Stage 3 or Stage 4, having a hemoglobin level below 10.5 g/dl, and having a TSAT (transferrin saturation) level above 20% with a complete blood count indicating normocytic red blood cell morphology.\n\nThere are also exclusion criteria, which include having a BMI (Body Mass Index) above 40, having received a red blood cell transfusion within the past 12 weeks, having undergone androgen therapy within the previous 21 days prior to the study, having received any approved or experimental erythropoiesis stimulating agent (ESA) within the past 10 weeks prior to the screening visit, meeting the criteria of ESA resistance within the previous 4 months, having received individual doses of intravenous iron of 250 mg or larger within the past 21 days, having AST (Aspartate Aminotransferase) or ALT (Alanine Aminotransferase) levels above 1.8 times the upper limit of normal (ULN), having alkaline phosphatase levels above 2 times ULN, having total bilirubin levels above 1.5 times ULN, having uncontrolled hypertension, having New York Heart Association Class III or IV congestive heart failure, or having experienced a myocardial infraction, acute coronary syndrome, or stroke within the past 6 months prior to dosing.",
    "The sample from the table is for a clinical trial in phase 2/phase 3. The trial is focused on the disease of obesity, which is identified by the ICD-10 codes ['E66.8', 'E66.9', 'E66.1', 'O99.214', 'O99.215', 'O99.210', 'O99.211']. The drugs being studied are cp-945,598 and sibutramine. The eligibility criteria for participants include having a body mass index (BMI) between 30 and 40 kg/m2 (or between 27 and 40 kg/m2 for those with co-morbidities), and not having any clinically relevant abnormalities based on medical history, physical examination, ECG, and laboratory tests. Exclusion criteria include having high blood pressure, type 2 diabetes, a history of eating disorders, or being on appetite or weight modifying drugs.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the disease \"hyponatremia\". The ICD-10 codes associated with this disease are \"P74.22\" and \"E87.1\". The drug being studied is \"tolvaptan\". The sample also includes the eligibility criteria for the trial, including inclusion and exclusion criteria. Inclusion criteria include having non-artifactual hyponatremia, being 18 years or older, and being able to give written informed consent. Exclusion criteria include being a breastfeeding woman or a female of childbearing potential not using acceptable contraceptive methods, having hyponatremia in hypovolemic states, and having certain medical conditions or taking certain medications.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is HIV infections, and the corresponding ICDCodes are ['Z21']. The drugs being investigated are enfuvirtide and amdoxovir. \n\nThe eligibility criteria for this study include being HIV infected, having taken at least two combination anti-HIV treatments containing three or more drugs for a minimum of 24 months, having failed two previous combination treatments, having a viral load of more than 5000 copies/ml on a stable antiretroviral regimen within 60 days prior to study entry, being willing to stay on the current failing anti-HIV treatment until starting the study treatment, using acceptable methods of contraception, having access to optimized background (OB) regimen drugs, and being able to bring the OB regimen drugs to the screening visit.\n\nThe exclusion criteria for this study include prior use of DAPD or ENF, drug or alcohol use that may interfere with the study, history of any illness that may interfere with study participation, having a single kidney or a history of two or more episodes of kidney stones, being pregnant or breastfeeding, recent use of experimental anti-HIV drugs or agents that act on the immune system, active immunization within 21 days prior to study entry, undergoing acute therapy for a serious infection or illness, having an active AIDS-defining opportunistic infection requiring acute treatment, experiencing unexplained fever within 7 days prior to study entry, having cancer that requires chemotherapy, prior HIV vaccination (except for subunit vaccines that contained only gp120), certain mutations in HIV-1 reverse transcriptase, measurable loss of vision due to lens opacity, posterior subcapsular cataract, cortical cataract of Grade C3 or higher on the Lens Opacities Classification System III (LOCS III) scale, nuclear opalescence Grade NO3 (LOCS III) or higher, and having best corrected vision worse than 20/200. Diabetes mellitus is not excluded, but gestational diabetes is.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is breast neoplasms. The ICDCodes associated with this disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being used in the trial is chemotherapy. \n\nThe eligibility criteria for this trial include the following inclusion criteria:\n- Patients must have histologically proven breast cancer with primary resistance to anthracyclines or taxane or both.\n- Patients with anthracycline/taxane resistance inoperable, locally advanced breast cancer are eligible.\n- Patients must have measurable disease in their breast/nodal regions or at a distant organ site(s) according to the RECIST criteria.\n- There is no limit on prior hormonal therapies, but only one prior chemotherapy for metastatic breast cancer is allowed.\n- Patients may receive concomitant bisphosphonate therapy for bone metastasis.\n- Patients may continue Herceptin if it has previously been started, but it cannot be added to the chemotherapy regimen as a new agent when XR9576 is initiated.\n- Patients must have recovered from acute toxic effects of any prior therapy.\n- Zubrod performance status must be less than or equal to 2.\n- Adequate bone marrow function, normal renal function, and adequate liver function are required.\n- Female patients must be non-lactating and using adequate contraception if premenopausal.\n- Patients with stable brain metastases for more than 3 months after completing therapy to the brain are eligible.\n- Written informed consent is required.\n\nThe exclusion criteria for this trial include:\n- More than one chemotherapy regimen for metastatic breast cancer.\n- Patients who relapsed more than 6 months after completion of anthracycline or taxane therapy.\n- Current treatment with a non-taxane, non-anthracycline based chemotherapy.\n- Uncontrolled psychiatric or social (addictive) disorders that would preclude obtaining informed consent or patient participation in the study.\n- Clinical contraindication of continued anthracycline or taxane therapy.\n- Patients with operable primary breast cancer are not eligible.\n- Patients who have developed primary resistance to the chemotherapy combination of doxorubicin/docetaxel.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 2, and the disease mentioned is \"irritable bowel syndrome.\" The ICDCodes associated with this disease are \"K58.2,\" \"K58.8,\" \"K58.0,\" \"K58.1,\" and \"K58.9.\" The drug mentioned is \"rifaximin.\" The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" The inclusion criteria include being 18 years or older, having irritable bowel syndrome confirmed by the Rome II Criteria, and having a lower endoscopic examination that shows normal colonic anatomy. The exclusion criteria include having exclusively constipation-predominant IBS, currently presenting with constipation-associated IBS symptoms, having adequate control of DIBS and bloating symptoms, having a positive stool culture for O & P or Clostridium difficile, and failing to record 2 negative weekly global assessments in the past 10 days prior to randomization.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is prostate cancer. The ICD-10 codes associated with this disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drugs being used in the trial are degarelix. The eligibility criteria for participants include being male and aged 18 or over, having histologically proven adenocarcinoma of the prostate (all stages), having completed a previous study (FE200486 CS07), and not meeting any withdrawal criteria at Visit 9 (day 28) in the previous study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"diabetes mellitus, type 2\" and \"hypertension\". The corresponding ICDCodes for these diseases are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44'] and ['I15.0', 'I97.3', 'K76.6', 'P29.2', 'G93.2', 'H40.053', 'I10'] respectively. The drugs being tested include various doses of ertugliflozin, hctz, and placebos. The eligibility criteria for participants include having type 2 diabetes and hypertension, being medically stable, being on at least one oral diabetes drug, and up to two medicines for blood pressure control. The exclusion criteria include having type 1 diabetes, a history of heart attack or stroke, uncontrolled blood pressure, and significant kidney disease.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are schizophrenia and insomnia related to schizophrenia, with the corresponding ICDCodes being F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, and F20.9. The drug being tested is sodium oxybate. The eligibility criteria for this trial include patients aged 18-45 with a DSM-IV diagnosis of schizophrenia and insomnia related to schizophrenia, confirmed by a structured interview (SCID). There are also exclusion criteria listed, such as lack of capacity to give informed consent, unstable medical illness, diagnosis of restless leg syndrome, seizure disorder, uncontrolled hypertension, unstable cardiac illness, or obstructive sleep apnea, pregnancy or lack of adequate birth control, history of substance dependence disorder, current treatment with valproic acid, succinic semialdehyde dehydrogenase deficiency (SSADH), and persistent need for treatment with benzodiazepines, barbiturates, opiates, or other sedative hypnotics.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease mentioned is \"coronary artery disease.\" The ICDCodes associated with this disease are \"I25.10,\" \"I25.110,\" \"I25.119,\" \"I25.111,\" and \"I25.118.\" The drugs mentioned in this sample are \"ticagrelor tablets,\" \"clopidogrel (over encapsulated) capsule,\" and \"aspirin tablets.\" The eligibility criteria for this trial include specific inclusion and exclusion criteria. The inclusion criteria state that participants must have documented stable coronary artery disease and females of childbearing potential must have a negative pregnancy test and be willing to use contraception. The exclusion criteria include a history of acute coronary syndromes within the past 12 months, liver or kidney disease, increased bleeding risk, and intolerance or allergy to aspirin or clopidogrel.",
    "The sample provided is for a phase 2 clinical trial. The diseases being studied are anorexia and weight changes. The corresponding ICD-10 codes for these diseases are \"R63.0\", \"F50.00\", \"F50.01\", and \"F50.02\". The drug being tested is megestrol acetate. The eligibility criteria for inclusion in the trial include being a pediatric patient with a non-hematological malignancy, having a weight loss of at least 5% since the diagnosis of the primary malignancy, and not actively receiving corticosteroid therapy. Exclusion criteria include receiving tube feedings or parenteral nutrition, evidence of ascites, current or planned treatment with certain medications, mechanical obstruction of the alimentary tract, history of brain tumor or metastasis to the brain, history of thromboembolic disease, insulin-requiring diabetes, congestive heart failure and/or uncontrolled hypertension, anticoagulation, previous history of thrombosis, and concurrent corticosteroid therapy (except as an antiemetic).",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on lung cancer, specifically non-small cell lung cancer. The ICD-10 codes associated with the disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being studied is pazopanib (gw786034). \n\nThe sample also includes the eligibility criteria for the trial. Inclusion criteria include having a confirmed diagnosis of Stage IIIB or IV non-small cell lung cancer, having failed no more than two prior chemotherapy regimens, and having measurable disease according to RECIST. Exclusion criteria include having a history of central nervous system metastases, having clinically significant gastrointestinal abnormalities, and having uncontrolled infection, among others.\n\nOverall, the sample provides information about the phase, diseases, ICD-10 codes, drugs, and eligibility criteria for a specific clinical trial focused on lung cancer.",
    "The sample from the table is for a phase 2 clinical trial for the treatment of multiple myeloma. The trial is evaluating the effectiveness of a combination of drugs including bortezomib, carmustine, etoposide, cytarabine, and melphalan. The eligibility criteria for the trial include having a confirmed diagnosis of multiple myeloma, having received a prior autologous stem cell transplantation with melphalan conditioning, and having available autologous stem cells for transplantation. Other criteria include being at least 18 years old, having a life expectancy of greater than 6 months, and meeting certain performance status and organ function requirements. Exclusion criteria include being refractory to induction therapy, having peripheral neuropathy grade 3 or higher, receiving renal replacement therapy, having another concurrent malignancy requiring treatment, and having known brain metastases. The sample also mentions that both men and women of all races and ethnic groups are eligible for the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is Parkinson's disease, which is represented by the ICDCodes [\"G20\"]. The drugs being used in the trial are saline and carbidopa. The eligibility criteria for this sample include requirements such as having idiopathic Parkinson's disease, experiencing motor fluctuations associated with LD/CD dosing, having a Modified Hoehn and Yahr stage less than 5, being on stable levodopa/dopa decarboxylase inhibitor therapy, being postmenopausal or using adequate birth control for women, being 30 years or older, and being willing and able to give informed consent. The exclusion criteria include having a clinically significant or unstable medical or surgical condition, having clinically significant psychiatric illness, being a pre-menopausal woman not using a birth control method, having taken experimental medications within 60 days prior to baseline, and having undergone a neurosurgical intervention for Parkinson's disease.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on Parkinson's disease and includes the following information: \n\n- Diseases: The trial is specifically targeting patients with Parkinson's disease.\n- ICD Codes: The ICD-10 code for Parkinson's disease is \"G20\".\n- Drugs: The trial involves the administration of two drugs, namely \"piclozotan\" and \"0.9% sodium chloride (normal saline)\".\n- Criteria: The eligibility criteria for the trial are as follows:\n\nMain Inclusion Criteria:\n- Patients must have been diagnosed with idiopathic Parkinson's disease for at least 5 years.\n- Patients must experience motor fluctuations and dyskinesia.\n- Patients must have been on a stable regimen of levodopa/carbidopa for 30 days.\n- Patients must show at least a 25% response or improvement in UPDRS part III scores after taking regular PD medications.\n- Patients must have a MMSE score of 25 or higher.\n\nMain Exclusion Criteria:\n- Patients with atypical or secondary parkinsonism are not eligible.\n- Patients who have previously used neuroleptic agents are not eligible.\n- Patients with a history of intracranial procedures for PD are not eligible.\n- Patients with active psychosis are not eligible.\n- Patients with a history of drug or alcohol abuse in the past 12 months are not eligible.\n- Patients with a cardiac conduction system abnormality are not eligible.\n- Patients with a predisposing medical condition that causes nausea or vomiting, or who routinely use an anti-emetic, are not eligible.",
    "The sample from the table represents a clinical trial in phase 2. The trial focuses on treating various diseases, including brain and central nervous system tumors, drug/agent toxicity by tissue/organ, lymphoma, and thrombocytopenia. The diseases are identified by their corresponding ICD-10 codes. The trial involves the use of drugs such as rituxan, cyclophosphamide, etoposide, etoposide phosphate, carboplatin, sodium thiosulfate, neupogen, neulasta, and cytarabine. \n\nThe eligibility criteria for participants in the trial include having a signed informed consent form, a confirmed diagnosis of primary CNS lymphoma, CD20 positive disease, progressive or relapsed disease after prior methotrexate-based chemotherapy, and being between 18 months and 75 years old. Other criteria include specific performance status, hematocrit, granulocyte count, platelet count, bilirubin levels, creatinine levels, cardiac and pulmonary function, availability for follow-up, and the use of effective contraception for fertile patients. \n\nExclusion criteria for the trial include radiographic signs of intra-cranial herniation and/or spinal block, being HIV positive, having systemic lymphoma, being pregnant or lactating, having allergies to the study agents, and testing positive for hepatitis B or hepatitis C.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on lupus erythematosus, specifically discoid and systemic lupus erythematosus. The ICD-10 codes associated with these diseases are provided. The trial involves two drugs, \"r932333\" and a placebo. The eligibility criteria for participants are also listed, including the requirement of a diagnosis of SLE or DLE, the presence of at least 2 active discoid lesions, and the stable use of certain medications. There are also exclusion criteria, such as immunodeficiency, uncontrolled hypertension, and a history of certain skin conditions. Additionally, participants should not have had excessive or chronic UV radiation exposure prior to or during the study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on lung cancer. The ICD-10 codes associated with the disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are carboplatin, gemcitabine hydrochloride, and paclitaxel. The eligibility criteria for participants include having histologically or cytologically confirmed non-small cell lung cancer, being inoperable stage IIIA or IIIB, and having specific characteristics related to the tumor location and size. There are also criteria related to the patient's age, performance status, hematopoietic, hepatic, renal, and pulmonary functions, as well as prior concurrent therapies.",
    "The sample is a phase 2 trial for asthma. The table includes information about the phase, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is phase 2 and the disease is asthma. The icd-10 codes associated with asthma are provided. The drugs being studied are albuterol spiromax, proair hfa, and placebo. The eligibility criteria include requirements such as written informed consent, age range of 4-11 years, a documented diagnosis of persistent asthma, ability to perform spirometry, specific spirometry values, reversible bronchoconstriction, and stable medication use. There are also exclusion criteria listed, such as hypersensitivity to albuterol, recent participation in other drug trials, severe milk protein allergy, recent respiratory infections or disorders, recent asthma exacerbations, history of life-threatening asthma, use of prohibited medications, unstable medication dosages, recent use of oral or injectable corticosteroids, and initiation or dose escalation of immunotherapy during the study period.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is leukemia, specifically Philadelphia (Ph) chromosome positive chronic myeloid leukemia (CML). The ICD-10 codes associated with this disease are C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, and C91.01. The drugs being used in the trial are busulfan, cyclophosphamide, g-csf, and gm-csf. \n\nThe eligibility criteria for the trial include patients with Ph positive CML who are younger than 65 and older than 21 years. This includes patients in late 1st chronic phase, early chronic phase who did not achieve complete cytogenetic remission after one year on imatinib, beyond first chronic phase, blastic phase that has responded to therapy, chronic phase developing imatinib resistance, and those with an HLA identical sibling who refuse allogeneic transplantation or are ineligible due to age. Other criteria include a Zubrod PS score less than 3, creatinine less than 1.8 mg/dl, serum bilirubin less than or equal to 1.5 mg/dl, SGPT less than 3 times normal values, DLCO greater than or equal to 50% of predicted, and cardiac ejection fraction greater than or equal to 40%.\n\nThe exclusion criteria for the trial include uncontrolled life-threatening infections or comorbid conditions that could impair tolerance to the regimen, HIV positivity, pregnancy or lactation, CML in blastic phase that has not responded to prior therapy, hepatitis B or C virus infection, and CML in first molecular remission.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on patients with non-small cell lung cancer. The ICD-10 codes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being studied in this trial are erlotinib, bevacizumab, and standard platinum-based chemotherapy. The eligibility criteria for inclusion in the trial include being an adult patient aged 18 years or older, having advanced (stage IIIb and IV) non-small cell lung cancer, having measurable disease, and having an ECOG performance status of 0-1. The exclusion criteria include having received prior chemotherapy or treatment with another systemic anti-cancer agent, having undergone radiotherapy within 4 weeks prior to the first dose of study treatment, having CNS metastases, and having had other malignancies in the past 5 years, except for adequately treated cancer in situ of the cervix, basal or squamous cell skin cancer.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is respiratory syncytial virus infections. The corresponding ICD-10 codes for these diseases are 'R09.2', 'A15.7', 'A15.8', 'A15.9', 'J98.9', 'R06.03', and 'J12.1'. The drugs being used in the trial are 'aln-rsv01' and 'normal saline'. The sample also includes the eligibility criteria for the trial, including inclusion criteria such as being a single or bilateral lung transplant recipient, having a confirmed RSV infection, being more than 90 days post lung transplant, and being rejection-free for at least 30 days. The exclusion criteria include having a known respiratory co-infection at the time of RSV diagnosis, having certain grades of bronchiolitis obliterans syndrome or unstable FEV1, recent use of certain medications, and active treatment for acute graft rejection.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on the disease called diabetic macular edema. The ICD-10 codes associated with this disease are ['E10.311', 'E10.319', 'E11.311', 'E11.319', 'E13.311', 'E13.319', 'E10.3513']. The drug being studied is fluocinolone acetonide. The sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being at least 18 years old, having DME in the study eye, having a certain level of edema and visual acuity, and having received a specific type of treatment prior to the study. Exclusion criteria include being pregnant or lactating, having allergies to fluocinolone acetonide, having any condition that would prevent participation, and having certain levels of intraocular pressure.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are non-small cell lung cancer and brain metastases. The ICDCodes associated with these diseases are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being tested is icotinib. \n\nThe eligibility criteria for this trial include the following inclusion criteria: histological or cytological confirmation of non-small cell lung cancer, diagnosis of brain metastases on a Gadolinium-enhanced MRI with more than 3 sites of intracranial metastases or the longest diameter of the intracranial lesion being more than 3cm, and a positive EGFR mutation. \n\nThe exclusion criteria for this trial include previous usage of EGFR-TKI or antibody to EGFR (gefitinib, erlotinib, herceptin, erbitux), and CSF or MRI findings consistent with metastases of the spinal cord, meninges, or meningeal.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is B-cell non-Hodgkin's lymphoma. The ICD-10 codes associated with this disease are S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, and S33.131S. The drugs being used in the trial are cyclophosphamide, etoposide, rituximab, cytarabine, doxorubicin, and tositumomab. The eligibility criteria for inclusion in the trial include being untreated with biopsy-proven B-cell non-Hodgkin's lymphoma, being at least 18 years old, and not having any other prior malignancy except for certain types of skin cancer or other cancer that has been disease-free for at least one year. The patient should also meet certain staging studies and laboratory tests. The exclusion criteria include having significant medical or psychiatric illness that may compromise treatment, being pregnant or lactating, having HIV infection, and having follicular lymphoma grade 1, 2, or 3A.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in Phase 2.\n- Diseases: The trial is focused on breast cancer.\n- ICD Codes: The ICD-10 codes associated with the breast cancer diseases are ['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60'].\n- Drugs: The drugs being used in the trial are 'rad001' and 'carboplatin'.\n- Criteria: The eligibility criteria for participants in the trial are listed, including requirements such as having metastatic breast cancer, being a certain age, having specific laboratory values within normal ranges, and not having certain medical conditions or taking certain medications.\n\nThe record also includes both inclusion and exclusion criteria, which outline the requirements and restrictions for potential participants in the trial. These criteria help to ensure that the trial is conducted with a specific target population and that the results are meaningful and applicable to that population.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is categorized as phase 2 and focuses on the treatment of advanced clear cell renal carcinoma. The trial includes eligibility criteria for patients to be enrolled, such as having histologically confirmed clear cell renal cell carcinoma, advanced disease, and measurable disease. Prior therapy with specific drugs is also required. Other criteria include age, life expectancy, performance status, and normal organ and marrow function. The sample also includes exclusion criteria, such as prior malignancy of other histology, VHL disease, and receiving other investigational agents. It also lists various medical conditions and medications that would exclude a patient from the trial. The sample concludes with a statement about the inclusion of both men and women and members of all races and ethnic groups in the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on breast cancer. The ICD-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being studied in the trial are gemcitabine and oxaliplatin. The eligibility criteria for participants include having confirmed ER-, PR-, Her2neu- (Triple Negative) metastatic breast cancer, measurable disease according to the RECIST criteria, having received a taxane in the adjuvant setting or as first-line treatment for metastatic breast cancer, being over 18 years old, having an ECOG Performance Score of 0, 1, or 2, and meeting certain requirements for bone marrow, renal function, and hepatic function. Participants must also have recovered from any prior surgeries, radiotherapy, or other antineoplastic therapies, and be able to provide informed consent. There are also exclusion criteria, such as having an active infection or fever, active CNS metastases, a history of prior malignancy within the past 5 years (with some exceptions), known hypersensitivity to the drugs being studied, recent chemotherapy or radiotherapy, receiving concurrent or recent investigational therapy, peripheral neuropathy Grade 2, pregnancy or lactation, and any other medical condition that may interfere with participation in the study. Additionally, a history of allogeneic transplant or known HIV or Hepatitis B or C is also excluded.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on patients with type 1 diabetes. The ICD-10 codes associated with the disease are E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, and E10.44. The drugs being studied in the trial are enalapril and losartan. \n\nThe inclusion criteria for the trial are as follows:\n- The patient must have had type 1 diabetes for 2-20 years.\n- The onset of type 1 diabetes must have occurred before the age of 45. If the onset was between ages 31-41, the patient must have a BMI less than 26. If the onset was between ages 41-45, a positive GAD or ICA test is required.\n- The patient must have a normal or increased GFR (glomerular filtration rate).\n- The patient must have normal blood pressure.\n- The patient must have normoalbuminuria, which means a urine collection test should show less than 20 ug/min on 2 out of 3 overnight urine collections.\n\nThe exclusion criteria for the trial are as follows:\n- The patient must not have had type 1 diabetes for longer than 20 years.\n- The patient must not have hypertension (blood pressure higher than 85/135 mmHg).\n- The patient must not have a reduced GFR (glomerular filtration rate less than 90 ml/min/1.73m2).\n- The patient must not have microalbuminuria.\n- The patient must not have a solitary kidney or evidence of unilateral renal disease.\n- The patient must not have evidence of other important kidney disease based on history, ultrasound, or biopsy.\n- The patient must not have other chronic diseases or conditions such as cystic fibrosis, serious mental illness, severe mental retardation, etc.\n- Pregnant women or females planning pregnancy within 2 years are excluded due to the drugs being used.\n- Patients who do not comply with taking at least 85% of the two-week placebo are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is melanoma (skin). The ICDCodes associated with this disease are C43.51, C43.9, C43.52, D03.51, C43.8, Z85.820, and D03.52. The drugs being used in the trial are temozolomide and thalidomide. The eligibility criteria for this trial include specific disease characteristics, patient characteristics, and prior concurrent therapy restrictions. The disease characteristics include histologically confirmed malignant cutaneous melanoma, unresectable stage IV disease, and the absence of brain metastases. The patient characteristics include being 18 years or older, having a Zubrod performance status of 0-1, and meeting certain hematopoietic, hepatic, renal, and other health criteria. The prior concurrent therapy restrictions include no prior thalidomide or temozolomide for stage IV disease, specific time intervals since prior therapy, and limitations on the number of prior systemic therapy regimens.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is breast cancer. The ICDCodes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are bevacizumab, doxorubicin, cyclophosphamide, capecitabine, and docetaxel. The eligibility criteria for this trial include being a female patient over 18 years old, having a diagnosis of invasive adenocarcinoma of the breast, having specific stage IIIA, IIIB, or IIIC disease, and meeting certain blood count, hepatic function, renal function, and cardiac function requirements. There are also exclusion criteria listed, such as having certain cardiac conditions, prior therapy with specific drugs, and other nonmalignant systemic diseases that would prevent the patient from receiving study treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease mentioned is \"myelodysplastic syndrome.\" The ICDCodes associated with this disease are \"D46.9,\" \"D46.C,\" and \"D46.Z.\" The drugs mentioned in this sample are \"erythropoietin,\" \"cyclosporin a,\" \"g-csf,\" and \"prednisone.\" The eligibility criteria for this trial include specific requirements for patients with MDS, such as the percentage of blasts, prior chemotherapy, and indications for therapy. Other criteria include performance status, liver and renal function, cardiac function, and the need for signed informed consent. The exclusion criteria mention that nursing and pregnant females are excluded, and patients with active and uncontrolled infections are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 2. The disease being studied is relapsing remitting multiple sclerosis. The corresponding ICD-10 codes for this disease are M94.1, A68.9, A68.0, A68.1, and M35.6. The drugs being tested in this trial are laquinimod 0.3 and laquinimod 0.6. The eligibility criteria for participants in this trial include having a confirmed diagnosis of MS according to the McDonald criteria, having a relapsing-remitting disease course, having at least one gadolinium-enhanced lesion on a screening MRI, practicing a reliable method of birth control for women of child-bearing potential, understanding and agreeing to comply with the study protocol. The exclusion criteria include having any form of progressive MS, having any condition that may interfere with participation in the study, having a clinically significant or unstable medical or surgical condition that would prevent safe and complete study participation, receiving any investigational medication, immunosuppressives, or cytotoxic agents within 6 months prior to screening, and receiving previous treatment with immunomodulators within two months prior to screening.",
    "The sample from the table represents a phase 2 clinical trial for Hodgkin lymphoma. The diseases included in this trial are adult lymphocyte depletion Hodgkin lymphoma, adult lymphocyte predominant Hodgkin lymphoma, adult mixed cellularity Hodgkin lymphoma, adult nodular sclerosis Hodgkin lymphoma, and recurrent adult Hodgkin lymphoma. The corresponding ICD-10 codes for these diseases are provided as well. The drugs being studied in this trial are vinorelbine tartrate, pegylated liposomal doxorubicin hydrochloride, and gemcitabine hydrochloride. The eligibility criteria for participants include having a histologically documented CD30-positive classical Hodgkin lymphoma that is recurrent or refractory after at least one prior therapy. Other criteria include specific requirements for previous treatments, cardiac health, performance status, measurable disease, pregnancy status, lung function, blood counts, and liver function.",
    "The sample from the table represents a clinical trial for a drug targeting schizophrenia and related disorders. The trial is in phase 2/phase 3, indicating that it is in an advanced stage of testing. The diseases being studied include schizophrenia, schizophreniform disorders, schizoaffective disorder, and other psychotic disorders. The corresponding ICD-10 codes for these diseases are provided as well. The drugs being investigated in the trial are ethyl-eicosapentaenoic acid (EPA) and a combination of vitamins E and C. \n\nThe eligibility criteria for participants in the trial are as follows: \n- Patients must have a diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder according to the DSM-IV criteria.\n- They must have been admitted to a psychiatric hospital or department within the previous twenty-one days before screening.\n- The onset of their first psychotic symptoms should be less than fifteen years ago.\n- Participants must be between the ages of 18 and 40.\n- They must be fluent in a Scandinavian language.\n- A written informed consent is required before participating in any trial-related activities.\n\nThere are also exclusion criteria, which include:\n- A diagnosis of substance dependence according to the DSM-IV criteria.\n- Known allergy to the study medication.\n- Current use of warfarin or indications of impaired haemostasis (excessive bleeding, except for nosebleeds) based on medical history.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are \"transfusional iron overload\" and \"transfusional hemosiderosis\". The corresponding ICDCodes for these diseases are \"E87.70\", \"E87.79\", and \"E87.71\". The drugs being used in the study include \"core study: deferasirox\", \"core study: deferoxamine\", \"extension: deferoxamine to deferasirox\", \"extension: deferasirox to deferoxamine\", \"deferasirox\", and \"deferoxamine\". \n\nThe eligibility criteria for this sample include:\n\n- Male or female patients aged 10 years and above with \u03b2-thalassemia major or DBA or sideroblastic anemia on chronic transfusion therapy, who have given written consent to participate in the study.\n- Patients with cardiac iron as measured by a myocardial T2* value that is \u2265 6ms but not \u2265 20 ms.\n- Patients with a lifetime history of at least 50 units of red cell transfusions and must be receiving at least \u226510 units/yr of red blood cell transfusions.\n- Patients with a left ventricular ejection fraction (LVEF) \u2265 56% as determined by cardiovascular magnetic resonance (CMR).\n- Patients with liver iron content (LIC) value \u2265 3 mg Fe / g dw, as determined by liver MRI.\n\nThe exclusion criteria for this sample include:\n\n- Patients with clinical symptoms of cardiac dysfunction.\n- Patients unable to undergo study assessments including MRI.\n- Patients participating in another clinical trial or receiving an investigational drug.\n\nIt is also mentioned that there may be other protocol-defined inclusion/exclusion criteria that apply.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on macular degeneration. The ICD-10 codes associated with the disease are provided. The trial involves two drugs: \"immune globulin intravenous [human], 10% caprylate/chromatography purified\" and \"albumin (human) 25%, united states pharmacopeia (usp)\". The eligibility criteria for the trial are listed, including inclusion criteria such as specific visual acuity range and recent visual loss, and exclusion criteria such as previous treatments, certain medical conditions, and allergies.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease being studied is HIV infection. The corresponding ICDCodes for this disease is \"Z21\". The drug being tested is apricitabine. The eligibility criteria for this sample include specific inclusion and exclusion criteria. Inclusion criteria state that the participant must have completed the AVX-201 protocol, have a plasma HIV RNA level of less than 5000 copies/ml, and have CD4 cells greater than 50. Exclusion criteria state that pregnant or breastfeeding females and those who have withdrawn from AVX-201 are not eligible for this trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease mentioned is \"stage III non-small cell lung cancer.\" The ICDCodes associated with this disease are \"C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2.\" The drug mentioned is \"chemotherapy following concurrent chemoradiotherapy.\" \n\nThe eligibility criteria for this trial are as follows:\n- Adult patients aged 18 years and older with histology-proven NSCLC with inoperable stage IIIA or IIIB disease.\n- Inoperable stage IIIA is defined by multiple and/or bulky N2 mediastinal lymph nodes on CT scan, making the patient ineligible for surgical resection.\n- N2 disease must be confirmed through biopsy, fluorodeoxyglucose PET, and/or CT scan if nodes are larger than 2 cm.\n- Stage IIIB patients must have N3 or T4 status. N3 status must be confirmed by the presence of contralateral mediastinal lymph nodes or supraclavicular or scalene lymph nodes, proven by biopsy, fluorodeoxyglucose PET, or CT scan showing a size larger than 2 cm.\n- Patients should not have received any prior treatment for lung cancer.\n- ECOG Performance status should be 0-1.\n- Consolidation chemotherapy should be initiated within 4-8 weeks of concurrent chemo-radiotherapy without progression.\n- Adequate organ function is required, including specific criteria for leukocytes, absolute neutrophil count, platelets, total bilirubin, AST/ALT, and creatinine.\n- All laboratory tests should be conducted within 14 days prior to the start of study drug treatment.\n- Patients should have the ability to give informed consent and willingness to adhere to the study protocol.\n\nThe exclusion criteria for this trial are as follows:\n- Patients who have had prior treatment for lung cancer.\n- Prior history of radiation to the chest.\n- Known malignancy other than the current cancer.\n- Uncontrolled intercurrent illness, including ongoing active infection, history of cardiac disease, psychiatric illness that would impair compliance with study requirements, etc.\n- Pregnant or lactating women.\n- Patients with documented or symptoms of peripheral neuropathy.\n- History of allergic reaction to compounds similar to the ones used in this study.\n- Malignant effusions (pleural or pericardial).\n- Superior sulcus (Pancoast) tumors.\n- Any condition that would hamper the ability to give informed consent or comply with the study protocol.\n- HIV patients on anti-retroviral therapy are ineligible to participate due to potential drug interactions and increased susceptibility to infections during marrow suppressive chemotherapy and radiotherapy.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of breast neoplasms. The trial includes patients with histologically confirmed invasive breast cancer at stage IV. The eligibility criteria include having documented amplification of ErbB2, not having received more than 1 prior chemotherapeutic regimen in the metastatic setting, and having measurable disease according to RECIST guidelines. The trial is open to females aged 18 and above with any menopausal status. Other criteria include normal organ and marrow function, a cardiac ejection fraction of at least 50%, and stable central nervous system metastases. The sample also includes exclusion criteria such as prior therapy with lapatinib or vinorelbine, concurrent anticancer or concomitant radiotherapy treatment, and certain cardiac conditions. The sample provides detailed inclusion and exclusion criteria for potential participants in the clinical trial.",
    "The sample from the table represents a phase 2 clinical trial for the treatment of multiple myeloma. The trial is evaluating the drug \"plitidepsin\" and includes specific eligibility criteria for patients to participate. \n\nThe inclusion criteria for patients to be eligible for the trial are as follows:\n1. Patients must provide written informed consent before any study-specific procedures.\n2. Patients must be at least 18 years old.\n3. Patients must have a performance status of Eastern Cooperative Oncology Group (ECOG) \u2264 2.\n4. Patients must have a life expectancy of at least 3 months.\n5. Patients must have been previously diagnosed with multiple myeloma and currently require treatment due to relapse or refractory disease.\n6. Patients must have measurable disease based on specific criteria for different types of multiple myeloma.\n7. Patients must have recovered from any non-hematological toxicity from previous treatments.\n8. Patients must have specific laboratory values within 14 days before starting the treatment.\n\nThe exclusion criteria for patients not eligible for the trial are as follows:\n1. Patients who have previously received therapy with Aplidin\u00ae.\n2. Pregnant or lactating women, and men and women of reproductive potential who are not using effective contraceptive methods.\n3. Patients with a history of another neoplastic disease, except for specific exceptions.\n4. Patients with other relevant diseases or adverse clinical conditions, such as heart disease, uncontrolled hypertension, previous treatment with doxorubicin at high doses, significant neurological or psychiatric disorders, active infection, and others.\n5. Patients with limitations in their ability to comply with the treatment or follow-up protocol.\n6. Patients who have received any investigational product or radiotherapy within a specific period before inclusion in the study.\n7. Patients with known hypersensitivity to Aplidin\u00ae, mannitol, cremophor, ethanol, or dexamethasone.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2/phase 3 and focuses on the treatment of end stage renal disease. The trial involves the use of two drugs, mycophenolate sodium delayed release tablets and mycophenolate mofetil. The eligibility criteria for participants include being between the ages of 18-75, weighing more than 40 kg, having a negative T cell crossmatch, and having a primary or secondary renal allograft from a living or deceased donor. Female participants of childbearing potential must have a negative pregnancy test and agree to use contraception during the study. There are also exclusion criteria, such as having received or currently receiving an organ transplant other than a kidney, being seropositive for HIV or Hepatitis B or C, having a current or recent history of malignancy, having significant liver disease, and having certain medical conditions or taking certain medications. The sample also includes additional details and restrictions related to the study.",
    "The sample is from a phase 2 trial and focuses on the disease of schizophrenia. The ICD-10 codes associated with this disease are F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, and F20.9. The drugs being studied in this trial are ly2140023, olanzapine, and a placebo. The eligibility criteria for inclusion in the trial include meeting the DSM-IV criteria for schizophrenia as confirmed by a modified SCID. The exclusion criteria include not meeting the full syndromal criteria for any other Axis I disorder, not having taken any depot antipsychotic within 4 weeks before screening, and not currently taking any mood-stabilizing agents.",
    "The sample provided is for a phase 2 clinical trial for the treatment of Fabry disease. The trial is specifically targeting females between the ages of 18 and 65 who are heterozygous for Fabry disease and have a confirmed diagnosis with a documented missense gene mutation. Participants must also have enhanceable enzyme activity based on in vitro tests and be na\u00efve to enzyme replacement therapy (ERT) or have stopped ERT for at least 18 weeks.\n\nIn addition, participants must have end organ dysfunction, such as abnormal electrocardiogram (ECG) or evidence of left ventricular hypertrophy, renal insufficiency, brain tissue dysfunction, or peripheral nervous tissue dysfunction. They must also be willing to undergo multiple biopsies.\n\nExclusion criteria include being pregnant or lactating, having a history of organ transplant or significant diseases other than Fabry disease, having certain laboratory values outside the specified range, having a pacemaker or contraindication for magnetic resonance imaging scanning, taking prohibited medications, participating in another clinical trial within the last 30 days, or having any other condition that may jeopardize safety or study validity.\n\nParticipants must provide written informed consent and agree to be sexually abstinent or practice effective contraception during the study and for 30 days after completion for women of childbearing potential.",
    "The sample provided is for a phase 2 clinical trial. The trial focuses on the treatment of iron deficiency and iron deficiency anemia. The diseases are represented by the names \"iron deficiency\" and \"iron deficiency anemia\" and their corresponding ICD-10 codes are \"E61.1\", \"D50.8\", \"D50.9\", and \"D50.0\". The drugs being tested in the trial are \"ferric citrate\" and \"placebo\". \n\nThe eligibility criteria for participants in the trial are as follows:\n- Participants must have stage III to V chronic kidney disease.\n- Their serum phosphorus levels should be between 4.0 and 6.0 mg/dL before randomization.\n- Ferritin levels should be 300 ng/mL or less.\n- Transferrin saturation (TSAT) should be 30% or less.\n- Hemoglobin levels should be greater than 9.0 and less than 12.0 g/dL.\n- Participants must consume a minimum of 2 meals per day.\n\nThe exclusion criteria for participants in the trial are as follows:\n- Participants who have undergone parathyroidectomy within the past 24 weeks.\n- Participants who have had gastrointestinal bleed or inflammatory bowel disease within the past 12 weeks.\n- Participants who require dialysis or have had kidney injury within the past 8 weeks.\n- Participants who require oral iron, intravenous iron, erythropoiesis-stimulating agents, blood transfusions, or Sensipar during the study.\n- Participants who require calcium-, magnesium-, or aluminum-containing drugs with meals.\n- Participants who require vitamin C, niacin, or nicotinamide outside of multivitamins.\n- Participants with a history of hemochromatosis.\n- Participants with allergies to iron products.\n- Participants with a history of malignancy within the past 5 years.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on lung cancer. The ICD-10 codes associated with the disease are provided. The trial is testing a drug called \"epothilone d\". The eligibility criteria for participants are listed, including disease characteristics such as the stage of lung cancer, previous treatments, and measurable disease. Patient characteristics such as age, performance status, and life expectancy are also specified. Various medical conditions and prior treatments are listed as exclusion criteria. The sample also includes information about prior concurrent therapies and the timing of previous treatments.",
    "The sample from the table represents a phase 2 trial for the treatment of glaucoma and ocular hypertension. The diseases included in this trial are primary open angle glaucoma, ocular hypertension, pigmentary glaucoma, and pseudoexfoliative glaucoma. The corresponding ICD-10 codes for these diseases are provided. The drugs being tested in this trial are pf-03187207 and latanoprost vehicle, as well as latanoprost 0.005% and pf-03187207 vehicle. The eligibility criteria for this trial include a diagnosis of primary open angle glaucoma, ocular hypertension, pigmentary glaucoma, or pseudoexfoliative glaucoma in one or both eyes. The exclusion criteria include a closed or barely open anterior chamber angle or a history of acute angle closure in either eye.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are carboplatin and irinotecan hydrochloride. \n\nThe eligibility criteria for this trial include specific disease characteristics such as histologically or cytologically confirmed small cell lung cancer, extensive stage disease, newly diagnosed and treatment-naive disease, and at least one measurable lesion. Other criteria include patient characteristics such as age over 18, performance status of ECOG 0-2, life expectancy of more than 3 months, and specific hematopoietic, hepatic, renal, cardiovascular, and pulmonary requirements. \n\nThere are also criteria related to pregnancy, diabetes, infections, gastrointestinal conditions, and other malignancies. The prior concurrent therapy section specifies that there are no specific requirements for biologic therapy, chemotherapy, or endocrine therapy. However, prior radiotherapy to the chest is not allowed, while other prior radiotherapy is allowed. Finally, there should be at least a 2-week gap since the last surgery and the patient should have fully recovered.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and focuses on the treatment of diabetic macular edema. The trial involves the drug ranibizumab. The eligibility criteria for participants are listed, including requirements such as a diagnosis of diabetes mellitus, retinal thickening, specific visual acuity scores, and confirmation of diagnosis through OCT images. There are also exclusion criteria, such as recent laser photocoagulation or steroid use in the study eye, previous participation in a similar study, and various ocular disorders that may affect the interpretation of results. Other exclusion criteria include uncontrolled glaucoma, uncontrolled diabetes, pregnancy, and certain medical conditions or surgeries within a specified timeframe.",
    "The sample provided is a record from a table that contains information about clinical trials. \n\nIn this particular sample, the trial is in phase 2 and focuses on coronary disease. The ICD-10 codes associated with this disease are ['I25.10', 'I25.110', 'I25.119', 'I25.111', 'I25.118']. The drugs being studied in this trial are 'placebo' and 'dabigatran etexilate', with the latter being mentioned multiple times. \n\nThe eligibility criteria for this trial include patients with acute coronary syndromes who have at least one additional risk factor for cardiovascular complications. The exclusion criteria include long-term treatment with any other oral anticoagulant, recent severe or disabling stroke, conditions associated with increased bleeding risk, anemia or thrombocytopenia, severe renal impairment, liver disease, and a positive pregnancy test.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is rectal cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are cetuximab and 5-fluorouracil. The eligibility criteria for participants in this trial include having histologically confirmed adenocarcinoma of the rectum, being K-ras wildtype, having a performance status of less than or equal to 2, being 18 years of age or older, having no evidence of metastatic disease, and meeting certain bone marrow, renal, and hepatic function requirements. There are also exclusion criteria, such as prior treatment for this malignancy, prior history of pelvic radiation therapy, and prior history of 5-FU based or EGFR receptor inhibitor therapy.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2. The disease mentioned is \"hemoglobin sc disease\" and its corresponding ICDCodes are ['D56.5', 'D56.4', 'D58.2', 'D59.5', 'D59.6', 'R82.3']. The drugs being tested are 'mg pidolate' and 'placebo'. The eligibility criteria for this trial include being a male or female patient of any race with a diagnosis of severe sickle hemoglobinopathy, being able to swallow the Mg pidolate preparation, and having experienced at least one prior painful crisis. The exclusion criteria include recent blood transfusion, abnormal kidney or liver function, regular use of magnesium-containing medications, progressive neuromuscular disease, and pregnancy.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease psoriasis. The ICD-10 codes associated with psoriasis are ['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50']. The drug being studied is desoximetasone 0.25% spray. The eligibility criteria for participants are listed, including having a clinical diagnosis of stable plaque psoriasis, a certain extent of body surface area affected, and a moderate or severe overall disease severity score. There are also exclusion criteria, such as being pregnant or having certain types of psoriasis or dermatological conditions. The sample provides detailed information about the inclusion and exclusion criteria for potential participants in the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. \n\nIn this particular sample, the trial is in phase 2. The disease being studied is renal cell carcinoma. The corresponding ICD-10 codes for this disease are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8. \n\nThe drugs being tested in this trial are sunitinib malate continuous daily dosing and sunitinib malate schedule 4/2. \n\nThe eligibility criteria for this trial are as follows: \n- Inclusion Criteria: The patient must have advanced renal cell carcinoma of clear cell origin or a component of clear cell histology. Additionally, the patient must have measurable disease.\n- Exclusion Criteria: The patient must not have received any prior systemic therapy for advanced renal cell cancer. They must also not have a history of brain metastases and must not have uncontrolled hypertension.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on the disease \"small cell lung carcinoma\". The ICD-10 codes associated with this disease are \"D02.20\", \"D02.21\", and \"D02.22\". The drug being studied is \"lbh581\". The sample also includes the eligibility criteria for participants in the trial. The inclusion criteria include having a histological/cytological diagnosis of SCLC, having \u2264 2 prior chemotherapy lines, and having an ECOG Performance Status of 0-1, among other requirements. The exclusion criteria include having progression while on previous chemotherapy, having a known history of HIV positivity, and having impaired cardiac function, among other factors.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The diseases being studied are male breast cancer, recurrent breast cancer, and stage IV breast cancer. The corresponding ICDCodes for these diseases are provided as well. The drug being tested in this trial is imatinib mesylate. The eligibility criteria for participants in this trial include having histologically or cytologically confirmed metastatic breast cancer, documented expression of CD117 (c-kit) or platelet-derived growth factor receptor, and having received prior chemotherapy with specific drugs. Other criteria include having measurable lesions of a certain size, not having brain metastases, and meeting certain performance status and blood count requirements. There are also various other criteria related to medical history, allergies, concurrent illnesses, and prior treatments. Additionally, there are restrictions on concurrent medications and dietary restrictions.",
    "The sample from the table is for a phase 2 clinical trial for asthma. The diseases column lists only one disease, which is asthma. The icdcodes column contains a list of ICD-10 codes associated with asthma. The drugs column includes a list of drugs being used in the trial, such as \"fp mdpi\", \"flovent diskus\", and \"albuterol/salbutamol\". The criteria column provides the eligibility criteria for participants in the trial, including requirements for age, general health, asthma diagnosis, severity of disease, reversibility of disease, current asthma therapy, short-acting \u03b22-agonists usage, pregnancy status, and understanding of study requirements. The exclusion criteria are also listed, which include conditions that would put the safety of the subject at risk or could affect the efficacy or safety analysis of the study.",
    "The sample provided is for a phase 2 clinical trial. The disease being studied is atrial fibrillation. The corresponding ICD-10 codes for atrial fibrillation are 'I48.0', 'I48.21', 'I48.91', 'I48.11', 'I48.19', and 'I48.20'. The drugs being tested in this trial are 'ym150' and 'warfarin'. The eligibility criteria for participants include having paroxysmal permanent or persistent non-valvular atrial fibrillation, having an INR (International Normalized Ratio) of 2.0 or below and an aPTT (Activated Partial Thromboplastin Time) \u2264 1.5 times the upper limit of normal at the baseline visit, meeting the legal minimum age requirement, and providing written informed consent. Exclusion criteria include a history of heart valve disorders, rheumatic fever, stroke and/or systemic embolism, acute coronary syndrome, indication for warfarin other than non-valvular atrial fibrillation, known hemorrhagic disorder and/or coagulation disorder, active bleeding, or any condition associated with an increased risk of bleeding.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is asthma. The ICDCodes associated with asthma are ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The drugs being tested in this trial are 'amg 827', 'placebo', and 'amg 827'. The eligibility criteria for participants in this trial include being between 18 to 65 years of age, having a percent of predicted FEV1 between 50% and 80%, showing at least 12% reversibility over pre-bronchodilator FEV1, using a specific dosage of inhaled corticosteroid (ICS), and having ongoing asthma symptoms with an ACQ composite score of at least 1.5 points. The exclusion criteria include having had a respiratory infection within 4 weeks of the screening visit or 1 week of the baseline visit, having a history of chronic obstructive pulmonary disease or other chronic pulmonary condition other than asthma, and having any uncontrolled or clinically significant systemic disease such as uncontrolled diabetes or liver disease.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and focuses on the disease \"medullary thyroid carcinoma.\" The associated ICD-10 codes for this disease are ['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']. The drug being studied in this trial is \"sorafenib.\" The eligibility criteria for participants in this trial include being 18 years or older, having histologically confirmed medullary thyroid carcinoma, having recurrent or persistent local disease and/or distant metastases, and having no more than one prior line of systemic therapy. Other criteria include specific laboratory values, performance status, renal function, and completion of staging studies. There are also exclusion criteria, such as unresolved toxicity from prior therapy, significant cardiovascular disease, and uncontrolled infections.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating metastatic breast cancer. The trial is specifically targeting patients with HER2-positive disease. The eligibility criteria for the trial include having documented breast cancer, disease progression on the last chemotherapy regimen received in the metastatic setting, and prior treatment with specific drugs such as anthracycline, trastuzumab, taxane, lapatinib, and capecitabine. Patients must have also received at least two lines of anti-HER2 therapy in the metastatic setting. The sample also includes exclusion criteria, such as recent chemotherapy, hormone therapy, or investigational therapy, as well as specific medical conditions or history that would make a patient ineligible for the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 2, and the disease being studied is lupus nephritis. The icd-10 codes associated with this disease are B26.83, A51.44, N11.8, N11.9, and N12. The drug being used in the trial is cyclophosphamide. \n\nThe eligibility criteria for this trial are as follows:\n- Patients must be male or non-pregnant females between the ages of 16 and 65.\n- Written informed consent must be obtained from the patient or their parents/guardian.\n- Patients must have systemic lupus erythematosus (SLE) that meets the American Rheumatism Association criteria and has a SLEDAI score greater than 8 or a BILAG score of A/B.\n- Patients must have newly diagnosed World Health Organization (WHO) Class III or IV Lupus Nephritis.\n\nThere are also exclusion criteria that would make patients ineligible for enrollment in the study, including being pregnant or nursing, having participated in any research involving investigational products within the past 30 days, having certain medical conditions or disabilities that would interfere with treatment or assessment, and having a history of alcohol or substance abuse or malignancy within the previous 5 years.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 2, and the disease being studied is kidney cancer. The ICDCodes associated with the disease are ['D17.71', 'D30.00', 'D30.01', 'D30.02', 'D41.00', 'D41.01', 'D41.02']. The drug being tested is sorafenib. The eligibility criteria for this trial include specific disease characteristics, such as histologically or cytologically confirmed renal cell carcinoma (RCC) with a component of conventional clear cell RCC. The patient must have metastatic or unresectable disease, and either measurable or nonmeasurable disease. There are also patient characteristics outlined, such as a Karnofsky performance status of 70-100%, not being pregnant or nursing, and having certain blood counts and liver function within normal ranges. The sample also includes information about prior concurrent therapy, including the time since major surgery or radiotherapy, the number of prior systemic therapies for RCC, and restrictions on certain medications or treatments during the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone b-cell lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent mantle cell lymphoma, and splenic marginal zone lymphoma. The corresponding ICDCodes for these diseases are also provided.\n\nThe drugs being used in the trial are bendamustine hydrochloride and obatoclax mesylate. The eligibility criteria for participants include having histologically confirmed indolent B-cell non-Hodgkin lymphoma, having received at least one prior therapy, and having a certain performance status, blood counts, liver and kidney function, and no active hepatitis B infection. Other criteria include not being pregnant or nursing, using effective contraception, and not having certain medical conditions or taking certain medications.\n\nOverall, this sample provides specific details about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 combination. The trial focuses on patients with non-small-cell lung carcinoma. The trial includes eligibility criteria for patients to be included or excluded from the study. Inclusion criteria include having histologically or cytologically confirmed NSCLC, being locally advanced or metastatic, not having received prior systemic chemotherapy, and meeting certain medical and health requirements. Exclusion criteria include having received prior systemic anticancer therapy, having certain cardiac conditions, having uncontrolled hypertension, having certain infections or bleeding disorders, and having other medical or psychological conditions that may interfere with participation in the study.",
    "The sample from the table is for a phase 2 clinical trial. The disease being studied is diabetic macular edema. The ICD-10 codes associated with this disease are E10.311, E10.319, E11.311, E11.319, E13.311, E13.319, and E10.3513. The drugs being tested in this trial are dexamethasone and sham injection. The eligibility criteria for participants include being 18 years of age or older with diabetic macular edema, experiencing a decrease in visual acuity in at least one eye due to macular edema (20/50 or worse), and having visual acuity in the other eye no worse than 20/200. Some of the exclusion criteria include a known anticipated need for ocular surgery within the next 12 months, a history of glaucoma or current high eye pressure requiring more than 1 medication, uncontrolled systemic disease, being a known steroid-responder, and the use of systemic steroids or Warfarin/Heparin.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 2 and focuses on the disease \"clostridium difficile infection\". The icd-10 codes associated with this disease are \"A05.2\", \"A04.71\", \"A04.72\", and \"B96.7\". The drugs being tested in this trial are \"cadazolid\", \"vancomycin\", \"placebo-matching cadazolid\", and \"placebo-matching vancomycin\". The eligibility criteria for participants include being at least 18 years old and having a diagnosis of Clostridium Difficile-associated diarrhea (CDAD) as either the first occurrence or first recurrence. There are also exclusion criteria, such as having a concurrent life-threatening condition, being immuno-compromised or receiving immuno-suppressive treatment, receiving concomitant antimicrobial treatment for CDAD, or having any circumstances or conditions that would affect full participation in the study or compliance with the protocol.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is phase 2. The disease being studied is gallbladder cancer. The icd-10 codes associated with this disease are C23 and D37.6. The drug being used in the trial is irinotecan hydrochloride. The eligibility criteria for participants include having histologically or cytologically proven gallbladder or bile duct carcinoma with metastatic or recurrent disease that is deemed unresectable and not considered a candidate for potentially curative therapy. Other criteria include specific age requirements, performance status, life expectancy, hematopoietic, hepatic, renal, and cardiovascular conditions, as well as prior concurrent therapies and other medical conditions.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on chronic obstructive pulmonary disease (COPD). The ICD-10 codes associated with COPD are ['G91.1', 'I42.1', 'N11.1', 'J05.0', 'G47.33', 'J44.9', 'N13.8']. The drugs being studied are glycopyrrolate, tiotropium, and placebo. The sample also includes the eligibility criteria for the trial. Inclusion criteria include being aged 40-75 years, having a diagnosis of moderate-severe COPD, being a current or ex-smoker with a smoking history of at least 10 pack-years, having specific lung function measurements, and meeting certain reversibility criteria. Exclusion criteria include having a history of allergies, certain blood eosinophil count, abnormal physical examination or ECG findings, significant diseases not related to COPD, recent respiratory tract infection, requiring daily oxygen therapy, having certain lung diseases, intolerance or contraindication to the treatment, history of alcohol or substance abuse, recent use of corticosteroids or tiotropium, and being pregnant or lactating without using contraception.",
    "The sample provided is for a phase 2 clinical trial focused on obesity. The trial is testing the effectiveness of a drug called gsk1521498 compared to a placebo. The eligibility criteria for participants include being obese but otherwise healthy, between the ages of 18 and 60, with a body mass index (BMI) of 30 or higher. Female participants of child-bearing potential must use contraception during the study. Male participants must also use contraception. Participants must be capable of giving informed consent and have a good understanding of English. Certain liver enzyme levels must be within normal range, and participants must be right-handed. \n\nExclusion criteria include a history of clinically significant eating disorders, high scores on depression or suicide risk assessments, current or recent psychiatric disorders, substance abuse or dependence, regular high alcohol consumption, positive drug/alcohol screen, recent tobacco or nicotine use, use of prohibited medications, unstable bodyweight, pregnancy or lactation, certain medical conditions or laboratory results, history of bariatric surgery, prolonged QT interval, liver or neurological disorders, positive HIV or Hepatitis C test, sleep apnea, gastrointestinal diseases, recent participation in another clinical trial, contraindications or complications related to MRI scanning or other assessments, special dietary requirements, unsuitability for cannulation, plans to start a calorie-controlled diet or major exercise routine, and consumption of certain foods or beverages within 7 days prior to the start of the study medication.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on the disease \"hepatitis C, chronic.\"\n- ICD Codes: The ICD-10 codes associated with the disease are \"B18.2\", \"B18.0\", \"B18.1\", \"B18.8\", \"B18.9\", \"K71.3\", and \"K71.4\".\n- Drugs: The trial involves the drugs \"idx719\" and \"placebo\".\n- Criteria: The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". These criteria include being in good general health, using double-barrier birth control for a specific period, having documented GT1, GT2, or GT3 chronic HCV infection, not being pregnant or breastfeeding, not having received prior HCV treatment, and not being co-infected with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV).",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 2. The disease being studied is functional dyspepsia. The corresponding ICD-10 code for functional dyspepsia is K30. The drugs being tested in this trial are rabeprazole and placebo. The eligibility criteria for participants include being diagnosed with functional dyspepsia according to the Rome III criteria. Participants with neuropsychiatric disorders, as well as those diagnosed with irritable bowel syndrome, inflammatory bowel disease, and serious constipation, are excluded from the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on treating squamous cell carcinoma of the head and neck and human papilloma virus. The diseases are represented by their respective ICD-10 codes. The trial involves the use of drugs such as docetaxel, cisplatin, 5-fu, cetuximab, and carboplatin. The eligibility criteria for participants are listed, including requirements such as histologically or cytologically confirmed cancer, specific disease stage, age, performance status, and absence of previous treatments. There are also exclusion criteria, such as pregnancy or breastfeeding, previous or current malignancies, and certain medical conditions. The sample provides a detailed description of the inclusion and exclusion criteria for potential participants in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is \"type 1 diabetes mellitus.\" The ICDCodes associated with this disease are \"E10.65,\" \"E10.9,\" \"E10.21,\" \"E10.36,\" \"E10.41,\" \"E10.42,\" and \"E10.44.\" The drugs being used in the trial are \"dapagliflozin\" and \"placebo matching dapagliflozin.\" \n\nThe eligibility criteria for this trial include:\n- Type 1 diabetes with a central lab Glycosylated hemoglobin (A1C) level between 7.0% and 10.0%.\n- Insulin use for at least 12 months, starting immediately after the diagnosis of diabetes.\n- Stable method of insulin administration (multiple daily injections or continuous subcutaneous insulin infusion) for at least 3 months.\n- Stable basal insulin dose for at least 2 weeks.\n- Age between 18 and 65 years.\n- Central laboratory C-peptide value of less than 0.7 ng/mL.\n- Body mass index (BMI) between 18.5 and 35.0 kg/m2.\n\nThe exclusion criteria for this trial include:\n- History of type 2 diabetes mellitus (T2DM), maturity onset diabetes of young (MODY), pancreatic surgery, or chronic pancreatitis.\n- Use of oral hypoglycemic agents.\n- History of diabetes ketoacidosis (DKA) within the past 24 weeks.\n- History of hospital admission for glycemic control within the past 6 months.\n- Frequent episodes of unexplained hypoglycemia (2 within 3 months) or hypoglycemic unawareness.\n- Elevated levels of Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), or Serum total bilirubin (> 2 times the upper limit of normal).\n- Abnormal Free T4 (if screening Thyroid Stimulating Hormone (TSH) is abnormal).\n- Estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) formula is less than or equal to 60 mL/min/1.73m2.\n- Presence of cardiovascular (CV)/vascular diseases within the past 6 months.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 2 and is focused on various diseases, including chronic myeloproliferative disorders, graft versus host disease, leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases. The diseases are associated with specific ICD-10 codes. The trial involves the use of drugs such as busulfan, fludarabine phosphate, methotrexate, and tacrolimus. The eligibility criteria for participants include having a diagnosis of certain myeloid malignancies, availability of a matched related or unrelated donor, and meeting specific patient characteristics such as normal AST and creatinine levels, absence of severe cardiac or coronary artery disease, and negative HIV status. Prior concurrent therapy restrictions include no use of post-transplantation growth factor during methotrexate administration.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 2. The disease being studied is \"carcinoma, renal cell.\" The ICDCodes associated with this disease are ['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']. The drug being tested is \"regorafenib (stivarga, bay73-4506).\" \n\nThe eligibility criteria for this trial include:\n- Patients must be 18 years of age or older.\n- Patients must have unresectable and/or metastatic, measurable predominantly clear cell RCC (renal cell carcinoma).\n- Patients must not have received prior treatment for advanced disease, except for palliative radiation therapy that did not include the target lesion(s) or more than 30% of the bone marrow.\n- Patients must have at least one measurable lesion according to RECIST criteria.\n- Patients must have an \"Intermediate\" or \"Low\" risk per the Motzer score.\n- Patients must have an Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1.\n- Patients must have adequate bone marrow, renal, and hepatic function.\n\nThe exclusion criteria for this trial include:\n- Patients who have received prior systemic treatment regimens for RCC.\n- Patients with uncontrolled/unstable cardiac disease.\n- Patients with uncontrolled hypertension.\n- Patients with active clinically serious infections.\n- Patients with a history of HIV infection or chronic hepatitis B or C.\n- Patients with a known history or symptomatic metastatic brain or meningeal tumors.\n- Patients with a seizure disorder requiring medication.\n- Patients with evidence or history of bleeding diathesis.\n- Pregnant or breastfeeding patients are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 2 trial and the disease being studied is lung cancer. The ICD-10 codes associated with the disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are 13-cis-retinoic acid and paclitaxel. The eligibility criteria for participants in the trial are listed, including requirements such as confirmed diagnosis of recurrent small cell lung cancer, age 18 and over, specific blood counts, liver and kidney function, and previous chemotherapy treatment. There are also exclusion criteria listed, such as history of other neoplasms, pregnancy or nursing, use of certain medications, and recent radiation or chemotherapy treatments.",
    "The sample is a phase 2 trial for the treatment of chronic hepatitis C. The trial focuses on patients with chronic HCV genotype 1 infection who have previously undergone treatment. The trial includes both non-cirrhotic and cirrhotic populations, with specific criteria for each. Inclusion criteria for non-cirrhotic patients include having a liver biopsy without evidence of cirrhosis and hepatocellular carcinoma. Inclusion criteria for cirrhotic patients include having a liver biopsy with evidence of cirrhosis and without evidence of hepatocellular carcinoma. Exclusion criteria include not tolerating previous treatment with peg-IFN and RBV, being unlikely to tolerate at least 24 weeks of continuous therapy with peg-IFN and RBV, co-infection with HIV and/or hepatitis B, excessive alcohol consumption, history of drug or alcohol abuse, pregnancy or breastfeeding for female participants, participation in a clinical trial with an investigational drug in the last 30 days, and use of IFN/Peg-IFN and RBV in the last 3 months. The drugs being tested in the trial are vaniprevir, pegylated interferon (peg-IFN), ribavirin (RBV), and placebo (PBO).",
    "The sample is a phase 2 trial for patients with type 2 diabetes mellitus. The trial includes patients who are male or post-menopausal/surgically sterilized females, aged between 18 and 75 years. The patients must have been on stable metformin treatment for at least 3 months and have a HbA1c level between 7.0% and 9.5% at screening. Their weight should have remained stable within a range of +/-10% for at least 3 months prior to screening.\n\nThe trial excludes patients with type 1 diabetes mellitus, clinically significant gastrointestinal disease, and those who have been on any anti-hyperglycemic medication other than metformin monotherapy in the last 3 months. Patients who have used weight-lowering medications in the last 3 months, have uncontrolled hypertension, or have been previously exposed to GLP-1 or GLP-1 analogues are also excluded."
]
